{"PMC7108449": [["The Coronaviridae familyCoronaviruses are enveloped, positive-stranded RNA viruses that can infect a variety of vertebrates and are mainly associated with respiratory and enteric diseases.", [["respiratory", "ANATOMY", 155, 166], ["respiratory and enteric diseases", "DISEASE", 155, 187], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 24, 37], ["Coronaviridae family", "PROTEIN", 4, 24], ["Coronaviruses", "PROBLEM", 24, 37], ["stranded RNA viruses", "PROBLEM", 62, 82], ["respiratory and enteric diseases", "PROBLEM", 155, 187], ["positive", "OBSERVATION_MODIFIER", 53, 61], ["stranded RNA viruses", "OBSERVATION", 62, 82], ["variety", "OBSERVATION_MODIFIER", 101, 108], ["mainly associated with", "UNCERTAINTY", 132, 154], ["enteric diseases", "OBSERVATION", 171, 187]]], ["They have long been recognized as important pathogens of livestock and companion animals, and coronaviruses are a common cause of respiratory tract infections in man [1], [2].", [["respiratory tract", "ANATOMY", 130, 147], ["respiratory tract infections", "DISEASE", 130, 158], ["coronaviruses", "ORGANISM", 94, 107], ["respiratory tract", "ORGANISM_SUBDIVISION", 130, 147], ["man", "SPECIES", 162, 165], ["coronaviruses", "PROBLEM", 94, 107], ["respiratory tract infections", "PROBLEM", 130, 158], ["respiratory tract", "ANATOMY", 130, 147]]], ["In 2003, a coronavirus has been identified as the causative agent of a new human disease, the severe acute respiratory syndrome (SARS) [3], [4], [5].", [["coronavirus", "DISEASE", 11, 22], ["human disease", "DISEASE", 75, 88], ["acute respiratory syndrome", "DISEASE", 101, 127], ["SARS", "DISEASE", 129, 133], ["coronavirus", "ORGANISM", 11, 22], ["human", "ORGANISM", 75, 80], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["a coronavirus", "PROBLEM", 9, 22], ["a new human disease", "PROBLEM", 69, 88], ["the severe acute respiratory syndrome", "PROBLEM", 90, 127], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory syndrome", "OBSERVATION", 107, 127]]], ["The SARS coronavirus (SARS-CoV) spread within few months to more than 30 countries and caused the first epidemic of the new millennium.", [["SARS coronavirus", "DISEASE", 4, 20], ["SARS", "DISEASE", 22, 26], ["SARS coronavirus", "ORGANISM", 4, 20], ["SARS-CoV", "ORGANISM", 22, 30], ["SARS coronavirus", "SPECIES", 4, 20], ["SARS-CoV", "SPECIES", 22, 30], ["The SARS coronavirus (SARS-CoV) spread", "PROBLEM", 0, 38], ["new", "OBSERVATION_MODIFIER", 120, 123]]], ["This event not only highlighted the potential of coronaviruses to seriously affect human health, but also gave a strong impetus on coronavirus research.", [["coronaviruses", "ORGANISM", 49, 62], ["human", "ORGANISM", 83, 88], ["coronavirus", "ORGANISM", 131, 142], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["coronaviruses", "PROBLEM", 49, 62], ["coronavirus research", "TREATMENT", 131, 151], ["coronaviruses", "OBSERVATION", 49, 62], ["coronavirus", "OBSERVATION", 131, 142]]], ["Since then, bats were identified as a possible reservoir species of SARS-CoV [6], and a wealth of knowledge about coronavirus replication and pathogenesis has been gained [7], [8], [9].The Coronaviridae familyThe family Coronaviridae comprise two genera, Coronaviruses and Toroviruses, and is grouped together with two other families, the Arteriviridae and the Roniviridae, into the order Nidovirales [1], [10].", [["SARS", "DISEASE", 68, 72], ["SARS-CoV", "ORGANISM", 68, 76], ["coronavirus", "ORGANISM", 114, 125], ["[8]", "SIMPLE_CHEMICAL", 176, 179], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 255, 268], ["Toroviruses", "GENE_OR_GENE_PRODUCT", 273, 284], ["Coronaviridae family", "PROTEIN", 189, 209], ["coronavirus", "SPECIES", 114, 125], ["SARS-CoV", "SPECIES", 68, 76], ["SARS", "PROBLEM", 68, 72], ["coronavirus replication", "PROBLEM", 114, 137], ["pathogenesis", "PROBLEM", 142, 154], ["The family Coronaviridae", "TREATMENT", 209, 233], ["Coronaviruses", "TREATMENT", 255, 268], ["Toroviruses", "TREATMENT", 273, 284], ["the Arteriviridae", "TREATMENT", 335, 352], ["the Roniviridae", "TREATMENT", 357, 372]]], ["Although Nidoviruses differ in their genome sizes, structural proteins and morphology, they share a common genome organization and common mechanisms of RNA replication [1], [8], [9], [10], [11].", [["Nidoviruses", "GENE_OR_GENE_PRODUCT", 9, 20], ["[8]", "SIMPLE_CHEMICAL", 173, 176], ["[9]", "SIMPLE_CHEMICAL", 178, 181], ["[10]", "SIMPLE_CHEMICAL", 183, 187], ["Nidoviruses", "PROTEIN", 9, 20]]], ["The name Nidovirus (from the Latin \u201cnido\u201d - nest) refers to the ability to transcribe a so-called \u201cnested set\u201d of subgenomic mRNAs [12].", [["Nidovirus", "GENE_OR_GENE_PRODUCT", 9, 18], ["subgenomic mRNAs", "RNA", 114, 130]]], ["Coronaviruses have genomes of approximately 30,000 nt, a length that is unprecedented amongst RNA viruses.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["Coronaviruses", "PROBLEM", 0, 13], ["RNA viruses", "OBSERVATION", 94, 105]]], ["The extreme genome size requires complex and only incompletely understood mechanisms of RNA replication, transcription, modification, and recombination, which are conducted by a multi-enzyme complex encoded by the replicase gene and the nucleocapsid gene [13], [14], [15].", [["multi-enzyme complex", "PROTEIN", 178, 198], ["replicase gene", "DNA", 214, 228], ["nucleocapsid gene", "DNA", 237, 254], ["RNA replication", "TREATMENT", 88, 103], ["the nucleocapsid gene", "TEST", 233, 254], ["extreme", "OBSERVATION_MODIFIER", 4, 11], ["genome", "OBSERVATION_MODIFIER", 12, 18], ["size", "OBSERVATION_MODIFIER", 19, 23]]], ["It is speculated that coronaviruses have evolved this complex replication machinery to stably maintain their large genomic RNA and to encode additional functions that impact on virus\u2013host interactions [10].", [["coronaviruses", "ORGANISM", 22, 35], ["genomic RNA", "RNA", 115, 126], ["coronaviruses", "PROBLEM", 22, 35], ["their large genomic RNA", "PROBLEM", 103, 126], ["coronaviruses", "OBSERVATION", 22, 35], ["large", "OBSERVATION_MODIFIER", 109, 114], ["genomic RNA", "OBSERVATION", 115, 126]]], ["Furthermore, the unique transcription strategy involves a discontinuous step during negative strand RNA synthesis that mechanistically reflects similarity-assisted RNA recombination.", [["strand RNA synthesis", "TREATMENT", 93, 113]]], ["Thus, coronaviruses are well equipped for high frequency RNA recombination which facilitates rapid adaptation to new hosts.The Coronaviridae familyCoronavirus particles are enveloped and display a typical solar or crown-like (\u201ccorona\u201d) appearance in electron microscopy.", [["coronaviruses", "ORGANISM", 6, 19], ["Coronaviridae family", "PROTEIN", 127, 147], ["coronaviruses", "PROBLEM", 6, 19], ["high frequency RNA recombination", "TREATMENT", 42, 74], ["Coronavirus particles", "PROBLEM", 147, 168], ["a typical solar or crown-like (\u201ccorona\u201d) appearance", "PROBLEM", 195, 246], ["electron microscopy", "TEST", 250, 269], ["typical", "OBSERVATION_MODIFIER", 197, 204], ["solar", "OBSERVATION_MODIFIER", 205, 210], ["crown", "OBSERVATION_MODIFIER", 214, 219]]], ["Historically, the family has been divided into three groups based on serological cross-reactivity.", [["serological cross-reactivity", "TEST", 69, 97]]], ["Later, this grouping has been confirmed by phylogenetic analyses based on genome sequencing data [8], [10], [16].", [["phylogenetic analyses", "TEST", 43, 64], ["genome sequencing data", "TEST", 74, 96]]], ["Soon after SARS-CoV has been recognized as a coronavirus, phylogenetic analyses revealed a relationship to group 2 coronaviruses, for which the mouse hepatitis virus (MHV) is the prototype.", [["SARS-CoV", "DISEASE", 11, 19], ["mouse hepatitis virus", "DISEASE", 144, 165], ["SARS-CoV", "ORGANISM", 11, 19], ["mouse hepatitis virus", "ORGANISM", 144, 165], ["MHV", "ORGANISM", 167, 170], ["mouse", "SPECIES", 144, 149], ["hepatitis virus", "SPECIES", 150, 165], ["SARS-CoV", "SPECIES", 11, 19], ["mouse hepatitis virus", "SPECIES", 144, 165], ["MHV", "SPECIES", 167, 170], ["SARS", "PROBLEM", 11, 15], ["CoV", "PROBLEM", 16, 19], ["a coronavirus", "PROBLEM", 43, 56], ["phylogenetic analyses", "TEST", 58, 79], ["group 2 coronaviruses", "PROBLEM", 107, 128], ["the mouse hepatitis virus", "PROBLEM", 140, 165]]], ["However, SARS-CoV also has unique features, suggesting that SARS-CoV represents an early split-off from the coronavirus group 2 lineage [8], [16].Diseases caused by coronavirusesCoronaviruses can cause a variety of diseases in animals and humans [2].", [["SARS", "DISEASE", 9, 13], ["SARS", "DISEASE", 60, 64], ["Diseases", "DISEASE", 146, 154], ["coronavirusesCoronaviruses", "DISEASE", 165, 191], ["SARS-CoV", "ORGANISM", 9, 17], ["SARS-CoV", "ORGANISM", 60, 68], ["humans", "ORGANISM", 239, 245], ["coronavirus group", "SPECIES", 108, 125], ["humans", "SPECIES", 239, 245], ["SARS-CoV", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 60, 68], ["humans", "SPECIES", 239, 245], ["SARS", "PROBLEM", 9, 13], ["unique features", "PROBLEM", 27, 42], ["SARS", "PROBLEM", 60, 64], ["CoV", "PROBLEM", 65, 68], ["an early split", "PROBLEM", 80, 94], ["Diseases", "PROBLEM", 146, 154], ["coronavirusesCoronaviruses", "PROBLEM", 165, 191], ["diseases", "PROBLEM", 215, 223], ["coronaviruses", "OBSERVATION", 165, 178]]], ["Of economical importance are coronaviruses such as porcine transmissible gastroenteritis virus, bovine coronavirus, feline infectious peritonitis virus, and avian infectious bronchitis virus.", [["transmissible gastroenteritis", "DISEASE", 59, 88], ["bovine coronavirus", "DISEASE", 96, 114], ["feline infectious peritonitis", "DISEASE", 116, 145], ["avian infectious bronchitis virus", "DISEASE", 157, 190], ["coronaviruses", "ORGANISM", 29, 42], ["porcine transmissible gastroenteritis virus", "ORGANISM", 51, 94], ["bovine coronavirus", "ORGANISM", 96, 114], ["feline infectious peritonitis virus", "ORGANISM", 116, 151], ["avian infectious bronchitis virus", "ORGANISM", 157, 190], ["porcine transmissible gastroenteritis virus", "SPECIES", 51, 94], ["bovine", "SPECIES", 96, 102], ["coronavirus", "SPECIES", 103, 114], ["feline infectious peritonitis virus", "SPECIES", 116, 151], ["avian infectious bronchitis virus", "SPECIES", 157, 190], ["porcine transmissible gastroenteritis virus", "SPECIES", 51, 94], ["bovine coronavirus", "SPECIES", 96, 114], ["feline infectious peritonitis virus", "SPECIES", 116, 151], ["infectious bronchitis virus", "SPECIES", 163, 190], ["coronaviruses", "PROBLEM", 29, 42], ["porcine transmissible gastroenteritis virus", "PROBLEM", 51, 94], ["bovine coronavirus", "PROBLEM", 96, 114], ["feline infectious peritonitis virus", "PROBLEM", 116, 151], ["avian infectious bronchitis virus", "PROBLEM", 157, 190], ["bovine coronavirus", "OBSERVATION", 96, 114], ["infectious", "OBSERVATION_MODIFIER", 123, 133], ["peritonitis", "OBSERVATION", 134, 145], ["infectious", "OBSERVATION_MODIFIER", 163, 173], ["bronchitis", "OBSERVATION", 174, 184]]], ["MHV, a natural mouse pathogen, has been extensively studied in the context of host immune responses and pathogenesis [2], [17], [18].", [["MHV", "ORGANISM", 0, 3], ["mouse", "ORGANISM", 15, 20], ["[17]", "SIMPLE_CHEMICAL", 122, 126], ["[18]", "SIMPLE_CHEMICAL", 128, 132], ["mouse", "SPECIES", 15, 20], ["MHV", "SPECIES", 0, 3], ["mouse", "SPECIES", 15, 20], ["MHV", "PROBLEM", 0, 3], ["a natural mouse pathogen", "PROBLEM", 5, 29], ["pathogenesis", "PROBLEM", 104, 116], ["natural mouse pathogen", "OBSERVATION", 7, 29]]], ["There are many different and well-characterized strains of MHV which, depending on organ tropism, virulence and host strain, can cause a wide array of diseases ranging from hepatitis, respiratory symptoms and gastroenteritis to CNS infection, demyelination, and acute meningitis [2], [17], [19], [20], [21], [22], [23].", [["organ", "ANATOMY", 83, 88], ["respiratory", "ANATOMY", 184, 195], ["CNS", "ANATOMY", 228, 231], ["hepatitis", "DISEASE", 173, 182], ["respiratory symptoms", "DISEASE", 184, 204], ["gastroenteritis", "DISEASE", 209, 224], ["CNS infection", "DISEASE", 228, 241], ["demyelination", "DISEASE", 243, 256], ["meningitis", "DISEASE", 268, 278], ["MHV", "ORGANISM", 59, 62], ["organ", "ORGAN", 83, 88], ["CNS", "ANATOMICAL_SYSTEM", 228, 231], ["[17], [19], [20]", "SIMPLE_CHEMICAL", 284, 300], ["[21], [22], [23]", "SIMPLE_CHEMICAL", 302, 318], ["MHV", "SPECIES", 59, 62], ["MHV", "PROBLEM", 59, 62], ["organ tropism", "PROBLEM", 83, 96], ["virulence", "PROBLEM", 98, 107], ["host strain", "PROBLEM", 112, 123], ["diseases", "PROBLEM", 151, 159], ["hepatitis", "PROBLEM", 173, 182], ["respiratory symptoms", "PROBLEM", 184, 204], ["gastroenteritis", "PROBLEM", 209, 224], ["CNS infection", "PROBLEM", 228, 241], ["demyelination", "PROBLEM", 243, 256], ["acute meningitis", "PROBLEM", 262, 278], ["many", "OBSERVATION_MODIFIER", 10, 14], ["different", "OBSERVATION_MODIFIER", 15, 24], ["well-characterized", "OBSERVATION_MODIFIER", 29, 47], ["MHV", "OBSERVATION", 59, 62], ["host strain", "OBSERVATION", 112, 123], ["wide", "OBSERVATION_MODIFIER", 137, 141], ["diseases", "OBSERVATION", 151, 159], ["hepatitis", "OBSERVATION", 173, 182], ["CNS", "ANATOMY", 228, 231], ["infection", "OBSERVATION", 232, 241], ["demyelination", "OBSERVATION", 243, 256], ["acute", "OBSERVATION_MODIFIER", 262, 267], ["meningitis", "OBSERVATION", 268, 278]]], ["Therefore, by using appropriate combinations of virus and mouse strains, MHV infections provide suitable models for a number of diseases that are of medical importance, such as encephalitis, immune-mediated demyelination (e.g. multiple sclerosis), hepatitis and acute respiratory infections (e.g. SARS).Diseases caused by coronavirusesBesides SARS-CoV, there are several human coronaviruses (HCoVs) which cause mainly mild respiratory tract infections (common cold; HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU) and sometimes enteric infections [2].", [["respiratory", "ANATOMY", 268, 279], ["respiratory tract", "ANATOMY", 423, 440], ["MHV infections", "DISEASE", 73, 87], ["encephalitis", "DISEASE", 177, 189], ["demyelination", "DISEASE", 207, 220], ["multiple sclerosis", "DISEASE", 227, 245], ["hepatitis", "DISEASE", 248, 257], ["acute respiratory infections", "DISEASE", 262, 290], ["SARS", "DISEASE", 297, 301], ["Diseases", "DISEASE", 303, 311], ["coronaviruses", "DISEASE", 322, 335], ["SARS-CoV", "DISEASE", 343, 351], ["respiratory tract infections", "DISEASE", 423, 451], ["HKU", "DISEASE", 507, 510], ["enteric infections", "DISEASE", 526, 544], ["mouse", "ORGANISM", 58, 63], ["MHV infections", "ORGANISM", 73, 87], ["coronaviruses", "ORGANISM", 322, 335], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 343, 351], ["human", "ORGANISM", 371, 376], ["coronaviruses", "ORGANISM", 377, 390], ["HCoVs", "CANCER", 392, 397], ["tract", "ORGANISM_SUBDIVISION", 435, 440], ["HCoV-HKU", "GENE_OR_GENE_PRODUCT", 502, 510], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 371, 376], ["mouse", "SPECIES", 58, 63], ["MHV", "SPECIES", 73, 76], ["SARS-CoV", "SPECIES", 343, 351], ["human coronaviruses", "SPECIES", 371, 390], ["virus and mouse strains", "TREATMENT", 48, 71], ["MHV infections", "PROBLEM", 73, 87], ["diseases", "PROBLEM", 128, 136], ["encephalitis", "PROBLEM", 177, 189], ["immune-mediated demyelination", "PROBLEM", 191, 220], ["multiple sclerosis)", "PROBLEM", 227, 246], ["hepatitis", "PROBLEM", 248, 257], ["acute respiratory infections", "PROBLEM", 262, 290], ["Diseases", "PROBLEM", 303, 311], ["coronaviruses", "PROBLEM", 322, 335], ["SARS", "PROBLEM", 343, 347], ["several human coronaviruses (HCoVs)", "PROBLEM", 363, 398], ["mainly mild respiratory tract infections", "PROBLEM", 411, 451], ["HCoV", "TEST", 466, 470], ["HCoV", "TEST", 477, 481], ["OC43", "TEST", 482, 486], ["HCoV", "TEST", 488, 492], ["HCoV", "TEST", 502, 506], ["sometimes enteric infections", "PROBLEM", 516, 544], ["demyelination", "OBSERVATION", 207, 220], ["multiple", "OBSERVATION_MODIFIER", 227, 235], ["sclerosis", "OBSERVATION", 236, 245], ["hepatitis", "OBSERVATION", 248, 257], ["acute", "OBSERVATION_MODIFIER", 262, 267], ["respiratory", "ANATOMY", 268, 279], ["infections", "OBSERVATION", 280, 290], ["coronaviruses", "OBSERVATION", 322, 335], ["SARS", "OBSERVATION", 343, 347], ["mild", "OBSERVATION_MODIFIER", 418, 422], ["respiratory tract", "ANATOMY", 423, 440], ["enteric", "ANATOMY", 526, 533], ["infections", "OBSERVATION", 534, 544]]], ["HCoV infections are prevalent in children, but more severe symptoms have been observed in immunocompromised individuals and occasionally in the elderly [24], [25].", [["HCoV infections", "DISEASE", 0, 15], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["HCoV", "SPECIES", 0, 4], ["HCoV infections", "PROBLEM", 0, 15], ["more severe symptoms", "PROBLEM", 47, 67], ["immunocompromised individuals", "PROBLEM", 90, 119], ["infections", "OBSERVATION", 5, 15]]], ["Notably, HCoV-NL63 appears to cause more severe respiratory symptoms and has been associated with croup in children [26].Interferon induction ::: Innate immunity\u2014the interferon systemEpithelial cells, fibroblasts and neurons mainly secrete IFN-\u03b2 as an initial response to infection but switch to IFN-\u03b1 during the subsequent amplification phase of the IFN response [36], [37].", [["respiratory", "ANATOMY", 48, 59], ["systemEpithelial cells", "ANATOMY", 177, 199], ["fibroblasts", "ANATOMY", 201, 212], ["neurons", "ANATOMY", 217, 224], ["HCoV-NL63", "CHEMICAL", 9, 18], ["respiratory symptoms", "DISEASE", 48, 68], ["croup", "DISEASE", 98, 103], ["infection", "DISEASE", 272, 281], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 9, 18], ["children", "ORGANISM", 107, 115], ["Interferon", "GENE_OR_GENE_PRODUCT", 121, 131], ["interferon systemEpithelial cells", "CELL", 166, 199], ["fibroblasts", "CELL", 201, 212], ["neurons", "CELL", 217, 224], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 240, 245], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 296, 301], ["HCoV", "PROTEIN", 9, 13], ["NL63", "PROTEIN", 14, 18], ["Interferon", "PROTEIN", 121, 131], ["interferon systemEpithelial cells", "CELL_TYPE", 166, 199], ["fibroblasts", "CELL_TYPE", 201, 212], ["IFN", "PROTEIN", 240, 243], ["\u03b2", "PROTEIN", 244, 245], ["IFN", "PROTEIN", 296, 299], ["\u03b1", "PROTEIN", 300, 301], ["IFN", "PROTEIN", 351, 354], ["children", "SPECIES", 107, 115], ["HCoV", "SPECIES", 9, 13], ["HCoV", "TEST", 9, 13], ["more severe respiratory symptoms", "PROBLEM", 36, 68], ["Innate immunity", "TREATMENT", 146, 161], ["the interferon systemEpithelial cells", "TREATMENT", 162, 199], ["fibroblasts and neurons", "PROBLEM", 201, 224], ["infection", "PROBLEM", 272, 281], ["IFN", "TREATMENT", 296, 299], ["the IFN response", "TEST", 347, 363], ["appears to cause", "UNCERTAINTY", 19, 35], ["more", "OBSERVATION_MODIFIER", 36, 40], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["respiratory symptoms", "OBSERVATION", 48, 68], ["interferon systemEpithelial cells", "OBSERVATION", 166, 199], ["infection", "OBSERVATION", 272, 281]]], ["By contrast, dendritic cells, which play an important role in immunosurveillance and provide an interface between innate and adaptive immunity, directly produce high levels of IFN-\u03b1 subtypes [38], [39].Interferon induction ::: Innate immunity\u2014the interferon systemIFN induction in fibroblasts occurs mainly by an intracellular pathway (Fig. 1A).", [["dendritic cells", "ANATOMY", 13, 28], ["fibroblasts", "ANATOMY", 281, 292], ["intracellular", "ANATOMY", 313, 326], ["dendritic cells", "CELL", 13, 28], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 176, 181], ["Interferon", "GENE_OR_GENE_PRODUCT", 202, 212], ["interferon systemIFN", "GENE_OR_GENE_PRODUCT", 247, 267], ["fibroblasts", "CELL", 281, 292], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 313, 326], ["dendritic cells", "CELL_TYPE", 13, 28], ["IFN", "PROTEIN", 176, 179], ["Interferon", "PROTEIN", 202, 212], ["interferon", "PROTEIN", 247, 257], ["systemIFN", "PROTEIN", 258, 267], ["fibroblasts", "CELL_TYPE", 281, 292], ["dendritic cells", "PROBLEM", 13, 28], ["an interface between innate and adaptive immunity", "TREATMENT", 93, 142], ["IFN", "TEST", 176, 179], ["Innate immunity", "TREATMENT", 227, 242], ["the interferon systemIFN induction", "TREATMENT", 243, 277], ["dendritic cells", "OBSERVATION", 13, 28]]], ["Hallmark molecules of RNA viruses such as double-stranded (ds) RNA and 5\u2032-triphosphorylated single-stranded (ss) RNA trigger a signaling chain which activates IFN-\u03b2 gene expression [40], [41], [42], [43].", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 159, 164], ["[41]", "SIMPLE_CHEMICAL", 187, 191], ["[42]", "SIMPLE_CHEMICAL", 193, 197], ["double-stranded (ds) RNA", "RNA", 42, 66], ["5\u2032-triphosphorylated single-stranded (ss) RNA", "RNA", 71, 116], ["signaling chain", "PROTEIN", 127, 142], ["IFN-\u03b2 gene", "DNA", 159, 169], ["Hallmark molecules of RNA viruses", "PROBLEM", 0, 33], ["RNA", "TEST", 63, 66], ["a signaling chain", "PROBLEM", 125, 142], ["IFN", "TEST", 159, 162], ["gene expression", "TEST", 165, 180], ["RNA viruses", "OBSERVATION", 22, 33]]], ["Two RNA helicases, RIG-I and MDA-5, are the main intracellular receptors of viral RNA [44], [45], [46], [47].", [["intracellular", "ANATOMY", 49, 62], ["RIG-I", "GENE_OR_GENE_PRODUCT", 19, 24], ["MDA-5", "GENE_OR_GENE_PRODUCT", 29, 34], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["RNA helicases", "PROTEIN", 4, 17], ["RIG-I", "PROTEIN", 19, 24], ["MDA", "PROTEIN", 29, 32], ["intracellular receptors", "PROTEIN", 49, 72], ["Two RNA helicases", "TEST", 0, 17], ["RIG", "TEST", 19, 22], ["MDA", "TEST", 29, 32], ["viral RNA", "TEST", 76, 85], ["RNA helicases", "OBSERVATION", 4, 17], ["viral RNA", "OBSERVATION", 76, 85]]], ["RIG-I and MDA-5 recognize different and non-overlapping sets of viruses, suggesting a degree of specificity in RNA recognition [45].", [["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["MDA-5", "GENE_OR_GENE_PRODUCT", 10, 15], ["RIG", "PROTEIN", 0, 3], ["MDA", "PROTEIN", 10, 13], ["MDA", "TEST", 10, 13], ["viruses", "PROBLEM", 64, 71], ["viruses", "OBSERVATION", 64, 71]]], ["Indeed, it was recently found that RIG-I has the unique ability to bind the triphosphate groups on the 5\u2032-end of uncapped viral ssRNA [40], [41], [42].", [["triphosphate", "CHEMICAL", 76, 88], ["triphosphate", "CHEMICAL", 76, 88], ["RIG-I", "GENE_OR_GENE_PRODUCT", 35, 40], ["triphosphate", "SIMPLE_CHEMICAL", 76, 88], ["RIG-I", "PROTEIN", 35, 40], ["5\u2032-end", "PROTEIN", 103, 109], ["uncapped viral ssRNA", "TREATMENT", 113, 133], ["viral ssRNA", "OBSERVATION", 122, 133]]], ["MDA-5, by contrast, is apparently more dependent on dsRNA structures since it is required for the IFN response against picornaviruses which have genomic RNAs with a protein-protected 5\u2032-end [45], [48] and produce high levels of dsRNA [43].", [["MDA-5", "CHEMICAL", 0, 5], ["MDA-5", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "GENE_OR_GENE_PRODUCT", 98, 101], ["IFN", "PROTEIN", 98, 101], ["genomic RNAs", "RNA", 145, 157], ["5\u2032", "PROTEIN", 183, 185], ["MDA", "TEST", 0, 3], ["dependent on dsRNA structures", "PROBLEM", 39, 68], ["the IFN response", "TREATMENT", 94, 110], ["picornaviruses", "PROBLEM", 119, 133], ["genomic RNAs", "PROBLEM", 145, 157], ["a protein", "TEST", 163, 172], ["high levels of dsRNA", "PROBLEM", 213, 233], ["more dependent", "OBSERVATION_MODIFIER", 34, 48]]], ["The binding of a viral RNA to RIG-I and MDA-5 induces a signaling chain which eventually results in the phosphorylation of the transcription factor IRF-3 [49], [50].", [["MDA-5", "CHEMICAL", 40, 45], ["RIG-I", "GENE_OR_GENE_PRODUCT", 30, 35], ["MDA-5", "GENE_OR_GENE_PRODUCT", 40, 45], ["IRF-3", "GENE_OR_GENE_PRODUCT", 148, 153], ["viral RNA", "RNA", 17, 26], ["RIG-I", "PROTEIN", 30, 35], ["MDA-5", "PROTEIN", 40, 45], ["signaling chain", "PROTEIN", 56, 71], ["transcription factor", "PROTEIN", 127, 147], ["IRF", "PROTEIN", 148, 151], ["a viral RNA", "PROBLEM", 15, 26], ["MDA", "TEST", 40, 43], ["a signaling chain", "PROBLEM", 54, 71], ["the transcription factor IRF", "TEST", 123, 151], ["viral RNA", "OBSERVATION", 17, 26]]], ["IRF-3 is a member of the IFN regulatory factor (IRF) family [51], [52] and plays a central role in the activation of the IFN-\u03b2 promoter [53].", [["IRF-3", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN regulatory factor", "GENE_OR_GENE_PRODUCT", 25, 46], ["IRF", "GENE_OR_GENE_PRODUCT", 48, 51], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 121, 126], ["IRF-3", "PROTEIN", 0, 5], ["IFN regulatory factor (IRF) family", "PROTEIN", 25, 59], ["IFN-\u03b2 promoter", "DNA", 121, 135]]], ["Phosphorylated IRF-3 homo-dimerizes and moves into the nucleus where it recruits the transcriptional coactivators p300 and CREB-binding protein (CBP) to initiate IFN-\u03b2 mRNA synthesis.", [["nucleus", "ANATOMY", 55, 62], ["IRF-3", "GENE_OR_GENE_PRODUCT", 15, 20], ["nucleus", "CELLULAR_COMPONENT", 55, 62], ["p300", "GENE_OR_GENE_PRODUCT", 114, 118], ["CREB-binding protein", "GENE_OR_GENE_PRODUCT", 123, 143], ["CBP", "GENE_OR_GENE_PRODUCT", 145, 148], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 162, 167], ["Phosphorylated IRF-3 homo-dimerizes", "PROTEIN", 0, 35], ["transcriptional coactivators", "PROTEIN", 85, 113], ["p300", "PROTEIN", 114, 118], ["CREB-binding protein", "PROTEIN", 123, 143], ["CBP", "PROTEIN", 145, 148], ["IFN-\u03b2 mRNA", "RNA", 162, 172], ["Phosphorylated IRF", "TEST", 0, 18], ["CREB-binding protein", "TEST", 123, 143], ["CBP", "TEST", 145, 148], ["IFN", "TEST", 162, 165], ["mRNA synthesis", "PROBLEM", 168, 182], ["nucleus", "ANATOMY", 55, 62]]], ["This first-wave IFN triggers expression of a related factor, IRF-7, which in fibroblasts is only present in low amounts [54].", [["fibroblasts", "ANATOMY", 77, 88], ["IRF-7", "GENE_OR_GENE_PRODUCT", 61, 66], ["fibroblasts", "CELL", 77, 88], ["IFN", "PROTEIN", 16, 19], ["IRF-7", "PROTEIN", 61, 66], ["fibroblasts", "CELL_TYPE", 77, 88], ["a related factor", "PROBLEM", 43, 59], ["IRF", "TEST", 61, 64]]], ["IRF-7 can be activated the same way as IRF-3 [55], [56], leading to a positive-feedback loop that initiates the synthesis of several IFN-\u03b1 subtypes as the second-wave IFNs [37], [54].", [["IRF-7", "GENE_OR_GENE_PRODUCT", 0, 5], ["IRF-3", "GENE_OR_GENE_PRODUCT", 39, 44], ["[56]", "SIMPLE_CHEMICAL", 51, 55], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 133, 138], ["IRF-7", "PROTEIN", 0, 5], ["IRF", "PROTEIN", 39, 42], ["IFN", "PROTEIN", 133, 136], ["\u03b1", "PROTEIN", 137, 138], ["IFNs", "PROTEIN", 167, 171], ["IRF", "TEST", 0, 3], ["IRF", "TEST", 39, 42], ["a positive-feedback loop", "PROBLEM", 68, 92]]], ["In addition, the transcription factors NF-\u03baB (activated by RIG-I, MDA-5 and the dsRNA-dependent kinase PKR) and AP-1 (activated by stress-induced Jun kinase) are triggered by viral replication [57], [58] to enhance IFN-\u03b2 gene expression.Interferon induction ::: Innate immunity\u2014the interferon systemMyeloid dendritic cells (mDCs) [39] and, most prominently, plasmacytoid dendritic cells (pDCs) [38] are the main IFN producers of the lymphatic system. mDCs can sense dsRNA by the classic intracellular pathway [39] and, in addition, by the endosomal toll-like receptor (TLR) 3 [59]. pDCs predominantly monitor RNA virus infections by the endosomal TLR7 and TLR8 which recognize ssRNA [60].", [["systemMyeloid dendritic cells", "ANATOMY", 293, 322], ["mDCs", "ANATOMY", 324, 328], ["plasmacytoid dendritic cells", "ANATOMY", 358, 386], ["pDCs", "ANATOMY", 388, 392], ["lymphatic system", "ANATOMY", 433, 449], ["mDCs", "ANATOMY", 451, 455], ["intracellular", "ANATOMY", 487, 500], ["endosomal", "ANATOMY", 539, 548], ["pDCs", "ANATOMY", 582, 586], ["endosomal", "ANATOMY", 637, 646], ["infections", "DISEASE", 619, 629], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 39, 44], ["RIG-I", "GENE_OR_GENE_PRODUCT", 59, 64], ["MDA-5", "GENE_OR_GENE_PRODUCT", 66, 71], ["dsRNA-dependent kinase PKR", "GENE_OR_GENE_PRODUCT", 80, 106], ["AP-1", "GENE_OR_GENE_PRODUCT", 112, 116], ["Jun kinase", "GENE_OR_GENE_PRODUCT", 146, 156], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 215, 220], ["Interferon", "GENE_OR_GENE_PRODUCT", 237, 247], ["systemMyeloid dendritic cells", "CELL", 293, 322], ["mDCs", "CELL", 324, 328], ["plasmacytoid dendritic cells", "CELL", 358, 386], ["pDCs", "CELL", 388, 392], ["IFN", "GENE_OR_GENE_PRODUCT", 412, 415], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 433, 449], ["mDCs", "CELL", 451, 455], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 487, 500], ["endosomal", "CELLULAR_COMPONENT", 539, 548], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 549, 567], ["TLR) 3", "GENE_OR_GENE_PRODUCT", 569, 575], ["pDCs", "CELL", 582, 586], ["endosomal", "CELLULAR_COMPONENT", 637, 646], ["TLR7", "GENE_OR_GENE_PRODUCT", 647, 651], ["TLR8", "GENE_OR_GENE_PRODUCT", 656, 660], ["transcription factors", "PROTEIN", 17, 38], ["NF-\u03baB", "PROTEIN", 39, 44], ["RIG-I", "PROTEIN", 59, 64], ["MDA-5", "PROTEIN", 66, 71], ["dsRNA-dependent kinase", "PROTEIN", 80, 102], ["PKR", "PROTEIN", 103, 106], ["AP-1", "PROTEIN", 112, 116], ["Jun kinase", "PROTEIN", 146, 156], ["IFN", "PROTEIN", 215, 218], ["Interferon", "PROTEIN", 237, 247], ["interferon systemMyeloid dendritic cells", "CELL_TYPE", 282, 322], ["mDCs", "CELL_TYPE", 324, 328], ["plasmacytoid dendritic cells", "CELL_TYPE", 358, 386], ["pDCs", "CELL_TYPE", 388, 392], ["IFN", "PROTEIN", 412, 415], ["mDCs", "CELL_TYPE", 451, 455], ["endosomal toll-like receptor", "PROTEIN", 539, 567], ["TLR", "PROTEIN", 569, 572], ["pDCs", "CELL_TYPE", 582, 586], ["endosomal TLR7", "PROTEIN", 637, 651], ["TLR8", "PROTEIN", 656, 660], ["the transcription factors", "TEST", 13, 38], ["NF", "TEST", 39, 41], ["\u03baB", "TEST", 42, 44], ["RIG", "TEST", 59, 62], ["MDA", "TEST", 66, 69], ["the dsRNA-dependent kinase PKR", "TEST", 76, 106], ["AP", "TEST", 112, 114], ["viral replication", "PROBLEM", 175, 192], ["IFN", "TEST", 215, 218], ["the interferon systemMyeloid dendritic cells", "TREATMENT", 278, 322], ["pDCs", "PROBLEM", 582, 586], ["RNA virus infections", "PROBLEM", 609, 629], ["the endosomal TLR7 and TLR8", "TREATMENT", 633, 660], ["dendritic cells", "OBSERVATION", 307, 322], ["most prominently", "OBSERVATION_MODIFIER", 340, 356], ["plasmacytoid", "OBSERVATION", 358, 370], ["dendritic cells", "OBSERVATION", 371, 386], ["main", "OBSERVATION_MODIFIER", 407, 411], ["lymphatic system", "ANATOMY", 433, 449], ["endosomal TLR7", "ANATOMY", 637, 651]]], ["Activated TLRs signal through different intracellular adaptor molecules to induce IRF- and NF-\u03baB-dependent IFN transcription [61] (Fig. 1B).", [["intracellular", "ANATOMY", 40, 53], ["TLRs", "GENE_OR_GENE_PRODUCT", 10, 14], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["IRF", "GENE_OR_GENE_PRODUCT", 82, 85], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 91, 96], ["TLRs", "PROTEIN", 10, 14], ["intracellular adaptor molecules", "PROTEIN", 40, 71], ["IRF", "PROTEIN", 82, 85], ["NF-\u03baB", "PROTEIN", 91, 96], ["IFN", "PROTEIN", 107, 110], ["different intracellular adaptor molecules", "TREATMENT", 30, 71], ["IRF", "TEST", 82, 85], ["NF", "TEST", 91, 93], ["B-dependent IFN transcription", "TREATMENT", 95, 124]]], ["Interestingly, in contrast to other cell types, pDCs contain considerable amounts of constitutively expressed IRF-7 [62], [63].", [["cell", "ANATOMY", 36, 40], ["pDCs", "ANATOMY", 48, 52], ["cell", "CELL", 36, 40], ["pDCs", "CELL", 48, 52], ["IRF-7", "GENE_OR_GENE_PRODUCT", 110, 115], ["pDCs", "CELL_TYPE", 48, 52], ["IRF", "PROTEIN", 110, 113], ["constitutively expressed IRF", "PROBLEM", 85, 113], ["considerable", "OBSERVATION_MODIFIER", 61, 73], ["amounts", "OBSERVATION_MODIFIER", 74, 81]]], ["IRF-7 is further upregulated in response to IFN and generates a positive-feedback loop for high IFN-\u03b1 and IFN-\u03b2 production [64], [65].", [["IRF-7", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "GENE_OR_GENE_PRODUCT", 44, 47], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 96, 101], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 106, 111], ["IRF-7", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 44, 47], ["IFN", "PROTEIN", 96, 99], ["IFN", "PROTEIN", 106, 109], ["\u03b2", "PROTEIN", 110, 111], ["IRF", "TEST", 0, 3], ["IFN", "TEST", 44, 47], ["a positive-feedback loop", "PROBLEM", 62, 86], ["high IFN", "PROBLEM", 91, 99], ["IFN", "TEST", 106, 109]]], ["In addition, TLR7 and TLR9 are retained in the endosomes of pDCs to allow prolonged IFN induction signaling [66].Interferon signaling ::: Innate immunity\u2014the interferon systemAll IFN-\u03b1/\u03b2 subtypes bind to and activate a common type I IFN receptor which is present on virtually all host cells [28], [67].", [["endosomes", "ANATOMY", 47, 56], ["pDCs", "ANATOMY", 60, 64], ["cells", "ANATOMY", 285, 290], ["TLR7", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR9", "GENE_OR_GENE_PRODUCT", 22, 26], ["endosomes", "CELLULAR_COMPONENT", 47, 56], ["pDCs", "CELL", 60, 64], ["IFN", "GENE_OR_GENE_PRODUCT", 84, 87], ["Interferon", "GENE_OR_GENE_PRODUCT", 113, 123], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 179, 184], ["\u03b2", "GENE_OR_GENE_PRODUCT", 185, 186], ["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 226, 245], ["cells", "CELL", 285, 290], ["TLR7", "PROTEIN", 13, 17], ["TLR9", "PROTEIN", 22, 26], ["pDCs", "CELL_TYPE", 60, 64], ["IFN", "PROTEIN", 84, 87], ["Interferon", "PROTEIN", 113, 123], ["interferon systemAll IFN-\u03b1/\u03b2 subtypes", "PROTEIN", 158, 195], ["common type I IFN receptor", "PROTEIN", 219, 245], ["host cells", "CELL_TYPE", 280, 290], ["TLR7 and TLR9", "TREATMENT", 13, 26], ["prolonged IFN induction signaling", "TREATMENT", 74, 107], ["the interferon systemAll IFN", "TREATMENT", 154, 182], ["subtypes bind", "PROBLEM", 187, 200], ["a common type I IFN receptor", "PROBLEM", 217, 245], ["TLR7", "ANATOMY", 13, 17]]], ["Binding of IFN-\u03b1/\u03b2 leads to conformational changes in the intracellular parts of the receptor which activate the so-called JAK-STAT signaling pathway.", [["intracellular", "ANATOMY", 58, 71], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 11, 16], ["\u03b2", "GENE_OR_GENE_PRODUCT", 17, 18], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 71], ["JAK", "GENE_OR_GENE_PRODUCT", 123, 126], ["STAT", "GENE_OR_GENE_PRODUCT", 127, 131], ["IFN", "PROTEIN", 11, 14], ["-\u03b1", "PROTEIN", 14, 16], ["\u03b2", "PROTEIN", 17, 18], ["JAK", "PROTEIN", 123, 126], ["STAT", "PROTEIN", 127, 131], ["conformational changes", "PROBLEM", 28, 50]]], ["The signal transducer and activator of transcription (STAT) proteins are latent cytoplasmic transcription factors which become phosphorylated by the Janus kinase (JAK) family members JAK-1 and TYK-2 [68], [69].", [["cytoplasmic", "ANATOMY", 80, 91], ["signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 4, 52], ["STAT", "GENE_OR_GENE_PRODUCT", 54, 58], ["cytoplasmic", "ORGANISM_SUBSTANCE", 80, 91], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 149, 161], ["JAK", "GENE_OR_GENE_PRODUCT", 163, 166], ["JAK-1", "GENE_OR_GENE_PRODUCT", 183, 188], ["TYK-2", "GENE_OR_GENE_PRODUCT", 193, 198], ["signal transducer and activator of transcription (STAT) proteins", "PROTEIN", 4, 68], ["latent cytoplasmic transcription factors", "PROTEIN", 73, 113], ["Janus kinase (JAK) family members", "PROTEIN", 149, 182], ["JAK", "PROTEIN", 183, 186], ["TYK", "PROTEIN", 193, 196], ["transcription (STAT) proteins", "TEST", 39, 68], ["latent cytoplasmic transcription factors", "PROBLEM", 73, 113], ["JAK", "TEST", 183, 186], ["TYK", "TEST", 193, 196]]], ["Phosphorylated STAT-1 and STAT-2 recruit a third factor, IRF-9 (also called p48), to form a complex known as IFN stimulated gene factor 3 (ISGF-3).", [["STAT-1", "GENE_OR_GENE_PRODUCT", 15, 21], ["STAT-2", "GENE_OR_GENE_PRODUCT", 26, 32], ["IRF-9", "GENE_OR_GENE_PRODUCT", 57, 62], ["p48", "GENE_OR_GENE_PRODUCT", 76, 79], ["IFN stimulated gene factor 3", "GENE_OR_GENE_PRODUCT", 109, 137], ["ISGF-3", "GENE_OR_GENE_PRODUCT", 139, 145], ["Phosphorylated STAT-1", "PROTEIN", 0, 21], ["STAT-2", "PROTEIN", 26, 32], ["IRF-9", "PROTEIN", 57, 62], ["p48", "PROTEIN", 76, 79], ["IFN stimulated gene factor 3", "PROTEIN", 109, 137], ["ISGF-3", "PROTEIN", 139, 145], ["Phosphorylated STAT", "TEST", 0, 19], ["a third factor", "TEST", 41, 55], ["IRF", "TEST", 57, 60], ["IFN stimulated gene factor", "TEST", 109, 135]]], ["The ISGF-3 heterotrimer translocates to the nucleus and binds to IFN-stimulated response elements (ISRE) in the promoter regions of IFN-stimulated genes (ISGs), thereby inducing their transcription.Interferon effector proteins ::: Innate immunity\u2014the interferon systemIFN-\u03b1/\u03b2 activate the expression of more than 300 IFN-stimulated genes (ISGs) which have antiviral, antiproliferative, and immunomodulatory functions [70].", [["nucleus", "ANATOMY", 44, 51], ["ISGF-3", "GENE_OR_GENE_PRODUCT", 4, 10], ["nucleus", "CELLULAR_COMPONENT", 44, 51], ["IFN-stimulated response elements", "GENE_OR_GENE_PRODUCT", 65, 97], ["ISRE", "GENE_OR_GENE_PRODUCT", 99, 103], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 132, 152], ["ISGs", "GENE_OR_GENE_PRODUCT", 154, 158], ["systemIFN-\u03b1", "GENE_OR_GENE_PRODUCT", 262, 273], ["\u03b2", "GENE_OR_GENE_PRODUCT", 274, 275], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 317, 337], ["ISGF-3 heterotrimer", "PROTEIN", 4, 23], ["IFN-stimulated response elements", "DNA", 65, 97], ["ISRE", "DNA", 99, 103], ["promoter regions", "DNA", 112, 128], ["IFN-stimulated genes", "DNA", 132, 152], ["ISGs", "DNA", 154, 158], ["Interferon effector proteins", "PROTEIN", 198, 226], ["interferon", "PROTEIN", 251, 261], ["systemIFN", "PROTEIN", 262, 271], ["\u03b1", "PROTEIN", 272, 273], ["\u03b2", "PROTEIN", 274, 275], ["IFN-stimulated genes", "DNA", 317, 337], ["ISGs", "DNA", 339, 343], ["the interferon systemIFN", "TREATMENT", 247, 271], ["antiviral, antiproliferative", "TREATMENT", 356, 384], ["immunomodulatory functions", "TEST", 390, 416], ["nucleus", "ANATOMY", 44, 51]]], ["IFN-induced proteins include enzymes, transcription factors, cell surface glycoproteins, cytokines, chemokines and a large number of factors with unknown function.", [["cell surface", "ANATOMY", 61, 73], ["IFN", "CHEMICAL", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 61, 65], ["IFN", "PROTEIN", 0, 3], ["enzymes", "PROTEIN", 29, 36], ["transcription factors", "PROTEIN", 38, 59], ["cell surface glycoproteins", "PROTEIN", 61, 87], ["cytokines", "PROTEIN", 89, 98], ["chemokines", "PROTEIN", 100, 110], ["induced proteins", "PROBLEM", 4, 20], ["enzymes", "TEST", 29, 36], ["transcription factors", "PROBLEM", 38, 59], ["cell surface glycoproteins", "TREATMENT", 61, 87], ["cytokines", "TREATMENT", 89, 98], ["chemokines", "TREATMENT", 100, 110], ["large", "OBSERVATION_MODIFIER", 117, 122]]], ["Up to now, only a few proteins with antiviral activity have been characterized in detail.", [["antiviral activity", "OBSERVATION", 36, 54]]], ["These are the Mx GTPases, the protein kinase R (PKR), the 2\u2032-5\u2032 oligoadenylate synthetases (2-5 OAS)/RNaseL system, the RNA-specific adenosine deaminase 1 (ADAR 1), and the products of the ISG56 (p56) and ISG20 genes.", [["adenosine", "CHEMICAL", 133, 142], ["adenosine", "CHEMICAL", 133, 142], ["Mx GTPases", "GENE_OR_GENE_PRODUCT", 14, 24], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 30, 46], ["PKR", "GENE_OR_GENE_PRODUCT", 48, 51], ["2\u2032-5\u2032 oligoadenylate synthetases", "GENE_OR_GENE_PRODUCT", 58, 90], ["2-5 OAS", "GENE_OR_GENE_PRODUCT", 92, 99], ["RNaseL", "GENE_OR_GENE_PRODUCT", 101, 107], ["adenosine deaminase 1", "GENE_OR_GENE_PRODUCT", 133, 154], ["ADAR 1", "GENE_OR_GENE_PRODUCT", 156, 162], ["ISG56", "GENE_OR_GENE_PRODUCT", 189, 194], ["p56", "GENE_OR_GENE_PRODUCT", 196, 199], ["ISG20", "GENE_OR_GENE_PRODUCT", 205, 210], ["Mx GTPases", "PROTEIN", 14, 24], ["protein kinase R", "PROTEIN", 30, 46], ["PKR", "PROTEIN", 48, 51], ["2\u2032-5\u2032 oligoadenylate synthetases", "PROTEIN", 58, 90], ["OAS", "PROTEIN", 96, 99], ["RNaseL", "PROTEIN", 101, 107], ["RNA-specific adenosine deaminase 1", "PROTEIN", 120, 154], ["ADAR 1", "PROTEIN", 156, 162], ["ISG56 (p56) and ISG20 genes", "DNA", 189, 216], ["the Mx GTPases", "TEST", 10, 24], ["the protein kinase", "TEST", 26, 44], ["PKR", "TEST", 48, 51], ["the 2\u2032", "TEST", 54, 60], ["oligoadenylate synthetases", "TEST", 64, 90], ["RNaseL system", "TEST", 101, 114], ["the RNA", "TEST", 116, 123], ["adenosine deaminase", "TEST", 133, 152], ["ADAR", "TEST", 156, 160]]], ["Mx proteins belong to the superfamily of dynamin-like large GTPases and have been discovered as mediators of genetic resistance against orthomyxoviruses in mice.", [["Mx", "GENE_OR_GENE_PRODUCT", 0, 2], ["dynamin", "GENE_OR_GENE_PRODUCT", 41, 48], ["mice", "ORGANISM", 156, 160], ["Mx proteins", "PROTEIN", 0, 11], ["dynamin", "PROTEIN", 41, 48], ["GTPases", "PROTEIN", 60, 67], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 156, 160], ["large", "OBSERVATION_MODIFIER", 54, 59], ["GTPases", "OBSERVATION", 60, 67]]], ["The human MxA protein blocks replication of the infecting virus soon after cell entry by targeting and missorting viral ribonucleoprotein particles [71], [72], [73], [74].", [["cell", "ANATOMY", 75, 79], ["human", "ORGANISM", 4, 9], ["MxA", "GENE_OR_GENE_PRODUCT", 10, 13], ["cell", "CELL", 75, 79], ["human MxA protein", "PROTEIN", 4, 21], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human MxA protein blocks replication", "TREATMENT", 0, 40], ["the infecting virus", "PROBLEM", 44, 63], ["cell entry", "TEST", 75, 85], ["missorting viral ribonucleoprotein particles", "TEST", 103, 147]]], ["PKR, 2-5 OAS and ADAR are constitutively expressed in a latent, inactive form.", [["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["2-5", "GENE_OR_GENE_PRODUCT", 5, 8], ["OAS", "GENE_OR_GENE_PRODUCT", 9, 12], ["ADAR", "GENE_OR_GENE_PRODUCT", 17, 21], ["PKR, 2-5 OAS", "PROTEIN", 0, 12], ["ADAR", "PROTEIN", 17, 21], ["PKR", "TEST", 0, 3], ["ADAR", "PROBLEM", 17, 21]]], ["Basal mRNA levels are upregulated by IFN-\u03b1/\u03b2 and these enzymes need to be activated by viral dsRNA.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 37, 42], ["\u03b2", "GENE_OR_GENE_PRODUCT", 43, 44], ["IFN", "PROTEIN", 37, 40], ["\u03b1", "PROTEIN", 41, 42], ["\u03b2", "PROTEIN", 43, 44], ["enzymes", "PROTEIN", 55, 62], ["Basal mRNA levels", "TEST", 0, 17], ["IFN", "TEST", 37, 40], ["these enzymes", "TEST", 49, 62], ["viral dsRNA", "PROBLEM", 87, 98], ["viral dsRNA", "OBSERVATION", 87, 98]]], ["PKR is a serine-threonine kinase that phosphorylates the alpha subunit of the eukaryotic translation initiation factor eIF2 [75], [76], thus blocking translation of cellular and viral mRNAs.", [["cellular", "ANATOMY", 165, 173], ["serine", "CHEMICAL", 9, 15], ["threonine", "CHEMICAL", 16, 25], ["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["serine", "AMINO_ACID", 9, 15], ["threonine", "AMINO_ACID", 16, 25], ["eIF2 [75]", "GENE_OR_GENE_PRODUCT", 119, 128], ["cellular", "CELL", 165, 173], ["PKR", "PROTEIN", 0, 3], ["serine-threonine kinase", "PROTEIN", 9, 32], ["alpha subunit", "PROTEIN", 57, 70], ["eukaryotic translation initiation factor", "PROTEIN", 78, 118], ["cellular and viral mRNAs", "RNA", 165, 189], ["a serine-threonine kinase", "TREATMENT", 7, 32], ["factor eIF2", "TEST", 112, 123], ["cellular and viral mRNAs", "PROBLEM", 165, 189], ["viral mRNAs", "OBSERVATION", 178, 189]]], ["The 2-5 OAS catalyses the synthesis of short 2\u2032-5\u2032 oligoadenylates [77] that activate the latent endoribonuclease RNaseL which in turn degrades both viral and cellular RNAs [78].", [["cellular", "ANATOMY", 159, 167], ["2\u2032-5\u2032 oligoadenylates", "CHEMICAL", 45, 66], ["2\u2032-5\u2032 oligoadenylates [77]", "SIMPLE_CHEMICAL", 45, 71], ["RNaseL", "GENE_OR_GENE_PRODUCT", 114, 120], ["cellular", "CELL", 159, 167], ["OAS", "PROTEIN", 8, 11], ["latent endoribonuclease", "PROTEIN", 90, 113], ["RNaseL", "PROTEIN", 114, 120], ["viral and cellular RNAs", "RNA", 149, 172], ["the synthesis", "TEST", 22, 35], ["the latent endoribonuclease RNaseL", "PROBLEM", 86, 120], ["latent", "OBSERVATION_MODIFIER", 90, 96], ["endoribonuclease", "OBSERVATION", 97, 113], ["cellular RNAs", "OBSERVATION", 159, 172]]], ["ADAR 1 catalyzes the deamination of adenosine on target dsRNAs to yield inosine.", [["adenosine", "CHEMICAL", 36, 45], ["inosine", "CHEMICAL", 72, 79], ["adenosine", "CHEMICAL", 36, 45], ["inosine", "CHEMICAL", 72, 79], ["ADAR 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["adenosine", "SIMPLE_CHEMICAL", 36, 45], ["inosine", "SIMPLE_CHEMICAL", 72, 79], ["ADAR 1", "PROTEIN", 0, 6], ["the deamination of adenosine", "TREATMENT", 17, 45], ["target dsRNAs", "TREATMENT", 49, 62], ["inosine", "TREATMENT", 72, 79]]], ["As a result the secondary structure is destabilized due to a change from an AU base pair to the less stable IU base pair and mutations accumulate within the viral genome [28].", [["AU base pair", "RNA", 76, 88], ["viral genome", "DNA", 157, 169], ["a change", "PROBLEM", 59, 67], ["an AU base pair", "TREATMENT", 73, 88], ["mutations", "PROBLEM", 125, 134], ["viral genome", "OBSERVATION", 157, 169]]], ["P56 binds the eukaryotic initiation factor 3e (eIF3e) subunit of the eukaryotic translation initiation factor eIF3.", [["P56", "GENE_OR_GENE_PRODUCT", 0, 3], ["eukaryotic initiation factor 3e", "GENE_OR_GENE_PRODUCT", 14, 45], ["eIF3e", "GENE_OR_GENE_PRODUCT", 47, 52], ["eIF3", "GENE_OR_GENE_PRODUCT", 110, 114], ["P56", "PROTEIN", 0, 3], ["eukaryotic initiation factor 3e (eIF3e) subunit", "PROTEIN", 14, 61], ["eukaryotic translation initiation factor", "PROTEIN", 69, 109], ["eIF3", "PROTEIN", 110, 114], ["the eukaryotic translation", "TREATMENT", 65, 91]]], ["It functions as an inhibitor of translation initiation at the level of eIF3 ternary complex formation and is likely to suppress viral RNA translation [79], [80].", [["eIF3", "GENE_OR_GENE_PRODUCT", 71, 75], ["eIF3 ternary complex", "PROTEIN", 71, 91], ["viral RNA", "RNA", 128, 137], ["an inhibitor", "TREATMENT", 16, 28], ["translation initiation", "TREATMENT", 32, 54], ["likely to", "UNCERTAINTY", 109, 118]]], ["ISG20 is an IFN-induced 3\u2032-5\u2032 exonuclease that specifically degrades ssRNA in vitro.", [["ISG20", "CHEMICAL", 0, 5], ["ISG20", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "GENE_OR_GENE_PRODUCT", 12, 15], ["ISG20", "PROTEIN", 0, 5], ["IFN-induced 3\u2032-5\u2032 exonuclease", "PROTEIN", 12, 41], ["an IFN", "TREATMENT", 9, 15], ["ssRNA", "OBSERVATION", 69, 74]]], ["In cell culture, expression of ISG20 leads to a reduction of vesicular stomatitis virus (VSV), influenza virus and retrovirus replication [81], [82], [83].Coronaviruses: protective role of the interferon systemMHV and several animal coronaviruses were shown to be sensitive to the antiviral action of type I IFNs [20], [84], [85], [86].", [["cell culture", "ANATOMY", 3, 15], ["vesicular stomatitis", "DISEASE", 61, 81], ["cell", "CELL", 3, 7], ["ISG20", "GENE_OR_GENE_PRODUCT", 31, 36], ["vesicular stomatitis virus", "ORGANISM", 61, 87], ["VSV", "ORGANISM", 89, 92], ["influenza virus", "ORGANISM", 95, 110], ["retrovirus", "ORGANISM", 115, 125], ["interferon systemMHV", "GENE_OR_GENE_PRODUCT", 193, 213], ["coronaviruses", "ORGANISM", 233, 246], ["[84]", "SIMPLE_CHEMICAL", 319, 323], ["[85]", "SIMPLE_CHEMICAL", 325, 329], ["ISG20", "PROTEIN", 31, 36], ["interferon systemMHV", "PROTEIN", 193, 213], ["type I IFNs", "PROTEIN", 301, 312], ["stomatitis virus", "SPECIES", 71, 87], ["influenza virus", "SPECIES", 95, 110], ["vesicular stomatitis virus", "SPECIES", 61, 87], ["VSV", "SPECIES", 89, 92], ["influenza virus", "SPECIES", 95, 110], ["cell culture", "TEST", 3, 15], ["ISG20", "TREATMENT", 31, 36], ["vesicular stomatitis virus", "PROBLEM", 61, 87], ["influenza virus", "PROBLEM", 95, 110], ["retrovirus replication", "TREATMENT", 115, 137], ["the interferon systemMHV", "TREATMENT", 189, 213], ["several animal coronaviruses", "PROBLEM", 218, 246], ["vesicular stomatitis", "ANATOMY", 61, 81]]], ["Growth of SARS-CoV can also be inhibited by exogenously added IFN-\u03b1/\u03b2 [87], [88], [89], [90], [91], and mice lacking STAT1 or the type I IFN receptor are more prone to SARS-CoV- or MHV-induced organ damages [92], [93].", [["organ", "ANATOMY", 193, 198], ["SARS", "DISEASE", 10, 14], ["organ damages", "DISEASE", 193, 206], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 10, 18], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 62, 67], ["\u03b2", "GENE_OR_GENE_PRODUCT", 68, 69], ["[88]", "SIMPLE_CHEMICAL", 76, 80], ["[89]", "SIMPLE_CHEMICAL", 82, 86], ["[90]", "SIMPLE_CHEMICAL", 88, 92], ["[91]", "SIMPLE_CHEMICAL", 94, 98], ["mice", "ORGANISM", 104, 108], ["STAT1", "GENE_OR_GENE_PRODUCT", 117, 122], ["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 130, 149], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 168, 176], ["MHV", "ORGANISM", 181, 184], ["organ", "ORGAN", 193, 198], ["IFN", "PROTEIN", 62, 65], ["STAT1", "PROTEIN", 117, 122], ["type I IFN receptor", "PROTEIN", 130, 149], ["mice", "SPECIES", 104, 108], ["SARS-CoV", "SPECIES", 10, 18], ["mice", "SPECIES", 104, 108], ["MHV", "SPECIES", 181, 184], ["IFN receptor", "TEST", 137, 149], ["SARS", "TEST", 168, 172], ["CoV", "TEST", 173, 176], ["MHV", "TEST", 181, 184], ["organ damages", "TEST", 193, 206]]], ["Direct IFN treatment of experimentally infected mice or macaques has a protective effect against SARS-CoV or MHV-1, respectively [20], [94], [95].", [["IFN", "CHEMICAL", 7, 10], ["IFN", "GENE_OR_GENE_PRODUCT", 7, 10], ["mice", "ORGANISM", 48, 52], ["macaques", "ORGANISM", 56, 64], ["SARS-CoV", "ORGANISM", 97, 105], ["MHV-1", "ORGANISM", 109, 114], ["[94]", "SIMPLE_CHEMICAL", 135, 139], ["IFN", "PROTEIN", 7, 10], ["mice", "SPECIES", 48, 52], ["macaques", "SPECIES", 56, 64], ["mice", "SPECIES", 48, 52], ["macaques", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 97, 105], ["MHV-1", "SPECIES", 109, 114], ["Direct IFN treatment", "TREATMENT", 0, 20], ["experimentally infected mice", "PROBLEM", 24, 52], ["SARS", "PROBLEM", 97, 101], ["MHV", "TEST", 109, 112]]], ["IFNs may also alleviate symptoms in SARS patients, but case numbers are too low for definite conclusions [96], [97].", [["SARS", "DISEASE", 36, 40], ["IFNs", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 41, 49], ["IFNs", "PROTEIN", 0, 4], ["patients", "SPECIES", 41, 49], ["symptoms in SARS patients", "PROBLEM", 24, 49], ["case numbers", "TEST", 55, 67]]], ["In the animal models for SARS, IFNs were most efficient if given before infection, but still have a certain antiviral effect if given after exposure to virus [94], [95].", [["SARS", "DISEASE", 25, 29], ["infection", "DISEASE", 72, 81], ["IFNs", "GENE_OR_GENE_PRODUCT", 31, 35], ["IFNs", "PROTEIN", 31, 35], ["SARS", "PROBLEM", 25, 29], ["IFNs", "TREATMENT", 31, 35], ["infection", "PROBLEM", 72, 81], ["virus", "PROBLEM", 152, 157]]], ["Thus, IFNs, which are an approved medication against several viral and malignant diseases [28], [98], may offer the possibility both of prevention and treatment of SARS with a licensed drug.Coronaviruses: protective role of the interferon systemAlthough IFN treatment has clear beneficial effects, the identification of the responsible effector protein(s) is still out.", [["viral and malignant diseases", "DISEASE", 61, 89], ["SARS", "DISEASE", 164, 168], ["IFN", "CHEMICAL", 254, 257], ["IFNs", "GENE_OR_GENE_PRODUCT", 6, 10], ["IFNs", "PROTEIN", 6, 10], ["interferon", "PROTEIN", 228, 238], ["IFN", "PROTEIN", 254, 257], ["effector protein", "PROTEIN", 336, 352], ["IFNs", "PROBLEM", 6, 10], ["an approved medication", "TREATMENT", 22, 44], ["several viral and malignant diseases", "PROBLEM", 53, 89], ["treatment", "TREATMENT", 151, 160], ["SARS", "PROBLEM", 164, 168], ["the interferon systemAlthough IFN treatment", "TREATMENT", 224, 267], ["malignant", "OBSERVATION_MODIFIER", 71, 80]]], ["The moderate inhibiting effect of IFN-\u03b3 is most likely caused by inducible NO synthetase [99], but which ISG confers the much stronger effect of IFN-\u03b1/\u03b2 is unknown.", [["IFN-\u03b3", "CHEMICAL", 34, 39], ["NO", "CHEMICAL", 75, 77], ["NO", "CHEMICAL", 75, 77], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 34, 39], ["NO synthetase", "GENE_OR_GENE_PRODUCT", 75, 88], ["ISG", "GENE_OR_GENE_PRODUCT", 105, 108], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 145, 150], ["\u03b2", "GENE_OR_GENE_PRODUCT", 151, 152], ["IFN-\u03b3", "PROTEIN", 34, 39], ["NO synthetase", "PROTEIN", 75, 88], ["IFN", "PROTEIN", 145, 148], ["\u03b1", "PROTEIN", 149, 150], ["\u03b2", "PROTEIN", 151, 152], ["The moderate inhibiting effect of IFN", "PROBLEM", 0, 37], ["inducible NO synthetase", "PROBLEM", 65, 88], ["IFN", "TEST", 145, 148], ["moderate", "OBSERVATION_MODIFIER", 4, 12], ["inhibiting", "OBSERVATION_MODIFIER", 13, 23], ["effect", "OBSERVATION_MODIFIER", 24, 30], ["most likely", "UNCERTAINTY", 43, 54]]], ["It is however established that MxA plays no role as an anti-SARS-CoV factor [89].How do coronaviruses cope with the IFN system?SARS-CoV, MHV, and a number of other coronaviruses are highly pathogenic despite their sensitivity to IFN-\u03b1/\u03b2.", [["SARS", "DISEASE", 127, 131], ["MxA", "GENE_OR_GENE_PRODUCT", 31, 34], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 55, 68], ["coronaviruses", "ORGANISM", 88, 101], ["SARS-CoV", "ORGANISM", 127, 135], ["MHV", "ORGANISM", 137, 140], ["coronaviruses", "ORGANISM", 164, 177], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 229, 234], ["MxA", "PROTEIN", 31, 34], ["anti-SARS-CoV factor", "PROTEIN", 55, 75], ["IFN", "PROTEIN", 116, 119], ["IFN", "PROTEIN", 229, 232], ["SARS-CoV", "SPECIES", 127, 135], ["MHV", "SPECIES", 137, 140], ["CoV factor", "TEST", 65, 75], ["the IFN system", "TREATMENT", 112, 126], ["SARS", "PROBLEM", 127, 131], ["MHV", "PROBLEM", 137, 140], ["other coronaviruses", "PROBLEM", 158, 177], ["MHV", "ANATOMY", 137, 140], ["coronaviruses", "OBSERVATION", 164, 177]]], ["Moreover, SARS-CoV [43] as well as MHV [100] were shown to generate substantial amounts of the IFN inducer dsRNA during infection.", [["infection", "DISEASE", 120, 129], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 10, 18], ["MHV", "ORGANISM", 35, 38], ["IFN", "GENE_OR_GENE_PRODUCT", 95, 98], ["IFN", "PROTEIN", 95, 98], ["SARS-CoV", "SPECIES", 10, 18], ["MHV", "SPECIES", 35, 38], ["the IFN inducer dsRNA during infection", "PROBLEM", 91, 129], ["substantial", "OBSERVATION_MODIFIER", 68, 79], ["amounts", "OBSERVATION_MODIFIER", 80, 87], ["infection", "OBSERVATION", 120, 129]]], ["This implies that coronaviruses somehow avoid or inhibit the production of IFN in a manner similar to other viruses [27], [29], [101].", [["coronaviruses", "ORGANISM", 18, 31], ["IFN", "GENE_OR_GENE_PRODUCT", 75, 78], ["[29]", "SIMPLE_CHEMICAL", 122, 126], ["IFN", "PROTEIN", 75, 78], ["coronaviruses", "PROBLEM", 18, 31], ["IFN", "PROBLEM", 75, 78], ["coronaviruses", "OBSERVATION", 18, 31]]], ["Indeed, in fibroblasts productively infected with SARS-CoV or MHV no detectable induction of IFN-\u03b2 occurs [102], [103], [104].", [["fibroblasts", "ANATOMY", 11, 22], ["fibroblasts", "CELL", 11, 22], ["SARS-CoV", "ORGANISM", 50, 58], ["MHV", "ORGANISM", 62, 65], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 93, 98], ["fibroblasts", "CELL_TYPE", 11, 22], ["IFN", "PROTEIN", 93, 96], ["SARS-CoV", "SPECIES", 50, 58], ["MHV", "SPECIES", 62, 65], ["SARS", "PROBLEM", 50, 54], ["MHV", "PROBLEM", 62, 65], ["IFN", "PROBLEM", 93, 96]]], ["Human macrophages, which become only non-productively infected with SARS-CoV, are also unable to launch an IFN response [105], [106].", [["macrophages", "ANATOMY", 6, 17], ["Human", "ORGANISM", 0, 5], ["macrophages", "CELL", 6, 17], ["SARS-CoV", "ORGANISM", 68, 76], ["Human macrophages", "CELL_TYPE", 0, 17], ["IFN", "PROTEIN", 107, 110], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["SARS-CoV", "SPECIES", 68, 76], ["Human macrophages", "PROBLEM", 0, 17], ["SARS-CoV", "PROBLEM", 68, 76], ["macrophages", "OBSERVATION", 6, 17]]], ["In fibroblasts, a lack of transcriptional induction was also observed for IFN-\u03b1, IFN-\u03bb, RANTES and IL-6 [107], suggesting that SARS-CoV-infected tissue cells are severely impaired in the production of a wide range of cytokines.", [["fibroblasts", "ANATOMY", 3, 14], ["tissue cells", "ANATOMY", 145, 157], ["fibroblasts", "CELL", 3, 14], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 79], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 81, 86], ["RANTES", "GENE_OR_GENE_PRODUCT", 88, 94], ["IL-6", "GENE_OR_GENE_PRODUCT", 99, 103], ["SARS-CoV", "ORGANISM", 127, 135], ["tissue cells", "CELL", 145, 157], ["fibroblasts", "CELL_TYPE", 3, 14], ["IFN", "PROTEIN", 74, 77], ["IFN", "PROTEIN", 81, 84], ["RANTES", "PROTEIN", 88, 94], ["infected tissue cells", "CELL_TYPE", 136, 157], ["cytokines", "PROTEIN", 217, 226], ["SARS-CoV", "SPECIES", 127, 135], ["transcriptional induction", "TREATMENT", 26, 51], ["IFN", "TEST", 74, 77], ["\u03b1", "TEST", 78, 79], ["IFN", "TEST", 81, 84], ["RANTES", "TEST", 88, 94], ["IL", "TEST", 99, 101], ["SARS", "PROBLEM", 127, 131], ["CoV", "TEST", 132, 135], ["infected tissue cells", "PROBLEM", 136, 157], ["severely impaired", "PROBLEM", 162, 179], ["fibroblasts", "OBSERVATION", 3, 14], ["infected tissue cells", "OBSERVATION", 136, 157], ["severely", "OBSERVATION_MODIFIER", 162, 170], ["impaired", "OBSERVATION_MODIFIER", 171, 179], ["wide", "OBSERVATION_MODIFIER", 203, 207]]], ["In line with this, we have recently shown that in cells infected with SARS-CoV, no phosphorylation, dimerisation or CBP-binding of IRF-3 occur [102].How do coronaviruses cope with the IFN system?One possible mechanism that may at least in part account for the absence of IRF-3 activation and type I IFN expression is impaired sensing of coronaviruses by host cell-encoded pathogen recognition receptors (PRRs), such as TLRs and the intracellular RNA sensors.", [["cells", "ANATOMY", 50, 55], ["cell", "ANATOMY", 359, 363], ["intracellular", "ANATOMY", 432, 445], ["SARS", "DISEASE", 70, 74], ["cells", "CELL", 50, 55], ["SARS-CoV", "ORGANISM", 70, 78], ["CBP", "GENE_OR_GENE_PRODUCT", 116, 119], ["IRF-3", "GENE_OR_GENE_PRODUCT", 131, 136], ["coronaviruses", "ORGANISM", 156, 169], ["IRF-3", "GENE_OR_GENE_PRODUCT", 271, 276], ["type I IFN", "GENE_OR_GENE_PRODUCT", 292, 302], ["coronaviruses", "ORGANISM", 337, 350], ["host cell", "CELL", 354, 363], ["pathogen recognition receptors", "GENE_OR_GENE_PRODUCT", 372, 402], ["PRRs", "GENE_OR_GENE_PRODUCT", 404, 408], ["TLRs", "GENE_OR_GENE_PRODUCT", 419, 423], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 432, 445], ["CBP", "PROTEIN", 116, 119], ["IRF", "PROTEIN", 131, 134], ["IFN", "PROTEIN", 184, 187], ["IRF-3", "PROTEIN", 271, 276], ["IFN", "PROTEIN", 299, 302], ["host cell-encoded pathogen recognition receptors", "PROTEIN", 354, 402], ["PRRs", "PROTEIN", 404, 408], ["TLRs", "PROTEIN", 419, 423], ["SARS-CoV", "SPECIES", 70, 78], ["SARS", "PROBLEM", 70, 74], ["phosphorylation", "PROBLEM", 83, 98], ["CBP", "PROBLEM", 116, 119], ["IRF", "PROBLEM", 131, 134], ["the IFN system", "TREATMENT", 180, 194], ["IRF", "PROBLEM", 271, 274], ["type I IFN expression", "PROBLEM", 292, 313], ["impaired sensing of coronaviruses", "PROBLEM", 317, 350], ["possible", "UNCERTAINTY", 199, 207], ["host cell", "OBSERVATION", 354, 363]]], ["Cytoplasmic viral RNAs could be recognized by RIG-I, MDA-5, or PKR (Fig. 2).", [["RIG-I", "GENE_OR_GENE_PRODUCT", 46, 51], ["MDA-5", "GENE_OR_GENE_PRODUCT", 53, 58], ["PKR", "GENE_OR_GENE_PRODUCT", 63, 66], ["Cytoplasmic viral RNAs", "RNA", 0, 22], ["RIG-I", "PROTEIN", 46, 51], ["MDA", "PROTEIN", 53, 56], ["PKR", "PROTEIN", 63, 66], ["Cytoplasmic viral RNAs", "PROBLEM", 0, 22], ["RIG", "TEST", 46, 49], ["MDA", "TEST", 53, 56], ["PKR", "TEST", 63, 66], ["viral RNAs", "OBSERVATION", 12, 22]]], ["As RIG-I is triggered by 5\u2032-triphosphates on ssRNA, it might not recognize the 5\u2032-capped genomic and subgenomic mRNAs.", [["5\u2032-triphosphates", "CHEMICAL", 25, 41], ["5\u2032-triphosphates", "CHEMICAL", 25, 41], ["RIG-I", "GENE_OR_GENE_PRODUCT", 3, 8], ["5\u2032-triphosphates", "SIMPLE_CHEMICAL", 25, 41], ["RIG-I", "PROTEIN", 3, 8], ["5\u2032-capped genomic and subgenomic mRNAs", "RNA", 79, 117], ["triphosphates", "TREATMENT", 28, 41], ["ssRNA", "TREATMENT", 45, 50], ["the 5\u2032-capped genomic and subgenomic mRNAs", "PROBLEM", 75, 117], ["capped genomic", "OBSERVATION", 82, 96], ["subgenomic mRNAs", "OBSERVATION", 101, 117]]], ["However, like all positive stranded RNA viruses, coronaviruses replicate their genome via negative-stranded RNA intermediates containing (most likely) 5\u2032-triphosphate ends.", [["triphosphate", "CHEMICAL", 154, 166], ["5\u2032-triphosphate", "CHEMICAL", 151, 166], ["coronaviruses", "ORGANISM", 49, 62], ["5\u2032-triphosphate", "SIMPLE_CHEMICAL", 151, 166], ["negative-stranded RNA intermediates", "RNA", 90, 125], ["all positive stranded RNA viruses", "PROBLEM", 14, 47], ["coronaviruses", "PROBLEM", 49, 62], ["stranded RNA intermediates", "PROBLEM", 99, 125], ["positive", "OBSERVATION_MODIFIER", 18, 26], ["stranded RNA viruses", "OBSERVATION", 27, 47], ["most likely", "UNCERTAINTY", 138, 149]]], ["Moreover, the dsRNAs which are detectably formed during virus replication [43], [100] should be recognized intracellularly by MDA-5 and PKR and extracellularly by TLR-3.", [["[100]", "SIMPLE_CHEMICAL", 80, 85], ["MDA-5", "GENE_OR_GENE_PRODUCT", 126, 131], ["PKR", "GENE_OR_GENE_PRODUCT", 136, 139], ["TLR-3", "GENE_OR_GENE_PRODUCT", 163, 168], ["dsRNAs", "DNA", 14, 20], ["MDA-5", "PROTEIN", 126, 131], ["PKR", "PROTEIN", 136, 139], ["TLR", "PROTEIN", 163, 166], ["the dsRNAs", "PROBLEM", 10, 20], ["MDA", "TEST", 126, 129], ["PKR", "TEST", 136, 139], ["TLR", "TEST", 163, 166], ["dsRNAs", "OBSERVATION", 14, 20]]], ["Coronaviruses may escape cellular RNA sensing by creating a microenvironment that is not accessible to cytoplasmic PRRs.", [["cellular", "ANATOMY", 25, 33], ["cytoplasmic", "ANATOMY", 103, 114], ["cellular", "CELL", 25, 33], ["cytoplasmic", "ORGANISM_SUBSTANCE", 103, 114], ["PRRs", "GENE_OR_GENE_PRODUCT", 115, 119], ["cytoplasmic PRRs", "PROTEIN", 103, 119], ["Coronaviruses", "PROBLEM", 0, 13], ["cellular RNA", "OBSERVATION", 25, 37]]], ["Indeed, it has been shown that infection induces formation of double membrane vesicles (DMV) at perinuclear sites within the cytoplasm where RNA synthesis takes place [108], [109], [110], [111] (Fig. 2).", [["membrane vesicles", "ANATOMY", 69, 86], ["perinuclear sites", "ANATOMY", 96, 113], ["cytoplasm", "ANATOMY", 125, 134], ["infection", "DISEASE", 31, 40], ["membrane vesicles", "CELLULAR_COMPONENT", 69, 86], ["DMV", "CELLULAR_COMPONENT", 88, 91], ["perinuclear sites", "CELLULAR_COMPONENT", 96, 113], ["cytoplasm", "ORGANISM_SUBSTANCE", 125, 134], ["infection", "PROBLEM", 31, 40], ["double membrane vesicles (DMV) at perinuclear sites", "PROBLEM", 62, 113], ["RNA synthesis", "TEST", 141, 154], ["infection", "OBSERVATION", 31, 40], ["double membrane vesicles", "OBSERVATION", 62, 86], ["cytoplasm", "OBSERVATION_MODIFIER", 125, 134], ["RNA synthesis", "OBSERVATION", 141, 154]]], ["It is tempting to speculate that dsRNA replication intermediates containing 5\u2032-triphosphorylated negative strands are located within DMVs and therefore protected from PRR sensing.", [["DMVs", "GENE_OR_GENE_PRODUCT", 133, 137], ["PRR", "GENE_OR_GENE_PRODUCT", 167, 170], ["5\u2032-triphosphorylated negative strands", "DNA", 76, 113], ["DMVs", "PROTEIN", 133, 137], ["PRR", "PROTEIN", 167, 170], ["dsRNA replication intermediates", "TREATMENT", 33, 64], ["5\u2032-triphosphorylated negative strands", "TREATMENT", 76, 113]]], ["In line with this, unimpeded IFN-\u03b2 mRNA production is observed in co-infections with Sendai Virus (SeV) and MHV or SARS-CoV [100], [112].", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 29, 34], ["Sendai Virus", "ORGANISM", 85, 97], ["SeV", "ORGANISM", 99, 102], ["MHV", "ORGANISM", 108, 111], ["SARS-CoV", "ORGANISM", 115, 123], ["IFN-\u03b2 mRNA", "RNA", 29, 39], ["Sendai Virus", "SPECIES", 85, 97], ["Sendai Virus", "SPECIES", 85, 97], ["SeV", "SPECIES", 99, 102], ["MHV", "SPECIES", 108, 111], ["SARS-CoV", "SPECIES", 115, 123], ["unimpeded IFN", "PROBLEM", 19, 32], ["mRNA production", "PROBLEM", 35, 50], ["co-infections", "PROBLEM", 66, 79], ["Sendai Virus", "TREATMENT", 85, 97], ["SARS", "PROBLEM", 115, 119]]], ["Similar findings were reported for MHV-infected cells treated with the IFN inducer poly I:C [104].", [["cells", "ANATOMY", 48, 53], ["MHV-infected", "DISEASE", 35, 47], ["MHV", "ORGANISM", 35, 38], ["cells", "CELL", 48, 53], ["MHV-infected cells", "CELL_TYPE", 35, 53], ["IFN", "PROTEIN", 71, 74], ["MHV", "SPECIES", 35, 38], ["MHV", "PROBLEM", 35, 38], ["infected cells", "PROBLEM", 39, 53], ["infected cells", "OBSERVATION", 39, 53]]], ["Apparently, the sensing of SeV RNA or poly I:C results in the transcription of IFN-\u03b2 mRNA, and coronaviruses are unable to interrupt this process.", [["SeV", "ORGANISM", 27, 30], ["poly I:C", "GENE_OR_GENE_PRODUCT", 38, 46], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 79, 84], ["coronaviruses", "ORGANISM", 95, 108], ["SeV RNA", "RNA", 27, 34], ["poly I:C", "PROTEIN", 38, 46], ["IFN-\u03b2 mRNA", "RNA", 79, 89], ["IFN", "TEST", 79, 82], ["mRNA", "TEST", 85, 89], ["coronaviruses", "PROBLEM", 95, 108]]], ["Noteworthy, despite significant IFN-\u03b2 mRNA transcription, only markedly reduced levels of IFN-\u03b2 protein are secreted from in SeV/MHV-infected cells [112].", [["cells", "ANATOMY", 142, 147], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 32, 37], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 90, 95], ["SeV/MHV", "ORGANISM", 125, 132], ["cells", "CELL", 142, 147], ["IFN", "PROTEIN", 32, 35], ["IFN-\u03b2 protein", "PROTEIN", 90, 103], ["SeV/MHV-infected cells", "CELL_LINE", 125, 147], ["MHV", "SPECIES", 129, 132], ["mRNA transcription", "TEST", 38, 56], ["markedly reduced levels", "PROBLEM", 63, 86], ["IFN", "TEST", 90, 93], ["\u03b2 protein", "TEST", 94, 103], ["infected cells", "PROBLEM", 133, 147], ["MHV", "ANATOMY", 129, 132], ["infected cells", "OBSERVATION", 133, 147]]], ["This indicates that MHV (and possibly other coronaviruses) counteract IFN-\u03b2 mRNA nuclear export and/or translation or affect downstream events such as IFN-\u03b2 protein stability and secretion.How do coronaviruses cope with the IFN system?In addition to those mechanisms, expression studies using cDNA plasmids of SARS-CoV have shown that the proteins encoded by ORF3b, ORF6 as well as the nucleocapsid (N) protein are capable of inhibiting activation of IRF-3, and the ORF3b and ORF6 gene products additionally inhibit IFN signaling [113].", [["nuclear", "ANATOMY", 81, 88], ["MHV", "ORGANISM", 20, 23], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 70, 75], ["nuclear", "CELLULAR_COMPONENT", 81, 88], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 151, 156], ["coronaviruses", "ORGANISM", 196, 209], ["SARS-CoV", "ORGANISM", 310, 318], ["ORF3b", "GENE_OR_GENE_PRODUCT", 359, 364], ["ORF6", "GENE_OR_GENE_PRODUCT", 366, 370], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 386, 402], ["IRF-3", "GENE_OR_GENE_PRODUCT", 451, 456], ["ORF3b", "GENE_OR_GENE_PRODUCT", 466, 471], ["ORF6", "GENE_OR_GENE_PRODUCT", 476, 480], ["IFN", "GENE_OR_GENE_PRODUCT", 516, 519], ["IFN-\u03b2 mRNA", "RNA", 70, 80], ["IFN", "PROTEIN", 151, 154], ["\u03b2", "PROTEIN", 155, 156], ["IFN", "PROTEIN", 224, 227], ["cDNA plasmids", "DNA", 293, 306], ["ORF3b", "PROTEIN", 359, 364], ["ORF6", "PROTEIN", 366, 370], ["nucleocapsid (N) protein", "PROTEIN", 386, 410], ["IRF-3", "PROTEIN", 451, 456], ["ORF3b and ORF6 gene products", "PROTEIN", 466, 494], ["IFN", "PROTEIN", 516, 519], ["MHV", "SPECIES", 20, 23], ["SARS-CoV", "SPECIES", 310, 318], ["MHV", "PROBLEM", 20, 23], ["other coronaviruses", "PROBLEM", 38, 57], ["downstream events", "PROBLEM", 125, 142], ["IFN", "TEST", 151, 154], ["the IFN system", "TREATMENT", 220, 234], ["expression studies", "TEST", 268, 286], ["cDNA plasmids", "TREATMENT", 293, 306], ["SARS", "PROBLEM", 310, 314], ["CoV", "PROBLEM", 315, 318], ["the nucleocapsid (N) protein", "TEST", 382, 410], ["IRF", "TEST", 451, 454], ["the ORF3b and ORF6 gene products", "TREATMENT", 462, 494], ["IFN signaling", "TEST", 516, 529], ["MHV", "OBSERVATION", 20, 23]]], ["The mechanism of IFN signaling suppression by the SARS-CoV ORF6 gene product has been characterized in detail and it was shown that it tethers karyopherin alpha 2 and karyopherin beta 1 to the ER/Golgi membrane to disrupt nuclear import of STAT1 [114].", [["ER/Golgi membrane", "ANATOMY", 193, 210], ["nuclear", "ANATOMY", 222, 229], ["IFN", "CHEMICAL", 17, 20], ["IFN", "GENE_OR_GENE_PRODUCT", 17, 20], ["SARS-CoV ORF6", "GENE_OR_GENE_PRODUCT", 50, 63], ["karyopherin alpha 2", "GENE_OR_GENE_PRODUCT", 143, 162], ["karyopherin beta 1", "GENE_OR_GENE_PRODUCT", 167, 185], ["ER", "GENE_OR_GENE_PRODUCT", 193, 195], ["Golgi membrane", "CELLULAR_COMPONENT", 196, 210], ["nuclear", "CELLULAR_COMPONENT", 222, 229], ["STAT1", "GENE_OR_GENE_PRODUCT", 240, 245], ["IFN", "PROTEIN", 17, 20], ["SARS-CoV ORF6 gene product", "PROTEIN", 50, 76], ["karyopherin alpha 2", "PROTEIN", 143, 162], ["karyopherin beta 1", "PROTEIN", 167, 185], ["ER", "PROTEIN", 193, 195], ["STAT1", "PROTEIN", 240, 245], ["SARS-CoV", "SPECIES", 50, 58], ["IFN signaling suppression", "PROBLEM", 17, 42], ["the SARS", "PROBLEM", 46, 54], ["karyopherin beta", "TREATMENT", 167, 183], ["Golgi membrane", "OBSERVATION", 196, 210]]], ["Additionally, the ORF7a protein has been shown to inhibit cellular protein synthesis [115], and the nsp 1 gene product has been suggested to promote host cell mRNA degradation [116].", [["cellular", "ANATOMY", 58, 66], ["cell", "ANATOMY", 154, 158], ["ORF7a", "GENE_OR_GENE_PRODUCT", 18, 23], ["cellular", "CELL", 58, 66], ["nsp 1", "GENE_OR_GENE_PRODUCT", 100, 105], ["cell", "CELL", 154, 158], ["ORF7a protein", "PROTEIN", 18, 31], ["nsp 1 gene product", "PROTEIN", 100, 118], ["the ORF7a protein", "TEST", 14, 31], ["cellular protein synthesis", "TEST", 58, 84], ["the nsp 1 gene product", "TREATMENT", 96, 118], ["host cell", "OBSERVATION", 149, 158]]], ["The role of nsp1 in counteracting host innate immune responses was further studied in the MHV system [117].", [["nsp1", "CHEMICAL", 12, 16], ["nsp1", "GENE_OR_GENE_PRODUCT", 12, 16], ["nsp1", "PROTEIN", 12, 16], ["MHV", "SPECIES", 90, 93], ["nsp1", "PROBLEM", 12, 16]]], ["A mutant virus containing a deletion in nsp1 was shown to replicate like wild-type virus in vitro but was strongly attenuated in mice, demonstrating that nsp1 is a major pathogenicity factor.", [["mutant virus", "ORGANISM", 2, 14], ["nsp1", "GENE_OR_GENE_PRODUCT", 40, 44], ["wild-type virus", "ORGANISM", 73, 88], ["mice", "ORGANISM", 129, 133], ["nsp1", "GENE_OR_GENE_PRODUCT", 154, 158], ["nsp1", "DNA", 40, 44], ["nsp1", "PROTEIN", 154, 158], ["major pathogenicity factor", "PROTEIN", 164, 190], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["A mutant virus", "PROBLEM", 0, 14], ["a deletion in nsp1", "PROBLEM", 26, 44], ["type virus", "PROBLEM", 78, 88], ["nsp1", "PROBLEM", 154, 158], ["a major pathogenicity factor", "PROBLEM", 162, 190], ["virus", "OBSERVATION", 9, 14]]], ["In type I IFN receptor-deficient mice, however, replication of the nsp1 mutant virus was restored almost to the level of wild-type virus.", [["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 3, 22], ["mice", "ORGANISM", 33, 37], ["nsp1 mutant virus", "ORGANISM", 67, 84], ["wild-type virus", "ORGANISM", 121, 136], ["type I IFN receptor", "PROTEIN", 3, 22], ["nsp1", "PROTEIN", 67, 71], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["type I IFN receptor-deficient mice", "TREATMENT", 3, 37], ["the nsp1 mutant virus", "PROBLEM", 63, 84], ["type virus", "PROBLEM", 126, 136]]], ["Detailed phenotypic analysis revealed that nsp1 mutant replication was particularly reduced in IFN-\u03b1-treated macrophages, indicating that nsp1 mainly affects IFN signaling or downstream events of the type I IFN response.How do coronaviruses cope with the IFN system?Thus, the picture emerges that coronaviruses counter the antiviral IFN response not by relying on one single IFN antagonistic factor, as many other RNA viruses do [27], [29], [101], [118], but by using a multitude of passive and active mechanisms.", [["macrophages", "ANATOMY", 109, 120], ["nsp1", "CHEMICAL", 138, 142], ["nsp1", "GENE_OR_GENE_PRODUCT", 43, 47], ["IFN-\u03b1-", "GENE_OR_GENE_PRODUCT", 95, 101], ["macrophages", "CELL", 109, 120], ["nsp1", "GENE_OR_GENE_PRODUCT", 138, 142], ["IFN", "GENE_OR_GENE_PRODUCT", 158, 161], ["type I IFN", "GENE_OR_GENE_PRODUCT", 200, 210], ["coronaviruses", "ORGANISM", 227, 240], ["coronaviruses", "ORGANISM", 297, 310], ["[29]", "SIMPLE_CHEMICAL", 435, 439], ["[101]", "SIMPLE_CHEMICAL", 441, 446], ["[118]", "SIMPLE_CHEMICAL", 448, 453], ["nsp1", "PROTEIN", 43, 47], ["IFN-\u03b1-treated macrophages", "CELL_LINE", 95, 120], ["nsp1", "PROTEIN", 138, 142], ["IFN", "PROTEIN", 158, 161], ["IFN", "PROTEIN", 207, 210], ["IFN", "PROTEIN", 255, 258], ["IFN", "PROTEIN", 333, 336], ["IFN antagonistic factor", "PROTEIN", 375, 398], ["Detailed phenotypic analysis", "TEST", 0, 28], ["nsp1 mutant replication", "PROBLEM", 43, 66], ["nsp1", "PROBLEM", 138, 142], ["IFN signaling", "PROBLEM", 158, 171], ["the type I IFN response", "PROBLEM", 196, 219], ["the IFN system", "TREATMENT", 251, 265], ["coronaviruses", "PROBLEM", 297, 310], ["the antiviral IFN response", "TREATMENT", 319, 345]]], ["Passive mechanisms include the induction of DMVs that may help to hide and protect RNA replication intermediates from getting sensed by intracellular PRRs.", [["intracellular", "ANATOMY", 136, 149], ["DMVs", "GENE_OR_GENE_PRODUCT", 44, 48], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 149], ["PRRs", "GENE_OR_GENE_PRODUCT", 150, 154], ["DMVs", "PROTEIN", 44, 48], ["intracellular PRRs", "PROTEIN", 136, 154], ["DMVs", "TREATMENT", 44, 48], ["RNA replication intermediates", "PROBLEM", 83, 112]]], ["Active mechanisms include functions provided by the ORF3b, ORF6, N, nsp1 and ORF7a gene products.", [["ORF3b", "GENE_OR_GENE_PRODUCT", 52, 57], ["ORF6", "GENE_OR_GENE_PRODUCT", 59, 63], ["N", "GENE_OR_GENE_PRODUCT", 65, 66], ["nsp1", "GENE_OR_GENE_PRODUCT", 68, 72], ["ORF7a", "GENE_OR_GENE_PRODUCT", 77, 82], ["ORF3b, ORF6, N, nsp1 and ORF7a gene products", "PROTEIN", 52, 96], ["nsp1", "TREATMENT", 68, 72], ["ORF7a gene products", "TREATMENT", 77, 96]]], ["Their combined effects may provide an explanation for the absence of the IRF-3-dependent IFN-\u03b2 and RANTES expression and the STAT-dependent transcription of the IFN-\u03b1 genes in coronavirus-infected cells.", [["cells", "ANATOMY", 197, 202], ["coronavirus-infected", "DISEASE", 176, 196], ["IRF-3", "GENE_OR_GENE_PRODUCT", 73, 78], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 89, 94], ["RANTES", "GENE_OR_GENE_PRODUCT", 99, 105], ["STAT", "GENE_OR_GENE_PRODUCT", 125, 129], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 161, 166], ["coronavirus", "ORGANISM", 176, 187], ["cells", "CELL", 197, 202], ["IRF-3", "PROTEIN", 73, 78], ["IFN", "PROTEIN", 89, 92], ["RANTES", "PROTEIN", 99, 105], ["STAT", "PROTEIN", 125, 129], ["IFN-\u03b1 genes", "DNA", 161, 172], ["coronavirus-infected cells", "CELL_TYPE", 176, 202], ["the IRF", "TEST", 69, 76], ["RANTES expression", "TEST", 99, 116], ["the STAT", "TEST", 121, 129], ["the IFN", "TEST", 157, 164], ["coronavirus", "PROBLEM", 176, 187], ["infected cells", "PROBLEM", 188, 202], ["infected cells", "OBSERVATION", 188, 202]]], ["Furthermore, on the effector side, the N protein of MHV was shown to contribute to viral IFN resistance by interfering with the 2-5 OAS pathway [119].How do coronaviruses cope with the IFN system?Interestingly, despite this multi-pronged IFN escape strategy, the fact that superinfection with SeV unleashes a strong transcriptional IFN response in SARS-CoV-infected cells suggests an unexpectedly high degree of coronavirus-specific inhibition of IRF-3 by ORF3b, ORF6 and N, which may be explained by the strong compartimentalization of the coronavirus factories in infected cells.", [["cells", "ANATOMY", 366, 371], ["cells", "ANATOMY", 575, 580], ["superinfection", "DISEASE", 273, 287], ["SARS-CoV-infected", "DISEASE", 348, 365], ["MHV", "ORGANISM", 52, 55], ["IFN", "GENE_OR_GENE_PRODUCT", 89, 92], ["coronaviruses", "ORGANISM", 157, 170], ["SeV", "ORGANISM", 293, 296], ["IFN", "GENE_OR_GENE_PRODUCT", 332, 335], ["SARS-CoV", "ORGANISM", 348, 356], ["cells", "CELL", 366, 371], ["coronavirus", "ORGANISM", 412, 423], ["IRF-3", "GENE_OR_GENE_PRODUCT", 447, 452], ["ORF3b", "GENE_OR_GENE_PRODUCT", 456, 461], ["ORF6", "GENE_OR_GENE_PRODUCT", 463, 467], ["coronavirus", "ORGANISM", 541, 552], ["cells", "CELL", 575, 580], ["N protein", "PROTEIN", 39, 48], ["MHV", "PROTEIN", 52, 55], ["IFN", "PROTEIN", 89, 92], ["OAS", "PROTEIN", 132, 135], ["IFN", "PROTEIN", 185, 188], ["IFN", "PROTEIN", 238, 241], ["IFN", "PROTEIN", 332, 335], ["SARS-CoV-infected cells", "CELL_TYPE", 348, 371], ["IRF-3", "PROTEIN", 447, 452], ["ORF3b", "PROTEIN", 456, 461], ["ORF6", "PROTEIN", 463, 467], ["infected cells", "CELL_TYPE", 566, 580], ["MHV", "SPECIES", 52, 55], ["SeV", "SPECIES", 293, 296], ["SARS-CoV", "SPECIES", 348, 356], ["the N protein", "TEST", 35, 48], ["viral IFN resistance", "PROBLEM", 83, 103], ["the IFN system", "TREATMENT", 181, 195], ["this multi-pronged IFN escape strategy", "TREATMENT", 219, 257], ["superinfection", "PROBLEM", 273, 287], ["SARS", "PROBLEM", 348, 352], ["CoV", "TEST", 353, 356], ["infected cells", "PROBLEM", 357, 371], ["coronavirus", "PROBLEM", 412, 423], ["IRF", "PROBLEM", 447, 450], ["the coronavirus factories in infected cells", "PROBLEM", 537, 580], ["superinfection", "OBSERVATION", 273, 287], ["infected cells", "OBSERVATION", 357, 371], ["high degree", "OBSERVATION_MODIFIER", 397, 408], ["coronavirus", "OBSERVATION", 412, 423], ["IRF", "OBSERVATION", 447, 450], ["may be explained", "UNCERTAINTY", 481, 497], ["coronavirus factories", "OBSERVATION", 541, 562], ["infected cells", "OBSERVATION", 566, 580]]], ["Also, it has to be kept in mind that viral IFN antagonism is usually not perfect and serves to delay rather than completely suppress IFN induction [27].How do coronaviruses cope with the IFN system?A notable exception from the general picture of an impeded IFN response in coronavirus-infected cells is provided by pDCs.", [["cells", "ANATOMY", 294, 299], ["pDCs", "ANATOMY", 315, 319], ["coronavirus-infected", "DISEASE", 273, 293], ["IFN", "GENE_OR_GENE_PRODUCT", 133, 136], ["coronaviruses", "ORGANISM", 159, 172], ["IFN", "GENE_OR_GENE_PRODUCT", 257, 260], ["coronavirus", "ORGANISM", 273, 284], ["cells", "CELL", 294, 299], ["pDCs", "CELL", 315, 319], ["IFN", "PROTEIN", 43, 46], ["IFN", "PROTEIN", 133, 136], ["IFN", "PROTEIN", 187, 190], ["IFN", "PROTEIN", 257, 260], ["coronavirus-infected cells", "CELL_TYPE", 273, 299], ["pDCs", "CELL_TYPE", 315, 319], ["coronavirus", "SPECIES", 273, 284], ["viral IFN antagonism", "PROBLEM", 37, 57], ["the IFN system", "TREATMENT", 183, 197], ["an impeded IFN response", "PROBLEM", 246, 269], ["coronavirus", "PROBLEM", 273, 284], ["infected cells", "PROBLEM", 285, 299], ["notable", "OBSERVATION_MODIFIER", 200, 207], ["infected cells", "OBSERVATION", 285, 299]]], ["Whereas mDCs infected with SARS-CoV or MHV have no detectable IFN synthesis (similar to fibroblasts), pDCs secrete substantial amounts of IFN in response to these coronaviruses [92].", [["mDCs", "ANATOMY", 8, 12], ["fibroblasts", "ANATOMY", 88, 99], ["pDCs", "ANATOMY", 102, 106], ["mDCs", "CELL", 8, 12], ["SARS-CoV", "ORGANISM", 27, 35], ["MHV", "ORGANISM", 39, 42], ["IFN", "GENE_OR_GENE_PRODUCT", 62, 65], ["fibroblasts", "CELL", 88, 99], ["pDCs", "CELL", 102, 106], ["IFN", "GENE_OR_GENE_PRODUCT", 138, 141], ["mDCs", "CELL_TYPE", 8, 12], ["IFN", "PROTEIN", 62, 65], ["fibroblasts", "CELL_TYPE", 88, 99], ["pDCs", "CELL_TYPE", 102, 106], ["IFN", "PROTEIN", 138, 141], ["SARS-CoV", "SPECIES", 27, 35], ["MHV", "SPECIES", 39, 42], ["SARS", "PROBLEM", 27, 31], ["MHV", "PROBLEM", 39, 42], ["detectable IFN synthesis", "PROBLEM", 51, 75], ["IFN", "PROBLEM", 138, 141], ["these coronaviruses", "PROBLEM", 157, 176], ["no detectable", "UNCERTAINTY", 48, 61]]], ["For MHV it was further shown that this response was dependent on the presence of TLR-7 and MyD88, which induce IFN-\u03b1 expression via constitutively expressed IRF-7.", [["MHV", "ORGANISM", 4, 7], ["TLR-7", "GENE_OR_GENE_PRODUCT", 81, 86], ["MyD88", "GENE_OR_GENE_PRODUCT", 91, 96], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 111, 116], ["IRF-7", "GENE_OR_GENE_PRODUCT", 157, 162], ["TLR", "PROTEIN", 81, 84], ["MyD88", "PROTEIN", 91, 96], ["IFN", "PROTEIN", 111, 114], ["\u03b1", "PROTEIN", 115, 116], ["IRF-7", "PROTEIN", 157, 162], ["MHV", "SPECIES", 4, 7], ["MHV", "TREATMENT", 4, 7], ["TLR", "TEST", 81, 84], ["MyD88", "TREATMENT", 91, 96], ["IFN", "TEST", 111, 114], ["IRF", "TEST", 157, 160]]], ["Apparently, in contrast to the ubiquitous IRF-3 signaling chain, the pDC-restricted TLR-7/IRF-7 pathway is not affected by the virus.", [["IRF-3", "GENE_OR_GENE_PRODUCT", 42, 47], ["pDC", "CELL", 69, 72], ["TLR-7", "GENE_OR_GENE_PRODUCT", 84, 89], ["IRF-7", "GENE_OR_GENE_PRODUCT", 90, 95], ["ubiquitous IRF-3 signaling chain", "PROTEIN", 31, 63], ["TLR", "PROTEIN", 84, 87], ["IRF", "PROTEIN", 90, 93], ["the pDC", "TEST", 65, 72], ["TLR", "TEST", 84, 87], ["the virus", "PROBLEM", 123, 132], ["IRF", "OBSERVATION", 42, 45], ["chain", "OBSERVATION_MODIFIER", 58, 63], ["virus", "OBSERVATION", 127, 132]]], ["TLR-7 is located in endosomes of pDCs and may sense the viral genome during virus entry, or sense viral RNA that has been shuttled to endosomes by autophagosomes [120].", [["endosomes", "ANATOMY", 20, 29], ["pDCs", "ANATOMY", 33, 37], ["endosomes", "ANATOMY", 134, 143], ["autophagosomes", "ANATOMY", 147, 161], ["TLR-7", "GENE_OR_GENE_PRODUCT", 0, 5], ["endosomes", "CELLULAR_COMPONENT", 20, 29], ["pDCs", "CELL", 33, 37], ["endosomes", "CELLULAR_COMPONENT", 134, 143], ["autophagosomes", "CELLULAR_COMPONENT", 147, 161], ["TLR-7", "PROTEIN", 0, 5], ["pDCs", "CELL_TYPE", 33, 37], ["viral genome", "DNA", 56, 68], ["viral RNA", "RNA", 98, 107], ["TLR", "TEST", 0, 3], ["pDCs", "PROBLEM", 33, 37], ["the viral genome during virus entry", "PROBLEM", 52, 87], ["sense viral RNA", "PROBLEM", 92, 107], ["viral genome", "OBSERVATION", 56, 68]]], ["The TLR-7-dependent activation of pDCs most probably provides an important protective mechanism from coronavirus infection.", [["pDCs", "ANATOMY", 34, 38], ["coronavirus infection", "DISEASE", 101, 122], ["TLR-7", "GENE_OR_GENE_PRODUCT", 4, 9], ["pDCs", "CELL", 34, 38], ["coronavirus", "ORGANISM", 101, 112], ["TLR-7", "PROTEIN", 4, 9], ["pDCs", "CELL_TYPE", 34, 38], ["The TLR", "TEST", 0, 7], ["coronavirus infection", "PROBLEM", 101, 122], ["coronavirus", "OBSERVATION_MODIFIER", 101, 112], ["infection", "OBSERVATION", 113, 122]]], ["Indeed, depletion of pDCs in mice significantly reduced serum IFN-\u03b1 levels, and led to increased virus replication, virus spread to multiple organs, and severe clinical signs of disease [92].", [["pDCs", "ANATOMY", 21, 25], ["serum", "ANATOMY", 56, 61], ["organs", "ANATOMY", 141, 147], ["pDCs", "CELL", 21, 25], ["mice", "ORGANISM", 29, 33], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 62, 67], ["organs", "ORGAN", 141, 147], ["pDCs", "CELL_TYPE", 21, 25], ["IFN", "PROTEIN", 62, 65], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["pDCs", "PROBLEM", 21, 25], ["serum IFN", "TEST", 56, 65], ["levels", "TEST", 68, 74], ["increased virus replication", "PROBLEM", 87, 114], ["virus", "PROBLEM", 116, 121], ["severe clinical signs of disease", "PROBLEM", 153, 185], ["depletion", "OBSERVATION_MODIFIER", 8, 17], ["pDCs", "OBSERVATION", 21, 25], ["severe", "OBSERVATION_MODIFIER", 153, 159]]], ["Thus, a weak type I IFN response early during coronavirus infection may explain why the prognosis for SARS worsens with increasing age, and it is feasible to suspect that the functionality and responsiveness of these professional IFN producers plays an important role in the protection from severe coronavirus-induced disease.How do coronaviruses cope with the IFN system?Interestingly, in an MHV-1-based in vivo model for SARS, it was shown that a mouse strain which develops severe SARS-like symptoms has little IFN production after infection, whereas another mouse strain which was protected from disease produces high amounts of type I IFNs [20].", [["coronavirus infection", "DISEASE", 46, 67], ["SARS", "DISEASE", 102, 106], ["IFN", "CHEMICAL", 230, 233], ["coronavirus", "DISEASE", 298, 309], ["SARS", "DISEASE", 423, 427], ["SARS", "DISEASE", 484, 488], ["infection", "DISEASE", 535, 544], ["type I IFN", "GENE_OR_GENE_PRODUCT", 13, 23], ["coronavirus", "ORGANISM", 46, 57], ["IFN", "GENE_OR_GENE_PRODUCT", 230, 233], ["coronavirus", "ORGANISM", 298, 309], ["coronaviruses", "ORGANISM", 333, 346], ["mouse", "ORGANISM", 449, 454], ["IFN", "GENE_OR_GENE_PRODUCT", 514, 517], ["mouse", "ORGANISM", 562, 567], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 633, 644], ["IFN", "PROTEIN", 20, 23], ["IFN", "PROTEIN", 230, 233], ["IFN", "PROTEIN", 361, 364], ["IFN", "PROTEIN", 514, 517], ["type I IFNs", "PROTEIN", 633, 644], ["mouse", "SPECIES", 449, 454], ["mouse", "SPECIES", 562, 567], ["coronavirus", "SPECIES", 46, 57], ["MHV", "SPECIES", 393, 396], ["mouse", "SPECIES", 449, 454], ["mouse", "SPECIES", 562, 567], ["a weak type I IFN response", "PROBLEM", 6, 32], ["coronavirus infection", "PROBLEM", 46, 67], ["SARS", "PROBLEM", 102, 106], ["these professional IFN producers", "TREATMENT", 211, 243], ["severe coronavirus-induced disease", "PROBLEM", 291, 325], ["the IFN system", "TREATMENT", 357, 371], ["SARS", "PROBLEM", 423, 427], ["a mouse strain", "PROBLEM", 447, 461], ["severe SARS-like symptoms", "PROBLEM", 477, 502], ["infection", "PROBLEM", 535, 544], ["another mouse strain", "PROBLEM", 554, 574], ["disease", "PROBLEM", 600, 607], ["severe", "OBSERVATION_MODIFIER", 291, 297], ["coronavirus", "OBSERVATION", 298, 309], ["severe", "OBSERVATION_MODIFIER", 477, 483], ["SARS", "OBSERVATION", 484, 488]]], ["Moreover, it is well known that the virulence and IFN resistance of MHV strains correlate [121].", [["IFN", "GENE_OR_GENE_PRODUCT", 50, 53], ["MHV strains", "ORGANISM", 68, 79], ["IFN", "PROTEIN", 50, 53], ["MHV", "SPECIES", 68, 71], ["the virulence", "PROBLEM", 32, 45], ["MHV strains", "TEST", 68, 79]]], ["In line with this, a recent study using SARS patient materials suggests the presence of high levels of type I IFNs which might be responsible for the recovery of the majority of patients [122].", [["SARS", "DISEASE", 40, 44], ["patient", "ORGANISM", 45, 52], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 103, 114], ["patients", "ORGANISM", 178, 186], ["type I IFNs", "PROTEIN", 103, 114], ["patient", "SPECIES", 45, 52], ["patients", "SPECIES", 178, 186], ["a recent study", "TEST", 19, 33], ["SARS patient materials", "TREATMENT", 40, 62], ["type I IFNs", "PROBLEM", 103, 114], ["line", "OBSERVATION_MODIFIER", 3, 7]]], ["Thus, the degree of IFN escape by coronaviruses may be host-specific as well as strain-specific and determine viral pathogenesis in a manner similar to what was observed, for e.g. Ebola virus [123], [124].Cytokines and chemokines induced by SARS-CoV and MHVIRF-3 is not only crucial for IFN induction, but also participates in transactivation of the genes for RANTES [125] and IP-10 [126].", [["IFN", "GENE_OR_GENE_PRODUCT", 20, 23], ["coronaviruses", "ORGANISM", 34, 47], ["Ebola virus", "ORGANISM", 180, 191], ["SARS-CoV", "ORGANISM", 241, 249], ["MHVIRF-3", "GENE_OR_GENE_PRODUCT", 254, 262], ["IFN", "GENE_OR_GENE_PRODUCT", 287, 290], ["RANTES [125]", "GENE_OR_GENE_PRODUCT", 360, 372], ["IP-10", "GENE_OR_GENE_PRODUCT", 377, 382], ["IFN", "PROTEIN", 20, 23], ["Cytokines", "PROTEIN", 205, 214], ["chemokines", "PROTEIN", 219, 229], ["MHVIRF", "PROTEIN", 254, 260], ["IFN", "PROTEIN", 287, 290], ["RANTES", "PROTEIN", 360, 366], ["Ebola virus", "SPECIES", 180, 191], ["Ebola virus", "SPECIES", 180, 191], ["SARS-CoV", "SPECIES", 241, 249], ["IFN escape", "PROBLEM", 20, 30], ["coronaviruses", "PROBLEM", 34, 47], ["strain", "PROBLEM", 80, 86], ["viral pathogenesis", "PROBLEM", 110, 128], ["Ebola virus", "PROBLEM", 180, 191], ["Cytokines", "TREATMENT", 205, 214], ["SARS", "PROBLEM", 241, 245], ["MHVIRF", "TEST", 254, 260], ["IFN induction", "TREATMENT", 287, 300], ["RANTES", "TEST", 360, 366], ["IP", "TEST", 377, 379], ["IFN escape", "OBSERVATION", 20, 30], ["chemokines", "OBSERVATION", 219, 229]]], ["It could therefore be expected that coronaviruses also suppress production of these chemokines (which are also termed CCL5 and CXCL10, respectively).", [["coronaviruses", "ORGANISM", 36, 49], ["CCL5", "GENE_OR_GENE_PRODUCT", 118, 122], ["CXCL10", "GENE_OR_GENE_PRODUCT", 127, 133], ["chemokines", "PROTEIN", 84, 94], ["CCL5", "PROTEIN", 118, 122], ["CXCL10", "PROTEIN", 127, 133], ["coronaviruses", "PROBLEM", 36, 49], ["these chemokines", "TEST", 78, 94], ["CXCL10", "TEST", 127, 133]]], ["Recent data indicate that RANTES transcripts are indeed absent in tissue cells productively infected with SARS-CoV [107], [127] or MHV [103].", [["tissue cells", "ANATOMY", 66, 78], ["RANTES", "GENE_OR_GENE_PRODUCT", 26, 32], ["tissue cells", "CELL", 66, 78], ["SARS-CoV", "ORGANISM", 106, 114], ["RANTES transcripts", "RNA", 26, 44], ["tissue cells", "CELL_TYPE", 66, 78], ["SARS-CoV", "SPECIES", 106, 114], ["Recent data", "TEST", 0, 11], ["RANTES transcripts", "PROBLEM", 26, 44], ["absent in tissue cells", "PROBLEM", 56, 78], ["CoV", "TEST", 111, 114], ["MHV", "TEST", 131, 134], ["RANTES transcripts", "OBSERVATION", 26, 44]]], ["IP-10 transcription, however, is upregulated in some SARS-CoV-infected fibroblast cell lines [107], [127] and in macrophages [105].", [["fibroblast cell lines", "ANATOMY", 71, 92], ["macrophages", "ANATOMY", 113, 124], ["SARS", "DISEASE", 53, 57], ["IP-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV", "ORGANISM", 53, 61], ["fibroblast cell lines [107]", "CELL", 71, 98], ["[127]", "CELL", 100, 105], ["macrophages", "CELL", 113, 124], ["SARS-CoV-infected fibroblast cell lines", "CELL_LINE", 53, 92], ["macrophages", "CELL_TYPE", 113, 124], ["SARS-CoV", "SPECIES", 53, 61], ["some SARS", "PROBLEM", 48, 57], ["infected fibroblast cell lines", "PROBLEM", 62, 92], ["infected", "OBSERVATION_MODIFIER", 62, 70], ["fibroblast cell lines", "OBSERVATION", 71, 92], ["macrophages", "ANATOMY", 113, 124]]], ["Similarly, MHV induces a strong IP-10 response in mouse brain [128], mDCs and in pDCs [92], whereas type I IFNs are only produced in pDCs [92].", [["brain", "ANATOMY", 56, 61], ["mDCs", "ANATOMY", 69, 73], ["pDCs", "ANATOMY", 81, 85], ["pDCs", "ANATOMY", 133, 137], ["MHV", "ORGANISM", 11, 14], ["IP-10", "GENE_OR_GENE_PRODUCT", 32, 37], ["mouse", "ORGANISM", 50, 55], ["brain [128]", "CELL", 56, 67], ["mDCs", "CELL", 69, 73], ["pDCs", "CELL", 81, 85], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 100, 111], ["pDCs", "CELL", 133, 137], ["mDCs", "CELL_TYPE", 69, 73], ["pDCs", "CELL_TYPE", 81, 85], ["type I IFNs", "PROTEIN", 100, 111], ["pDCs", "CELL_TYPE", 133, 137], ["mouse", "SPECIES", 50, 55], ["MHV", "SPECIES", 11, 14], ["mouse", "SPECIES", 50, 55], ["MHV", "OBSERVATION", 11, 14], ["brain", "ANATOMY", 56, 61]]], ["This suggests that transcription of IP-10 is (i) less dependent on IRF-3 than RANTES and IFN-\u03b2 are, and (ii) therefore largely unaffected by coronaviral inhibition mechanisms.", [["IP-10", "GENE_OR_GENE_PRODUCT", 36, 41], ["IRF-3", "GENE_OR_GENE_PRODUCT", 67, 72], ["RANTES", "GENE_OR_GENE_PRODUCT", 78, 84], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 89, 94], ["IRF-3", "PROTEIN", 67, 72], ["RANTES", "PROTEIN", 78, 84], ["IFN", "PROTEIN", 89, 92], ["\u03b2", "PROTEIN", 93, 94], ["transcription of IP", "TREATMENT", 19, 38], ["IRF", "TEST", 67, 70], ["RANTES", "TEST", 78, 84], ["IFN", "TEST", 89, 92], ["IRF", "OBSERVATION", 67, 70]]], ["Transactivation of the IP-10 gene is not only triggered by IRF-3, but also by the important transcription factor NF-\u03baB [126].", [["IP-10", "GENE_OR_GENE_PRODUCT", 23, 28], ["IRF-3", "GENE_OR_GENE_PRODUCT", 59, 64], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 113, 118], ["IP-10 gene", "DNA", 23, 33], ["IRF-3", "PROTEIN", 59, 64], ["transcription factor", "PROTEIN", 92, 112], ["NF-\u03baB", "PROTEIN", 113, 118], ["Transactivation of the IP", "TREATMENT", 0, 25], ["not only", "UNCERTAINTY", 37, 45]]], ["There are some reports that SARS-CoV [127], [129] and MHV [103], [130] trigger an NF-\u03baB response, although other groups could not verify these finding in their systems [104], [131].", [["SARS", "DISEASE", 28, 32], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 28, 36], ["[129]", "SIMPLE_CHEMICAL", 44, 49], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 82, 87], ["NF-\u03baB", "PROTEIN", 82, 87], ["SARS-CoV", "SPECIES", 28, 36], ["SARS-CoV", "TEST", 28, 36], ["MHV", "TEST", 54, 57], ["an NF", "TEST", 79, 84]]], ["Moreover, the SARS-CoV N protein is a strong antagonist of NF-\u03baB [113] and the NF-\u03baB-dependent proinflammatory TNF-\u03b1 is suspiciously absent in the SARS cytokine profile (see below).", [["SARS", "DISEASE", 147, 151], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 59, 64], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 79, 84], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 111, 116], ["SARS-CoV N protein", "PROTEIN", 14, 32], ["NF-\u03baB", "PROTEIN", 79, 84], ["proinflammatory TNF-\u03b1", "PROTEIN", 95, 116], ["cytokine", "PROTEIN", 152, 160], ["SARS-CoV", "SPECIES", 14, 22], ["the SARS", "TEST", 10, 18], ["CoV N protein", "TEST", 19, 32], ["NF", "TEST", 59, 61], ["the NF", "TEST", 75, 81], ["proinflammatory TNF", "TEST", 95, 114], ["the SARS cytokine profile", "TEST", 143, 168], ["proinflammatory TNF", "OBSERVATION", 95, 114]]], ["Activation of NF-\u03baB may therefore not be the final explanation for the upregulation of the IP-10 gene in SARS-CoV-infected cells.", [["cells", "ANATOMY", 123, 128], ["SARS-CoV-infected", "DISEASE", 105, 122], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 14, 19], ["IP-10", "GENE_OR_GENE_PRODUCT", 91, 96], ["SARS-CoV", "ORGANISM", 105, 113], ["cells", "CELL", 123, 128], ["NF-\u03baB", "PROTEIN", 14, 19], ["IP-10 gene", "DNA", 91, 101], ["SARS-CoV-infected cells", "CELL_TYPE", 105, 128], ["SARS-CoV", "SPECIES", 105, 113], ["the IP", "TEST", 87, 93], ["SARS", "PROBLEM", 105, 109], ["infected cells", "PROBLEM", 114, 128], ["infected cells", "OBSERVATION", 114, 128]]], ["Indeed, recent reports indicate that IRF-5 can be activated by virus infection in a manner similar to IRF-3 [132], and that IRF-5 participates in induction of proinflammatory cytokines rather than type I IFNs [52], [133].", [["infection", "DISEASE", 69, 78], ["IRF-5", "GENE_OR_GENE_PRODUCT", 37, 42], ["IRF-3", "GENE_OR_GENE_PRODUCT", 102, 107], ["IRF-5", "GENE_OR_GENE_PRODUCT", 124, 129], ["IRF-5", "PROTEIN", 37, 42], ["IRF", "PROTEIN", 102, 105], ["IRF-5", "PROTEIN", 124, 129], ["proinflammatory cytokines", "PROTEIN", 159, 184], ["type I IFNs", "PROTEIN", 197, 208], ["IRF", "PROBLEM", 37, 40], ["virus infection", "PROBLEM", 63, 78], ["IRF", "TEST", 102, 105], ["proinflammatory cytokines", "PROBLEM", 159, 184]]], ["It can be speculated that IRF-5 is involved in the prominent upregulation of the IP-10 gene by SARS-CoV.Cytokines and chemokines induced by SARS-CoV and MHVSome SARS-CoV-infected cell lines also produce significant amounts of the chemokine IL-8 (CXCL8) [107], [127], an activity which was traced back to the viral spike and nucleocapsid proteins [134], [135].", [["cell lines", "ANATOMY", 179, 189], ["IRF-5", "GENE_OR_GENE_PRODUCT", 26, 31], ["IP-10", "GENE_OR_GENE_PRODUCT", 81, 86], ["SARS-CoV", "ORGANISM", 95, 103], ["SARS-CoV", "ORGANISM", 140, 148], ["MHVSome SARS-CoV", "ORGANISM", 153, 169], ["cell lines", "CELL", 179, 189], ["IL-8", "GENE_OR_GENE_PRODUCT", 240, 244], ["CXCL8", "GENE_OR_GENE_PRODUCT", 246, 251], ["[127]", "SIMPLE_CHEMICAL", 260, 265], ["IRF-5", "PROTEIN", 26, 31], ["IP-10 gene", "DNA", 81, 91], ["Cytokines", "PROTEIN", 104, 113], ["chemokines", "PROTEIN", 118, 128], ["MHVSome SARS-CoV-infected cell lines", "CELL_LINE", 153, 189], ["chemokine IL-8", "PROTEIN", 230, 244], ["CXCL8", "PROTEIN", 246, 251], ["nucleocapsid proteins", "PROTEIN", 324, 345], ["SARS-CoV", "SPECIES", 161, 169], ["SARS-CoV", "SPECIES", 95, 103], ["SARS-CoV", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 161, 169], ["Cytokines", "TEST", 104, 113], ["chemokines", "TEST", 118, 128], ["SARS", "TEST", 140, 144], ["CoV", "TEST", 145, 148], ["MHVSome SARS", "TEST", 153, 165], ["CoV", "TEST", 166, 169], ["infected cell lines", "TREATMENT", 170, 189], ["the chemokine IL", "TEST", 226, 242], ["CXCL8", "TEST", 246, 251], ["the viral spike", "TEST", 304, 319], ["nucleocapsid proteins", "TEST", 324, 345], ["IRF", "OBSERVATION", 26, 29], ["prominent", "OBSERVATION_MODIFIER", 51, 60], ["upregulation", "OBSERVATION_MODIFIER", 61, 73], ["chemokines", "ANATOMY", 118, 128], ["infected cell lines", "OBSERVATION", 170, 189], ["significant", "OBSERVATION_MODIFIER", 203, 214], ["amounts", "OBSERVATION_MODIFIER", 215, 222]]], ["Similarly, the mouse counterpart of human IL-8, CXCL2, is upregulated in fibroblasts after MHV infection [103].", [["fibroblasts", "ANATOMY", 73, 84], ["MHV infection", "DISEASE", 91, 104], ["mouse", "ORGANISM", 15, 20], ["human", "ORGANISM", 36, 41], ["IL-8", "GENE_OR_GENE_PRODUCT", 42, 46], ["CXCL2", "GENE_OR_GENE_PRODUCT", 48, 53], ["fibroblasts", "CELL", 73, 84], ["MHV", "ORGANISM", 91, 94], ["human IL-8", "PROTEIN", 36, 46], ["CXCL2", "PROTEIN", 48, 53], ["fibroblasts", "CELL_TYPE", 73, 84], ["mouse", "SPECIES", 15, 20], ["human", "SPECIES", 36, 41], ["mouse", "SPECIES", 15, 20], ["human", "SPECIES", 36, 41], ["MHV", "SPECIES", 91, 94], ["human IL", "TREATMENT", 36, 44], ["MHV infection", "PROBLEM", 91, 104], ["MHV", "OBSERVATION_MODIFIER", 91, 94], ["infection", "OBSERVATION", 95, 104]]], ["Expression of IL-8 is dependent on the transcription factor AP-1, and molecular analyses revealed that SARS-CoV and MHV strongly activate AP-1 [103], [129], [135].", [["IL-8", "GENE_OR_GENE_PRODUCT", 14, 18], ["AP-1", "GENE_OR_GENE_PRODUCT", 60, 64], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["MHV", "ORGANISM", 116, 119], ["AP-1", "GENE_OR_GENE_PRODUCT", 138, 142], ["IL-8", "PROTEIN", 14, 18], ["transcription factor AP-1", "PROTEIN", 39, 64], ["AP", "PROTEIN", 138, 140], ["SARS-CoV", "SPECIES", 103, 111], ["MHV", "SPECIES", 116, 119], ["the transcription factor AP", "TEST", 35, 62], ["molecular analyses", "TEST", 70, 88], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["MHV", "TEST", 116, 119], ["AP", "TEST", 138, 140]]], ["Interestingly, human IL-8 was shown to inhibit the antiviral action of IFN [136].", [["IFN", "CHEMICAL", 71, 74], ["human", "ORGANISM", 15, 20], ["IL-8", "GENE_OR_GENE_PRODUCT", 21, 25], ["human IL-8", "PROTEIN", 15, 25], ["IFN", "PROTEIN", 71, 74], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20]]], ["Therefore, besides the direct inhibition of IFN induction by viral proteins (see above), secreted human IL-8 (and possibly mouse CXCL2 as well) might contribute to diminish the IFN response in coronavirus infections.Cytokines and chemokines induced by SARS-CoV and MHVTaken together, the in vitro cytokine profiles of SARS-CoV and MHV infection appear to be mainly based on the transcriptional activation of IP-10 and IL-8, possibly mediated by NF-\u03baB or IRF-5, and AP-1.", [["coronavirus infections", "DISEASE", 193, 215], ["SARS", "DISEASE", 318, 322], ["MHV infection", "DISEASE", 331, 344], ["IFN", "GENE_OR_GENE_PRODUCT", 44, 47], ["human", "ORGANISM", 98, 103], ["IL-8", "GENE_OR_GENE_PRODUCT", 104, 108], ["mouse", "ORGANISM", 123, 128], ["CXCL2", "GENE_OR_GENE_PRODUCT", 129, 134], ["IFN", "GENE_OR_GENE_PRODUCT", 177, 180], ["coronavirus", "ORGANISM", 193, 204], ["SARS-CoV", "ORGANISM", 252, 260], ["MHVTaken", "GENE_OR_GENE_PRODUCT", 265, 273], ["SARS-CoV", "ORGANISM", 318, 326], ["MHV", "ORGANISM", 331, 334], ["IP-10", "GENE_OR_GENE_PRODUCT", 408, 413], ["IL-8", "GENE_OR_GENE_PRODUCT", 418, 422], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 445, 450], ["IRF-5", "GENE_OR_GENE_PRODUCT", 454, 459], ["AP-1", "GENE_OR_GENE_PRODUCT", 465, 469], ["IFN", "PROTEIN", 44, 47], ["viral proteins", "PROTEIN", 61, 75], ["secreted human IL-8", "PROTEIN", 89, 108], ["CXCL2", "PROTEIN", 129, 134], ["IFN", "PROTEIN", 177, 180], ["Cytokines", "PROTEIN", 216, 225], ["chemokines", "PROTEIN", 230, 240], ["cytokine", "PROTEIN", 297, 305], ["IL-8", "PROTEIN", 418, 422], ["NF-\u03baB", "PROTEIN", 445, 450], ["IRF-5", "PROTEIN", 454, 459], ["AP", "PROTEIN", 465, 467], ["human", "SPECIES", 98, 103], ["mouse", "SPECIES", 123, 128], ["human", "SPECIES", 98, 103], ["mouse", "SPECIES", 123, 128], ["SARS-CoV", "SPECIES", 252, 260], ["SARS-CoV", "SPECIES", 318, 326], ["MHV", "SPECIES", 331, 334], ["IFN induction", "TREATMENT", 44, 57], ["viral proteins", "PROBLEM", 61, 75], ["secreted human IL", "TEST", 89, 106], ["the IFN response", "PROBLEM", 173, 189], ["coronavirus infections", "PROBLEM", 193, 215], ["Cytokines", "TREATMENT", 216, 225], ["chemokines", "TREATMENT", 230, 240], ["SARS", "PROBLEM", 252, 256], ["MHVTaken", "TREATMENT", 265, 273], ["SARS", "PROBLEM", 318, 322], ["CoV", "PROBLEM", 323, 326], ["MHV infection", "PROBLEM", 331, 344], ["IP", "TEST", 408, 410], ["IL", "TEST", 418, 420], ["IRF", "TEST", 454, 457], ["AP", "TEST", 465, 467], ["coronavirus infections", "OBSERVATION", 193, 215], ["chemokines", "OBSERVATION", 230, 240], ["MHV", "ANATOMY", 331, 334], ["infection", "OBSERVATION", 335, 344]]], ["IRF-3-depending genes for antiviral cytokines such as type I IFNs, by contrast, remain mostly silenced during the initial phase of infection.Cytokines and chemokines induced by SARS-CoV and MHVIP-10 is a chemoattractant causing T cell infiltration into coronavirus-infected organs [137].", [["T cell", "ANATOMY", 228, 234], ["organs", "ANATOMY", 274, 280], ["infection", "DISEASE", 131, 140], ["IRF-3", "GENE_OR_GENE_PRODUCT", 0, 5], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 54, 65], ["SARS-CoV", "ORGANISM", 177, 185], ["MHVIP-10", "GENE_OR_GENE_PRODUCT", 190, 198], ["T cell", "CELL", 228, 234], ["coronavirus", "ORGANISM", 253, 264], ["organs", "ORGAN", 274, 280], ["IRF-3-depending genes", "DNA", 0, 21], ["antiviral cytokines", "PROTEIN", 26, 45], ["type I IFNs", "PROTEIN", 54, 65], ["Cytokines", "PROTEIN", 141, 150], ["chemokines", "PROTEIN", 155, 165], ["SARS-CoV", "SPECIES", 177, 185], ["IRF", "TEST", 0, 3], ["antiviral cytokines", "PROBLEM", 26, 45], ["type I IFNs", "PROBLEM", 54, 65], ["infection", "PROBLEM", 131, 140], ["Cytokines", "TREATMENT", 141, 150], ["SARS", "PROBLEM", 177, 181], ["MHVIP", "TEST", 190, 195], ["a chemoattractant", "PROBLEM", 202, 219], ["T cell infiltration", "PROBLEM", 228, 247], ["coronavirus", "PROBLEM", 253, 264], ["infected organs", "PROBLEM", 265, 280], ["infection", "OBSERVATION", 131, 140], ["chemokines", "OBSERVATION", 155, 165], ["cell infiltration", "OBSERVATION", 230, 247]]], ["Initially identified as an IFN-\u03b3-responsive gene, it was later shown to be induced by IFN-\u03b1/\u03b2 [138] and virus infections including those with SARS-CoV [129], [139].", [["infections", "DISEASE", 110, 120], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 27, 33], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 86, 91], ["\u03b2", "GENE_OR_GENE_PRODUCT", 92, 93], ["IFN-\u03b3-responsive gene", "DNA", 27, 48], ["IFN", "PROTEIN", 86, 89], ["SARS-CoV", "SPECIES", 142, 150], ["an IFN", "TEST", 24, 30], ["IFN", "TEST", 86, 89], ["virus infections", "PROBLEM", 104, 120], ["SARS", "TEST", 142, 146], ["CoV", "TEST", 147, 150]]], ["Interestingly, IP-10 is an excellent prognostic marker for SARS disease progression [140], [141], [142].", [["SARS", "DISEASE", 59, 63], ["IP-10", "GENE_OR_GENE_PRODUCT", 15, 20], ["SARS disease progression", "PROBLEM", 59, 83]]], ["This implicates that the findings in cell culture reflect the in vivo situation to a considerable extent, and that IP-10-mediated lymphocyte infiltrations may play a major part in SARS pathology in a manner similar to other viral diseases [143].In vivo cytokine profile and SARS pathologyPatient studies can rarely be standardized and controlled with the same accuracy as in vitro studies.", [["cell culture", "ANATOMY", 37, 49], ["lymphocyte", "ANATOMY", 130, 140], ["SARS", "DISEASE", 180, 184], ["viral diseases", "DISEASE", 224, 238], ["SARS", "DISEASE", 274, 278], ["cell culture", "CELL", 37, 49], ["IP-10", "GENE_OR_GENE_PRODUCT", 115, 120], ["lymphocyte", "CELL", 130, 140], ["cytokine", "PROTEIN", 253, 261], ["Patient", "SPECIES", 288, 295], ["cell culture", "TEST", 37, 49], ["IP-10-mediated lymphocyte infiltrations", "PROBLEM", 115, 154], ["SARS pathology", "PROBLEM", 180, 194], ["other viral diseases", "PROBLEM", 218, 238], ["vivo cytokine profile", "TEST", 248, 269], ["SARS pathology", "TEST", 274, 288], ["Patient studies", "TEST", 288, 303], ["vitro studies", "TEST", 375, 388], ["lymphocyte infiltrations", "OBSERVATION", 130, 154], ["cytokine profile", "OBSERVATION", 253, 269]]], ["Moreover, the kinetics and interrelation of cytokine production and SARS-CoV spread, a critical point for data interpretation, cannot be properly investigated with human subjects.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 68, 76], ["human", "ORGANISM", 164, 169], ["cytokine", "PROTEIN", 44, 52], ["human", "SPECIES", 164, 169], ["SARS-CoV", "SPECIES", 68, 76], ["human", "SPECIES", 164, 169], ["the kinetics", "PROBLEM", 10, 22], ["cytokine production", "PROBLEM", 44, 63], ["SARS", "PROBLEM", 68, 72], ["data interpretation", "TEST", 106, 125], ["cytokine production", "OBSERVATION", 44, 63]]], ["Nonetheless data obtained from ex vivo peripheral blood mononuclear cells or from SARS patients\u2019 sera are largely in agreement with the above-discussed findings in cell culture.In vivo cytokine profile and SARS pathologyMost studies involving patient materials found no significant upregulation for \u03b1/\u03b2-IFNs or for IFN-induced genes [139], [140], [144], [145], [146], [147], [148].", [["peripheral blood mononuclear cells", "ANATOMY", 39, 73], ["sera", "ANATOMY", 97, 101], ["cell culture", "ANATOMY", 164, 176], ["SARS", "DISEASE", 82, 86], ["SARS", "DISEASE", 206, 210], ["peripheral blood mononuclear cells", "CELL", 39, 73], ["patients", "ORGANISM", 87, 95], ["sera", "ORGANISM_SUBSTANCE", 97, 101], ["cell culture", "CELL", 164, 176], ["patient", "ORGANISM", 243, 250], ["\u03b2-IFNs", "GENE_OR_GENE_PRODUCT", 301, 307], ["IFN", "GENE_OR_GENE_PRODUCT", 315, 318], ["[140]", "SIMPLE_CHEMICAL", 340, 345], ["peripheral blood mononuclear cells", "CELL_TYPE", 39, 73], ["cytokine", "PROTEIN", 185, 193], ["\u03b1", "PROTEIN", 299, 300], ["\u03b2", "PROTEIN", 301, 302], ["IFNs", "PROTEIN", 303, 307], ["IFN", "PROTEIN", 315, 318], ["patients", "SPECIES", 87, 95], ["patient", "SPECIES", 243, 250], ["peripheral blood mononuclear cells", "TEST", 39, 73], ["cell culture", "TEST", 164, 176], ["vivo cytokine profile", "TEST", 180, 201], ["SARS pathology", "TEST", 206, 220], ["Most studies", "TEST", 220, 232], ["patient materials", "TEST", 243, 260], ["significant upregulation", "PROBLEM", 270, 294], ["\u03b1/\u03b2", "TEST", 299, 302], ["IFNs", "PROBLEM", 303, 307], ["IFN", "PROBLEM", 315, 318], ["peripheral", "ANATOMY_MODIFIER", 39, 49], ["blood", "ANATOMY", 50, 55], ["mononuclear cells", "OBSERVATION", 56, 73], ["cytokine profile", "OBSERVATION", 185, 201]]], ["Interestingly, however, a recent study investigating immune responses of 40 clinically well-defined SARS cases revealed high levels of plasma IFN-\u03b1 (but not IFN-\u03b2) and an untypical ISG expression profile in pre-crisis patients, but not in the crisis patients [122].", [["plasma", "ANATOMY", 135, 141], ["SARS", "DISEASE", 100, 104], ["plasma", "ORGANISM_SUBSTANCE", 135, 141], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 142, 147], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 157, 162], ["ISG", "GENE_OR_GENE_PRODUCT", 181, 184], ["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 250, 258], ["plasma IFN-\u03b1", "PROTEIN", 135, 147], ["IFN", "PROTEIN", 157, 160], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 250, 258], ["a recent study", "TEST", 24, 38], ["immune responses", "TEST", 53, 69], ["SARS cases", "TEST", 100, 110], ["high levels of plasma IFN-\u03b1", "PROBLEM", 120, 147], ["an untypical ISG expression profile", "PROBLEM", 168, 203], ["high levels", "OBSERVATION_MODIFIER", 120, 131]]], ["Possibly, these significant amounts of IFN-\u03b1 early in infection are produced by infected pDCs, as those cells are capable of a full response to SARS-CoV [92].In vivo cytokine profile and SARS pathologyHigh levels of the chemokines IL-8 and IP-10 along with the proinflammatory cytokine IL-6 [139], [140], [146], [148], [149], [150], [151], [152], [153] were often detected in patients.", [["pDCs", "ANATOMY", 89, 93], ["cells", "ANATOMY", 104, 109], ["infection", "DISEASE", 54, 63], ["SARS", "DISEASE", 144, 148], ["SARS", "DISEASE", 187, 191], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 39, 44], ["pDCs", "CELL", 89, 93], ["cells", "CELL", 104, 109], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 144, 152], ["IL-8", "GENE_OR_GENE_PRODUCT", 231, 235], ["IP-10", "GENE_OR_GENE_PRODUCT", 240, 245], ["IL-6", "GENE_OR_GENE_PRODUCT", 286, 290], ["[140]", "SIMPLE_CHEMICAL", 298, 303], ["[146]", "SIMPLE_CHEMICAL", 305, 310], ["[148]", "SIMPLE_CHEMICAL", 312, 317], ["[149]", "SIMPLE_CHEMICAL", 319, 324], ["[150]", "SIMPLE_CHEMICAL", 326, 331], ["[151]", "SIMPLE_CHEMICAL", 333, 338], ["[152]", "SIMPLE_CHEMICAL", 340, 345], ["[153]", "SIMPLE_CHEMICAL", 347, 352], ["patients", "ORGANISM", 376, 384], ["IFN", "PROTEIN", 39, 42], ["pDCs", "CELL_TYPE", 89, 93], ["cytokine", "PROTEIN", 166, 174], ["chemokines", "PROTEIN", 220, 230], ["IL-8", "PROTEIN", 231, 235], ["IP-10", "PROTEIN", 240, 245], ["proinflammatory cytokine", "PROTEIN", 261, 285], ["patients", "SPECIES", 376, 384], ["SARS-CoV", "SPECIES", 144, 152], ["IFN", "PROBLEM", 39, 42], ["infection", "PROBLEM", 54, 63], ["infected pDCs", "PROBLEM", 80, 93], ["SARS", "TEST", 144, 148], ["CoV", "TEST", 149, 152], ["vivo cytokine profile", "TEST", 161, 182], ["SARS pathology", "TEST", 187, 201], ["the chemokines IL", "TEST", 216, 233], ["IP", "TEST", 240, 242], ["the proinflammatory cytokine IL", "TEST", 257, 288], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["amounts", "OBSERVATION_MODIFIER", 28, 35], ["IFN", "OBSERVATION", 39, 42], ["infection", "OBSERVATION", 54, 63], ["cytokine profile", "OBSERVATION", 166, 182]]], ["Given the cell culture results for SARS-CoV, at least for IL-8 and IP-10 a direct production by virus-infected cells is conceivable.", [["cell", "ANATOMY", 10, 14], ["cells", "ANATOMY", 111, 116], ["SARS", "DISEASE", 35, 39], ["cell", "CELL", 10, 14], ["SARS-CoV", "ORGANISM", 35, 43], ["IL-8", "GENE_OR_GENE_PRODUCT", 58, 62], ["IP-10", "GENE_OR_GENE_PRODUCT", 67, 72], ["cells", "CELL", 111, 116], ["IL", "PROTEIN", 58, 60], ["virus-infected cells", "CELL_TYPE", 96, 116], ["SARS-CoV", "SPECIES", 35, 43], ["the cell culture", "TEST", 6, 22], ["SARS", "PROBLEM", 35, 39], ["CoV", "TEST", 40, 43], ["IL", "TEST", 58, 60], ["IP", "TEST", 67, 69], ["infected cells", "PROBLEM", 102, 116], ["infected cells", "OBSERVATION", 102, 116]]], ["IL-6, however, is not or only weakly induced in productively infected tissue cells [107], [127], [154], [155] but moderately upregulated in abortively infected macrophages and DCs [156].", [["tissue cells", "ANATOMY", 70, 82], ["macrophages", "ANATOMY", 160, 171], ["DCs", "ANATOMY", 176, 179], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissue cells", "CELL", 70, 82], ["macrophages", "CELL", 160, 171], ["DCs", "CELL", 176, 179], ["IL-6", "PROTEIN", 0, 4], ["productively infected tissue cells", "CELL_TYPE", 48, 82], ["abortively infected macrophages", "CELL_TYPE", 140, 171], ["DCs", "CELL_TYPE", 176, 179], ["IL", "TEST", 0, 2], ["productively infected tissue cells", "PROBLEM", 48, 82], ["DCs", "TEST", 176, 179], ["infected", "OBSERVATION", 61, 69], ["moderately upregulated", "OBSERVATION_MODIFIER", 114, 136], ["infected macrophages", "OBSERVATION", 151, 171]]], ["Interestingly, IL-6 induction by SARS-CoV could be strongly boosted by priming of macrophages with bacterial LPS [157].", [["macrophages", "ANATOMY", 82, 93], ["SARS", "DISEASE", 33, 37], ["LPS", "CHEMICAL", 109, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["SARS-CoV", "ORGANISM", 33, 41], ["macrophages", "CELL", 82, 93], ["IL-6", "PROTEIN", 15, 19], ["macrophages", "CELL_TYPE", 82, 93], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV", "PROBLEM", 38, 41], ["bacterial LPS", "TEST", 99, 112]]], ["Thus, it can be speculated that IL-8 and IP-10 in SARS patients are directly produced by virus-infected cells, whereas upregulation of the proinflammatory cytokine IL-6 is more likely a secondary response due to an activation of the immune system.In vivo cytokine profile and SARS pathologyHigh viral load, systemic and multiorgan infection, massive lung infiltrations by monocytes and macrophages, and rapid depletion of T cells are the hallmarks of full-blown SARS [2], [7], [158], [159], [160], [161], [162], [163], [164], [165], [166].", [["cells", "ANATOMY", 104, 109], ["immune system", "ANATOMY", 233, 246], ["multiorgan", "ANATOMY", 320, 330], ["lung", "ANATOMY", 350, 354], ["monocytes", "ANATOMY", 372, 381], ["macrophages", "ANATOMY", 386, 397], ["T cells", "ANATOMY", 422, 429], ["SARS", "DISEASE", 50, 54], ["SARS", "DISEASE", 276, 280], ["infection", "DISEASE", 331, 340], ["SARS", "DISEASE", 462, 466], ["IL-8", "GENE_OR_GENE_PRODUCT", 32, 36], ["IP-10", "GENE_OR_GENE_PRODUCT", 41, 46], ["SARS", "ORGANISM", 50, 54], ["patients", "ORGANISM", 55, 63], ["cells", "CELL", 104, 109], ["IL-6", "GENE_OR_GENE_PRODUCT", 164, 168], ["lung", "ORGAN", 350, 354], ["monocytes", "CELL", 372, 381], ["macrophages", "CELL", 386, 397], ["T cells", "CELL", 422, 429], ["[7]", "SIMPLE_CHEMICAL", 472, 475], ["[158]", "SIMPLE_CHEMICAL", 477, 482], ["[159]", "SIMPLE_CHEMICAL", 484, 489], ["[160]", "SIMPLE_CHEMICAL", 491, 496], ["[161]", "SIMPLE_CHEMICAL", 498, 503], ["[162]", "SIMPLE_CHEMICAL", 505, 510], ["[163]", "SIMPLE_CHEMICAL", 512, 517], ["[164]", "SIMPLE_CHEMICAL", 519, 524], ["[165]", "SIMPLE_CHEMICAL", 526, 531], ["IL-8", "PROTEIN", 32, 36], ["virus-infected cells", "CELL_TYPE", 89, 109], ["proinflammatory cytokine IL-6", "PROTEIN", 139, 168], ["cytokine", "PROTEIN", 255, 263], ["monocytes", "CELL_TYPE", 372, 381], ["macrophages", "CELL_TYPE", 386, 397], ["T cells", "CELL_TYPE", 422, 429], ["patients", "SPECIES", 55, 63], ["IL", "TEST", 32, 34], ["IP", "TEST", 41, 43], ["SARS", "PROBLEM", 50, 54], ["infected cells", "PROBLEM", 95, 109], ["the proinflammatory cytokine IL", "TEST", 135, 166], ["an activation of the immune system", "PROBLEM", 212, 246], ["vivo cytokine profile", "TEST", 250, 271], ["SARS pathology", "TEST", 276, 290], ["High viral load", "PROBLEM", 290, 305], ["systemic and multiorgan infection", "PROBLEM", 307, 340], ["massive lung infiltrations", "PROBLEM", 342, 368], ["monocytes", "TEST", 372, 381], ["macrophages", "PROBLEM", 386, 397], ["rapid depletion of T cells", "PROBLEM", 403, 429], ["infected cells", "OBSERVATION", 95, 109], ["proinflammatory", "OBSERVATION_MODIFIER", 139, 154], ["more likely", "UNCERTAINTY", 172, 183], ["secondary response", "OBSERVATION", 186, 204], ["immune system", "OBSERVATION", 233, 246], ["cytokine profile", "OBSERVATION", 255, 271], ["viral load", "OBSERVATION", 295, 305], ["systemic", "OBSERVATION_MODIFIER", 307, 315], ["multiorgan", "ANATOMY", 320, 330], ["infection", "OBSERVATION", 331, 340], ["massive", "OBSERVATION_MODIFIER", 342, 349], ["lung", "ANATOMY", 350, 354], ["infiltrations", "OBSERVATION", 355, 368], ["monocytes", "OBSERVATION_MODIFIER", 372, 381], ["macrophages", "OBSERVATION_MODIFIER", 386, 397], ["rapid", "OBSERVATION_MODIFIER", 403, 408], ["depletion", "OBSERVATION_MODIFIER", 409, 418], ["T cells", "OBSERVATION", 422, 429]]], ["It is debated whether the disease is caused by the virus or is the result of a dysregulated immune response.", [["the disease", "PROBLEM", 22, 33], ["the virus", "PROBLEM", 47, 56], ["a dysregulated immune response", "PROBLEM", 77, 107], ["disease", "OBSERVATION", 26, 33], ["virus", "OBSERVATION", 51, 56], ["dysregulated immune response", "OBSERVATION", 79, 107]]], ["After primary infection, SARS-CoV grows at a fast rate and spreads to different organs, including the lungs [161], [164], [167].", [["organs", "ANATOMY", 80, 86], ["lungs", "ANATOMY", 102, 107], ["primary infection", "DISEASE", 6, 23], ["SARS", "DISEASE", 25, 29], ["SARS-CoV", "ORGANISM", 25, 33], ["organs", "ORGAN", 80, 86], ["lungs", "ORGAN", 102, 107], ["SARS-CoV", "SPECIES", 25, 33], ["primary infection", "PROBLEM", 6, 23], ["SARS", "PROBLEM", 25, 29], ["CoV", "PROBLEM", 30, 33], ["infection", "OBSERVATION", 14, 23], ["lungs", "ANATOMY", 102, 107]]], ["Autopsies from deceased patients revealed severe damage of the lungs and lymphatic tissues, accompanied by infiltrations of monocytic cells [168], [169], [170].", [["lungs", "ANATOMY", 63, 68], ["lymphatic tissues", "ANATOMY", 73, 90], ["monocytic cells", "ANATOMY", 124, 139], ["damage of the lungs", "DISEASE", 49, 68], ["patients", "ORGANISM", 24, 32], ["lungs", "ORGAN", 63, 68], ["lymphatic tissues", "TISSUE", 73, 90], ["monocytic cells", "CELL", 124, 139], ["monocytic cells", "CELL_TYPE", 124, 139], ["patients", "SPECIES", 24, 32], ["severe damage of the lungs and lymphatic tissues", "PROBLEM", 42, 90], ["infiltrations of monocytic cells", "PROBLEM", 107, 139], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["damage", "OBSERVATION", 49, 55], ["lungs", "ANATOMY", 63, 68], ["lymphatic tissues", "ANATOMY", 73, 90], ["infiltrations", "OBSERVATION", 107, 120], ["monocytic cells", "OBSERVATION", 124, 139]]], ["This may indicate that immunopathogenesis is involved in the severe outcome of the disease, providing the rationale for SARS therapy with immunosuppressant corticosteroids [171].", [["SARS", "DISEASE", 120, 124], ["corticosteroids", "CHEMICAL", 156, 171], ["immunopathogenesis", "PROBLEM", 23, 41], ["the disease", "PROBLEM", 79, 90], ["SARS therapy", "TREATMENT", 120, 132], ["immunosuppressant corticosteroids", "TREATMENT", 138, 171], ["may indicate", "UNCERTAINTY", 5, 17], ["immunopathogenesis", "OBSERVATION", 23, 41], ["severe", "OBSERVATION_MODIFIER", 61, 67]]], ["On the other hand, cell damages could have been directly caused by the virus, as SARS-CoV is cytolytic [172], and high titers of virus have been found in several organs of deceased patients [160], [161], [173].", [["cell", "ANATOMY", 19, 23], ["organs", "ANATOMY", 162, 168], ["SARS", "DISEASE", 81, 85], ["cell", "CELL", 19, 23], ["SARS-CoV", "ORGANISM", 81, 89], ["organs", "ORGAN", 162, 168], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["SARS-CoV", "SPECIES", 81, 89], ["cell damages", "PROBLEM", 19, 31], ["the virus", "PROBLEM", 67, 76], ["cytolytic", "TEST", 93, 102], ["high titers of virus", "PROBLEM", 114, 134], ["cell damages", "OBSERVATION", 19, 31], ["virus", "OBSERVATION", 71, 76]]], ["In addition, signs of necrosis were found besides virus particles in affected tissues [170], and high viral loads are predictive of adverse clinical outcome [174].In vivo cytokine profile and SARS pathologyThe cytokine profile outlined above most probably plays a significant role in SARS pathology.", [["tissues", "ANATOMY", 78, 85], ["necrosis", "DISEASE", 22, 30], ["SARS", "DISEASE", 192, 196], ["SARS", "DISEASE", 284, 288], ["tissues", "TISSUE", 78, 85], ["cytokine", "PROTEIN", 171, 179], ["cytokine", "PROTEIN", 210, 218], ["necrosis", "PROBLEM", 22, 30], ["virus particles in affected tissues", "PROBLEM", 50, 85], ["high viral loads", "PROBLEM", 97, 113], ["adverse clinical outcome", "PROBLEM", 132, 156], ["vivo cytokine profile", "TEST", 166, 187], ["SARS pathology", "TEST", 192, 206], ["The cytokine profile", "TEST", 206, 226], ["SARS pathology", "PROBLEM", 284, 298], ["necrosis", "OBSERVATION", 22, 30], ["viral loads", "OBSERVATION", 102, 113], ["cytokine profile", "OBSERVATION", 171, 187], ["significant", "OBSERVATION_MODIFIER", 264, 275], ["SARS", "OBSERVATION", 284, 288]]], ["In the initial phase of infection, dampening and misregulating the antiviral IFN response may allow the virus to grow rapidly and spread to different organs, including the lungs [161], [175].", [["organs", "ANATOMY", 150, 156], ["lungs", "ANATOMY", 172, 177], ["infection", "DISEASE", 24, 33], ["organs", "ORGAN", 150, 156], ["lungs", "ORGAN", 172, 177], ["IFN", "PROTEIN", 77, 80], ["infection", "PROBLEM", 24, 33], ["dampening", "PROBLEM", 35, 44], ["misregulating the antiviral IFN response", "TREATMENT", 49, 89], ["the virus", "PROBLEM", 100, 109], ["infection", "OBSERVATION", 24, 33], ["dampening", "OBSERVATION_MODIFIER", 35, 44], ["lungs", "ANATOMY", 172, 177]]], ["The early IFN-\u03b1 detected in patients before the onset of disease [122] may be derived from pDCs which are capable of responding to SARS-CoV [92], whereas IFN-\u03b2 production by tissue cells is suppressed [102].", [["pDCs", "ANATOMY", 91, 95], ["tissue cells", "ANATOMY", 174, 186], ["SARS", "DISEASE", 131, 135], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 10, 15], ["patients", "ORGANISM", 28, 36], ["pDCs", "CELL", 91, 95], ["SARS-CoV", "ORGANISM", 131, 139], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 154, 159], ["tissue cells", "CELL", 174, 186], ["IFN", "PROTEIN", 10, 13], ["\u03b1", "PROTEIN", 14, 15], ["pDCs", "CELL_TYPE", 91, 95], ["IFN", "PROTEIN", 154, 157], ["\u03b2", "PROTEIN", 158, 159], ["tissue cells", "CELL_TYPE", 174, 186], ["patients", "SPECIES", 28, 36], ["SARS-CoV", "SPECIES", 131, 139], ["The early IFN", "TEST", 0, 13], ["disease", "PROBLEM", 57, 64], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["IFN", "TEST", 154, 157], ["disease", "OBSERVATION", 57, 64]]], ["Thus, the virus buys time during the initial, critical phase of infection in order to establish itself in the host.", [["infection", "DISEASE", 64, 73], ["infection", "PROBLEM", 64, 73], ["infection", "OBSERVATION", 64, 73]]], ["At the same time, the virus-induced chemokines IP-10 and IL-8 attract immune cells.", [["immune cells", "ANATOMY", 70, 82], ["IP-10", "GENE_OR_GENE_PRODUCT", 47, 52], ["IL-8", "GENE_OR_GENE_PRODUCT", 57, 61], ["immune cells", "CELL", 70, 82], ["chemokines", "PROTEIN", 36, 46], ["IP-10 and IL-8", "PROTEIN", 47, 61], ["immune cells", "CELL_TYPE", 70, 82], ["the virus", "TEST", 18, 27], ["chemokines IP", "TEST", 36, 49], ["IL", "TEST", 57, 59], ["immune cells", "OBSERVATION", 70, 82]]], ["These invading cells can themselves be infected [161] and might produce even more chemokines and cytokines such as the proinflammatory cytokine IL-6 [142], [156] and possibly also IFN-\u03b3 (which can induce even more IP-10) and the anti-inflammatory cytokine TGF-\u03b2 [139], [140], [146], [176].", [["cells", "ANATOMY", 15, 20], ["invading cells", "CELL", 6, 20], ["IL-6", "GENE_OR_GENE_PRODUCT", 144, 148], ["[156]", "SIMPLE_CHEMICAL", 156, 161], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 180, 185], ["IP-10", "GENE_OR_GENE_PRODUCT", 214, 219], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 256, 261], ["[140]", "SIMPLE_CHEMICAL", 269, 274], ["[146]", "SIMPLE_CHEMICAL", 276, 281], ["invading cells", "CELL_TYPE", 6, 20], ["chemokines", "PROTEIN", 82, 92], ["cytokines", "PROTEIN", 97, 106], ["proinflammatory cytokine", "PROTEIN", 119, 143], ["IFN-\u03b3", "PROTEIN", 180, 185], ["anti-inflammatory cytokine", "PROTEIN", 229, 255], ["TGF", "PROTEIN", 256, 259], ["cytokines", "TEST", 97, 106], ["the proinflammatory cytokine IL", "TEST", 115, 146], ["IFN", "TEST", 180, 183], ["the anti-inflammatory cytokine TGF", "TEST", 225, 259]]], ["This mixture of high-level virus replication followed by the invasion of activated immune cells and production of both pro- and anti-inflammatory cytokines may result in a cytokine storm which leads to organ destruction and exhaustion of the immune system, eventually culminating in the severe and often fatal respiratory distress, the hallmark of full-blown SARS.Concluding remarksMuch has been learned about coronaviruses and their interactions with the IFN and cytokine responses, but a lot of questions still remain to be answered:\u2022How do coronaviruses escape from getting sensed by cytoplasmic PRRs?\u2022To which extend do the recently discovered IFN antagonists contribute to coronavirus-induced disease and pathology?\u2022Plasmid-expressed ORF3b, ORF6 and N of SARS-CoV are all able to inhibit IRF-3 [113], but coronavirus-infected cells fail to block IRF-3 activation by heterologous inducers [100], [104], [112].", [["immune cells", "ANATOMY", 83, 95], ["organ", "ANATOMY", 202, 207], ["immune system", "ANATOMY", 242, 255], ["respiratory", "ANATOMY", 310, 321], ["cytoplasmic", "ANATOMY", 587, 598], ["cells", "ANATOMY", 831, 836], ["organ destruction", "DISEASE", 202, 219], ["respiratory distress", "DISEASE", 310, 330], ["SARS", "DISEASE", 359, 363], ["coronavirus", "DISEASE", 678, 689], ["immune cells", "CELL", 83, 95], ["organ", "ORGAN", 202, 207], ["immune system", "ANATOMICAL_SYSTEM", 242, 255], ["coronaviruses", "ORGANISM", 410, 423], ["IFN", "GENE_OR_GENE_PRODUCT", 456, 459], ["coronaviruses", "ORGANISM", 543, 556], ["cytoplasmic", "ORGANISM_SUBSTANCE", 587, 598], ["PRRs", "GENE_OR_GENE_PRODUCT", 599, 603], ["IFN antagonists", "GENE_OR_GENE_PRODUCT", 648, 663], ["coronavirus", "ORGANISM", 678, 689], ["ORF3b", "GENE_OR_GENE_PRODUCT", 739, 744], ["ORF6", "GENE_OR_GENE_PRODUCT", 746, 750], ["SARS-CoV", "ORGANISM", 760, 768], ["IRF-3", "GENE_OR_GENE_PRODUCT", 793, 798], ["coronavirus", "ORGANISM", 810, 821], ["cells", "CELL", 831, 836], ["IRF-3", "GENE_OR_GENE_PRODUCT", 851, 856], ["[104]", "SIMPLE_CHEMICAL", 900, 905], ["activated immune cells", "CELL_TYPE", 73, 95], ["anti-inflammatory cytokines", "PROTEIN", 128, 155], ["cytokine", "PROTEIN", 172, 180], ["IFN", "PROTEIN", 456, 459], ["cytokine", "PROTEIN", 464, 472], ["cytoplasmic PRRs", "PROTEIN", 587, 603], ["IFN", "PROTEIN", 648, 651], ["ORF3b", "PROTEIN", 739, 744], ["ORF6", "PROTEIN", 746, 750], ["N", "PROTEIN", 755, 756], ["IRF", "PROTEIN", 793, 796], ["coronavirus-infected cells", "CELL_TYPE", 810, 836], ["IRF-3", "PROTEIN", 851, 856], ["coronavirus", "SPECIES", 678, 689], ["SARS-CoV", "SPECIES", 760, 768], ["high-level virus replication", "TREATMENT", 16, 44], ["activated immune cells", "PROBLEM", 73, 95], ["anti-inflammatory cytokines", "TREATMENT", 128, 155], ["a cytokine storm", "PROBLEM", 170, 186], ["organ destruction", "PROBLEM", 202, 219], ["exhaustion of the immune system", "PROBLEM", 224, 255], ["the severe and often fatal respiratory distress", "PROBLEM", 283, 330], ["coronaviruses", "PROBLEM", 410, 423], ["coronaviruses escape", "PROBLEM", 543, 563], ["IFN antagonists", "TREATMENT", 648, 663], ["coronavirus", "PROBLEM", 678, 689], ["induced disease", "PROBLEM", 690, 705], ["pathology", "PROBLEM", 710, 719], ["Plasmid", "TREATMENT", 721, 728], ["ORF6", "TEST", 746, 750], ["SARS", "PROBLEM", 760, 764], ["CoV", "PROBLEM", 765, 768], ["IRF", "TEST", 793, 796], ["coronavirus", "PROBLEM", 810, 821], ["infected cells", "PROBLEM", 822, 836], ["IRF", "TEST", 851, 854], ["virus replication", "OBSERVATION", 27, 44], ["immune cells", "OBSERVATION", 83, 95], ["cytokine storm", "OBSERVATION", 172, 186], ["organ", "ANATOMY", 202, 207], ["destruction", "OBSERVATION", 208, 219], ["immune system", "OBSERVATION", 242, 255], ["severe", "OBSERVATION_MODIFIER", 287, 293], ["often", "OBSERVATION_MODIFIER", 298, 303], ["fatal", "OBSERVATION_MODIFIER", 304, 309], ["respiratory distress", "OBSERVATION", 310, 330], ["hallmark", "OBSERVATION_MODIFIER", 336, 344], ["blown SARS", "OBSERVATION", 353, 363], ["coronavirus", "OBSERVATION", 678, 689]]], ["How is this specificity of the coronaviral IRF-3 antagonists achieved?\u2022Are there other, evolutionary conserved IFN antagonists encoded by all coronaviruses, and do they target the same signaling pathway(s)?\u2022Are other IRFs, such as IRF-7 or IRF-5, inhibited to the same extent as IRF-3?\u2022How important is the early type I IFN response in vivo?", [["IRF-3", "GENE_OR_GENE_PRODUCT", 43, 48], ["IFN antagonists", "GENE_OR_GENE_PRODUCT", 111, 126], ["IRF-7", "GENE_OR_GENE_PRODUCT", 231, 236], ["IRF-5", "GENE_OR_GENE_PRODUCT", 240, 245], ["IRF-3", "GENE_OR_GENE_PRODUCT", 279, 284], ["type I IFN", "GENE_OR_GENE_PRODUCT", 313, 323], ["coronaviral IRF-3", "PROTEIN", 31, 48], ["IFN antagonists", "PROTEIN", 111, 126], ["IRFs", "PROTEIN", 217, 221], ["IRF-7", "PROTEIN", 231, 236], ["IRF-5", "PROTEIN", 240, 245], ["IRF", "PROTEIN", 279, 282], ["IFN", "PROTEIN", 320, 323], ["the coronaviral IRF", "PROBLEM", 27, 46], ["antagonists", "TREATMENT", 49, 60], ["other IRFs", "PROBLEM", 211, 221], ["IRF", "TEST", 231, 234], ["IRF", "PROBLEM", 240, 243], ["IRFs", "OBSERVATION", 217, 221], ["IRF", "OBSERVATION", 279, 282]]], ["Data in the MHV system indicate that early, mainly pDC-mediated, type I IFN responses are essential to control MHV infections [92].", [["MHV infections", "DISEASE", 111, 125], ["MHV", "ORGANISM", 12, 15], ["pDC", "CELL", 51, 54], ["type I IFN", "GENE_OR_GENE_PRODUCT", 65, 75], ["MHV", "ORGANISM", 111, 114], ["pDC", "CELL_TYPE", 51, 54], ["IFN", "PROTEIN", 72, 75], ["MHV", "SPECIES", 12, 15], ["MHV", "SPECIES", 111, 114], ["type I IFN responses", "PROBLEM", 65, 85], ["MHV infections", "PROBLEM", 111, 125]]], ["In agreement with this it has recently been shown that SARS-CoV infection triggers an early type I IFN response in cynomolgus macaques [177].", [["SARS-CoV infection", "DISEASE", 55, 73], ["SARS-CoV", "ORGANISM", 55, 63], ["type I IFN", "GENE_OR_GENE_PRODUCT", 92, 102], ["cynomolgus macaques", "ORGANISM", 115, 134], ["IFN", "PROTEIN", 99, 102], ["cynomolgus macaques", "SPECIES", 115, 134], ["SARS-CoV", "SPECIES", 55, 63], ["cynomolgus macaques", "SPECIES", 115, 134], ["SARS", "PROBLEM", 55, 59], ["CoV infection", "PROBLEM", 60, 73], ["an early type I IFN response", "PROBLEM", 83, 111]]], ["Interestingly, STAT 1 nuclear import was impaired in SARS-CoV infected cells, but not in surrounding non-infected cells.\u2022What are the main type I IFN responder cells and how important are they to control coronavirus infection in vivo?\u2022Which ISG(s) is/are responsible for inhibiting coronavirus replication?", [["nuclear", "ANATOMY", 22, 29], ["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 114, 119], ["cells", "ANATOMY", 160, 165], ["SARS-CoV infected", "DISEASE", 53, 70], ["coronavirus infection", "DISEASE", 204, 225], ["STAT 1", "GENE_OR_GENE_PRODUCT", 15, 21], ["nuclear", "CELLULAR_COMPONENT", 22, 29], ["SARS-CoV", "ORGANISM", 53, 61], ["cells", "CELL", 71, 76], ["cells", "CELL", 114, 119], ["cells", "CELL", 160, 165], ["coronavirus", "ORGANISM", 204, 215], ["ISG", "GENE_OR_GENE_PRODUCT", 241, 244], ["coronavirus", "ORGANISM", 282, 293], ["STAT 1", "PROTEIN", 15, 21], ["SARS-CoV infected cells", "CELL_LINE", 53, 76], ["non-infected cells", "CELL_TYPE", 101, 119], ["type I IFN responder cells", "CELL_TYPE", 139, 165], ["SARS-CoV", "SPECIES", 53, 61], ["SARS", "PROBLEM", 53, 57], ["CoV infected cells", "PROBLEM", 58, 76], ["coronavirus infection", "PROBLEM", 204, 225], ["inhibiting coronavirus replication", "PROBLEM", 271, 305], ["infected cells", "OBSERVATION", 62, 76], ["non-infected cells", "OBSERVATION", 101, 119]]], ["Given the high amount of dsRNA in infected cells [43], [100], PKR, RNaseL and ADAR qualify as the prime candidates.\u2022How do the observed cell type-specific IFN and cytokine expression patterns impact on coronavirus disease and pathology?", [["cells", "ANATOMY", 43, 48], ["cell", "ANATOMY", 136, 140], ["coronavirus disease", "DISEASE", 202, 221], ["cells", "CELL", 43, 48], ["PKR", "GENE_OR_GENE_PRODUCT", 62, 65], ["RNaseL", "GENE_OR_GENE_PRODUCT", 67, 73], ["ADAR", "GENE_OR_GENE_PRODUCT", 78, 82], ["cell", "CELL", 136, 140], ["IFN", "GENE_OR_GENE_PRODUCT", 155, 158], ["coronavirus", "ORGANISM", 202, 213], ["infected cells", "CELL_TYPE", 34, 48], ["PKR", "PROTEIN", 62, 65], ["RNaseL", "PROTEIN", 67, 73], ["ADAR", "PROTEIN", 78, 82], ["IFN", "PROTEIN", 155, 158], ["cytokine", "PROTEIN", 163, 171], ["coronavirus", "SPECIES", 202, 213], ["dsRNA in infected cells", "PROBLEM", 25, 48], ["PKR", "TEST", 62, 65], ["cytokine expression patterns", "PROBLEM", 163, 191], ["coronavirus disease", "PROBLEM", 202, 221], ["pathology", "TEST", 226, 235], ["high amount", "OBSERVATION_MODIFIER", 10, 21], ["dsRNA", "OBSERVATION", 25, 30], ["infected cells", "OBSERVATION", 34, 48], ["coronavirus disease", "OBSERVATION", 202, 221]]]], "09f86f2f97cc4fad18e9e26ac2fac7d8a3518d05": [], "PMC7152164": [["IntroductionBiological warfare has complex and permanent impact on the environment in comparison to other war types (conventional, nuclear, chemical).", [["nuclear", "CELLULAR_COMPONENT", 131, 138]]], ["Today, the most probable type and the key issue of biological war is bioterrorism.", [["most probable type", "OBSERVATION_MODIFIER", 11, 29], ["bioterrorism", "OBSERVATION", 69, 81]]], ["Bioterrorism itself is defined as a release of biological agents or toxins that affect human beings, animals, or plants with the intent to harm or intimidate.", [["Bioterrorism", "DISEASE", 0, 12], ["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["biological agents", "TREATMENT", 47, 64], ["toxins", "TREATMENT", 68, 74]]], ["The essence of bioterrorism is a biological attack.", [["bioterrorism", "PROBLEM", 15, 27], ["a biological attack", "PROBLEM", 31, 50], ["bioterrorism", "OBSERVATION", 15, 27]]], ["Four components are required for a biological attack: perpetrators, agents, mediums/means of delivery, and targets.IntroductionTo simplify the correlation and impact of the environment on bioterrorism, each component of biological attack, and its correlation to environmental health, has been analyzed.", [["delivery", "TREATMENT", 93, 101], ["biological attack", "PROBLEM", 220, 237]]], ["Considering these facts, it is practically impossible to have a unique doctrine for each eventual threat.", [["a unique doctrine", "TREATMENT", 62, 79]]], ["In the modern world, the \u2018global environment\u2019 \u2013 political, social, economic, and psychological environments \u2013 and the mass media distinguish themselves as very important, thus adding a new dimension to natural epidemics and biological attacks.IntroductionDiscoveries that certain bioterrorist (emerging and reemerging) pathogens have their origin in environmental changes have given rise to an urgent need to understand how these environmental changes impact bioterrorism.", [["pathogens", "PROBLEM", 319, 328]]], ["An environmental change manifests itself through a complex web of ecologic and social factors that may ultimately affect bioterrorism activities.", [["An environmental change", "PROBLEM", 0, 23], ["environmental change", "OBSERVATION", 3, 23]]], ["Transmission dynamics of infectious pathogens mediate the effects that environmental changes have on bioterrorism activities.", [["infectious pathogens", "PROBLEM", 25, 45], ["infectious", "OBSERVATION", 25, 35]]], ["Bioterrorist occurrence could be the outcome of the interplay between environmental change and the transmission cycle of a pathogen.IntroductionEnvironmental changes include anthropogenic changes that affect landscape ecology, human ecology, and human-created environments as well as natural perturbations and natural disasters.", [["human", "ORGANISM", 227, 232], ["human", "ORGANISM", 246, 251], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 246, 251], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 246, 251], ["a pathogen", "PROBLEM", 121, 131], ["anthropogenic changes", "PROBLEM", 174, 195], ["anthropogenic", "OBSERVATION", 174, 187]]], ["Environmental characteristics are defined as directly measurable physical, chemical, biological, or social components of the environments including populations and traits of relevant organisms.", [["relevant organisms", "PROBLEM", 174, 192]]], ["Every environmental perturbation influences the ecological balance and context within populations, in which disease manifests itself.", [["disease", "OBSERVATION", 108, 115]]], ["Many outbreaks are interrelated to global and local changes caused by climate change, human-induced landscape changes, or the direct impact of human activities.", [["human", "ORGANISM", 86, 91], ["human", "ORGANISM", 143, 148], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 143, 148], ["outbreaks", "OBSERVATION", 5, 14], ["global", "OBSERVATION_MODIFIER", 35, 41], ["local", "OBSERVATION_MODIFIER", 46, 51], ["climate change", "OBSERVATION", 70, 84]]], ["Landscape impacts such as de(re)forestation, human settlement sprawl, industrial development, road construction (e.g., linear disturbances), large water control projects (e.g., dams, canals, irrigation systems, and reservoirs), and climate change have been accompanied by the spread of pathogens into new areas.", [["human", "ORGANISM", 45, 50], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["human settlement sprawl", "TREATMENT", 45, 68], ["linear disturbances", "PROBLEM", 119, 138], ["large water control", "TREATMENT", 141, 160], ["irrigation systems", "TREATMENT", 191, 209], ["large", "OBSERVATION_MODIFIER", 141, 146], ["canals", "ANATOMY", 183, 189]]], ["Changing environmental process might affect transmission cycles of infectious pathogens.", [["infectious pathogens", "PROBLEM", 67, 87], ["infectious", "OBSERVATION_MODIFIER", 67, 77]]], ["These changes affect the hosts or vectors of disease and the pathogens and parasites that breed, develop, and transmit disease.", [["disease", "PROBLEM", 45, 52], ["the pathogens", "PROBLEM", 57, 70], ["parasites", "PROBLEM", 75, 84], ["transmit disease", "PROBLEM", 110, 126]]], ["Vector-borne zoonoses tend to be the most ecologically complex infectious diseases in which environmental change may have the greatest number and diversity of effects, some promoting transmission and others diminishing it.", [["complex infectious diseases", "PROBLEM", 55, 82], ["infectious", "OBSERVATION", 63, 73]]], ["Habitat and species losses may reduce the normal buffering within ecosystems, leading to disease outbreaks.", [["species losses", "PROBLEM", 12, 26], ["disease outbreaks", "PROBLEM", 89, 106]]], ["Finally, the juxtaposition of new vectors, hosts, and parasites within disturbed ecosystems provides a potential for the evolution of novel transmission pathways and thus new \u2018emerging diseases.\u2019", [["new vectors", "TREATMENT", 30, 41], ["parasites", "PROBLEM", 54, 63], ["new \u2018emerging diseases", "PROBLEM", 171, 193], ["new", "OBSERVATION_MODIFIER", 30, 33]]], ["It is needed to learn more about the underlying complex causal relationships and apply this information to the prediction of future impacts, using more complete, better validated, integrated, models.IntroductionThe World Health Organization (WHO) has recorded over 36 new emerging infectious diseases since 1976; many of these are reemerging diseases, resulting directly from the landscape influence on disease ecology.", [["infectious diseases", "DISEASE", 281, 300], ["reemerging diseases", "PROBLEM", 331, 350], ["infectious", "OBSERVATION", 281, 291], ["reemerging", "OBSERVATION_MODIFIER", 331, 341], ["diseases", "OBSERVATION", 342, 350]]], ["It is estimated that 75% of all emerging diseases stem from animal zoonoses.", [["zoonoses", "DISEASE", 67, 75], ["all emerging diseases stem", "PROBLEM", 28, 54], ["diseases", "OBSERVATION", 41, 49]]], ["Habitat fragmentation causes a reduction in biodiversity within the host communities, increasing disease risk through the increase in both the absolute and relative density of the primary reservoir.", [["communities", "ANATOMY", 73, 84], ["Habitat fragmentation", "PROBLEM", 0, 21], ["a reduction in biodiversity", "TREATMENT", 29, 56], ["increasing disease risk", "PROBLEM", 86, 109], ["fragmentation", "OBSERVATION", 8, 21], ["reduction", "OBSERVATION_MODIFIER", 31, 40], ["biodiversity", "OBSERVATION_MODIFIER", 44, 56], ["increasing", "OBSERVATION_MODIFIER", 86, 96], ["disease", "OBSERVATION", 97, 104], ["increase", "OBSERVATION_MODIFIER", 122, 130], ["both", "OBSERVATION_MODIFIER", 134, 138], ["absolute", "OBSERVATION_MODIFIER", 143, 151], ["relative", "OBSERVATION_MODIFIER", 156, 164], ["density", "OBSERVATION", 165, 172], ["primary", "OBSERVATION_MODIFIER", 180, 187], ["reservoir", "OBSERVATION_MODIFIER", 188, 197]]], ["Since urban growth in many countries occurs without planned sanitation, water treatment, and sewerage, increased exposure to mosquitoes, rodents, and other vermin provides more opportunities for diseases such as tuberculosis and hantavirus.", [["vermin", "CHEMICAL", 156, 162], ["tuberculosis", "DISEASE", 212, 224], ["hantavirus", "DISEASE", 229, 239], ["vermin", "GENE_OR_GENE_PRODUCT", 156, 162], ["water treatment", "TREATMENT", 72, 87], ["diseases", "PROBLEM", 195, 203], ["tuberculosis", "PROBLEM", 212, 224], ["hantavirus", "PROBLEM", 229, 239], ["tuberculosis", "OBSERVATION", 212, 224]]], ["Mining, damming of rivers, and increased irrigation for agriculture also give mosquitoes more standing water to breed in.", [["increased irrigation", "TREATMENT", 31, 51], ["agriculture", "TREATMENT", 56, 67]]], ["Man, in so doing, makes himself his major bioterrorist.", [["Man", "SPECIES", 0, 3]]], ["Carefully controlled use of resources would gain great benefits to struggle against bioterrorism, and other threats of natural pathogens.", [["bioterrorism", "PROBLEM", 84, 96], ["natural pathogens", "PROBLEM", 119, 136], ["natural pathogens", "OBSERVATION", 119, 136]]], ["In the context of bioterrorism, infectious diseases are not only the public health issue, but also the issue of national and international security.Perpetrators ::: Bioterrorism Related to HumansThe first link in conducting biological attack is perpetrator.", [["infectious diseases", "DISEASE", 32, 51], ["bioterrorism", "PROBLEM", 18, 30], ["Bioterrorism", "PROBLEM", 165, 177], ["bioterrorism", "OBSERVATION", 18, 30], ["infectious", "OBSERVATION", 32, 42]]], ["The most prevailing and dangerous bioterrorist is man through his numerous activities (auto-bioterrorism).", [["man", "ORGANISM", 50, 53], ["man", "SPECIES", 50, 53]]], ["Auto-bioterrorism could be performed through many environmental changes (Table 1).Perpetrators ::: Bioterrorism Related to HumansSome changes affect disease only through a series of casual linkages.", [["Bioterrorism", "PROBLEM", 99, 111], ["Some changes affect disease", "PROBLEM", 129, 156]]], ["Instead, it causes changes in water flow, which affects mosquito habitats, and that, in turn, could affect transmission potential of biological agent.", [["water", "SIMPLE_CHEMICAL", 30, 35], ["changes in water flow", "PROBLEM", 19, 40], ["biological agent", "TREATMENT", 133, 149], ["water flow", "OBSERVATION", 30, 40]]], ["A new road may affect disease through major demographic shifts.Perpetrators ::: Bioterrorism Related to HumansThe real threats are terrorist/disaffected groups, making environment very important source of agents.", [["disease", "PROBLEM", 22, 29], ["Bioterrorism", "PROBLEM", 80, 92]]], ["Highly motivated perpetrators (mainly poor terrorists/fanatics with suicidal tendency, e.g., suicidal bio-bombers) are the most probable candidates for getting biological agents from the nature.", [["suicidal tendency", "PROBLEM", 68, 85], ["biological agents", "TREATMENT", 160, 177]]], ["At least 22 countries are believed to have had active biowarfare research programs over the recent years.", [["active", "OBSERVATION_MODIFIER", 47, 53], ["biowarfare", "OBSERVATION", 54, 64]]], ["Several major international terrorist organizations, such as the Osama Bin Ladin-associated Al Qaeda network, are believed to have the financial resources and political contacts needed to access state-of-the-art bioweapon disease cultures and production technologies.", [["production technologies", "TREATMENT", 243, 266]]], ["Aum Shinriko was also involved in developing terrorist bioweapons employing anthrax bacilli, botulinum toxin, Ebola virus, and Q fever (Coxiella burnetii).Agents ::: Bioterrorism Related to HumansThe World Health Organization (WHO) defines a biological agent as an agent that produces its effect through multiplication within a target host intended for use in war to cause disease or death in human beings, animals, or plants.", [["anthrax bacilli", "DISEASE", 76, 91], ["Ebola virus", "DISEASE", 110, 121], ["Q fever", "DISEASE", 127, 134], ["Coxiella burnetii", "DISEASE", 136, 153], ["death", "DISEASE", 384, 389], ["anthrax bacilli", "ORGANISM", 76, 91], ["botulinum toxin", "SIMPLE_CHEMICAL", 93, 108], ["Ebola virus", "ORGANISM", 110, 121], ["Q fever", "ORGANISM", 127, 134], ["Coxiella burnetii", "ORGANISM", 136, 153], ["human", "ORGANISM", 393, 398], ["botulinum toxin", "SPECIES", 93, 108], ["Ebola virus", "SPECIES", 110, 121], ["Coxiella burnetii", "SPECIES", 136, 153], ["human", "SPECIES", 393, 398], ["Ebola virus", "SPECIES", 110, 121], ["Q fever", "SPECIES", 127, 134], ["Coxiella burnetii", "SPECIES", 136, 153], ["human", "SPECIES", 393, 398], ["anthrax bacilli", "PROBLEM", 76, 91], ["botulinum toxin", "PROBLEM", 93, 108], ["Ebola virus", "PROBLEM", 110, 121], ["Q fever (Coxiella burnetii", "PROBLEM", 127, 153], ["Bioterrorism", "PROBLEM", 166, 178], ["a biological agent", "TREATMENT", 240, 258], ["an agent", "TREATMENT", 262, 270], ["disease", "PROBLEM", 373, 380], ["death", "PROBLEM", 384, 389]]], ["Biological agents also include protein biotoxins produced by microorganisms, poisonous animals, and plants.", [["Biological agents", "TREATMENT", 0, 17], ["protein biotoxins", "TREATMENT", 31, 48]]], ["The Centers for Disease Control and Prevention (CDC) has classified critical biological agents into three major categories (A, B, and C).Agents ::: Bioterrorism Related to Humans", [["Disease Control", "TREATMENT", 16, 31], ["Bioterrorism", "PROBLEM", 148, 160]]]], "PMC7358282": [["To the Editor:Ting et al. [1] recognized that prevention of exposure keratopathy is paramount in critically ill patients with COVID-19.", [["keratopathy", "DISEASE", 69, 80], ["critically ill", "DISEASE", 97, 111], ["COVID-19", "CHEMICAL", 126, 134], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["exposure keratopathy", "PROBLEM", 60, 80], ["COVID", "TEST", 126, 131], ["keratopathy", "OBSERVATION", 69, 80]]], ["We agree, particularly as the COVID-19 patients who require mechanical ventilation and sedation tend to have longer stays in critical care, which increases their risk of developing exposure keratopathy.", [["keratopathy", "DISEASE", 190, 201], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["mechanical ventilation", "TREATMENT", 60, 82], ["sedation", "TREATMENT", 87, 95], ["developing exposure keratopathy", "PROBLEM", 170, 201], ["exposure keratopathy", "OBSERVATION", 181, 201]]], ["However, eye care may be overlooked in busy critical care units under strain during this pandemic.", [["eye", "ANATOMY", 9, 12], ["eye", "ORGAN", 9, 12]]], ["Using guidelines from the Royal College of Ophthalmologists [2], we audited our experience (see Table 1).To the Editor:We found 51% of COVID-19 patients in critical care had some degree of eye exposure due to incomplete lid closure (lagophthalmos) in our first audit.", [["eye", "ANATOMY", 189, 192], ["patients", "ORGANISM", 144, 152], ["eye", "ORGAN", 189, 192], ["lid", "ORGANISM_SUBDIVISION", 220, 223], ["patients", "SPECIES", 144, 152], ["COVID", "TEST", 135, 140], ["eye exposure", "PROBLEM", 189, 201], ["incomplete lid closure (lagophthalmos", "PROBLEM", 209, 246], ["eye", "ANATOMY", 189, 192], ["closure", "OBSERVATION", 224, 231]]], ["Only a third of these patients had adequate lubrication, and less than a quarter with severe exposure (grade 2: cornea visible) had any form of assisted lid closure.", [["cornea", "ANATOMY", 112, 118], ["patients", "ORGANISM", 22, 30], ["cornea", "ORGAN", 112, 118], ["lid", "ORGANISM_SUBDIVISION", 153, 156], ["patients", "SPECIES", 22, 30], ["adequate lubrication", "TREATMENT", 35, 55], ["severe exposure", "PROBLEM", 86, 101], ["assisted lid closure", "TREATMENT", 144, 164], ["adequate", "OBSERVATION_MODIFIER", 35, 43], ["lubrication", "OBSERVATION", 44, 55], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["cornea", "ANATOMY", 112, 118], ["closure", "OBSERVATION", 157, 164]]], ["Those who needed to be nursed \u2018proned\u2019 fared slightly better in eye treatment; perhaps by virtue of being sicker with COVID-19, these patients were seen to more attentively.To the Editor:Whilst redeployed from our eye departments to critical care, we instituted an eye teaching program in the intensive care unit, with a simple message:", [["eye", "ANATOMY", 64, 67], ["eye", "ANATOMY", 214, 217], ["eye", "ANATOMY", 265, 268], ["eye", "ORGAN", 64, 67], ["patients", "ORGANISM", 134, 142], ["eye", "ORGAN", 214, 217], ["eye", "ORGAN", 265, 268], ["patients", "SPECIES", 134, 142], ["eye treatment", "TREATMENT", 64, 77], ["COVID", "TREATMENT", 118, 123]]]], "PMC7273254": [["BackgroundThe Coronavirus Disease (COVID-19), was first reported in December of 2019 in Wuhan, China and by January 31, 2020, the World Health Organization declared the outbreak to be a Public Health Emergency of International concern1 (see Figure 1 for the timeline).", [["Coronavirus Disease", "DISEASE", 14, 33], ["The Coronavirus Disease", "PROBLEM", 10, 33], ["COVID", "TEST", 35, 40], ["Coronavirus Disease", "OBSERVATION", 14, 33]]], ["As of April 18, 2020 in the United States (U.S.), there were approximately 691,000 COVID-19 cases and 35,000 COVID-19 related deaths2.", [["COVID", "TEST", 83, 88], ["COVID", "TEST", 109, 114], ["related deaths2", "PROBLEM", 118, 133]]], ["As of April 20, 2020 in the United States (U.S.), there were approximately 773,863 COVID-19 cases and 41,400 COVID-19 related deaths2.", [["COVID-19 related deaths2", "DNA", 109, 133], ["COVID", "TEST", 83, 88], ["COVID", "TEST", 109, 114], ["related deaths2", "PROBLEM", 118, 133]]], ["As of April 28, 2020 in the United States (U.S.), there were approximately 982,000 COVID-19 cases and 56,000 COVID-19 related deaths.2 As data are collected and analyzed, researchers can better understand risk factors associated with disease transmission.BackgroundThus far, one of the findings of ongoing and evolving research related to social disparities and health inequities in the U.S. is that, compared to other races/ethnicities, Blacks/African Americans are disproportionately represented in the COVID-19 epidemic.3,4 This is not a unique experience for African American communities, as prevailing research provide evidence of Blacks experiencing overall higher morbidities, earlier onset of morbidities and higher mortality rates when compared to non-Hispanic Whites in the U.S.5,6 Specifically, African Americans adults a) are 60% more likely to have diabetes than non-Hispanic White adults;7 b) are responsible for 42% of new HIV cases even though they make up only 13% of the population;8 c) are 20% more likely to die from heart disease when compared to non-Hispanic Whites;9 d) have a higher prevalence of asthma;10 and e) are 1.3 times more likely to be obese than non-Hispanic Whites.11BackgroundSocial determinants of health such as the places individuals live and work, their access to quality health care, and the resources to lead a healthy lifestyle play a major role in determining health status and health outcomes.5,12 Additionally, a higher percentage of Blacks live in densely populated communities and work as essential workers in service industries where they are at greater risk of exposure.13,14 Public health research shows that in comparison to their counterparts, Blacks are more likely to be uninsured or underinsured and as a result have lower access to quality healthcare and tend to receive lower quality healthcare.5,15BackgroundSimilar to influenza, for COVID-19, vulnerable and marginalized populations may be at greater risk for having more severe outcomes or death if they contract the virus.", [["heart", "ANATOMY", 1037, 1042], ["deaths", "DISEASE", 126, 132], ["diabetes", "DISEASE", 862, 870], ["heart disease", "DISEASE", 1037, 1050], ["asthma", "DISEASE", 1121, 1127], ["influenza", "DISEASE", 1879, 1888], ["death", "DISEASE", 2002, 2007], ["Americans", "ORGANISM", 453, 462], ["heart", "ORGAN", 1037, 1042], ["Blacks", "ORGANISM", 1698, 1704], ["HIV", "SPECIES", 938, 941], ["COVID", "TEST", 83, 88], ["COVID", "TEST", 109, 114], ["disease transmission", "PROBLEM", 234, 254], ["the COVID", "TEST", 501, 510], ["overall higher morbidities", "PROBLEM", 656, 682], ["morbidities", "PROBLEM", 701, 712], ["higher mortality rates", "PROBLEM", 717, 739], ["diabetes", "PROBLEM", 862, 870], ["new HIV cases", "PROBLEM", 934, 947], ["heart disease", "PROBLEM", 1037, 1050], ["asthma", "PROBLEM", 1121, 1127], ["obese", "PROBLEM", 1170, 1175], ["Public health research", "TEST", 1627, 1649], ["influenza", "PROBLEM", 1879, 1888], ["COVID", "TEST", 1894, 1899], ["death", "PROBLEM", 2002, 2007], ["the virus", "PROBLEM", 2025, 2034], ["heart", "ANATOMY", 1037, 1042], ["disease", "OBSERVATION", 1043, 1050], ["asthma", "OBSERVATION", 1121, 1127], ["obese", "OBSERVATION", 1170, 1175], ["higher", "OBSERVATION_MODIFIER", 1460, 1466], ["percentage", "OBSERVATION_MODIFIER", 1467, 1477], ["densely", "OBSERVATION_MODIFIER", 1496, 1503]]], ["For COVID-19, vulnerable and at-risk populations (i.e. those with comorbidities like asthma, diabetes, serious heart conditions, chronic kidney disease and severe obesity) are at greater risk of negative outcomes.16 Due to many social and economic factors, Blacks are disproportionately affected by a number of these conditions6,17 and are more likely to have poor outcomes if COVID-19 is contracted.", [["heart", "ANATOMY", 111, 116], ["kidney", "ANATOMY", 137, 143], ["asthma", "DISEASE", 85, 91], ["diabetes", "DISEASE", 93, 101], ["heart conditions", "DISEASE", 111, 127], ["chronic kidney disease", "DISEASE", 129, 151], ["obesity", "DISEASE", 163, 170], ["COVID-19", "CHEMICAL", 377, 385], ["heart", "ORGAN", 111, 116], ["kidney", "ORGAN", 137, 143], ["COVID", "TEST", 4, 9], ["asthma", "PROBLEM", 85, 91], ["diabetes", "PROBLEM", 93, 101], ["serious heart conditions", "PROBLEM", 103, 127], ["chronic kidney disease", "PROBLEM", 129, 151], ["severe obesity", "PROBLEM", 156, 170], ["COVID", "TEST", 377, 382], ["asthma", "OBSERVATION", 85, 91], ["diabetes", "OBSERVATION", 93, 101], ["chronic", "OBSERVATION_MODIFIER", 129, 136], ["kidney", "ANATOMY", 137, 143], ["disease", "OBSERVATION", 144, 151], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["obesity", "OBSERVATION", 163, 170], ["negative outcomes", "OBSERVATION", 195, 212], ["more likely", "UNCERTAINTY", 340, 351], ["contracted", "OBSERVATION", 389, 399]]], ["This preliminarily study aims to understand the relationship between AA density and other social determinants with COVID-19 prevalence and death rates nationally.MethodsAn ecological analysis was completed using multivariable linear regression.", [["AA", "CHEMICAL", 69, 71], ["death", "DISEASE", 139, 144], ["This preliminarily study", "TEST", 0, 24], ["MethodsAn ecological analysis", "TEST", 162, 191], ["multivariable linear regression", "PROBLEM", 212, 243], ["density", "OBSERVATION", 72, 79]]], ["The three most populous counties of each U.S. state and territory were identified and included in the data analysis, with the exception of Washington, DC which is not considered a state so had only one entry, and California for which four counties and parishes were included (see Appendix A for the full list).", [["DC", "ANATOMY", 151, 153], ["the data analysis", "TEST", 98, 115]]], ["This resulted in a final sample size of 152 counties and parishes.", [["size", "OBSERVATION_MODIFIER", 32, 36]]], ["The data were sourced from USA Facts,18 and population estimates were derived from the U.S. and population estimates were derived from the U.S. Census.19MethodsIndependent variables were African American density (percentage of county/parish population who identified as African American), poverty level (percent of county/parish population at the defined poverty level), and median age for the counties/parishes.", [["The data", "TEST", 0, 8], ["USA Facts", "TEST", 27, 36], ["population estimates", "TEST", 44, 64]]], ["Primary outcomes were the percentage of COVID-19 confirmed cases (prevalence) and rate of COVID-19 deaths per 100,000 persons/parish (death rate).", [["deaths", "DISEASE", 99, 105], ["death", "DISEASE", 134, 139], ["persons", "SPECIES", 118, 125], ["COVID", "TEST", 40, 45], ["death rate", "TEST", 134, 144]]], ["Prevalence was used as estimate of the existing burden of disease by county, and death rate provides inference on the health status of a community and the overall status of a public health system.20MethodsDescriptive statistics including overlapping frequencies were used to describe COVID-19 prevalence and African American density by county.", [["death", "DISEASE", 81, 86], ["Prevalence", "TREATMENT", 0, 10], ["disease", "PROBLEM", 58, 65], ["death rate", "TEST", 81, 91], ["COVID", "TEST", 284, 289], ["disease", "OBSERVATION", 58, 65]]], ["Linear regression models were used to determine the relationship between AA density and poverty, and, COVID-19 prevalence and death rates across U.S. counties and parishes.", [["AA", "CHEMICAL", 73, 75], ["death", "DISEASE", 126, 131], ["Linear regression models", "PROBLEM", 0, 24], ["COVID", "TEST", 102, 107], ["density", "OBSERVATION", 76, 83]]], ["Both models for prevalence and death rate were adjusted for median age.", [["death", "DISEASE", 31, 36], ["death rate", "TEST", 31, 41]]], ["All results were considered to be statistically significant at an alpha level of 0.05.", [["an alpha level", "TEST", 63, 77]]], ["Analyses were conducted using SPSS version 22.0.21Prevalence: ::: ResultsA multivariable linear regression was conducted to predict COVID-19 prevalence based on AA density and county/parish poverty level.", [["SPSS version", "TEST", 30, 42], ["COVID", "TEST", 132, 137], ["AA density", "TEST", 161, 171]]], ["There was a significant regression equation for this model: (F (3,148) = 5.7, p<0.01) with an R2 of 0.32.", [["p", "TEST", 78, 79], ["an R2", "TEST", 91, 96], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["regression", "OBSERVATION", 24, 34]]], ["After adjusting for the county median age, there was a direct association between county AA ethnic density and COVID-19 prevalence; COVID-19 prevalence increased 5% for 1% increase in county AA density (p<.01).", [["AA", "CHEMICAL", 89, 91], ["AA", "CHEMICAL", 191, 193], ["COVID", "TEST", 111, 116], ["COVID", "TEST", 132, 137]]], ["There was no significant association between county poverty level and COVID-19 cases.Death rate: ::: ResultsA multivariable linear regression was conducted to predict COVID-19 death rate based on AA density and county/parish poverty level.", [["Death", "DISEASE", 85, 90], ["death", "DISEASE", 176, 181], ["COVID", "TEST", 70, 75], ["Death rate", "TEST", 85, 95], ["COVID", "TEST", 167, 172], ["death rate", "TEST", 176, 186], ["AA density", "TEST", 196, 206], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["There was a significant regression equation for this model: (F (3,148) = 5.15, p=.02) with an R2 of 0.30.", [["p", "TEST", 79, 80], ["an R2", "TEST", 91, 96], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["regression", "OBSERVATION", 24, 34]]], ["After adjusting for the county median age, there was an association between county AA ethnic density and COVID-19 deaths; the death rate increased 2 per 100,000 for every percentage point increase in county AA density (p=.02).", [["AA", "CHEMICAL", 83, 85], ["deaths", "DISEASE", 114, 120], ["death", "DISEASE", 126, 131], ["AA", "CHEMICAL", 207, 209], ["COVID", "TEST", 105, 110], ["the death rate", "TEST", 122, 136], ["density", "OBSERVATION", 93, 100], ["increase", "OBSERVATION_MODIFIER", 188, 196]]], ["Although not statistically significant, the data trended toward an association between county poverty level and the death rate (p=0.12).", [["death", "DISEASE", 116, 121], ["the data", "TEST", 40, 48], ["the death rate", "TEST", 112, 126], ["not", "UNCERTAINTY", 9, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION", 27, 38]]], ["(See Table 1 for all results)Death rate: ::: ResultsIllustration of the descriptive analysis (Figure 2) demonstrates in some geographical areas or counties with higher AA density, there are peaks in prevalence.DiscussionAccording to this ecologic study, in the U.S., higher African American density was more strongly associated with COVID-19 prevalence and death than higher median age in a community.", [["Death", "DISEASE", 29, 34], ["AA", "CHEMICAL", 168, 170], ["death", "DISEASE", 357, 362], ["the descriptive analysis", "TEST", 68, 92], ["higher AA density", "PROBLEM", 161, 178], ["this ecologic study", "TEST", 233, 252], ["some", "OBSERVATION_MODIFIER", 120, 124], ["geographical", "OBSERVATION_MODIFIER", 125, 137], ["areas", "OBSERVATION_MODIFIER", 138, 143], ["higher", "OBSERVATION_MODIFIER", 161, 167], ["AA density", "OBSERVATION", 168, 178], ["peaks", "OBSERVATION_MODIFIER", 190, 195]]], ["These study findings support earlier research that suggested differences in cases, hospitalizations and deaths could be due to the high prevalence of comorbidities among African Americans and the jobs as essential that many African Americans do, placing them at a higher risk of exposure to the virus.3,4DiscussionMost U.S. states and territories have peaked in incidence and have started to see a decline in new cases.22 Despite this general abatement, some researchers have predicted a resurgence of cases in the later part of year due to several factors including relaxation of policies related to mitigation and social distancing, and possibly also an increase in travel related/imported cases due to less travel restrictions.23DiscussionIn the anticipated surge in the later part of the year, the most at-risk vulnerable populations, including African American populations, will be disproportionately represented, more so than in the first wave of COVID-19 infections.", [["deaths", "DISEASE", 104, 110], ["infections", "DISEASE", 962, 972], ["Americans", "ORGANISM", 232, 241], ["These study", "TEST", 0, 11], ["the virus", "PROBLEM", 291, 300], ["COVID-19 infections", "PROBLEM", 953, 972], ["increase", "OBSERVATION_MODIFIER", 656, 664], ["vulnerable", "OBSERVATION_MODIFIER", 815, 825], ["populations", "OBSERVATION", 826, 837], ["infections", "OBSERVATION", 962, 972]]], ["Much of this may be due to the living conditions of many African Americans, where the close proximity and housing conditions result in a higher likelihood of community spread.13 Additionally, it is more difficult for African Americans to be tested for COVID-19, and if they are able to receive the test and are tested positive, they are less likely to receive quality care.24DiscussionIn the long term, with the availability of vaccines and efficacious therapeutic lines,25 COVID-19 will likely become endemic, where it will constantly exist amongst minority populations,26 as is the other case with other historical pandemics.27 Part of working toward this \u2018new normal\u2019 successfully and living with this novel coronavirus is to use all scientific and research efforts to minimize the number of fatalities.", [["coronavirus", "DISEASE", 711, 722], ["fatalities", "DISEASE", 795, 805], ["coronavirus", "ORGANISM", 711, 722], ["community spread", "PROBLEM", 158, 174], ["African Americans", "TREATMENT", 217, 234], ["COVID", "TEST", 252, 257], ["the test", "TEST", 294, 302], ["quality care", "TREATMENT", 360, 372], ["vaccines", "TREATMENT", 428, 436], ["efficacious therapeutic lines", "TREATMENT", 441, 470], ["community spread", "OBSERVATION", 158, 174]]], ["Implicit in this approach is ensuring that there is adequate testing in underserved areas such as AA communities.28,29 Screening and services should be comprehensively available regardless of insurance status or ability of the individuals to pay for medical care.", [["medical care", "TREATMENT", 250, 262]]], ["Widespread availability of these services as well as vaccines and treatment when they are available, will contribute to the reduction in overall incidence, transmission and community spread.29,30LimitationsThere are several limitations associated with this study, First, this is an ecologic analysis and there is a lot of potential unmeasured confounding, Second, non-Hispanic Whites were not included in the analysis as a possible reference group.", [["these services", "TREATMENT", 27, 41], ["vaccines", "TREATMENT", 53, 61], ["treatment", "TREATMENT", 66, 75], ["this study", "TEST", 252, 262], ["an ecologic analysis", "TEST", 279, 299], ["the analysis", "TEST", 405, 417]]], ["Finally, it is possible that prevalence estimates can be skewed depending on the availability of the test per county population.ConclusionStudy findings indicate an association between communities that have higher percentage of African Americans and negative COVID-19 health outcomes including higher prevalence and higher death rates.", [["death", "DISEASE", 323, 328], ["the test", "TEST", 97, 105], ["higher death rates", "PROBLEM", 316, 334], ["higher", "OBSERVATION_MODIFIER", 207, 213], ["percentage", "OBSERVATION_MODIFIER", 214, 224]]], ["Additionally, although not statistically significant in this study, the data suggested that the odds of surviving the epidemic may also be related to poverty levels suggesting that other at-risk minority populations, affected by poverty, may also be disproportionately affected.31 Further comprehensive analysis is needed to understand state, community and individual levels of social determinants on COVID-19 health outcomes for all racial/ethnic minority and other vulnerable populations living in the United States.", [["this study", "TEST", 56, 66], ["poverty levels", "TEST", 150, 164], ["Further comprehensive analysis", "TEST", 281, 311], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["may also be", "UNCERTAINTY", 238, 249], ["disproportionately", "OBSERVATION_MODIFIER", 250, 268]]]], "PMC7114435": [["ForewordsDuring the past hundred years or so investigations on retroviruses have triggered seminal discoveries in biology and medicine such as that of oncogenes and their implications in cancer (Bishop, 1983, Brugge and Erikson, 1977, Hanafusa, 1969, Hu et al., 2003a, Hu and Temin, 1990, Huebner and Todaro, 1969) and the fact that retroelements constitute a large fraction of all eukaryotic genomes acting as a driving force in genome plasticity and evolution (Baltimore, 1970, Garfinkel et al., 1985, Hansen et al., 1988).ForewordsIn this context, our understanding of the structure and functions of the retroviral nucleocapsid protein (i.e. NC) has come a long way since the first descriptions of oncoretroviruses and the oncoviral nucleoprotein (Ellermann and Bang, 1908, Rous, 1910, Davis and Rueckert, 1972).", [["seminal", "ANATOMY", 91, 98], ["cancer", "ANATOMY", 187, 193], ["cancer", "DISEASE", 187, 193], ["retroviruses", "ORGANISM", 63, 75], ["cancer", "CANCER", 187, 193], ["retroviral", "ORGANISM", 607, 617], ["oncoretroviruses", "CANCER", 701, 717], ["Rous", "ORGANISM", 777, 781], ["oncogenes", "DNA", 151, 160], ["eukaryotic genomes", "DNA", 382, 400], ["retroviral nucleocapsid protein", "PROTEIN", 607, 638], ["NC", "PROTEIN", 645, 647], ["oncoviral nucleoprotein", "PROTEIN", 726, 749], ["Rous", "SPECIES", 777, 781], ["retroviruses", "TREATMENT", 63, 75], ["the retroviral nucleocapsid protein", "PROBLEM", 603, 638], ["large", "OBSERVATION_MODIFIER", 360, 365], ["fraction", "OBSERVATION", 366, 374], ["eukaryotic genomes", "OBSERVATION", 382, 400], ["genome plasticity", "OBSERVATION", 430, 447]]], ["Initially studies on the retroviral NC focused on that of alpharetroviruses and gammaretroviruses, namely avian sarcoma leukosis viruses (ASLV) and the murine leukemia viruses (MuLV), respectively.", [["avian sarcoma leukosis", "DISEASE", 106, 128], ["murine leukemia viruses", "DISEASE", 152, 175], ["retroviral", "ORGANISM", 25, 35], ["alpharetroviruses", "CANCER", 58, 75], ["avian sarcoma leukosis viruses", "ORGANISM", 106, 136], ["ASLV", "ORGANISM", 138, 142], ["murine leukemia viruses", "ORGANISM", 152, 175], ["MuLV", "ORGANISM", 177, 181], ["avian sarcoma leukosis viruses", "SPECIES", 106, 136], ["murine", "SPECIES", 152, 158], ["avian sarcoma leukosis viruses", "SPECIES", 106, 136], ["ASLV", "SPECIES", 138, 142], ["murine leukemia viruses", "SPECIES", 152, 175], ["the retroviral NC", "TREATMENT", 21, 38], ["alpharetroviruses and gammaretroviruses", "PROBLEM", 58, 97], ["avian sarcoma leukosis viruses", "PROBLEM", 106, 136], ["the murine leukemia viruses", "PROBLEM", 148, 175], ["sarcoma leukosis viruses", "OBSERVATION", 112, 136], ["murine leukemia viruses", "OBSERVATION", 152, 175]]], ["This has fueled a large number of multidisciplinary studies on HIV-1 NC structure and functions as well as on NC of ancient yeast retroelements (Gabus et al., 1998, Garfinkel et al., 1985, Hansen et al., 1988) and on NC-like proteins encoded by Flaviviruses as well as other RNA viruses (Cristofari et al., 2004, Mir and Panganiban, 2005).ForewordsThe retroviral NC story began with the isolation of large ribonucleoprotein complexes (RNPs) (Davis and Rueckert, 1972) from purified viral particles of ASLV and MoMuLV, which were able to support viral DNA synthesis.", [["HIV-1 NC", "ORGANISM", 63, 71], ["NC-like proteins", "GENE_OR_GENE_PRODUCT", 217, 233], ["Flaviviruses", "GENE_OR_GENE_PRODUCT", 245, 257], ["retroviral", "ORGANISM", 352, 362], ["ASLV", "GENE_OR_GENE_PRODUCT", 501, 505], ["MoMuLV", "GENE_OR_GENE_PRODUCT", 510, 516], ["DNA", "CELLULAR_COMPONENT", 551, 554], ["NC-like proteins", "PROTEIN", 217, 233], ["ribonucleoprotein complexes", "PROTEIN", 406, 433], ["RNPs", "PROTEIN", 435, 439], ["ASLV", "PROTEIN", 501, 505], ["MoMuLV", "PROTEIN", 510, 516], ["HIV-1", "SPECIES", 63, 68], ["yeast", "SPECIES", 124, 129], ["HIV-1", "SPECIES", 63, 68], ["yeast", "SPECIES", 124, 129], ["ASLV", "SPECIES", 501, 505], ["multidisciplinary studies", "TEST", 34, 59], ["HIV", "TEST", 63, 66], ["NC", "TREATMENT", 110, 112], ["ancient yeast retroelements", "TREATMENT", 116, 143], ["NC", "TREATMENT", 217, 219], ["Flaviviruses", "PROBLEM", 245, 257], ["large ribonucleoprotein complexes", "PROBLEM", 400, 433], ["viral DNA synthesis", "PROBLEM", 545, 564], ["large", "OBSERVATION_MODIFIER", 18, 23], ["number", "OBSERVATION_MODIFIER", 24, 30], ["yeast retroelements", "OBSERVATION", 124, 143], ["retroviral NC", "OBSERVATION", 352, 365], ["large", "OBSERVATION_MODIFIER", 400, 405], ["ribonucleoprotein complexes", "OBSERVATION", 406, 433], ["viral particles", "OBSERVATION", 482, 497]]], ["These viral RNP complexes, consisting of the 60\u201370S genomic RNA dimer coated by about 2000 NC molecules, represent the most stable inner structure of the viral particle, with a circular chromatin-like conformation (Chen et al., 1980, Pager et al., 1994).", [["chromatin", "ANATOMY", 186, 195], ["chromatin", "CELLULAR_COMPONENT", 186, 195], ["viral RNP complexes", "PROTEIN", 6, 25], ["60\u201370S genomic RNA dimer", "PROTEIN", 45, 69], ["chromatin", "DNA", 186, 195], ["These viral RNP complexes", "PROBLEM", 0, 25], ["the viral particle", "PROBLEM", 150, 168], ["viral", "OBSERVATION", 6, 11], ["RNP complexes", "OBSERVATION", 12, 25], ["stable", "OBSERVATION_MODIFIER", 124, 130], ["inner", "OBSERVATION_MODIFIER", 131, 136], ["structure", "OBSERVATION", 137, 146], ["viral particle", "OBSERVATION", 154, 168], ["circular chromatin", "OBSERVATION", 177, 195]]], ["These viral RNPs or nucleocores also contain molecules of the viral reverse transcriptase (RT) and integrase (IN) enzymes together with molecules of cellular tRNAs and ribosomal RNA (Chen et al., 1980, Darlix et al., 1995, Dickson et al., 1985).ForewordsThe hallmark of all retroviral NC proteins, with the exception of Foamy viruses (Stenbak and Linial, 2004), is the presence of one or two small highly conserved CX2CX4HX4C (CCHC) motifs called zinc fingers (ZFs) or zinc knuckles that bind zinc ions with high affinity (Berg, 1986, Mely et al., 1991, Mely et al., 1996, Summers et al., 1990, Summers et al., 1992), and that are flanked by unstructured basic sequences.", [["cellular", "ANATOMY", 149, 157], ["zinc", "CHEMICAL", 469, 473], ["zinc", "CHEMICAL", 493, 497], ["zinc", "CHEMICAL", 447, 451], ["zinc", "CHEMICAL", 469, 473], ["zinc", "CHEMICAL", 493, 497], ["nucleocores", "GENE_OR_GENE_PRODUCT", 20, 31], ["viral reverse transcriptase", "GENE_OR_GENE_PRODUCT", 62, 89], ["integrase (IN) enzymes", "GENE_OR_GENE_PRODUCT", 99, 121], ["cellular", "CELL", 149, 157], ["ribosomal", "CELLULAR_COMPONENT", 168, 177], ["retroviral", "ORGANISM", 274, 284], ["NC", "GENE_OR_GENE_PRODUCT", 285, 287], ["Foamy viruses", "ORGANISM", 320, 333], ["CX2CX4HX4C", "GENE_OR_GENE_PRODUCT", 415, 425], ["ZFs", "GENE_OR_GENE_PRODUCT", 461, 464], ["zinc knuckles", "SIMPLE_CHEMICAL", 469, 482], ["zinc ions", "SIMPLE_CHEMICAL", 493, 502], ["viral RNPs", "PROTEIN", 6, 16], ["nucleocores", "PROTEIN", 20, 31], ["viral reverse transcriptase", "PROTEIN", 62, 89], ["RT", "PROTEIN", 91, 93], ["integrase (IN) enzymes", "PROTEIN", 99, 121], ["cellular tRNAs", "RNA", 149, 163], ["ribosomal RNA", "RNA", 168, 181], ["retroviral NC proteins", "PROTEIN", 274, 296], ["CX2CX4HX4C (CCHC) motifs", "PROTEIN", 415, 439], ["zinc fingers", "PROTEIN", 447, 459], ["ZFs", "PROTEIN", 461, 464], ["zinc knuckles", "PROTEIN", 469, 482], ["These viral RNPs", "PROBLEM", 0, 16], ["nucleocores", "TREATMENT", 20, 31], ["the viral reverse transcriptase", "TREATMENT", 58, 89], ["integrase (IN) enzymes", "TREATMENT", 99, 121], ["cellular tRNAs and ribosomal RNA", "PROBLEM", 149, 181], ["all retroviral NC proteins", "TREATMENT", 270, 296], ["Foamy viruses", "PROBLEM", 320, 333], ["zinc knuckles", "PROBLEM", 469, 482], ["viral RNPs", "OBSERVATION", 6, 16], ["cellular tRNAs", "OBSERVATION", 149, 163], ["ribosomal RNA", "OBSERVATION", 168, 181], ["Foamy viruses", "OBSERVATION", 320, 333]]], ["In retrospect, some 38 years ago NC of alpha- and gammaretroviruses was first isolated from purified virions and considered to be an unspecific nucleic acid binding protein (NABP) with some preference for single stranded sequences within structured RNA domains (Davis et al., 1976).ForewordsThirty years of multidisciplinary research, notably on HIV-1, radically changed our views since NC was discovered to be a potent nucleic acid chaperoning factor exerting key functions throughout the virus replication cycle.", [["virions", "ANATOMY", 101, 108], ["NC of alpha- and gammaretroviruses", "CHEMICAL", 33, 67], ["nucleic acid", "CHEMICAL", 420, 432], ["alpha", "GENE_OR_GENE_PRODUCT", 39, 44], ["gammaretroviruses", "GENE_OR_GENE_PRODUCT", 50, 67], ["HIV-1", "ORGANISM", 346, 351], ["alpha", "PROTEIN", 39, 44], ["gammaretroviruses", "PROTEIN", 50, 67], ["unspecific nucleic acid binding protein", "PROTEIN", 133, 172], ["NABP", "PROTEIN", 174, 178], ["RNA domains", "DNA", 249, 260], ["nucleic acid chaperoning factor", "PROTEIN", 420, 451], ["HIV-1", "SPECIES", 346, 351], ["HIV-1", "SPECIES", 346, 351], ["alpha- and gammaretroviruses", "PROBLEM", 39, 67], ["purified virions", "PROBLEM", 92, 108], ["an unspecific nucleic acid binding protein", "PROBLEM", 130, 172], ["single stranded sequences", "PROBLEM", 205, 230], ["NC", "TREATMENT", 387, 389], ["a potent nucleic acid chaperoning factor", "PROBLEM", 411, 451]]], ["In addition to being a viral structural protein, NC assists the viral RT enzyme throughout viral DNA synthesis (Allain et al., 1994, Barat et al., 1989), ensuring viral DNA completion and maintenance during the early phase of retrovirus (RV) replication (reviewed in Bampi et al., 2004, Darlix et al., 1995, Darlix et al., 2000, Darlix et al., 2011, Levin et al., 2005, Rein et al., 1998, Rein et al., 2011, Thomas et al., 2008, Wu et al., 2010).", [["NC", "GENE_OR_GENE_PRODUCT", 49, 51], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["DNA", "CELLULAR_COMPONENT", 169, 172], ["retrovirus", "ORGANISM", 226, 236], ["viral structural protein", "PROTEIN", 23, 47], ["NC", "PROTEIN", 49, 51], ["viral RT enzyme", "PROTEIN", 64, 79], ["retrovirus", "SPECIES", 226, 236], ["RV", "SPECIES", 238, 240], ["a viral structural protein", "PROBLEM", 21, 47], ["the viral RT enzyme", "TEST", 60, 79], ["viral DNA synthesis", "PROBLEM", 91, 110], ["viral DNA completion", "TREATMENT", 163, 183], ["retrovirus (RV) replication", "TREATMENT", 226, 253], ["viral DNA", "OBSERVATION", 163, 172]]], ["At the same time NC was found to foster recombination reactions during reverse transcription of the dimeric viral RNA template, generating a large genetic diversity that precludes a sustained antiviral immune response and causes the emergence of antiviral resistance (Brenner et al., 2002, Coffin, 1995, Galetto and Negroni, 2005, Gallant et al., 2003, Negroni and Buc, 2001, Onafuwa-Nuga and Telesnitsky, 2009).", [["dimeric viral RNA template", "DNA", 100, 126], ["NC", "TREATMENT", 17, 19], ["foster recombination reactions", "PROBLEM", 33, 63], ["the dimeric viral RNA template", "TREATMENT", 96, 126], ["a large genetic diversity", "PROBLEM", 139, 164], ["a sustained antiviral immune response", "TREATMENT", 180, 217], ["viral RNA template", "OBSERVATION", 108, 126], ["large", "OBSERVATION_MODIFIER", 141, 146], ["genetic diversity", "OBSERVATION", 147, 164], ["antiviral immune response", "OBSERVATION", 192, 217], ["antiviral resistance", "OBSERVATION", 246, 266]]], ["At the start of virus assembly during the late phase, NC initially as part of the structural polyprotein Gag drives specific interactions between the ZF region of NC and specific sequences in the 5\u2032 leader of the genomic RNA causing its dimerization and forming a GagNC assembly plateform (Cimarelli and Darlix, 2002, D'Souza and Summers, 2005, Lu et al., 2011a, Mirambeau et al., 2010, Muriaux et al., 2001).", [["Gag", "GENE_OR_GENE_PRODUCT", 105, 108], ["NC", "GENE_OR_GENE_PRODUCT", 163, 165], ["structural polyprotein Gag", "PROTEIN", 82, 108], ["ZF region", "PROTEIN", 150, 159], ["5\u2032 leader", "DNA", 196, 205], ["genomic RNA", "RNA", 213, 224], ["virus", "TREATMENT", 16, 21], ["NC", "TREATMENT", 54, 56], ["NC", "TREATMENT", 163, 165], ["specific sequences", "TEST", 170, 188], ["polyprotein Gag", "OBSERVATION", 93, 108], ["genomic RNA", "OBSERVATION", 213, 224]]], ["Later in assembly, the mature NC molecules drive the maturation of the 60S RNA (Feng et al., 1996, Fu et al., 1994) and condensation of the core structure that ensures stability of the viral particle while exerting a negative control over the reverse transcription reaction (Mirambeau et al., 2006, Mougel et al., 2009).ForewordsThis review aims at presenting a brief retrospect on the retroviral NC protein, now recognized as a central player during retrovirus replication (Fig. 1).", [["NC", "GENE_OR_GENE_PRODUCT", 30, 32], ["60S", "CELLULAR_COMPONENT", 71, 74], ["retroviral", "ORGANISM", 386, 396], ["NC", "GENE_OR_GENE_PRODUCT", 397, 399], ["retrovirus", "ORGANISM", 451, 461], ["mature NC molecules", "PROTEIN", 23, 42], ["60S RNA", "RNA", 71, 78], ["retroviral NC protein", "PROTEIN", 386, 407], ["the mature NC molecules", "TREATMENT", 19, 42], ["condensation of the core structure", "PROBLEM", 120, 154], ["the viral particle", "PROBLEM", 181, 199], ["the retroviral NC protein", "TREATMENT", 382, 407], ["retrovirus replication", "TREATMENT", 451, 473], ["mature", "OBSERVATION_MODIFIER", 23, 29], ["NC molecules", "OBSERVATION", 30, 42], ["stability", "OBSERVATION_MODIFIER", 168, 177], ["viral particle", "OBSERVATION", 185, 199], ["retrovirus replication", "OBSERVATION", 451, 473]]], ["In addition we will discuss the notion that NC protein is endowed with a high level of flexibility (Dunker et al., 2001, Wright and Dyson, 1999), which may account for its multiple functions as a viral DNA and RNA chaperone during virus replication.", [["NC", "GENE_OR_GENE_PRODUCT", 44, 46], ["DNA", "CELLULAR_COMPONENT", 202, 205], ["NC protein", "PROTEIN", 44, 54], ["viral DNA", "DNA", 196, 205], ["RNA chaperone", "PROTEIN", 210, 223], ["NC protein", "TREATMENT", 44, 54], ["a viral DNA", "PROBLEM", 194, 205], ["RNA chaperone", "TREATMENT", 210, 223], ["virus replication", "TREATMENT", 231, 248]]], ["Due to its multiple implications in HIV replication NC represents an ideal target for anti-HIV drugs, which will also be reviewed here.Characterization of NC protein as the major viral RNA ligand ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneThe interactions between NC protein and the genomic RNA in alpha- (RSV) and gamma-RV (MoMuLV) virions were initially examined using UV light at 252 nm for cross-linking since this approach allows the specific spatial relationship of certain amino acids and RNA bases to be characterized (see Burd and Dreyfuss, 1994).", [["nucleic acid", "CHEMICAL", 217, 229], ["nucleic acid", "CHEMICAL", 285, 297], ["amino acids", "CHEMICAL", 548, 559], ["amino acids", "CHEMICAL", 548, 559], ["HIV", "ORGANISM", 36, 39], ["HIV", "ORGANISM", 91, 94], ["NC", "GENE_OR_GENE_PRODUCT", 155, 157], ["nucleic acid", "SIMPLE_CHEMICAL", 285, 297], ["NC", "GENE_OR_GENE_PRODUCT", 332, 334], ["alpha- (RSV)", "GENE_OR_GENE_PRODUCT", 366, 378], ["gamma-RV", "GENE_OR_GENE_PRODUCT", 383, 391], ["MoMuLV", "GENE_OR_GENE_PRODUCT", 393, 399], ["amino acids", "AMINO_ACID", 548, 559], ["NC protein", "PROTEIN", 155, 165], ["simple nucleic acid binding protein", "PROTEIN", 210, 245], ["NABP", "PROTEIN", 247, 251], ["nucleic acid chaperone", "PROTEIN", 285, 307], ["NC protein", "PROTEIN", 332, 342], ["genomic RNA", "RNA", 351, 362], ["MoMuLV", "PROTEIN", 393, 399], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 91, 94], ["RSV", "SPECIES", 374, 377], ["HIV replication NC", "TREATMENT", 36, 54], ["anti-HIV drugs", "TREATMENT", 86, 100], ["NC protein", "TEST", 155, 165], ["NC", "TREATMENT", 200, 202], ["a simple nucleic acid binding protein", "TREATMENT", 208, 245], ["nucleic acid chaperone", "TREATMENT", 285, 307], ["NC protein", "TEST", 332, 342], ["the genomic RNA", "TEST", 347, 362], ["alpha", "TEST", 366, 371], ["RSV", "TEST", 374, 377], ["gamma-RV (MoMuLV) virions", "TREATMENT", 383, 408], ["UV light", "TREATMENT", 439, 447], ["this approach", "TREATMENT", 482, 495], ["certain amino acids and RNA bases", "PROBLEM", 540, 573], ["multiple", "OBSERVATION_MODIFIER", 11, 19], ["NC protein", "OBSERVATION", 155, 165], ["RV", "ANATOMY", 389, 391]]], ["Results showed that NC was by far the major protein tightly bound to the genomic 70S RNA in the nucleocapsid (Darlix and Spahr, 1985, Meric et al., 1984, Prats et al., 1990, Tanchou et al., 1995).", [["NC", "GENE_OR_GENE_PRODUCT", 20, 22], ["nucleocapsid", "CELLULAR_COMPONENT", 96, 108], ["genomic 70S RNA", "RNA", 73, 88], ["NC", "TREATMENT", 20, 22], ["70S RNA", "OBSERVATION", 81, 88], ["nucleocapsid", "ANATOMY", 96, 108]]], ["But these results were obscured and a matter of intense debate because MAp19 protein of RSV and pp12 protein of MoMuLV were originally reported to be the viral proteins tightly linked to the genome in virions (Darlix and Spahr, 1982, Sen et al., 1977).Characterization of NC protein as the major viral RNA ligand ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneThe NC cross-linked RNA fragments were recovered and upon sequencing it was found that NC tightly binds a small number of genomic RNA sites rich in U and G residues, located in the multifunctional 5\u2032 untranslated leader region (5\u2032 UTR) (Dannull et al., 1994, Darlix and Spahr, 1982, Meric et al., 1984, Tanchou et al., 1995).", [["virions", "ANATOMY", 201, 208], ["nucleic acid", "CHEMICAL", 334, 346], ["nucleic acid", "CHEMICAL", 402, 414], ["MAp19", "GENE_OR_GENE_PRODUCT", 71, 76], ["RSV", "ORGANISM", 88, 91], ["pp12", "GENE_OR_GENE_PRODUCT", 96, 100], ["MoMuLV", "GENE_OR_GENE_PRODUCT", 112, 118], ["genome", "CELLULAR_COMPONENT", 191, 197], ["NC", "GENE_OR_GENE_PRODUCT", 272, 274], ["nucleic acid", "SIMPLE_CHEMICAL", 402, 414], ["NC", "GENE_OR_GENE_PRODUCT", 511, 513], ["U and G residues", "GENE_OR_GENE_PRODUCT", 572, 588], ["MAp19 protein", "PROTEIN", 71, 84], ["RSV and pp12 protein", "PROTEIN", 88, 108], ["MoMuLV", "PROTEIN", 112, 118], ["viral proteins", "PROTEIN", 154, 168], ["NC protein", "PROTEIN", 272, 282], ["simple nucleic acid binding protein", "PROTEIN", 327, 362], ["NABP", "PROTEIN", 364, 368], ["nucleic acid chaperone", "PROTEIN", 402, 424], ["NC cross-linked RNA fragments", "DNA", 428, 457], ["genomic RNA sites", "DNA", 546, 563], ["multifunctional 5\u2032 untranslated leader region", "DNA", 605, 650], ["5\u2032 UTR", "DNA", 652, 658], ["RSV", "SPECIES", 88, 91], ["MAp19 protein", "TEST", 71, 84], ["RSV", "TEST", 88, 91], ["pp12 protein", "TEST", 96, 108], ["the viral proteins", "PROBLEM", 150, 168], ["NC protein", "TEST", 272, 282], ["NC", "TREATMENT", 317, 319], ["a simple nucleic acid binding protein", "TREATMENT", 325, 362], ["nucleic acid chaperone", "TREATMENT", 402, 424], ["The NC cross-linked RNA fragments", "PROBLEM", 424, 457], ["NC tightly binds", "PROBLEM", 511, 527], ["G residues", "PROBLEM", 578, 588], ["NC protein", "OBSERVATION", 272, 282], ["NC", "OBSERVATION_MODIFIER", 428, 430], ["fragments", "OBSERVATION_MODIFIER", 448, 457], ["small", "OBSERVATION_MODIFIER", 530, 535], ["number", "OBSERVATION_MODIFIER", 536, 542], ["genomic RNA", "OBSERVATION", 546, 557], ["sites", "OBSERVATION_MODIFIER", 558, 563], ["rich", "OBSERVATION_MODIFIER", 564, 568]]], ["This was of special interest since these sites are close to the dimer linkage structure (DLS) (Darlix and Spahr, 1982, Prats et al., 1990) that holds together the two genomic RNA in the virion nucleocapsid (Murti et al., 1981), and the DLS is part of the packaging psi signal (Pugatsch and Stacey, 1983).", [["genomic RNA", "RNA", 167, 178], ["virion nucleocapsid", "PROTEIN", 186, 205], ["these sites", "PROBLEM", 35, 46], ["genomic RNA", "OBSERVATION", 167, 178], ["virion nucleocapsid", "ANATOMY", 186, 205], ["packaging psi", "OBSERVATION", 255, 268]]], ["These findings suggested that NC interaction with high affinity sites presents in the 5\u2032 leader region, close to the DLS, might be required for the selective packaging of the genomic RNA during virus morphogenesis (Aldovini and Young, 1990, Lever et al., 1989).", [["NC", "GENE_OR_GENE_PRODUCT", 30, 32], ["5\u2032 leader region", "DNA", 86, 102], ["DLS", "DNA", 117, 120], ["genomic RNA", "RNA", 175, 186], ["NC interaction", "PROBLEM", 30, 44], ["high affinity sites", "PROBLEM", 50, 69], ["the selective packaging", "TREATMENT", 144, 167], ["high affinity", "OBSERVATION", 50, 63], ["genomic RNA", "OBSERVATION", 175, 186]]], ["In fact, mutations in the ZF or flanking basic residues of NC have a strong negative impact on genomic RNA packaging as initially reported for RSV and MoMuLV and later for HIV-1 (Aldovini and Young, 1990, Dorfman et al., 1993, Gorelick et al., 1990, Meric and Spahr, 1986) (see section on NC functions in the late phase of RV replication, Fig. 1b).The original reports on NC functions ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneIn the 1980s, two series of findings effectively kick-started the NC story.", [["nucleic acid", "CHEMICAL", 406, 418], ["nucleic acid", "CHEMICAL", 474, 486], ["ZF", "GENE_OR_GENE_PRODUCT", 26, 28], ["NC", "GENE_OR_GENE_PRODUCT", 59, 61], ["RSV", "ORGANISM", 143, 146], ["MoMuLV", "CANCER", 151, 157], ["HIV-1", "ORGANISM", 172, 177], ["nucleic acid", "SIMPLE_CHEMICAL", 474, 486], ["ZF", "DNA", 26, 28], ["simple nucleic acid binding protein", "PROTEIN", 399, 434], ["NABP", "PROTEIN", 436, 440], ["nucleic acid chaperone", "PROTEIN", 474, 496], ["HIV", "SPECIES", 172, 175], ["RSV", "SPECIES", 143, 146], ["HIV-1", "SPECIES", 172, 177], ["mutations in the ZF", "PROBLEM", 9, 28], ["flanking basic residues of NC", "PROBLEM", 32, 61], ["genomic RNA packaging", "TREATMENT", 95, 116], ["RSV", "PROBLEM", 143, 146], ["HIV", "PROBLEM", 172, 175], ["NC functions", "TREATMENT", 289, 301], ["RV replication", "TREATMENT", 323, 337], ["NC", "TREATMENT", 389, 391], ["a simple nucleic acid binding protein", "TREATMENT", 397, 434], ["nucleic acid chaperone", "TREATMENT", 474, 496]]], ["Firstly, NC was shown to be the driving force in genomic RNA selection, dimerization and packaging during ASLV and MoMuLV assembly (Fig. 1IX and X) (Gorelick et al., 1999, Meric et al., 1988).", [["ASLV", "GENE_OR_GENE_PRODUCT", 106, 110], ["ASLV", "SPECIES", 106, 110], ["NC", "TREATMENT", 9, 11], ["genomic RNA selection", "TREATMENT", 49, 70], ["dimerization", "TREATMENT", 72, 84], ["packaging", "TREATMENT", 89, 98]]], ["Secondly, NC was found to direct viral RNA dimerization in vitro and annealing of the replication primer tRNA to the genomic primer binding site (PBS) both in vitro and in ASLV and MuLV virions (Darlix et al., 1990, Prats et al., 1991, Prats et al., 1988).", [["ASLV", "CANCER", 172, 176], ["MuLV", "ORGANISM", 181, 185], ["replication primer tRNA", "DNA", 86, 109], ["genomic primer binding site", "DNA", 117, 144], ["ASLV", "SPECIES", 172, 176], ["NC", "TREATMENT", 10, 12], ["viral RNA dimerization", "TREATMENT", 33, 55], ["the replication primer tRNA", "TREATMENT", 82, 109], ["primer tRNA", "OBSERVATION", 98, 109], ["MuLV virions", "OBSERVATION", 181, 193]]], ["This second series of observations led to the discovery that NC was a viral protein having potent nucleic acid chaperoning activities that was later found to be necessary for bona fide proviral DNA synthesis (reviewed in Darlix et al., 1995, Rein et al., 1998).", [["nucleic acid", "CHEMICAL", 98, 110], ["NC", "GENE_OR_GENE_PRODUCT", 61, 63], ["DNA", "CELLULAR_COMPONENT", 194, 197], ["viral protein", "PROTEIN", 70, 83], ["NC", "TREATMENT", 61, 63], ["a viral protein", "PROBLEM", 68, 83], ["potent nucleic acid chaperoning activities", "PROBLEM", 91, 133], ["bona fide proviral DNA synthesis", "PROBLEM", 175, 207]]], ["These findings have since been confirmed (Allain et al., 1998, Auxilien et al., 1999, Barat et al., 1989, Buckman et al., 2003, Darlix et al., 1993, Gao et al., 2003, Godet et al., 2006, Gorelick et al., 1990, Gorelick et al., 1999, Guo et al., 1997, You and McHenry, 1994, Yu and Darlix, 1996) paving the way for attempts to identify anti-HIV drugs specifically targeting NC (Breuer et al., 2012, de Rocquigny et al., 2008, Druillennec et al., 1999b, Goldschmidt et al., 2010, Grigorov et al., 2011, Jenkins et al., 2005, Mori et al., 2012, Rice et al., 1993, Rice et al., 1995, Schito et al., 2003, Tummino et al., 1996).Large scale synthesis of RV NC proteins and zinc binding ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneOriginally NC proteins were purified from RV virions (Davis et al., 1976, Henderson et al., 1981, Henderson et al., 1988, Henderson et al., 1990, Henderson et al., 1992, Hizi et al., 1987, Prats et al., 1988, Prats et al., 1990) and later from recombinant Escherichia coli or synthesized in vitro by chemical methods (see below) and found to bind a wide variety of nucleic acids (NA) molecules with a preference for the genomic 70S RNA (Darlix and Spahr, 1985, Wu et al., 1996).", [["zinc", "CHEMICAL", 667, 671], ["nucleic acid", "CHEMICAL", 701, 713], ["nucleic acid", "CHEMICAL", 769, 781], ["nucleic acids", "CHEMICAL", 1156, 1169], ["NA", "CHEMICAL", 1171, 1173], ["zinc", "CHEMICAL", 667, 671], ["zinc", "SIMPLE_CHEMICAL", 667, 671], ["nucleic acid", "SIMPLE_CHEMICAL", 769, 781], ["NC", "GENE_OR_GENE_PRODUCT", 802, 804], ["Escherichia coli", "ORGANISM", 1047, 1063], ["nucleic acids", "SIMPLE_CHEMICAL", 1156, 1169], ["RV NC proteins", "PROTEIN", 648, 662], ["simple nucleic acid binding protein", "PROTEIN", 694, 729], ["NABP", "PROTEIN", 731, 735], ["nucleic acid chaperone", "PROTEIN", 769, 791], ["NC proteins", "PROTEIN", 802, 813], ["nucleic acids (NA) molecules", "PROTEIN", 1156, 1184], ["genomic 70S RNA", "RNA", 1211, 1226], ["Escherichia coli", "SPECIES", 1047, 1063], ["Escherichia coli", "SPECIES", 1047, 1063], ["anti-HIV drugs", "TREATMENT", 335, 349], ["Large scale synthesis", "TEST", 623, 644], ["NC", "TREATMENT", 684, 686], ["a simple nucleic acid binding protein", "TREATMENT", 692, 729], ["nucleic acid chaperone", "TREATMENT", 769, 791], ["Prats", "TEST", 980, 985], ["Prats", "TEST", 1000, 1005], ["recombinant Escherichia coli", "PROBLEM", 1035, 1063], ["nucleic acids", "TEST", 1156, 1169], ["RV", "ANATOMY", 648, 650], ["zinc binding", "OBSERVATION", 667, 679], ["RV virions", "ANATOMY", 833, 843], ["Escherichia coli", "OBSERVATION", 1047, 1063]]], ["Accordingly, the relative affinity of in vitro synthesized NC protein for retroviral RNA, DNA and oligonucleotides is in the order \u2018retroviral RNA > ssDNA > dsDNA > oligonucleotides\u2019 where the apparent affinity constant for the genomic RNA is 5 \u00d7 107M\u22121, about 25 times higher than that for poly(rA) (You and McHenry, 1993).Large scale synthesis of RV NC proteins and zinc binding ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneNC from various retroviruses such as NCp12 from ASLV, NCp10 of MoMuLV, NCp12 from BLV and NCp15 from HTLV have been sequenced and comparison of their primary sequences revealed the presence of a common highly conserved CCHC domain (Copeland et al., 1983a, Copeland et al., 1983b, Henderson et al., 1981), later called zinc fingers (ZFs).", [["zinc", "CHEMICAL", 368, 372], ["nucleic acid", "CHEMICAL", 402, 414], ["nucleic acid", "CHEMICAL", 470, 482], ["poly(rA)", "CHEMICAL", 291, 299], ["zinc", "CHEMICAL", 368, 372], ["zinc", "CHEMICAL", 810, 814], ["NC", "GENE_OR_GENE_PRODUCT", 59, 61], ["retroviral", "ORGANISM", 74, 84], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["ssDNA", "CELLULAR_COMPONENT", 149, 154], ["dsDNA", "CELLULAR_COMPONENT", 157, 162], ["zinc", "SIMPLE_CHEMICAL", 368, 372], ["nucleic acid", "SIMPLE_CHEMICAL", 470, 482], ["retroviruses", "ORGANISM", 508, 520], ["ASLV", "GENE_OR_GENE_PRODUCT", 540, 544], ["NCp10", "ORGANISM", 546, 551], ["MoMuLV", "GENE_OR_GENE_PRODUCT", 555, 561], ["NCp12", "ORGANISM", 563, 568], ["BLV", "ORGANISM", 574, 577], ["NCp15", "GENE_OR_GENE_PRODUCT", 582, 587], ["HTLV", "ORGANISM", 593, 597], ["zinc fingers", "GENE_OR_GENE_PRODUCT", 810, 822], ["in vitro synthesized NC protein", "PROTEIN", 38, 69], ["retroviral RNA", "RNA", 74, 88], ["retroviral RNA", "RNA", 132, 146], ["genomic RNA", "RNA", 228, 239], ["RV NC proteins", "PROTEIN", 349, 363], ["simple nucleic acid binding protein", "PROTEIN", 395, 430], ["NABP", "PROTEIN", 432, 436], ["nucleic acid chaperoneNC", "PROTEIN", 470, 494], ["ASLV", "PROTEIN", 540, 544], ["MoMuLV", "PROTEIN", 555, 561], ["NCp12", "PROTEIN", 563, 568], ["NCp15", "PROTEIN", 582, 587], ["CCHC domain", "PROTEIN", 711, 722], ["zinc fingers", "PROTEIN", 810, 822], ["ZFs", "PROTEIN", 824, 827], ["retroviral", "SPECIES", 74, 84], ["BLV", "SPECIES", 574, 577], ["vitro synthesized NC protein", "TREATMENT", 41, 69], ["retroviral RNA", "TREATMENT", 74, 88], ["DNA and oligonucleotides", "TREATMENT", 90, 114], ["retroviral RNA", "TREATMENT", 132, 146], ["dsDNA > oligonucleotides", "TREATMENT", 157, 181], ["the apparent affinity", "PROBLEM", 189, 210], ["Large scale synthesis", "TEST", 324, 345], ["NC", "TREATMENT", 385, 387], ["a simple nucleic acid binding protein", "TREATMENT", 393, 430], ["nucleic acid chaperoneNC", "TREATMENT", 470, 494], ["various retroviruses", "PROBLEM", 500, 520], ["NCp", "TREATMENT", 529, 532], ["their primary sequences", "TEST", 636, 659], ["retroviral RNA", "OBSERVATION", 74, 88], ["RV", "ANATOMY", 349, 351], ["zinc binding", "OBSERVATION", 368, 380]]], ["Up to the 90s NC protein was purified from virions or recombinant bacteria.", [["virions", "ANATOMY", 43, 50], ["virions", "ORGANISM_SUBSTANCE", 43, 50], ["90s NC protein", "PROTEIN", 10, 24], ["virions", "PROBLEM", 43, 50], ["recombinant bacteria", "PROBLEM", 54, 74]]], ["Therefore, in addition to a series of affinity or mass exclusion chromatographies, the protein solutions were treated with reducing agents (\u03b2 mercapto and DTT) in the presence of EDTA.", [["\u03b2 mercapto and DTT", "CHEMICAL", 140, 158], ["EDTA", "CHEMICAL", 179, 183], ["mercapto", "CHEMICAL", 142, 150], ["DTT", "CHEMICAL", 155, 158], ["EDTA", "CHEMICAL", 179, 183], ["\u03b2 mercapto", "SIMPLE_CHEMICAL", 140, 150], ["DTT", "SIMPLE_CHEMICAL", 155, 158], ["EDTA", "SIMPLE_CHEMICAL", 179, 183], ["affinity", "PROBLEM", 38, 46], ["mass exclusion chromatographies", "PROBLEM", 50, 81], ["the protein solutions", "TREATMENT", 83, 104], ["reducing agents (\u03b2 mercapto and DTT", "TREATMENT", 123, 158], ["mass", "OBSERVATION", 50, 54], ["EDTA", "OBSERVATION", 179, 183]]], ["As a consequence, the initial RNA binding experiments showed that the stoechiometry and affinity of NCs for various RNA/DNA substrates were independent from zinc ions (Casas-Finet et al., 1988, Karpel et al., 1987).", [["zinc", "CHEMICAL", 157, 161], ["zinc", "CHEMICAL", 157, 161], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["zinc ions", "SIMPLE_CHEMICAL", 157, 166], ["the initial RNA binding experiments", "TEST", 18, 53], ["the stoechiometry", "PROBLEM", 66, 83], ["NCs", "TEST", 100, 103], ["various RNA/DNA substrates", "PROBLEM", 108, 134]]], ["These data were reinforced by results from the group of Leis who showed that the CCHC domain was essential for viral replication but not required as a zinc binding domain (Jentoft et al., 1988).", [["zinc", "CHEMICAL", 151, 155], ["zinc", "CHEMICAL", 151, 155], ["CCHC", "GENE_OR_GENE_PRODUCT", 81, 85], ["CCHC domain", "PROTEIN", 81, 92], ["zinc binding domain", "PROTEIN", 151, 170], ["the CCHC domain", "PROBLEM", 77, 92], ["viral replication", "PROBLEM", 111, 128], ["a zinc binding domain", "PROBLEM", 149, 170]]], ["However it remained that the CCHC sequence was a zinc binding domain as suggested by Berg (1986).", [["zinc", "CHEMICAL", 49, 53], ["zinc", "CHEMICAL", 49, 53], ["CCHC sequence", "DNA", 29, 42], ["zinc binding domain", "PROTEIN", 49, 68], ["the CCHC sequence", "PROBLEM", 25, 42], ["a zinc binding domain", "PROBLEM", 47, 68]]], ["In support of this notion, site directed mutageneses of zinc ligands namely the cysteine or histidine residues were found to render the virus replication defective (Gorelick et al., 1988, Meric and Goff, 1989).", [["zinc", "CHEMICAL", 56, 60], ["cysteine", "CHEMICAL", 80, 88], ["histidine", "CHEMICAL", 92, 101], ["zinc", "CHEMICAL", 56, 60], ["cysteine", "CHEMICAL", 80, 88], ["histidine", "CHEMICAL", 92, 101], ["zinc ligands", "SIMPLE_CHEMICAL", 56, 68], ["cysteine", "AMINO_ACID", 80, 88], ["histidine", "AMINO_ACID", 92, 101], ["zinc ligands", "TREATMENT", 56, 68], ["the cysteine", "TREATMENT", 76, 88], ["histidine residues", "PROBLEM", 92, 110]]], ["At last original biophysical studies notably by NMR demonstrated that one zinc atom was interacting per CCHC domain (Bess et al., 1992, Chance et al., 1992, Summers et al., 1992) which in turn was causing a structural organization of the primary CCHC sequence around the zinc ion (South et al., 1990, Summers et al., 1990).Large scale synthesis of RV NC proteins and zinc binding ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneTherefore it is likely that the lack of consensus on the role of zinc in NC activity and structure was due, at least in part, to the purification method.", [["zinc", "CHEMICAL", 74, 78], ["zinc", "CHEMICAL", 271, 275], ["zinc", "CHEMICAL", 367, 371], ["nucleic acid", "CHEMICAL", 401, 413], ["nucleic acid", "CHEMICAL", 469, 481], ["zinc", "CHEMICAL", 556, 560], ["zinc", "CHEMICAL", 74, 78], ["zinc", "CHEMICAL", 271, 275], ["zinc", "CHEMICAL", 367, 371], ["zinc", "CHEMICAL", 556, 560], ["zinc atom", "SIMPLE_CHEMICAL", 74, 83], ["zinc", "SIMPLE_CHEMICAL", 367, 371], ["nucleic acid", "SIMPLE_CHEMICAL", 469, 481], ["zinc", "SIMPLE_CHEMICAL", 556, 560], ["NC", "GENE_OR_GENE_PRODUCT", 564, 566], ["CCHC domain", "PROTEIN", 104, 115], ["primary CCHC sequence", "PROTEIN", 238, 259], ["RV NC proteins", "PROTEIN", 348, 362], ["simple nucleic acid binding protein", "PROTEIN", 394, 429], ["NABP", "PROTEIN", 431, 435], ["nucleic acid chaperone", "PROTEIN", 469, 491], ["original biophysical studies", "TEST", 8, 36], ["Large scale synthesis", "TEST", 323, 344], ["NC", "TREATMENT", 384, 386], ["a simple nucleic acid binding protein", "TREATMENT", 392, 429], ["nucleic acid chaperone", "TREATMENT", 469, 491], ["zinc in NC activity", "TREATMENT", 556, 575], ["the purification method", "TEST", 620, 643], ["RV", "ANATOMY", 348, 350], ["zinc binding", "OBSERVATION", 367, 379], ["is likely", "UNCERTAINTY", 504, 513]]], ["This is why it appeared necessary to in vitro synthesize NC proteins in order to tightly control the oxidation state of the cysteine residues.", [["cysteine", "CHEMICAL", 124, 132], ["NC proteins", "GENE_OR_GENE_PRODUCT", 57, 68], ["cysteine", "AMINO_ACID", 124, 132], ["NC proteins", "PROTEIN", 57, 68], ["vitro synthesize NC proteins", "TREATMENT", 40, 68], ["the cysteine residues", "PROBLEM", 120, 141], ["cysteine residues", "OBSERVATION", 124, 141]]], ["The first attempt was carried out on MoMuLV NCp10 which is 56 residues long with one zinc finger flanked by basic residues.", [["zinc", "CHEMICAL", 85, 89], ["MoMuLV NCp10", "DNA", 37, 49], ["zinc finger", "PROTEIN", 85, 96], ["MoMuLV NCp", "TREATMENT", 37, 47], ["basic residues", "OBSERVATION", 108, 122]]], ["NCp10 was obtained in a pure form by solid phase peptide synthesis (SPPS) using the tBoc strategy (Cornille et al., 1990).", [["NCp10", "CHEMICAL", 0, 5], ["NCp10", "CHEMICAL", 0, 5], ["NCp10", "SIMPLE_CHEMICAL", 0, 5], ["NCp10", "PROTEIN", 0, 5], ["the tBoc strategy", "TREATMENT", 80, 97]]], ["However the tBoc chemistry was found to exhibit a number of drawbacks that hamper the synthesis of large peptides.", [["the tBoc chemistry", "TEST", 8, 26], ["large", "OBSERVATION_MODIFIER", 99, 104], ["peptides", "OBSERVATION", 105, 113]]], ["This is why in a next step the synthesis of the HIV-1 NC protein was performed using the Fmoc chemistry.", [["Fmoc", "CHEMICAL", 89, 93], ["HIV-1", "ORGANISM", 48, 53], ["NC", "ORGANISM", 54, 56], ["HIV-1 NC protein", "PROTEIN", 48, 64], ["HIV-", "SPECIES", 48, 52], ["HIV-1", "SPECIES", 48, 53], ["the HIV", "TEST", 44, 51], ["NC protein", "TEST", 54, 64], ["the Fmoc chemistry", "TEST", 85, 103]]], ["HIV-1 NC contains two zinc fingers surrounded by a series of basic residues and the first NC obtained represented the 1\u201372 sequence corresponding to fully mature NCp7 (55 residues) and spacer peptide sp2 (56\u201372) (Dannull et al., 1994, de Rocquigny et al., 1991, de Rocquigny et al., 1992, de Rocquigny et al., 1997, Dong et al., 1997, Surovoy et al., 1993).Large scale synthesis of RV NC proteins and zinc binding ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneAll together such a chemical-based challenging production of RV NCs and other NA chaperones turned out to have several advantages: (i) the quantity of peptide was easily adapted using various resin types and scales; (ii) the peptides were not contaminated by nucleic acid and cysteine residues were preserved from oxidation since purification was performed in acidic conditions and further handling carried out using oxygen free solutions in the presence of Zn2+; (iii) synthesis of NC fragments and/or replacement of key residues for structure activity analyses or substitution of natural amino acids for exotic ones (fluorescent derivatives, biotins, etc.) became routine procedures.", [["zinc", "CHEMICAL", 401, 405], ["nucleic acid", "CHEMICAL", 435, 447], ["nucleic acid", "CHEMICAL", 503, 515], ["nucleic acid", "CHEMICAL", 784, 796], ["cysteine", "CHEMICAL", 801, 809], ["oxygen", "CHEMICAL", 942, 948], ["Zn2", "CHEMICAL", 983, 986], ["amino acids", "CHEMICAL", 1115, 1126], ["zinc", "CHEMICAL", 22, 26], ["zinc", "CHEMICAL", 401, 405], ["cysteine", "CHEMICAL", 801, 809], ["oxygen", "CHEMICAL", 942, 948], ["Zn2+", "CHEMICAL", 983, 987], ["amino acids", "CHEMICAL", 1115, 1126], ["HIV-1 NC", "ORGANISM", 0, 8], ["NCp7", "GENE_OR_GENE_PRODUCT", 162, 166], ["zinc", "SIMPLE_CHEMICAL", 401, 405], ["nucleic acid", "SIMPLE_CHEMICAL", 503, 515], ["RV NCs", "SIMPLE_CHEMICAL", 586, 592], ["nucleic acid", "SIMPLE_CHEMICAL", 784, 796], ["cysteine", "AMINO_ACID", 801, 809], ["oxygen", "SIMPLE_CHEMICAL", 942, 948], ["Zn2+", "SIMPLE_CHEMICAL", 983, 987], ["amino acids", "AMINO_ACID", 1115, 1126], ["fluorescent derivatives", "SIMPLE_CHEMICAL", 1144, 1167], ["biotins", "SIMPLE_CHEMICAL", 1169, 1176], ["zinc fingers", "PROTEIN", 22, 34], ["basic residues", "PROTEIN", 61, 75], ["NC", "PROTEIN", 90, 92], ["1\u201372 sequence", "DNA", 118, 131], ["NCp7", "PROTEIN", 162, 166], ["RV NC proteins", "PROTEIN", 382, 396], ["simple nucleic acid binding protein", "PROTEIN", 428, 463], ["NABP", "PROTEIN", 465, 469], ["nucleic acid chaperone", "PROTEIN", 503, 525], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["two zinc fingers", "TREATMENT", 18, 34], ["basic residues", "PROBLEM", 61, 75], ["the first NC", "TREATMENT", 80, 92], ["Large scale synthesis", "TEST", 357, 378], ["NC", "TREATMENT", 418, 420], ["a simple nucleic acid binding protein", "TREATMENT", 426, 463], ["nucleic acid chaperone", "TREATMENT", 503, 525], ["RV NCs", "TREATMENT", 586, 592], ["other NA chaperones", "TREATMENT", 597, 616], ["various resin types and scales", "TREATMENT", 709, 739], ["the peptides", "TREATMENT", 746, 758], ["nucleic acid and cysteine residues", "TREATMENT", 784, 818], ["purification", "TREATMENT", 855, 867], ["oxygen free solutions", "TREATMENT", 942, 963], ["synthesis of NC fragments", "TREATMENT", 995, 1020], ["replacement of key residues", "TREATMENT", 1028, 1055], ["structure activity analyses", "TEST", 1060, 1087], ["natural amino acids", "TREATMENT", 1107, 1126], ["exotic ones", "TREATMENT", 1131, 1142], ["fluorescent derivatives", "TREATMENT", 1144, 1167], ["biotins", "TREATMENT", 1169, 1176], ["routine procedures", "TREATMENT", 1191, 1209], ["RV", "ANATOMY", 382, 384], ["zinc binding", "OBSERVATION", 401, 413], ["RV", "ANATOMY", 586, 588], ["NC fragments", "OBSERVATION", 1008, 1020]]], ["This rendered possible a great deal of in vitro investigations on RV NCs ranging from structure analyses, NA binding, chaperoning and condensing activities to NC implications and functions in viral DNA synthesis and integration (see below).Large scale synthesis of RV NC proteins and zinc binding ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneDue to its merits this chemical protocol was also used to synthesize active SIV NCp8 (Morellet et al., 2006) together with many other NC proteins from FIV, ASLV and yeast Ty3 as well as HIV-1 TAT, and HCV core and HBV core peptides (Peloponese et al., 1999, Sharma et al., 2012) as well as putative NA chaperone domains of cellular proteins such as the SEVI (Munch et al., 2007) and the human prion protein (Gabus et al., 2001b).", [["cellular", "ANATOMY", 731, 739], ["zinc", "CHEMICAL", 284, 288], ["nucleic acid", "CHEMICAL", 318, 330], ["nucleic acid", "CHEMICAL", 386, 398], ["zinc", "CHEMICAL", 284, 288], ["RV NCs", "CELL", 66, 72], ["NA", "SIMPLE_CHEMICAL", 106, 108], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["zinc", "SIMPLE_CHEMICAL", 284, 288], ["nucleic acid", "SIMPLE_CHEMICAL", 386, 398], ["SIV", "ORGANISM", 484, 487], ["NCp8", "GENE_OR_GENE_PRODUCT", 488, 492], ["NC", "GENE_OR_GENE_PRODUCT", 542, 544], ["FIV", "ORGANISM", 559, 562], ["ASLV", "GENE_OR_GENE_PRODUCT", 564, 568], ["yeast", "ORGANISM", 573, 578], ["Ty3", "GENE_OR_GENE_PRODUCT", 579, 582], ["HIV-1", "ORGANISM", 594, 599], ["TAT", "GENE_OR_GENE_PRODUCT", 600, 603], ["HCV", "ORGANISM", 609, 612], ["HBV", "ORGANISM", 622, 625], ["cellular", "CELL", 731, 739], ["human", "ORGANISM", 795, 800], ["RV NC proteins", "PROTEIN", 265, 279], ["nucleic acid binding protein", "PROTEIN", 318, 346], ["NABP", "PROTEIN", 348, 352], ["NC proteins", "PROTEIN", 542, 553], ["ASLV", "PROTEIN", 564, 568], ["yeast Ty3", "PROTEIN", 573, 582], ["NA chaperone domains", "PROTEIN", 707, 727], ["cellular proteins", "PROTEIN", 731, 748], ["SEVI", "PROTEIN", 761, 765], ["human prion protein", "PROTEIN", 795, 814], ["yeast", "SPECIES", 573, 578], ["HIV-1", "SPECIES", 594, 599], ["human", "SPECIES", 795, 800], ["FIV", "SPECIES", 559, 562], ["ASLV", "SPECIES", 564, 568], ["yeast", "SPECIES", 573, 578], ["HIV-1", "SPECIES", 594, 599], ["HCV", "SPECIES", 609, 612], ["HBV", "SPECIES", 622, 625], ["human", "SPECIES", 795, 800], ["vitro investigations", "TEST", 42, 62], ["RV NCs", "TEST", 66, 72], ["NA binding", "PROBLEM", 106, 116], ["NC implications", "TREATMENT", 159, 174], ["viral DNA synthesis", "TREATMENT", 192, 211], ["Large scale synthesis", "TEST", 240, 261], ["NC", "TREATMENT", 301, 303], ["a simple nucleic acid binding protein", "TREATMENT", 309, 346], ["one nucleic acid chaperoneDue", "TREATMENT", 382, 411], ["this chemical protocol", "TREATMENT", 426, 448], ["NC proteins", "TREATMENT", 542, 553], ["FIV", "PROBLEM", 559, 562], ["ASLV", "PROBLEM", 564, 568], ["yeast Ty3", "PROBLEM", 573, 582], ["HIV", "TEST", 594, 597], ["TAT", "TEST", 600, 603], ["HCV core", "PROBLEM", 609, 617], ["HBV core peptides", "PROBLEM", 622, 639], ["cellular proteins", "PROBLEM", 731, 748], ["the human prion protein", "TEST", 791, 814], ["RV", "ANATOMY", 265, 267], ["zinc binding", "OBSERVATION", 284, 296], ["cellular proteins", "OBSERVATION", 731, 748]]], ["All these peptides were found to exhibit potent NA binding, chaperoning and condensing activities in vitro under physiological like conditions (see below and data not shown for the SEVI).Brief description of HIV-1 NC and NC\u2013nucleic acid complex structures ::: NC from a simple nucleic acid binding protein (NABP) to a multifunctional all-in-one nucleic acid chaperoneThree-dimensional structures of intact nucleocapsid proteins from HIV-1 have been determined using nuclear magnetic resonance (NMR) methods (Morellet et al., 1992, Summers et al., 1992).", [["NA", "CHEMICAL", 48, 50], ["NC\u2013nucleic acid", "CHEMICAL", 221, 236], ["nucleic acid", "CHEMICAL", 277, 289], ["nucleic acid", "CHEMICAL", 345, 357], ["NC\u2013nucleic acid", "CHEMICAL", 221, 236], ["NA", "SIMPLE_CHEMICAL", 48, 50], ["HIV-1", "ORGANISM", 208, 213], ["NC", "ORGANISM", 214, 216], ["NC\u2013nucleic acid", "SIMPLE_CHEMICAL", 221, 236], ["nucleic acid", "SIMPLE_CHEMICAL", 345, 357], ["HIV-1", "ORGANISM", 433, 438], ["SEVI", "PROTEIN", 181, 185], ["simple nucleic acid binding protein", "PROTEIN", 270, 305], ["NABP", "PROTEIN", 307, 311], ["nucleic acid chaperone", "PROTEIN", 345, 367], ["nucleocapsid proteins", "PROTEIN", 406, 427], ["HIV-1", "SPECIES", 208, 213], ["HIV-1", "SPECIES", 433, 438], ["HIV-1", "SPECIES", 208, 213], ["HIV-1", "SPECIES", 433, 438], ["potent NA binding", "PROBLEM", 41, 58], ["HIV", "TEST", 208, 211], ["NC", "TREATMENT", 260, 262], ["a simple nucleic acid binding protein", "TREATMENT", 268, 305], ["nucleic acid chaperone", "TREATMENT", 345, 367], ["intact nucleocapsid proteins", "PROBLEM", 399, 427], ["HIV", "TEST", 433, 436], ["nuclear magnetic resonance", "TEST", 466, 492], ["intact", "OBSERVATION_MODIFIER", 399, 405], ["nucleocapsid proteins", "OBSERVATION", 406, 427]]], ["Moreover, the structure of different NC\u2013nucleic acid complexes has been solved by the same technique and data show that such nucleoprotein complexes are different while displaying some common features (Amarasinghe et al., 2000b, Bazzi et al., 2011, Bourbigot et al., 2008, De Guzman et al., 1998, Morellet et al., 1998, Spriggs et al., 2008).", [["NC\u2013nucleic acid", "CHEMICAL", 37, 52], ["NC\u2013nucleic acid", "CHEMICAL", 37, 52], ["NC\u2013nucleic acid", "SIMPLE_CHEMICAL", 37, 52], ["NC\u2013nucleic acid complexes", "PROTEIN", 37, 62], ["nucleoprotein complexes", "PROTEIN", 125, 148], ["different NC\u2013nucleic acid complexes", "PROBLEM", 27, 62], ["such nucleoprotein complexes", "PROBLEM", 120, 148], ["different", "OBSERVATION_MODIFIER", 27, 36], ["NC\u2013nucleic", "OBSERVATION_MODIFIER", 37, 47], ["acid complexes", "OBSERVATION", 48, 62]]], ["The contacts between NC and the NA partner involve electrostatic, hydrophobic (Fig. 2) and hydrogen bonds (not shown) components.", [["hydrogen", "CHEMICAL", 91, 99], ["hydrogen bonds", "SIMPLE_CHEMICAL", 91, 105], ["NC", "TREATMENT", 21, 23], ["hydrogen bonds", "PROBLEM", 91, 105]]], ["The main features are that guanines bind deeply into the ZF1 and ZF2 hydrophobic pockets (Fig. 2).", [["guanines", "CHEMICAL", 27, 35], ["guanines", "CHEMICAL", 27, 35], ["ZF2", "CHEMICAL", 65, 68], ["guanines", "SIMPLE_CHEMICAL", 27, 35], ["ZF1", "SIMPLE_CHEMICAL", 57, 60], ["ZF1", "PROTEIN", 57, 60], ["ZF2", "PROTEIN", 65, 68], ["guanines bind", "TREATMENT", 27, 40], ["main", "OBSERVATION_MODIFIER", 4, 8], ["hydrophobic pockets", "OBSERVATION", 69, 88]]], ["With respect to NC protein alone (Fig. 2a), the hydrophobic platform, formed of residues V13, F16, T24, A25, W37, Q45 and M46, undergoes important structure changes upon nucleic acid binding.", [["nucleic acid", "CHEMICAL", 170, 182], ["V13", "GENE_OR_GENE_PRODUCT", 89, 92], ["nucleic acid", "SIMPLE_CHEMICAL", 170, 182], ["NC protein", "PROTEIN", 16, 26], ["Q45", "PROTEIN", 114, 117], ["M46", "PROTEIN", 122, 125], ["NC protein", "TREATMENT", 16, 26], ["the hydrophobic platform", "TEST", 44, 68], ["T24", "TEST", 99, 102], ["nucleic acid binding", "PROBLEM", 170, 190], ["nucleic acid", "OBSERVATION", 170, 182]]], ["In NC\u2013RNA complexes, one guanine is inserted in the hydrophobic platform of each zinc finger and this insertion is stabilized by hydrogen bonding of the basic residues spread along the NC sequence (K14, K20, K26, R29, R32, K38) (not shown).", [["guanine", "CHEMICAL", 25, 32], ["guanine", "CHEMICAL", 25, 32], ["zinc", "CHEMICAL", 81, 85], ["hydrogen", "CHEMICAL", 129, 137], ["guanine", "SIMPLE_CHEMICAL", 25, 32], ["hydrogen", "SIMPLE_CHEMICAL", 129, 137], ["K14", "GENE_OR_GENE_PRODUCT", 198, 201], ["NC\u2013RNA complexes", "PROTEIN", 3, 19], ["zinc finger", "PROTEIN", 81, 92], ["NC sequence", "PROTEIN", 185, 196], ["K14", "PROTEIN", 198, 201], ["one guanine", "TREATMENT", 21, 32], ["this insertion", "TREATMENT", 97, 111], ["the NC sequence", "TEST", 181, 196], ["K14", "TEST", 198, 201], ["K20", "TEST", 203, 206], ["K26", "TEST", 208, 211], ["RNA complexes", "OBSERVATION", 6, 19], ["hydrophobic", "ANATOMY_MODIFIER", 52, 63], ["zinc finger", "ANATOMY", 81, 92], ["hydrogen bonding", "OBSERVATION", 129, 145]]], ["In NC\u2013DNA complexes only one guanine is inserted in ZF2 while a thymine partly interacts with ZF1 (Fig. 2d).", [["guanine", "CHEMICAL", 29, 36], ["thymine", "CHEMICAL", 64, 71], ["guanine", "CHEMICAL", 29, 36], ["thymine", "CHEMICAL", 64, 71], ["guanine", "SIMPLE_CHEMICAL", 29, 36], ["ZF2", "SIMPLE_CHEMICAL", 52, 55], ["thymine", "SIMPLE_CHEMICAL", 64, 71], ["ZF1", "SIMPLE_CHEMICAL", 94, 97], ["NC\u2013DNA complexes", "PROTEIN", 3, 19], ["ZF2", "PROTEIN", 52, 55], ["ZF1", "PROTEIN", 94, 97], ["one guanine", "TREATMENT", 25, 36], ["one", "OBSERVATION_MODIFIER", 25, 28], ["guanine", "OBSERVATION", 29, 36]]], ["Another key structural feature involved in NC\u2013NA complex stabilization is the strong stacking interactions between the guanine nucleobases and the ZF-aromatic residues (F16 for ZF1 and W37 for ZF2 see Fig. 2b).", [["NA", "CHEMICAL", 46, 48], ["guanine", "CHEMICAL", 119, 126], ["ZF-aromatic", "CHEMICAL", 147, 158], ["NC\u2013", "CHEMICAL", 43, 46], ["guanine nucleobases", "CHEMICAL", 119, 138], ["NC\u2013NA", "SIMPLE_CHEMICAL", 43, 48], ["guanine nucleobases", "SIMPLE_CHEMICAL", 119, 138], ["NC\u2013NA complex", "PROTEIN", 43, 56], ["ZF", "PROTEIN", 147, 149], ["ZF1", "PROTEIN", 177, 180], ["W37", "PROTEIN", 185, 188], ["ZF2", "PROTEIN", 193, 196], ["the guanine nucleobases", "TREATMENT", 115, 138], ["aromatic residues", "PROBLEM", 150, 167], ["ZF1", "TREATMENT", 177, 180], ["ZF2", "TREATMENT", 193, 196], ["complex", "OBSERVATION_MODIFIER", 49, 56], ["stabilization", "OBSERVATION", 57, 70], ["strong", "OBSERVATION_MODIFIER", 78, 84], ["guanine nucleobases", "OBSERVATION", 119, 138], ["aromatic residues", "OBSERVATION", 150, 167]]], ["There is an additional important difference between NC\u2013DNA complexes (three complexes resolved (Bazzi et al., 2011, Bourbigot et al., 2008, Morellet et al., 1998)) and the NC\u2013RNA complexes (three complexes (Amarasinghe et al., 2000a, De Guzman et al., 1998, Spriggs et al., 2008)) where the orientation of ZF1 and ZF2 along the nucleic acid chain is opposite in NC\u2013RNA complexes as compared to NC\u2013DNA complexes.The NC network of molecular interactionsOur comprehension of the nature of NC profoundly changed once it was realized that the RV NC could interact in multiple ways with NA (see Fig. 2) and with distinct NA molecules at the same time and by so doing, NC has an impact on NA conformation.", [["nucleic acid", "CHEMICAL", 328, 340], ["NC\u2013DNA", "CHEMICAL", 52, 58], ["NC\u2013DNA", "CHEMICAL", 394, 400], ["NC\u2013DNA", "SIMPLE_CHEMICAL", 52, 58], ["ZF1", "GENE_OR_GENE_PRODUCT", 306, 309], ["ZF2", "GENE_OR_GENE_PRODUCT", 314, 317], ["NC\u2013DNA", "GENE_OR_GENE_PRODUCT", 394, 400], ["NA", "SIMPLE_CHEMICAL", 581, 583], ["NC\u2013DNA complexes", "PROTEIN", 52, 68], ["NC\u2013RNA complexes", "PROTEIN", 172, 188], ["ZF1", "PROTEIN", 306, 309], ["ZF2", "PROTEIN", 314, 317], ["nucleic acid chain", "PROTEIN", 328, 346], ["NC\u2013RNA complexes", "PROTEIN", 362, 378], ["NC\u2013DNA complexes", "PROTEIN", 394, 410], ["NA molecules", "PROTEIN", 615, 627], ["ZF1", "TREATMENT", 306, 309], ["ZF2", "TREATMENT", 314, 317], ["the nucleic acid chain", "TEST", 324, 346], ["NC", "TREATMENT", 486, 488], ["the RV NC", "TREATMENT", 534, 543], ["distinct NA molecules", "PROBLEM", 606, 627], ["NC", "TREATMENT", 662, 664], ["nucleic", "OBSERVATION", 328, 335], ["acid chain", "OBSERVATION", 336, 346], ["RNA complexes", "OBSERVATION", 365, 378], ["molecular interactions", "OBSERVATION", 429, 451], ["RV", "ANATOMY", 538, 540], ["distinct", "OBSERVATION_MODIFIER", 606, 614], ["NA molecules", "OBSERVATION", 615, 627]]], ["In fact the present view is that RV NCs are members of a growing family of nucleic acid binding proteins (NABPs) named RNA chaperones that are abundant in all living organisms and viruses where they perform essential functions ranging from gene transcription and regulation to mRNA translation and maintenance (Cristofari and Darlix, 2002, Herschlag, 1995, Schroeder et al., 2004, Tompa and Csermely, 2004).", [["nucleic acid", "CHEMICAL", 75, 87], ["RV NCs", "CELL", 33, 39], ["nucleic acid binding proteins", "GENE_OR_GENE_PRODUCT", 75, 104], ["NABPs", "GENE_OR_GENE_PRODUCT", 106, 111], ["nucleic acid binding proteins", "PROTEIN", 75, 104], ["NABPs", "PROTEIN", 106, 111], ["RNA chaperones", "PROTEIN", 119, 133], ["nucleic acid binding proteins", "PROBLEM", 75, 104], ["RNA chaperones", "PROBLEM", 119, 133], ["viruses", "PROBLEM", 180, 187], ["gene transcription", "TREATMENT", 240, 258], ["mRNA translation", "TREATMENT", 277, 293]]], ["These chaperone proteins belong to a large class of intrinsically disordered proteins (IDPs) because they contain flexible/disordered domains (Dunker et al., 2001, Uversky, 2002, Wright and Dyson, 1999) rich in basic residues and bind nucleic acids with broad sequence specificity and different modes (see Fig. 2) (Herschlag, 1995, Schroeder et al., 2004).The NC network of molecular interactionsSuch RNA chaperone proteins are indispensable partners of NAs because they assist RNA folding by preventing misfolding or by resolving misfolded RNA species (Cristofari and Darlix, 2002, Herschlag, 1995, Schroeder et al., 2004, Tompa and Csermely, 2004).", [["nucleic acids", "CHEMICAL", 235, 248], ["chaperone proteins", "PROTEIN", 6, 24], ["intrinsically disordered proteins", "PROTEIN", 52, 85], ["IDPs", "PROTEIN", 87, 91], ["disordered domains", "PROTEIN", 123, 141], ["RNA chaperone proteins", "PROTEIN", 401, 423], ["bind nucleic acids", "TEST", 230, 248], ["broad sequence specificity", "TEST", 254, 280], ["misfolding", "PROBLEM", 504, 514], ["misfolded RNA species", "PROBLEM", 531, 552], ["misfolded RNA species", "OBSERVATION", 531, 552]]], ["This RNA folding assistance is essential to ensure that RNAs reach their correct functional conformation in a rapid manner under physiological conditions (Schroeder et al., 2004).", [["RNAs", "RNA", 56, 60], ["This RNA folding assistance", "TREATMENT", 0, 27], ["RNAs", "TREATMENT", 56, 60]]], ["Examples of cellular RNA chaperones with essential functions include the tumor suppressor P53, hnRNP A1, the major mRNA binding protein YB1/P50, the fragile X mental retardation protein FMRP and the Prion protein (Cristofari and Darlix, 2002, Evdokimova et al., 2006, Gabus et al., 2001b, Ivanyi-Nagy et al., 2005).", [["cellular", "ANATOMY", 12, 20], ["tumor", "ANATOMY", 73, 78], ["tumor", "DISEASE", 73, 78], ["cellular", "CELL", 12, 20], ["tumor", "CANCER", 73, 78], ["P53", "GENE_OR_GENE_PRODUCT", 90, 93], ["hnRNP A1", "GENE_OR_GENE_PRODUCT", 95, 103], ["YB1", "GENE_OR_GENE_PRODUCT", 136, 139], ["P50", "GENE_OR_GENE_PRODUCT", 140, 143], ["fragile X mental retardation protein", "GENE_OR_GENE_PRODUCT", 149, 185], ["FMRP", "GENE_OR_GENE_PRODUCT", 186, 190], ["cellular RNA chaperones", "PROTEIN", 12, 35], ["tumor suppressor P53", "PROTEIN", 73, 93], ["hnRNP A1", "PROTEIN", 95, 103], ["major mRNA binding protein", "PROTEIN", 109, 135], ["YB1", "PROTEIN", 136, 139], ["P50", "PROTEIN", 140, 143], ["fragile X mental retardation protein", "PROTEIN", 149, 185], ["FMRP", "PROTEIN", 186, 190], ["Prion protein", "PROTEIN", 199, 212], ["cellular RNA chaperones", "PROBLEM", 12, 35], ["the major mRNA binding protein YB1", "TEST", 105, 139], ["P50", "TEST", 140, 143], ["the fragile X mental retardation protein FMRP", "PROBLEM", 145, 190], ["the Prion protein", "TEST", 195, 212], ["cellular RNA", "OBSERVATION", 12, 24]]], ["In this context RV NCs represent remarkable examples of multifunctional NA chaperones that drive the necessary structural rearrangements of the genomic RNA during the early and late phases of virus replication (see below; reviewed in Darlix et al., 1995, Levin et al., 2005).", [["multifunctional NA chaperones", "PROTEIN", 56, 85], ["genomic RNA", "RNA", 144, 155], ["multifunctional NA chaperones", "TREATMENT", 56, 85], ["the genomic RNA", "PROBLEM", 140, 155], ["virus replication", "TREATMENT", 192, 209], ["genomic RNA", "OBSERVATION", 144, 155]]], ["In addition RV NCs might well be endowed with protein chaperoning activity by providing assistance to the viral RT and IN enzymes during viral DNA synthesis and integration (Buckman et al., 2003, Carteau et al., 1997, Lapadat-Tapolsky et al., 1993, Poljak et al., 2003; reviewed in Darlix et al., 2011).The NC network of molecular interactionsBased on simple and advanced in vitro assays to examine the properties of RNA chaperones that involve rearrangement of nucleic acid structures in physiological conditions (reviewed in Cristofari and Darlix, 2002, Godet and Mely, 2010, Schroeder et al., 2004) other RV proteins with NA chaperone activities \u2013 or with nucleic acid annealing activity \u2013 have been identified and include TAT (Boudier et al., 2010, Boudier et al., 2014, Godet et al., 2012, Kameoka et al., 2002b, Kuciak et al., 2008) and VIF (Batisse et al., 2012, Henriet et al., 2005) that perform essential functions in HIV replication.The NC network of molecular interactionsIn conclusion the NA chaperoning activities of NC indicate that this small viral protein can direct NA structure remodeling so that the most thermodynamically stable conformations are gained (Fig. 2).", [["nucleic acid", "CHEMICAL", 462, 474], ["IN enzymes", "GENE_OR_GENE_PRODUCT", 119, 129], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["NA chaperone", "GENE_OR_GENE_PRODUCT", 625, 637], ["TAT", "GENE_OR_GENE_PRODUCT", 726, 729], ["HIV", "ORGANISM", 928, 931], ["NC", "GENE_OR_GENE_PRODUCT", 1031, 1033], ["viral RT and IN enzymes", "PROTEIN", 106, 129], ["RNA chaperones", "PROTEIN", 417, 431], ["RV proteins", "PROTEIN", 608, 619], ["TAT", "PROTEIN", 726, 729], ["small viral protein", "PROTEIN", 1053, 1072], ["HIV", "SPECIES", 928, 931], ["RV NCs", "TEST", 12, 18], ["protein chaperoning activity", "TREATMENT", 46, 74], ["the viral RT", "TREATMENT", 102, 114], ["enzymes", "TEST", 122, 129], ["viral DNA synthesis", "TREATMENT", 137, 156], ["vitro assays", "TEST", 375, 387], ["RNA chaperones", "TREATMENT", 417, 431], ["nucleic acid structures", "PROBLEM", 462, 485], ["NA chaperone activities", "TREATMENT", 625, 648], ["nucleic acid annealing activity", "TREATMENT", 659, 690], ["HIV replication", "TREATMENT", 928, 943], ["the NA chaperoning activities of NC", "TREATMENT", 998, 1033], ["this small viral protein", "PROBLEM", 1048, 1072], ["RV", "ANATOMY", 12, 14], ["molecular interactions", "OBSERVATION", 962, 984]]], ["This remodeling reaction appears to rely on three essential NC properties, that are (i) its binding to NAs causing their condensation as large nucleoprotein complexes where molecular crowding can take place (Echols, 1990, Le Cam et al., 1998, Mirambeau et al., 2006, Williams et al., 2001), (ii) the partial destabilization of NA structures in an ATP-independent manner (Azoulay et al., 2003, Beltz et al., 2003, Beltz et al., 2005, Bernacchi et al., 2002, Bourbigot et al., 2008, Heilman-Miller et al., 2004) and (iii) a rapid on-and-off NA binding kinetics (Cruceanu et al., 2006a, Cruceanu et al., 2006b).", [["NA", "CHEMICAL", 327, 329], ["ATP", "CHEMICAL", 347, 350], ["ATP", "CHEMICAL", 347, 350], ["ATP", "SIMPLE_CHEMICAL", 347, 350], ["nucleoprotein complexes", "PROTEIN", 143, 166], ["This remodeling reaction", "PROBLEM", 0, 24], ["their condensation", "PROBLEM", 115, 133], ["large nucleoprotein complexes", "PROBLEM", 137, 166], ["molecular crowding", "PROBLEM", 173, 191]]], ["The mechanism whereby RV NC protein can remodel NA structures in an ATP-independent manner is yet poorly understood but it might be a direct consequence of the multiple modes of NC binding to single and double stranded RNA and DNA molecules (Fig. 2, compare panels a with b\u2013d) and the rapid on and off binding kinetics of NC possibly involving an entropy exchange between NC and the NA (see Section 6 on NC flexibility) (Ivanyi-Nagy et al., 2005).NC as an essential cofactor of RT ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseA canonical hallmark of retroviruses, shared by LTR and non-LTR retroelements, is their replication strategy that necessitates the reverse transcription of the genomic RNA (gRNA) by the viral DNA polymerase, known as reverse transcriptase (RT) during the early phase of virus replication that spans virus-cell recognition and entry to viral DNA synthesis and integration into the host genome.", [["LTR", "ANATOMY", 630, 633], ["cell", "ANATOMY", 887, 891], ["ATP", "CHEMICAL", 68, 71], ["nucleic acid", "CHEMICAL", 510, 522], ["ATP", "CHEMICAL", 68, 71], ["RV NC", "GENE_OR_GENE_PRODUCT", 22, 27], ["ATP", "SIMPLE_CHEMICAL", 68, 71], ["NC", "GENE_OR_GENE_PRODUCT", 178, 180], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["NC", "GENE_OR_GENE_PRODUCT", 507, 509], ["DNA", "CELLULAR_COMPONENT", 544, 547], ["retroviruses", "ORGANISM", 606, 618], ["LTR", "CELLULAR_COMPONENT", 630, 633], ["DNA", "CELLULAR_COMPONENT", 774, 777], ["cell", "CELL", 887, 891], ["DNA", "CELLULAR_COMPONENT", 923, 926], ["RV NC protein", "PROTEIN", 22, 35], ["double stranded RNA", "RNA", 203, 222], ["DNA molecules", "PROTEIN", 227, 240], ["reverse transcriptaseA", "PROTEIN", 561, 583], ["LTR", "DNA", 630, 633], ["non-LTR retroelements", "DNA", 638, 659], ["genomic RNA", "RNA", 742, 753], ["gRNA", "RNA", 755, 759], ["viral DNA polymerase", "PROTEIN", 768, 788], ["reverse transcriptase", "PROTEIN", 799, 820], ["host genome", "DNA", 962, 973], ["RV NC protein", "TREATMENT", 22, 35], ["NC binding", "PROBLEM", 178, 188], ["single and double stranded RNA and DNA molecules", "PROBLEM", 192, 240], ["NC", "TREATMENT", 322, 324], ["an entropy exchange", "TREATMENT", 344, 363], ["NC", "TREATMENT", 372, 374], ["NC flexibility", "TREATMENT", 404, 418], ["NC", "TREATMENT", 447, 449], ["NC nucleic acid chaperoning", "TREATMENT", 507, 534], ["viral DNA synthesis", "TREATMENT", 538, 557], ["non-LTR retroelements", "TREATMENT", 638, 659], ["the viral DNA polymerase", "PROBLEM", 764, 788], ["virus replication", "TREATMENT", 852, 869], ["cell recognition", "TEST", 887, 903], ["viral DNA synthesis", "TREATMENT", 917, 936], ["RV", "ANATOMY", 22, 24], ["NC protein", "OBSERVATION", 25, 35], ["entropy", "OBSERVATION", 347, 354], ["multiple", "OBSERVATION_MODIFIER", 489, 497], ["viral DNA", "OBSERVATION", 538, 547], ["retroviruses", "OBSERVATION", 606, 618], ["non-LTR retroelements", "OBSERVATION", 638, 659], ["genomic RNA", "OBSERVATION", 742, 753], ["host genome", "OBSERVATION", 962, 973]]], ["The double stranded viral DNA is synthesized by the viral RT during a succession of specific reactions that take place in an RT-complex (RTC) most probably corresponding to the viral nucleocapsid (reviewed in Darlix et al., 1995, Levin et al., 2005, Rein et al., 1998).", [["DNA", "CELLULAR_COMPONENT", 26, 29], ["double stranded viral DNA", "DNA", 4, 29], ["RT-complex", "PROTEIN", 125, 135], ["RTC", "PROTEIN", 137, 140], ["viral nucleocapsid", "PROTEIN", 177, 195], ["The double stranded viral DNA", "PROBLEM", 0, 29], ["the viral RT", "TREATMENT", 48, 60], ["specific reactions", "PROBLEM", 84, 102], ["an RT-complex (RTC", "TREATMENT", 122, 140], ["the viral nucleocapsid", "PROBLEM", 173, 195], ["viral DNA", "OBSERVATION", 20, 29]]], ["The overall process of reverse transcription necessitates profound structural rearrangements of the genomic RNA, the cellular primer tRNA and of the newly made viral DNA, which are all assisted by NC (Fig. 1III and IV).", [["cellular", "ANATOMY", 117, 125], ["cellular", "CELL", 117, 125], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["genomic RNA", "RNA", 100, 111], ["cellular primer tRNA", "DNA", 117, 137], ["viral DNA", "DNA", 160, 169], ["reverse transcription", "TREATMENT", 23, 44], ["profound structural rearrangements of the genomic RNA", "PROBLEM", 58, 111], ["the cellular primer tRNA", "TREATMENT", 113, 137], ["viral DNA", "PROBLEM", 160, 169], ["profound", "OBSERVATION_MODIFIER", 58, 66], ["structural rearrangements", "OBSERVATION", 67, 92], ["genomic RNA", "OBSERVATION", 100, 111], ["primer tRNA", "OBSERVATION", 126, 137], ["viral DNA", "OBSERVATION", 160, 169]]], ["Subsequently the viral DNA is imported into the nucleus within the preintegration complex (PIC) and ultimately integrated into the host cell genome, then called the provirus (Fig. 1I\u2013V).NC as an essential cofactor of RT ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseIt is not the purpose of this short review to provide once more a simplified scheme of the reverse transcription process which ultimately leads to the synthesis of a complete viral DNA flanked by the 5\u2032 and 3\u2032 LTR with the inverted repeats (ir) required for vDNA integration (see a number of reviews, i.e. Bampi et al., 2004, Levin et al., 2005).NC as an essential cofactor of RT ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseThe present view is that NC protein assists RT from the initiation to the completion of reverse transcription (RTion) to ensure fidelity and completeness of vDNA synthesis with the LTRs.", [["nucleus", "ANATOMY", 48, 55], ["cell", "ANATOMY", 136, 140], ["LTR", "ANATOMY", 531, 534], ["nucleic acid", "CHEMICAL", 249, 261], ["nucleic acid", "CHEMICAL", 730, 742], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["nucleus", "CELLULAR_COMPONENT", 48, 55], ["PIC", "CELLULAR_COMPONENT", 91, 94], ["host cell", "CELL", 131, 140], ["NC", "GENE_OR_GENE_PRODUCT", 246, 248], ["DNA", "CELLULAR_COMPONENT", 283, 286], ["DNA", "CELLULAR_COMPONENT", 502, 505], ["LTR", "CELLULAR_COMPONENT", 531, 534], ["NC", "GENE_OR_GENE_PRODUCT", 727, 729], ["DNA", "CELLULAR_COMPONENT", 764, 767], ["NC", "GENE_OR_GENE_PRODUCT", 827, 829], ["vDNA", "SIMPLE_CHEMICAL", 959, 963], ["viral DNA", "DNA", 17, 26], ["preintegration complex", "PROTEIN", 67, 89], ["PIC", "PROTEIN", 91, 94], ["host cell genome", "DNA", 131, 147], ["reverse transcriptase", "PROTEIN", 300, 321], ["viral DNA", "DNA", 496, 505], ["5\u2032 and 3\u2032", "DNA", 521, 530], ["LTR", "DNA", 531, 534], ["inverted repeats", "DNA", 544, 560], ["reverse transcriptase", "PROTEIN", 781, 802], ["NC protein", "PROTEIN", 827, 837], ["vDNA", "DNA", 959, 963], ["LTRs", "DNA", 983, 987], ["the viral DNA", "PROBLEM", 13, 26], ["the provirus (Fig", "TREATMENT", 161, 178], ["NC", "TREATMENT", 186, 188], ["NC nucleic acid chaperoning", "TREATMENT", 246, 273], ["viral DNA synthesis", "TREATMENT", 277, 296], ["the reverse transcription process", "PROBLEM", 408, 441], ["LTR", "PROBLEM", 531, 534], ["vDNA integration", "TREATMENT", 579, 595], ["NC", "TREATMENT", 667, 669], ["NC nucleic acid chaperoning", "TREATMENT", 727, 754], ["viral DNA synthesis", "TREATMENT", 758, 777], ["reverse transcription (RTion)", "TREATMENT", 890, 919], ["vDNA synthesis", "PROBLEM", 959, 973], ["the LTRs", "TREATMENT", 979, 987], ["viral DNA", "OBSERVATION", 17, 26], ["nucleus", "ANATOMY", 48, 55], ["host cell genome", "OBSERVATION", 131, 147]]], ["Firstly, NC chaperones a number of specific obligatory viral nucleic acid annealing reactions, namely primer tRNA annealing to the RTion initiation site (PBS), and the minus strand and the plus strand DNA strand transfers.", [["nucleic acid", "CHEMICAL", 61, 73], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["NC chaperones", "PROTEIN", 9, 22], ["RTion initiation site", "DNA", 131, 152], ["PBS", "DNA", 154, 157], ["minus strand", "DNA", 168, 180], ["plus strand DNA strand", "DNA", 189, 211], ["NC chaperones", "TREATMENT", 9, 22], ["viral nucleic acid annealing reactions", "TREATMENT", 55, 93], ["primer tRNA annealing", "TREATMENT", 102, 123], ["the minus strand", "TREATMENT", 164, 180], ["strand DNA strand transfers", "TREATMENT", 194, 221], ["viral nucleic", "OBSERVATION", 55, 68], ["acid annealing", "OBSERVATION", 69, 83]]], ["Secondly NC protein possibly through direct interactions with both the NA and the RT enzyme (Druillennec et al., 1999a, Lener et al., 1998) appears to contribute to the fidelity of vDNA synthesis (i) by preventing minus strand and plus strand false initiations (Beltz et al., 2005, Guo et al., 1997, Lapadat-Tapolsky et al., 1997), (ii) by largely increasing the time of residence of active RT molecules on the genomic RNA template (Grohmann et al., 2008) and (iii) by eliciting a nucleotide excision-repair activity of RT (Bampi et al., 2006; reviewed in Darlix et al., 2007).NC as an essential cofactor of RT ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseThus NC can be considered as an essential cofactor of RT chaperoning both the viral NA annealing reactions and the RT enzyme in order to ensure fidelity and completeness of viral DNA synthesis.", [["nucleotide", "CHEMICAL", 481, 491], ["nucleic acid", "CHEMICAL", 640, 652], ["nucleotide", "CHEMICAL", 481, 491], ["NC", "GENE_OR_GENE_PRODUCT", 9, 11], ["vDNA", "SIMPLE_CHEMICAL", 181, 185], ["NC", "GENE_OR_GENE_PRODUCT", 637, 639], ["DNA", "CELLULAR_COMPONENT", 674, 677], ["NC", "GENE_OR_GENE_PRODUCT", 717, 719], ["DNA", "CELLULAR_COMPONENT", 891, 894], ["NC protein", "PROTEIN", 9, 19], ["RT enzyme", "PROTEIN", 82, 91], ["vDNA", "PROTEIN", 181, 185], ["RT molecules", "PROTEIN", 391, 403], ["reverse transcriptase", "PROTEIN", 691, 712], ["RT enzyme", "PROTEIN", 827, 836], ["Secondly NC protein", "TREATMENT", 0, 19], ["the NA", "TEST", 67, 73], ["the RT enzyme", "TEST", 78, 91], ["vDNA synthesis", "PROBLEM", 181, 195], ["minus strand", "PROBLEM", 214, 226], ["strand false initiations", "PROBLEM", 236, 260], ["active RT molecules", "PROBLEM", 384, 403], ["a nucleotide excision", "TREATMENT", 479, 500], ["repair activity of RT", "TREATMENT", 501, 522], ["NC", "TREATMENT", 577, 579], ["NC nucleic acid chaperoning", "TREATMENT", 637, 664], ["viral DNA synthesis", "TREATMENT", 668, 687], ["NC", "TREATMENT", 717, 719], ["RT chaperoning", "TREATMENT", 766, 780], ["the viral NA annealing reactions", "TREATMENT", 786, 818], ["the RT enzyme", "TEST", 823, 836], ["viral DNA synthesis", "PROBLEM", 885, 904], ["increasing", "OBSERVATION_MODIFIER", 348, 358], ["active", "OBSERVATION_MODIFIER", 384, 390], ["excision", "OBSERVATION", 492, 500], ["viral DNA synthesis", "OBSERVATION", 885, 904]]], ["Hence NC could be viewed as a Janus chaperone assisting both nucleic acids and proteins to the benefit of their functional interactions (Kovacs et al., 2009).NC as an essential cofactor of RT ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseAt this point, it should be mentioned that two other viral factors, namely the viral trans-acting factor TAT and the viral infectivity factor VIF endowed with NA chaperoning activities (Henriet et al., 2005, Kuciak et al., 2008) can provide assistance to vDNA synthesis (Apolloni et al., 2003, Boudier et al., 2010, Boudier et al., 2014, Kameoka et al., 2002a).", [["nucleic acids", "CHEMICAL", 61, 74], ["nucleic acid", "CHEMICAL", 221, 233], ["Janus", "GENE_OR_GENE_PRODUCT", 30, 35], ["NC", "GENE_OR_GENE_PRODUCT", 218, 220], ["DNA", "CELLULAR_COMPONENT", 255, 258], ["TAT", "GENE_OR_GENE_PRODUCT", 398, 401], ["VIF", "GENE_OR_GENE_PRODUCT", 435, 438], ["vDNA", "SIMPLE_CHEMICAL", 548, 552], ["Janus chaperone", "PROTEIN", 30, 45], ["reverse transcriptase", "PROTEIN", 272, 293], ["viral factors", "PROTEIN", 346, 359], ["viral trans-acting factor", "PROTEIN", 372, 397], ["TAT", "PROTEIN", 398, 401], ["viral infectivity factor VIF", "PROTEIN", 410, 438], ["NC", "TREATMENT", 6, 8], ["a Janus chaperone", "TREATMENT", 28, 45], ["both nucleic acids", "TREATMENT", 56, 74], ["NC", "TREATMENT", 158, 160], ["NC nucleic acid chaperoning", "TREATMENT", 218, 245], ["viral DNA synthesis", "TREATMENT", 249, 268], ["two other viral factors", "PROBLEM", 336, 359], ["the viral trans-acting factor TAT", "TREATMENT", 368, 401], ["the viral infectivity factor VIF", "PROBLEM", 406, 438]]], ["But this is still a debated issue since only low to very low amounts of TAT and VIF are found in virions.", [["virions", "ANATOMY", 97, 104], ["TAT", "GENE_OR_GENE_PRODUCT", 72, 75], ["VIF", "GENE_OR_GENE_PRODUCT", 80, 83], ["virions", "CELLULAR_COMPONENT", 97, 104], ["TAT", "PROTEIN", 72, 75], ["VIF", "PROTEIN", 80, 83], ["TAT and VIF", "TREATMENT", 72, 83]]], ["On the other hand, TAT and VIF could assist the initiation of vDNA synthesis which can already take place in the infected cell (Lori et al., 1992, Trono, 1992, Zhang et al., 1994).", [["cell", "ANATOMY", 122, 126], ["TAT", "GENE_OR_GENE_PRODUCT", 19, 22], ["VIF", "GENE_OR_GENE_PRODUCT", 27, 30], ["vDNA", "GENE_OR_GENE_PRODUCT", 62, 66], ["cell", "CELL", 122, 126], ["TAT", "PROTEIN", 19, 22], ["VIF", "PROTEIN", 27, 30], ["vDNA", "PROTEIN", 62, 66], ["TAT and VIF", "TREATMENT", 19, 30], ["vDNA synthesis", "TREATMENT", 62, 76], ["infected cell", "OBSERVATION", 113, 126]]], ["Along this line, a cellular factor called SEVI present in abundance in the seminal fluid was found to be a potent NA chaperone resembling NC in vitro (Darlix, unpublished data) and to augment the level of vDNA synthesized in vitro and in cell culture (Munch et al., 2007).", [["cellular", "ANATOMY", 19, 27], ["seminal fluid", "ANATOMY", 75, 88], ["cell culture", "ANATOMY", 238, 250], ["cellular", "CELL", 19, 27], ["SEVI", "GENE_OR_GENE_PRODUCT", 42, 46], ["seminal fluid", "ORGANISM_SUBSTANCE", 75, 88], ["vDNA", "SIMPLE_CHEMICAL", 205, 209], ["cell culture", "CELL", 238, 250], ["cellular factor", "PROTEIN", 19, 34], ["SEVI", "PROTEIN", 42, 46], ["NA chaperone", "PROTEIN", 114, 126], ["vDNA", "PROTEIN", 205, 209], ["a cellular factor", "PROBLEM", 17, 34], ["cell culture", "TEST", 238, 250], ["seminal", "ANATOMY", 75, 82], ["fluid", "OBSERVATION", 83, 88]]], ["This same component of the seminal fluid was found to drastically increase the virus titer on primary human blood cells (Munch et al., 2007, Zhang et al., 1996, Zhang et al., 1998).NC as an essential cofactor of RT ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseThe potent NC chaperoning activity is also believed to drive recombination reactions during reverse transcription of the dimeric RNA genome (Galetto et al., 2006, Galetto and Negroni, 2005, Onafuwa-Nuga and Telesnitsky, 2009).", [["seminal fluid", "ANATOMY", 27, 40], ["blood cells", "ANATOMY", 108, 119], ["nucleic acid", "CHEMICAL", 244, 256], ["seminal fluid", "ORGANISM_SUBSTANCE", 27, 40], ["human", "ORGANISM", 102, 107], ["blood cells", "CELL", 108, 119], ["NC", "GENE_OR_GENE_PRODUCT", 241, 243], ["DNA", "CELLULAR_COMPONENT", 278, 281], ["NC", "GENE_OR_GENE_PRODUCT", 327, 329], ["primary human blood cells", "CELL_TYPE", 94, 119], ["reverse transcriptase", "PROTEIN", 295, 316], ["dimeric RNA genome", "DNA", 437, 455], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["the seminal fluid", "PROBLEM", 23, 40], ["the virus titer", "PROBLEM", 75, 90], ["primary human blood cells", "TREATMENT", 94, 119], ["NC", "TREATMENT", 181, 183], ["NC nucleic acid chaperoning", "TREATMENT", 241, 268], ["viral DNA synthesis", "TREATMENT", 272, 291], ["The potent NC chaperoning activity", "TREATMENT", 316, 350], ["recombination reactions", "PROBLEM", 377, 400], ["component", "OBSERVATION_MODIFIER", 10, 19], ["seminal", "ANATOMY", 27, 34], ["fluid", "OBSERVATION", 35, 40], ["virus titer", "OBSERVATION", 79, 90], ["potent", "OBSERVATION_MODIFIER", 320, 326]]], ["In fact the pseudiploidy of the RV genome constitutes the basis for forced and unforced recombinations (Hu et al., 2003b, Hu and Temin, 1990, Katz and Skalka, 1990, Zhang and Temin, 1993) in the course of minus strand DNA synthesis, which ultimately lead to the formation of a complete viral DNA despite nicks in each monomeric RNA.", [["DNA", "CELLULAR_COMPONENT", 218, 221], ["DNA", "CELLULAR_COMPONENT", 292, 295], ["nicks", "CELLULAR_COMPONENT", 304, 309], ["RV genome", "DNA", 32, 41], ["viral DNA", "DNA", 286, 295], ["monomeric RNA", "RNA", 318, 331], ["Hu", "TEST", 122, 124], ["Temin", "TEST", 129, 134], ["minus strand DNA synthesis", "PROBLEM", 205, 231], ["a complete viral DNA", "PROBLEM", 275, 295], ["nicks in each monomeric RNA", "TREATMENT", 304, 331], ["RV", "ANATOMY", 32, 34], ["genome", "OBSERVATION", 35, 41], ["viral DNA", "OBSERVATION", 286, 295], ["monomeric RNA", "OBSERVATION", 318, 331]]], ["Moreover these NC-directed recombination reactions should cause the reassortment of specific genetic traits when the two RNAs are different as it is in heterozogous viruses, which constitutes the basis for a high level of viral variability as indicated by the presence of large quasispecies populations in HIV infected person (Wain-Hobson et al., 2003).", [["HIV infected", "DISEASE", 306, 318], ["HIV", "ORGANISM", 306, 309], ["HIV", "SPECIES", 306, 309], ["person", "SPECIES", 319, 325], ["HIV", "SPECIES", 306, 309], ["these NC", "TREATMENT", 9, 17], ["directed recombination reactions", "TREATMENT", 18, 50], ["specific genetic traits", "PROBLEM", 84, 107], ["the two RNAs", "PROBLEM", 113, 125], ["heterozogous viruses", "PROBLEM", 152, 172], ["viral variability", "PROBLEM", 222, 239], ["large quasispecies populations", "PROBLEM", 272, 302], ["heterozogous viruses", "OBSERVATION", 152, 172], ["viral variability", "OBSERVATION", 222, 239], ["large", "OBSERVATION_MODIFIER", 272, 277], ["quasispecies", "OBSERVATION", 278, 290]]], ["This rather high level of virus variability as indicated by high throughput sequencing analyses (HTPS) allows the virus to escape the immune response and HAART (highly active antiretroviral therapies) (Barbaro et al., 2005, Gallant et al., 2003).", [["virus variability", "PROBLEM", 26, 43], ["sequencing analyses", "TEST", 76, 95], ["the virus", "PROBLEM", 110, 119], ["HAART", "TREATMENT", 154, 159], ["active antiretroviral therapies", "TREATMENT", 168, 199], ["virus", "OBSERVATION", 26, 31]]], ["Thus the emerging view is that NC is central to the network of dynamic interactions taking place between RT, the dimeric RNA template and the viral cDNA being synthesized.", [["NC", "GENE_OR_GENE_PRODUCT", 31, 33], ["dimeric RNA template", "RNA", 113, 133], ["viral cDNA", "DNA", 142, 152], ["RT", "TREATMENT", 105, 107], ["the dimeric RNA template", "TREATMENT", 109, 133], ["the viral cDNA", "TREATMENT", 138, 152], ["viral cDNA", "OBSERVATION", 142, 152]]], ["This NC network fulfills two functions, firstly by ensuring the synthesis of a complete functional vDNA flanked by the LTRs and secondly by fueling the genetic diversity of newly made virus by reassorting genetic traits through recombination reactions to the benefit of HIV-1 fitness in vivo (Barbour and Grant, 2005, Bocharov et al., 2005, Wain-Hobson et al., 2003).Impacts of zinc finger mutations on viral DNA synthesis and integration ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseAt this stage it should be mentioned that synthesis of a complete double stranded viral DNA flanked by the LTR is a slow process that takes 6\u20138 h in human T cell lines and up to 16\u201324 h in PBLs and macrophages that are the major cells infected by HIV-1 in vivo (Arfi et al., 2008).", [["LTR", "ANATOMY", 647, 650], ["T cell lines", "ANATOMY", 695, 707], ["PBLs", "ANATOMY", 729, 733], ["macrophages", "ANATOMY", 738, 749], ["cells", "ANATOMY", 769, 774], ["zinc", "CHEMICAL", 378, 382], ["nucleic acid", "CHEMICAL", 468, 480], ["zinc", "CHEMICAL", 378, 382], ["NC network", "MULTI-TISSUE_STRUCTURE", 5, 15], ["HIV-1", "ORGANISM", 270, 275], ["DNA", "CELLULAR_COMPONENT", 409, 412], ["NC", "GENE_OR_GENE_PRODUCT", 465, 467], ["DNA", "CELLULAR_COMPONENT", 502, 505], ["DNA", "CELLULAR_COMPONENT", 628, 631], ["LTR", "CELLULAR_COMPONENT", 647, 650], ["human", "ORGANISM", 689, 694], ["T cell lines", "CELL", 695, 707], ["PBLs", "CELL", 729, 733], ["macrophages", "CELL", 738, 749], ["cells", "CELL", 769, 774], ["HIV-1", "ORGANISM", 787, 792], ["vDNA", "DNA", 99, 103], ["LTRs", "DNA", 119, 123], ["reverse transcriptase", "PROTEIN", 519, 540], ["double stranded viral DNA", "DNA", 606, 631], ["LTR", "DNA", 647, 650], ["human T cell lines", "CELL_LINE", 689, 707], ["PBLs", "CELL_TYPE", 729, 733], ["macrophages", "CELL_TYPE", 738, 749], ["HIV-1", "SPECIES", 270, 275], ["human", "SPECIES", 689, 694], ["HIV-1", "SPECIES", 787, 792], ["HIV-1", "SPECIES", 270, 275], ["human", "SPECIES", 689, 694], ["HIV-1", "SPECIES", 787, 792], ["virus", "TREATMENT", 184, 189], ["HIV", "PROBLEM", 270, 273], ["zinc finger mutations", "PROBLEM", 378, 399], ["NC nucleic acid chaperoning", "TREATMENT", 465, 492], ["viral DNA synthesis", "TREATMENT", 496, 515], ["a complete double stranded viral DNA flanked", "TREATMENT", 595, 639], ["a slow process", "PROBLEM", 654, 668], ["human T cell lines", "TREATMENT", 689, 707], ["macrophages", "PROBLEM", 738, 749], ["zinc finger mutations", "OBSERVATION", 378, 399], ["cell lines", "OBSERVATION", 697, 707]]], ["Once vDNA synthesis is completed, NC is thought to protect the vDNA product against nuclease attack (Krishnamoorthy et al., 2003), notably the ir ends required for integration.", [["vDNA", "SIMPLE_CHEMICAL", 5, 9], ["vDNA", "PROTEIN", 5, 9], ["vDNA product", "PROTEIN", 63, 75], ["NC", "TREATMENT", 34, 36]]], ["In fact mutating either one of the highly conserved CCHC residues of the zinc fingers (ZFs) caused a lower affinity of NC for DNA in vitro and rendered the LTR ends accessible to nucleases in an in vitro model system containing the IN enzyme and the LTR DNA (Bampi et al., 2004).Impacts of zinc finger mutations on viral DNA synthesis and integration ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseAlong this line, early observations show that point mutations in the highly conserved CCHC ZFs resulted in the formation of incomplete LTR ends and in the production of replication defective viruses (Buckman et al., 2003, Tanchou et al., 1998) where viral DNA synthesis was partially impaired and at the same time being unstable (Demene et al., 1994, Gorelick et al., 1996, Gorelick et al., 1999).", [["LTR", "ANATOMY", 156, 159], ["LTR", "ANATOMY", 250, 253], ["LTR", "ANATOMY", 587, 590], ["zinc", "CHEMICAL", 73, 77], ["zinc", "CHEMICAL", 290, 294], ["nucleic acid", "CHEMICAL", 380, 392], ["zinc", "CHEMICAL", 73, 77], ["zinc", "CHEMICAL", 290, 294], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["LTR", "CELLULAR_COMPONENT", 156, 159], ["IN enzyme", "GENE_OR_GENE_PRODUCT", 232, 241], ["LTR", "CELLULAR_COMPONENT", 250, 253], ["DNA", "CELLULAR_COMPONENT", 254, 257], ["DNA", "CELLULAR_COMPONENT", 321, 324], ["NC", "GENE_OR_GENE_PRODUCT", 377, 379], ["DNA", "CELLULAR_COMPONENT", 414, 417], ["CCHC", "GENE_OR_GENE_PRODUCT", 538, 542], ["LTR ends", "CELLULAR_COMPONENT", 587, 595], ["DNA", "CELLULAR_COMPONENT", 708, 711], ["CCHC residues", "PROTEIN", 52, 65], ["zinc fingers", "PROTEIN", 73, 85], ["ZFs", "PROTEIN", 87, 90], ["LTR ends", "DNA", 156, 164], ["IN enzyme", "PROTEIN", 232, 241], ["LTR DNA", "DNA", 250, 257], ["reverse transcriptase", "PROTEIN", 431, 452], ["CCHC ZFs", "DNA", 538, 546], ["LTR ends", "DNA", 587, 595], ["NC", "TREATMENT", 119, 121], ["DNA in vitro", "TREATMENT", 126, 138], ["nucleases", "TREATMENT", 179, 188], ["zinc finger mutations", "PROBLEM", 290, 311], ["NC nucleic acid chaperoning", "TREATMENT", 377, 404], ["viral DNA synthesis", "TREATMENT", 408, 427], ["point mutations in the highly conserved CCHC ZFs", "PROBLEM", 498, 546], ["incomplete LTR ends", "PROBLEM", 576, 595], ["replication defective viruses", "PROBLEM", 621, 650], ["viral DNA synthesis", "PROBLEM", 702, 721], ["CCHC residues", "OBSERVATION", 52, 65], ["zinc fingers", "ANATOMY", 73, 85], ["zinc finger mutations", "OBSERVATION", 290, 311], ["LTR ends", "OBSERVATION", 587, 595], ["replication", "OBSERVATION_MODIFIER", 621, 632], ["defective viruses", "OBSERVATION", 633, 650]]], ["Additional results by Gorelick et al. also indicated that the integration reaction was impaired (Buckman et al., 2003, Thomas et al., 2006), supporting the view that functional interactions exist between NC and IN as it stands between NC and RT since mutating the ZF strongly diminish NC\u2013RT interactions (Druillennec et al., 1999a, Lener et al., 1998).", [["NC", "GENE_OR_GENE_PRODUCT", 204, 206], ["IN", "GENE_OR_GENE_PRODUCT", 211, 213], ["NC", "GENE_OR_GENE_PRODUCT", 235, 237], ["ZF", "GENE_OR_GENE_PRODUCT", 264, 266], ["NC\u2013RT", "GENE_OR_GENE_PRODUCT", 285, 290], ["IN", "PROTEIN", 211, 213], ["ZF", "PROTEIN", 264, 266], ["the integration reaction", "PROBLEM", 58, 82], ["NC", "TREATMENT", 204, 206], ["NC", "TREATMENT", 235, 237], ["RT", "TREATMENT", 242, 244]]], ["The existence of critical interactions between NC and IN is further supported by the fact that NC can strongly stimulate concerted LTR DNA integration by IN under physiological conditions in vitro (Buckman et al., 2003, Carteau et al., 1997, Carteau et al., 1999, Poljak et al., 2003, Thomas et al., 2006).Impacts of zinc finger mutations on viral DNA synthesis and integration ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseIn conclusion, these findings support the view that NC and notably the CCHC ZFs play a central role in viral DNA synthesis, maintenance and integration possibly through chaperoning interactions with both the viral NAs and the viral enzymes.NC and the timing of viral DNA synthesis ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseThe interplay of NC with the viral replication machinery also extends into the late phase of the replication cycle corresponding to virus assembly and budding (Gottlinger, 2001) (see below).", [["LTR", "ANATOMY", 131, 134], ["zinc", "CHEMICAL", 317, 321], ["nucleic acid", "CHEMICAL", 407, 419], ["nucleic acid", "CHEMICAL", 789, 801], ["zinc", "CHEMICAL", 317, 321], ["NC", "GENE_OR_GENE_PRODUCT", 47, 49], ["IN", "GENE_OR_GENE_PRODUCT", 54, 56], ["NC", "GENE_OR_GENE_PRODUCT", 95, 97], ["LTR", "CELLULAR_COMPONENT", 131, 134], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["IN", "GENE_OR_GENE_PRODUCT", 154, 156], ["DNA", "CELLULAR_COMPONENT", 348, 351], ["NC", "GENE_OR_GENE_PRODUCT", 404, 406], ["DNA", "CELLULAR_COMPONENT", 441, 444], ["NC", "GENE_OR_GENE_PRODUCT", 531, 533], ["CCHC", "GENE_OR_GENE_PRODUCT", 550, 554], ["ZFs", "GENE_OR_GENE_PRODUCT", 555, 558], ["DNA", "CELLULAR_COMPONENT", 588, 591], ["DNA", "CELLULAR_COMPONENT", 746, 749], ["NC", "GENE_OR_GENE_PRODUCT", 786, 788], ["DNA", "CELLULAR_COMPONENT", 823, 826], ["NC", "GENE_OR_GENE_PRODUCT", 878, 880], ["IN", "PROTEIN", 54, 56], ["LTR", "DNA", 131, 134], ["IN", "PROTEIN", 154, 156], ["reverse transcriptase", "PROTEIN", 458, 479], ["CCHC ZFs", "PROTEIN", 550, 558], ["viral enzymes", "PROTEIN", 705, 718], ["reverse transcriptase", "PROTEIN", 840, 861], ["NC", "TREATMENT", 47, 49], ["NC", "TREATMENT", 95, 97], ["zinc finger mutations", "PROBLEM", 317, 338], ["NC nucleic acid chaperoning", "TREATMENT", 404, 431], ["viral DNA synthesis", "TREATMENT", 435, 454], ["NC", "TREATMENT", 531, 533], ["the CCHC ZFs", "PROBLEM", 546, 558], ["viral DNA synthesis", "TREATMENT", 582, 601], ["the viral NAs", "TEST", 683, 696], ["the viral enzymes", "TEST", 701, 718], ["NC", "TREATMENT", 719, 721], ["viral DNA synthesis", "PROBLEM", 740, 759], ["NC nucleic acid chaperoning", "TREATMENT", 786, 813], ["viral DNA synthesis", "TREATMENT", 817, 836], ["NC", "TREATMENT", 878, 880], ["the viral replication machinery", "TREATMENT", 886, 917], ["virus", "PROBLEM", 993, 998], ["zinc finger mutations", "OBSERVATION", 317, 338], ["viral DNA", "OBSERVATION", 582, 591], ["viral replication", "OBSERVATION", 890, 907], ["late phase", "OBSERVATION_MODIFIER", 940, 950]]], ["As said before, the highly conserved CCHC ZFs flanked by basic amino acids are a hallmark of RV NC proteins and were originally shown to drive the specific packaging of the genomic RNA, most probably in a dimeric form, during RSV and MoMuLV virion formation (Gorelick et al., 1988, Gorelick et al., 1996, Housset et al., 1993, Meric et al., 1988, Meric and Spahr, 1986).NC and the timing of viral DNA synthesis ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseInterestingly, active reverse transcription was shown to occur in newly made RSV, MuLV and HIV-1 virions (Lori et al., 1992, Trono, 1992, Zhang et al., 1994; reviewed in Darlix et al., 1995).", [["amino acids", "CHEMICAL", 63, 74], ["nucleic acid", "CHEMICAL", 440, 452], ["amino acids", "CHEMICAL", 63, 74], ["CCHC", "GENE_OR_GENE_PRODUCT", 37, 41], ["ZFs", "GENE_OR_GENE_PRODUCT", 42, 45], ["amino acids", "AMINO_ACID", 63, 74], ["RSV", "ORGANISM", 226, 229], ["DNA", "CELLULAR_COMPONENT", 397, 400], ["NC", "GENE_OR_GENE_PRODUCT", 437, 439], ["DNA", "CELLULAR_COMPONENT", 474, 477], ["RSV", "ORGANISM", 589, 592], ["MuLV", "ORGANISM", 594, 598], ["HIV-1 virions", "ORGANISM", 603, 616], ["CCHC ZFs", "DNA", 37, 45], ["RV NC proteins", "PROTEIN", 93, 107], ["genomic RNA", "RNA", 173, 184], ["reverse transcriptase", "PROTEIN", 491, 512], ["HIV-1", "SPECIES", 603, 608], ["RSV", "SPECIES", 226, 229], ["RSV", "SPECIES", 589, 592], ["HIV-1", "SPECIES", 603, 608], ["basic amino acids", "TEST", 57, 74], ["RV NC proteins", "TREATMENT", 93, 107], ["the genomic RNA", "PROBLEM", 169, 184], ["RSV", "PROBLEM", 226, 229], ["NC", "TREATMENT", 370, 372], ["viral DNA synthesis", "PROBLEM", 391, 410], ["NC nucleic acid chaperoning", "TREATMENT", 437, 464], ["viral DNA synthesis", "TREATMENT", 468, 487], ["RSV", "PROBLEM", 589, 592], ["RV", "ANATOMY", 93, 95], ["genomic RNA", "OBSERVATION", 173, 184], ["most probably", "UNCERTAINTY", 186, 199]]], ["More recently the impact of NC mutations on cDNA synthesis in newly made HIV-1 virions was investigated.", [["NC", "GENE_OR_GENE_PRODUCT", 28, 30], ["cDNA", "CELLULAR_COMPONENT", 44, 48], ["HIV-1 virions", "ORGANISM", 73, 86], ["cDNA", "DNA", 44, 48], ["HIV-1", "SPECIES", 73, 78], ["HIV-1", "SPECIES", 73, 78], ["NC mutations", "TREATMENT", 28, 40], ["cDNA synthesis", "TREATMENT", 44, 58], ["HIV-1 virions", "TREATMENT", 73, 86]]], ["In fact point mutations of the NC CCHC motif resulted in the formation of virions where the core was only partially condensed (Gelderblom et al., 1987, Grigorov et al., 2006, Grigorov et al., 2007, Tanchou et al., 1998).", [["NC CCHC motif", "DNA", 31, 44], ["the NC CCHC motif", "TREATMENT", 27, 44]]], ["Moreover such virions were changed to DNA containing particles since they contained a rather large amount of vDNA including two LTR DNA molecules, and much less genomic RNA as compared to wild-type virions.", [["virions", "ANATOMY", 14, 21], ["LTR", "ANATOMY", 128, 131], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["vDNA", "GENE_OR_GENE_PRODUCT", 109, 113], ["LTR", "CELLULAR_COMPONENT", 128, 131], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["vDNA", "PROTEIN", 109, 113], ["LTR DNA molecules", "PROTEIN", 128, 145], ["genomic RNA", "RNA", 161, 172], ["such virions", "PROBLEM", 9, 21], ["DNA containing particles", "TREATMENT", 38, 62], ["vDNA", "PROBLEM", 109, 113], ["two LTR DNA molecules", "PROBLEM", 124, 145], ["much less genomic RNA", "PROBLEM", 151, 172], ["large", "OBSERVATION_MODIFIER", 93, 98], ["amount", "OBSERVATION_MODIFIER", 99, 105], ["much less", "OBSERVATION_MODIFIER", 151, 160], ["genomic RNA", "OBSERVATION", 161, 172]]], ["This endogenous reverse transcription reaction was shown to occur in virus producer cells, most probably during morphogenesis of the ZF mutant virus (Thomas and Gorelick, 2008; see review Mougel et al., 2009 and references therein).NC and the timing of viral DNA synthesis ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseThese results indicate that NC exerts a dual control over the timing of viral DNA synthesis by RT, a positive one after viral entry in target cells, and a negative one that delays the process in the course of virus production (Houzet et al., 2008; reviewed in Mougel et al., 2009).", [["cells", "ANATOMY", 84, 89], ["cells", "ANATOMY", 516, 521], ["nucleic acid", "CHEMICAL", 302, 314], ["NC", "CHEMICAL", 402, 404], ["cells", "CELL", 84, 89], ["ZF mutant virus", "ORGANISM", 133, 148], ["DNA", "CELLULAR_COMPONENT", 259, 262], ["NC", "GENE_OR_GENE_PRODUCT", 299, 301], ["DNA", "CELLULAR_COMPONENT", 336, 339], ["NC", "GENE_OR_GENE_PRODUCT", 402, 404], ["DNA", "CELLULAR_COMPONENT", 452, 455], ["cells", "CELL", 516, 521], ["virus producer cells", "CELL_TYPE", 69, 89], ["reverse transcriptase", "PROTEIN", 353, 374], ["target cells", "CELL_TYPE", 509, 521], ["This endogenous reverse transcription reaction", "PROBLEM", 0, 46], ["virus producer cells", "PROBLEM", 69, 89], ["NC", "TREATMENT", 232, 234], ["viral DNA synthesis", "PROBLEM", 253, 272], ["NC nucleic acid chaperoning", "TREATMENT", 299, 326], ["viral DNA synthesis", "TREATMENT", 330, 349], ["NC", "TREATMENT", 402, 404], ["a dual control", "TREATMENT", 412, 426], ["viral DNA synthesis", "TREATMENT", 446, 465], ["viral entry in target cells", "PROBLEM", 494, 521], ["most probably", "UNCERTAINTY", 91, 104], ["target cells", "OBSERVATION", 509, 521]]], ["Therefore, NC should be viewed as an essential viral component of the replicative machinery, a all-in-one small chaperone impacting on the timing, kinetics and completeness of reverse transcription from the initiation up to the synthesis of the complete viral DNA with the two LTRs and its maintenance (Fig. 1).NC and the timing of viral DNA synthesis ::: The multiple roles of NC nucleic acid chaperoning in viral DNA synthesis by reverse transcriptaseAs soon as the proviral DNA is imported into the cell nucleus and before its integration, viral genes can be expressed by the host cell transcription and translation machineries to produce the essential viral factors TAT, REV and NEF (Wu and Marsh, 2001).", [["cell nucleus", "ANATOMY", 502, 514], ["cell", "ANATOMY", 584, 588], ["nucleic acid", "CHEMICAL", 381, 393], ["NC", "GENE_OR_GENE_PRODUCT", 11, 13], ["DNA", "CELLULAR_COMPONENT", 260, 263], ["DNA", "CELLULAR_COMPONENT", 338, 341], ["NC", "GENE_OR_GENE_PRODUCT", 378, 380], ["DNA", "CELLULAR_COMPONENT", 415, 418], ["DNA", "CELLULAR_COMPONENT", 477, 480], ["cell nucleus", "CELLULAR_COMPONENT", 502, 514], ["cell", "CELL", 584, 588], ["TAT", "GENE_OR_GENE_PRODUCT", 670, 673], ["NEF", "GENE_OR_GENE_PRODUCT", 683, 686], ["viral DNA", "DNA", 254, 263], ["LTRs", "DNA", 277, 281], ["reverse transcriptase", "PROTEIN", 432, 453], ["proviral DNA", "DNA", 468, 480], ["viral genes", "DNA", 543, 554], ["essential viral factors", "PROTEIN", 646, 669], ["TAT", "PROTEIN", 670, 673], ["REV", "PROTEIN", 675, 678], ["NEF", "PROTEIN", 683, 686], ["NC", "TREATMENT", 11, 13], ["reverse transcription", "TREATMENT", 176, 197], ["the complete viral DNA", "TREATMENT", 241, 263], ["the two LTRs", "TREATMENT", 269, 281], ["NC", "TREATMENT", 311, 313], ["viral DNA synthesis", "PROBLEM", 332, 351], ["NC nucleic acid chaperoning", "TREATMENT", 378, 405], ["viral DNA synthesis", "TREATMENT", 409, 428], ["the proviral DNA", "PROBLEM", 464, 480], ["viral genes", "PROBLEM", 543, 554], ["the host cell transcription", "TREATMENT", 575, 602], ["translation machineries", "TREATMENT", 607, 630], ["viral", "OBSERVATION", 47, 52], ["replicative machinery", "OBSERVATION", 70, 91], ["viral DNA", "OBSERVATION", 254, 263]]], ["The very early and efficient synthesis of TAT is central to the late steps of HIV-1 replication since it boosts provirus transcription by the cellular RNA polymerase B machinery.NC, the nucleation of retrovirus assembly and structure switchesTwo distinct mechanisms of retrovirus assembly have been described so far and have been the subject of many reviews.", [["cellular", "ANATOMY", 142, 150], ["TAT", "GENE_OR_GENE_PRODUCT", 42, 45], ["HIV-1", "ORGANISM", 78, 83], ["provirus", "ORGANISM", 112, 120], ["cellular", "CELL", 142, 150], ["polymerase B", "GENE_OR_GENE_PRODUCT", 155, 167], ["retrovirus", "ORGANISM", 200, 210], ["retrovirus", "ORGANISM", 269, 279], ["TAT", "PROTEIN", 42, 45], ["cellular RNA polymerase B", "PROTEIN", 142, 167], ["HIV-1", "SPECIES", 78, 83], ["HIV-1", "SPECIES", 78, 83], ["HIV-1 replication", "TREATMENT", 78, 95], ["provirus transcription", "TREATMENT", 112, 134], ["NC", "TREATMENT", 178, 180], ["the nucleation of retrovirus", "TREATMENT", 182, 210], ["retrovirus", "PROBLEM", 269, 279], ["retrovirus", "OBSERVATION", 200, 210], ["distinct", "OBSERVATION_MODIFIER", 246, 254], ["retrovirus", "OBSERVATION", 269, 279]]], ["In the first instance retroviral particles are preformed in the cytoplasm of infected cells and transported to the plasma membrane in the case of the betaretroviruses (MMTV, MPMV).", [["cytoplasm", "ANATOMY", 64, 73], ["cells", "ANATOMY", 86, 91], ["plasma membrane", "ANATOMY", 115, 130], ["retroviral", "ORGANISM", 22, 32], ["cytoplasm", "ORGANISM_SUBSTANCE", 64, 73], ["cells", "CELL", 86, 91], ["plasma membrane", "CELLULAR_COMPONENT", 115, 130], ["betaretroviruses", "GENE_OR_GENE_PRODUCT", 150, 166], ["MMTV", "ORGANISM", 168, 172], ["MPMV", "GENE_OR_GENE_PRODUCT", 174, 178], ["infected cells", "CELL_TYPE", 77, 91], ["betaretroviruses", "PROTEIN", 150, 166], ["MMTV", "SPECIES", 168, 172], ["infected cells", "PROBLEM", 77, 91], ["the plasma membrane", "TREATMENT", 111, 130], ["retroviral particles", "OBSERVATION", 22, 42], ["cytoplasm", "OBSERVATION_MODIFIER", 64, 73], ["infected cells", "OBSERVATION", 77, 91], ["plasma membrane", "OBSERVATION", 115, 130]]], ["In the second case, RV particles directly assemble underneath the plasma membrane (PM) as for alpha- and gammaretroviruses (ASLV and MLV, respectively) (Dickson et al., 1985).", [["RV particles", "ANATOMY", 20, 32], ["plasma membrane", "ANATOMY", 66, 81], ["PM", "ANATOMY", 83, 85], ["plasma membrane", "CELLULAR_COMPONENT", 66, 81], ["alpha", "GENE_OR_GENE_PRODUCT", 94, 99], ["gammaretroviruses", "GENE_OR_GENE_PRODUCT", 105, 122], ["MLV", "ORGANISM", 133, 136], ["alpha", "PROTEIN", 94, 99], ["gammaretroviruses", "PROTEIN", 105, 122], ["ASLV", "PROTEIN", 124, 128], ["RV particles", "PROBLEM", 20, 32], ["alpha", "TEST", 94, 99], ["gammaretroviruses", "PROBLEM", 105, 122], ["RV", "ANATOMY", 20, 22], ["particles", "OBSERVATION", 23, 32]]], ["Until recently, HIV-1 assembly was thought to follow the second mode (Ivanchenko et al., 2009, Jouvenet et al., 2006, Jouvenet et al., 2008, Ono et al., 2004) but recent findings indicate that this may not be the sole mechanism.", [["HIV-1", "ORGANISM", 16, 21], ["HIV-1", "SPECIES", 16, 21], ["HIV-1", "SPECIES", 16, 21], ["HIV", "PROBLEM", 16, 19]]], ["Indeed, according to several reports HIV-1 assembly can also take place in intracellular vesicles such as endosomes in human macrophages, and in T cells (Grigorov et al., 2006, Ono and Freed, 2004, Pelchen-Matthews et al., 2003, Raposo et al., 2002, Rudner et al., 2005).NC, the nucleation of retrovirus assembly and structure switchesIt is not the purpose of the present report to review the choreography of RV assembly and budding as there are many excellent reviews on the subject (Adamson and Freed, 2007, Resh, 2005), notably on the role of each Gag domain, including NC, in Gag trafficking and Gag-vRNA oligomer formation.", [["intracellular vesicles", "ANATOMY", 75, 97], ["endosomes", "ANATOMY", 106, 115], ["macrophages", "ANATOMY", 125, 136], ["T cells", "ANATOMY", 145, 152], ["HIV-1", "ORGANISM", 37, 42], ["intracellular vesicles", "CELLULAR_COMPONENT", 75, 97], ["endosomes", "CELLULAR_COMPONENT", 106, 115], ["human", "ORGANISM", 119, 124], ["macrophages", "CELL", 125, 136], ["T cells", "CELL", 145, 152], ["retrovirus", "ORGANISM", 293, 303], ["NC", "GENE_OR_GENE_PRODUCT", 573, 575], ["Gag", "GENE_OR_GENE_PRODUCT", 580, 583], ["Gag", "GENE_OR_GENE_PRODUCT", 600, 603], ["human macrophages", "CELL_TYPE", 119, 136], ["T cells", "CELL_TYPE", 145, 152], ["Gag domain", "PROTEIN", 551, 561], ["NC", "PROTEIN", 573, 575], ["Gag", "PROTEIN", 580, 583], ["Gag", "PROTEIN", 600, 603], ["human", "SPECIES", 119, 124], ["HIV-1", "SPECIES", 37, 42], ["human", "SPECIES", 119, 124], ["intracellular vesicles", "PROBLEM", 75, 97], ["NC", "TREATMENT", 271, 273], ["the nucleation of retrovirus assembly", "TREATMENT", 275, 312], ["NC", "TREATMENT", 573, 575], ["Gag-vRNA oligomer formation", "PROBLEM", 600, 627], ["retrovirus", "OBSERVATION", 293, 303], ["RV", "ANATOMY", 409, 411], ["excellent", "OBSERVATION_MODIFIER", 451, 460], ["Gag-vRNA", "OBSERVATION", 600, 608], ["oligomer formation", "OBSERVATION", 609, 627]]], ["However much less is known on how and where the very first step of RV assembly is taking place and the possible role of NC in this nucleation reaction.NC, the nucleation of retrovirus assembly and structure switchesThe Gag polyprotein precursor contains all the signals and domains required for viral particle assembly, and as such it orchestrates the particle assembly from the nucleation step to virus release by budding (Kutluay and Bieniasz, 2010, Muriaux and Darlix, 2010, Sundquist and Krausslich, 2012).", [["RV", "MULTI-TISSUE_STRUCTURE", 67, 69], ["NC", "GENE_OR_GENE_PRODUCT", 120, 122], ["retrovirus", "ORGANISM", 173, 183], ["Gag polyprotein precursor", "PROTEIN", 219, 244], ["NC", "TREATMENT", 120, 122], ["this nucleation reaction", "PROBLEM", 126, 150], ["NC", "TREATMENT", 151, 153], ["the nucleation of retrovirus", "TREATMENT", 155, 183], ["The Gag polyprotein precursor", "PROBLEM", 215, 244], ["viral particle", "PROBLEM", 295, 309], ["retrovirus", "OBSERVATION", 173, 183], ["Gag polyprotein", "OBSERVATION", 219, 234]]], ["In infected cells, the unspliced viral RNA acts both as the messenger coding for Gag and Gag-Pol and as the genome to be recruited, dimerized and packaged into assembling Gag particles (Butsch and Boris-Lawrie, 2000, Dorman and Lever, 2000, Griffin et al., 2001, Levin and Rosenak, 1976, Ni et al., 2011).", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["Gag", "GENE_OR_GENE_PRODUCT", 81, 84], ["Gag-Pol", "GENE_OR_GENE_PRODUCT", 89, 96], ["Gag", "GENE_OR_GENE_PRODUCT", 171, 174], ["unspliced viral RNA", "RNA", 23, 42], ["Gag", "PROTEIN", 81, 84], ["Gag", "PROTEIN", 89, 92], ["Pol", "PROTEIN", 93, 96], ["infected cells", "PROBLEM", 3, 17], ["Gag", "TEST", 81, 84], ["infected cells", "OBSERVATION", 3, 17], ["viral RNA", "OBSERVATION", 33, 42], ["Gag particles", "OBSERVATION", 171, 184]]], ["But the full length (FL) viral RNA cannot fulfill both functions at the same time, thus raising a long standing issue on how the fate of the FL viral RNA, translation versus packaging, is regulated (Brasey et al., 2003, Lopez-Lastra et al., 2005).", [["FL", "GENE_OR_GENE_PRODUCT", 141, 143], ["full length (FL) viral RNA", "RNA", 8, 34], ["FL viral RNA", "RNA", 141, 153], ["viral RNA", "PROBLEM", 25, 34], ["a long standing issue", "PROBLEM", 96, 117], ["the FL viral RNA", "TREATMENT", 137, 153]]], ["As originally reported for ASLV and MoMuLV and more recently for HIV and SIV (Attal et al., 1996, Berlioz and Darlix, 1995, Berlioz et al., 1995, Brasey et al., 2003, Buck et al., 2001, Deffaud and Darlix, 2000, Herbreteau et al., 2005, Lopez-Lastra et al., 2010, Ohlmann et al., 2000, Vagner et al., 1995), Gag is synthesized by an IRES dependent mechanism whereby the active ribosomes directly bind to sequences within the 5\u2032 untranslated region (UTR or leader) of the FL RNA, upstream of the initiator AUG of Gag.", [["ribosomes", "ANATOMY", 377, 386], ["ASLV", "GENE_OR_GENE_PRODUCT", 27, 31], ["MoMuLV", "CANCER", 36, 42], ["HIV", "ORGANISM", 65, 68], ["SIV", "ORGANISM", 73, 76], ["Gag", "GENE_OR_GENE_PRODUCT", 308, 311], ["ribosomes", "CELLULAR_COMPONENT", 377, 386], ["FL", "GENE_OR_GENE_PRODUCT", 471, 473], ["Gag", "GENE_OR_GENE_PRODUCT", 512, 515], ["ASLV", "PROTEIN", 27, 31], ["MoMuLV", "PROTEIN", 36, 42], ["Gag", "PROTEIN", 308, 311], ["IRES", "DNA", 333, 337], ["5\u2032 untranslated region", "DNA", 425, 447], ["UTR", "DNA", 449, 452], ["FL RNA", "RNA", 471, 477], ["initiator AUG", "DNA", 495, 508], ["Gag", "PROTEIN", 512, 515], ["HIV", "SPECIES", 65, 68], ["ASLV", "SPECIES", 27, 31], ["HIV", "SPECIES", 65, 68], ["SIV", "SPECIES", 73, 76], ["ASLV and MoMuLV", "PROBLEM", 27, 42], ["HIV", "PROBLEM", 65, 68], ["active ribosomes", "OBSERVATION", 370, 386], ["FL RNA", "ANATOMY", 471, 477], ["Gag", "OBSERVATION", 512, 515]]], ["At this stage it is believed that newly made Gag molecules accumulate on or in the vicinity of the translating polysomes.", [["polysomes", "ANATOMY", 111, 120], ["polysomes", "CELLULAR_COMPONENT", 111, 120], ["Gag molecules", "PROTEIN", 45, 58], ["Gag molecules", "PROBLEM", 45, 58], ["Gag molecules", "OBSERVATION", 45, 58]]], ["Next or concomitant with translation, the nucleation step would take place via specific interactions between GagNC and the high affinity binding sites present in the IRES/Packaging signals within the 5\u2032 UTR (Aldovini and Young, 1990, Baudin et al., 1993, Berkhout, 1996, Clever et al., 1995, Clever et al., 2000, Clever et al., 2002, Hayashi et al., 1992, Lever et al., 1989, McBride and Panganiban, 1996, Sakaguchi et al., 1993, Shubsda et al., 2002) for reviews (Cimarelli and Darlix, 2002, Lever, 2007, Muriaux and Darlix, 2010).NC, the nucleation of retrovirus assembly and structure switchesThis proposed mechanism stipulates that binding of several just-made GagNC molecules to the Packaging region of the FL viral RNA would render it inaccessible to translating ribosomes due to structural rearrangements of the 5\u2032 UTR such as base pairing interactions involving the Gag AUG initiation codon (Abbink and Berkhout, 2003, Berkhout, 1996, D'Souza and Summers, 2004, Lu et al., 2011a, Lu et al., 2011b).", [["ribosomes", "ANATOMY", 769, 778], ["GagNC", "CHEMICAL", 109, 114], ["GagNC", "GENE_OR_GENE_PRODUCT", 109, 114], ["retrovirus", "ORGANISM", 554, 564], ["GagNC", "GENE_OR_GENE_PRODUCT", 665, 670], ["FL", "GENE_OR_GENE_PRODUCT", 712, 714], ["ribosomes", "CELLULAR_COMPONENT", 769, 778], ["GagNC", "PROTEIN", 109, 114], ["high affinity binding sites", "PROTEIN", 123, 150], ["IRES", "DNA", 166, 170], ["UTR", "DNA", 203, 206], ["GagNC molecules", "PROTEIN", 665, 680], ["Packaging region", "DNA", 688, 704], ["FL viral RNA", "RNA", 712, 724], ["UTR", "DNA", 822, 825], ["Gag AUG initiation codon", "DNA", 874, 898], ["the nucleation step", "PROBLEM", 38, 57], ["GagNC", "TREATMENT", 109, 114], ["the high affinity binding sites", "PROBLEM", 119, 150], ["McBride", "TEST", 376, 383], ["NC", "TREATMENT", 532, 534], ["the nucleation of retrovirus assembly", "TREATMENT", 536, 573], ["GagNC molecules", "TREATMENT", 665, 680], ["the FL viral RNA", "TREATMENT", 708, 724], ["UTR", "PROBLEM", 822, 825], ["retrovirus", "OBSERVATION", 554, 564], ["FL", "ANATOMY", 712, 714]]], ["This together with bound Gag molecules (Huthoff and Berkhout, 2001a, Huthoff and Berkhout, 2001b, Huthoff and Berkhout, 2002) would cause a functional reorientation of the FL RNA from translation to dimerization and packaging (Heng et al., 2012) effectively starting Gag assembly where the FL RNA acts as the initial platform or scaffold (Burniston et al., 1999, Cimarelli et al., 2000, Muriaux et al., 2001, Ott et al., 2009; reviewed in Butsch and Boris-Lawrie, 2000, Butsch and Boris-Lawrie, 2002, Darlix et al., 1995, Darlix et al., 2000).", [["FL", "GENE_OR_GENE_PRODUCT", 172, 174], ["Gag", "GENE_OR_GENE_PRODUCT", 267, 270], ["FL", "GENE_OR_GENE_PRODUCT", 290, 292], ["Gag molecules", "PROTEIN", 25, 38], ["FL RNA", "RNA", 172, 178], ["FL RNA", "RNA", 290, 296], ["bound Gag molecules", "PROBLEM", 19, 38], ["the FL RNA", "TREATMENT", 168, 178], ["packaging", "TREATMENT", 216, 225]]], ["As a result of the nucleation event is the targeting of the viral Gag\u2013RNP complex to cellular membranes due to another conformational switch at the opposite end of Gag.", [["cellular membranes", "ANATOMY", 85, 103], ["Gag\u2013RNP", "GENE_OR_GENE_PRODUCT", 66, 73], ["cellular membranes", "CELLULAR_COMPONENT", 85, 103], ["Gag", "GENE_OR_GENE_PRODUCT", 164, 167], ["viral Gag\u2013RNP complex", "PROTEIN", 60, 81], ["Gag", "PROTEIN", 164, 167], ["the nucleation event", "PROBLEM", 15, 35], ["the viral Gag\u2013RNP complex to cellular membranes", "PROBLEM", 56, 103], ["Gag", "OBSERVATION", 164, 167]]], ["In fact the N-terminal matrix myristyl group undergoes a switch whereby the myristate becomes accessible, enabling the anchoring of the Gag\u2013RNP complex to cellular membranes to pursue and complete virus assembly (Freed and Mouland, 2006, Hamard-Peron and Muriaux, 2011, Saad et al., 2006).NC, the nucleation of retrovirus assembly and structure switchesTaken together, these findings suggest that the NC domain of Gag plays a major role in determining the fate of the genomic RNA and that this contribution will depend on both NC-induced RNA structural rearrangements (Huthoff and Berkhout, 2001a, Huthoff and Berkhout, 2002) and molecular crowding brought about by Gag molecules bound to the 5\u2032 UTR via the NC domain (Abbink and Berkhout, 2003, Brasey et al., 2003, Darlix et al., 1995, Heng et al., 2012).", [["cellular membranes", "ANATOMY", 155, 173], ["myristyl", "CHEMICAL", 30, 38], ["myristate", "CHEMICAL", 76, 85], ["N", "CHEMICAL", 12, 13], ["myristyl", "CHEMICAL", 30, 38], ["myristate", "CHEMICAL", 76, 85], ["myristate", "SIMPLE_CHEMICAL", 76, 85], ["Gag\u2013RNP", "GENE_OR_GENE_PRODUCT", 136, 143], ["cellular membranes", "CELLULAR_COMPONENT", 155, 173], ["retrovirus", "ORGANISM", 311, 321], ["Gag", "GENE_OR_GENE_PRODUCT", 414, 417], ["NC", "GENE_OR_GENE_PRODUCT", 527, 529], ["N-terminal matrix myristyl group", "PROTEIN", 12, 44], ["Gag\u2013RNP complex", "PROTEIN", 136, 151], ["NC domain", "PROTEIN", 401, 410], ["Gag", "PROTEIN", 414, 417], ["genomic RNA", "RNA", 468, 479], ["Gag molecules", "PROTEIN", 666, 679], ["UTR", "DNA", 696, 699], ["NC domain", "DNA", 708, 717], ["the N-terminal matrix myristyl group", "TREATMENT", 8, 44], ["cellular membranes", "TREATMENT", 155, 173], ["NC", "TREATMENT", 289, 291], ["the nucleation of retrovirus assembly", "TREATMENT", 293, 330], ["the NC domain of Gag", "PROBLEM", 397, 417], ["the genomic RNA", "PROBLEM", 464, 479], ["both NC", "TREATMENT", 522, 529], ["molecular crowding", "PROBLEM", 630, 648], ["retrovirus", "OBSERVATION", 311, 321], ["Gag", "OBSERVATION", 414, 417], ["genomic RNA", "OBSERVATION", 468, 479], ["NC", "ANATOMY", 708, 710]]], ["In support of this possible mechanism, we found HIV-1 Gag\u2013viral RNA complexes together with unbound Gag molecules cosedimenting with a fraction of polyribosomes of high sedimentation values (250\u2013350S) purified from HIV-1 Gag-Pol expressing 293 cells (unpublished data).", [["polyribosomes", "ANATOMY", 147, 160], ["293 cells", "ANATOMY", 240, 249], ["HIV-1", "ORGANISM", 48, 53], ["polyribosomes", "CELLULAR_COMPONENT", 147, 160], ["HIV-1", "ORGANISM", 215, 220], ["Gag", "ORGANISM", 221, 224], ["Pol", "GENE_OR_GENE_PRODUCT", 225, 228], ["293 cells", "CELL", 240, 249], ["HIV-1 Gag\u2013viral RNA complexes", "PROTEIN", 48, 77], ["Gag molecules", "PROTEIN", 100, 113], ["Gag", "PROTEIN", 221, 224], ["Pol", "PROTEIN", 225, 228], ["293 cells", "CELL_LINE", 240, 249], ["HIV-1", "SPECIES", 48, 53], ["HIV-1", "SPECIES", 215, 220], ["HIV-1", "SPECIES", 48, 53], ["HIV-1", "SPECIES", 215, 220], ["HIV", "TEST", 48, 51], ["Gag\u2013viral RNA complexes", "PROBLEM", 54, 77], ["unbound Gag molecules", "PROBLEM", 92, 113], ["high sedimentation values", "PROBLEM", 164, 189], ["HIV", "TEST", 215, 218], ["high sedimentation", "OBSERVATION_MODIFIER", 164, 182]]], ["Upon addition of EDTA to dissociate the ribosomes from the RNA template, Gag\u2013RNA complexes and free Gag molecules were recovered by sucrose gradient centrifugation (unpublished data).Viral NC\u2013RNA RNPs, fuzziness and functionsThe all-in-one retroviral NC performs multiple functions in the virus replication cycle, during both the early and late phases, which represents a significant body of scientific research since its original description as a non-specific simple NABP.", [["ribosomes", "ANATOMY", 40, 49], ["EDTA", "CHEMICAL", 17, 21], ["sucrose", "CHEMICAL", 132, 139], ["EDTA", "CHEMICAL", 17, 21], ["sucrose", "CHEMICAL", 132, 139], ["EDTA", "SIMPLE_CHEMICAL", 17, 21], ["ribosomes", "CELLULAR_COMPONENT", 40, 49], ["Gag\u2013RNA", "GENE_OR_GENE_PRODUCT", 73, 80], ["sucrose", "SIMPLE_CHEMICAL", 132, 139], ["retroviral", "ORGANISM", 240, 250], ["NABP", "GENE_OR_GENE_PRODUCT", 468, 472], ["RNA template", "RNA", 59, 71], ["Gag\u2013RNA complexes", "PROTEIN", 73, 90], ["Gag molecules", "PROTEIN", 100, 113], ["Viral NC\u2013RNA RNPs", "PROTEIN", 183, 200], ["NABP", "PROTEIN", 468, 472], ["EDTA", "TREATMENT", 17, 21], ["the RNA template", "TREATMENT", 55, 71], ["Gag\u2013RNA complexes and free Gag molecules", "PROBLEM", 73, 113], ["sucrose gradient centrifugation", "TREATMENT", 132, 163], ["Viral NC\u2013RNA RNPs", "PROBLEM", 183, 200], ["fuzziness", "PROBLEM", 202, 211], ["one retroviral NC", "TREATMENT", 236, 253], ["a non-specific simple NABP", "PROBLEM", 446, 472], ["Gag molecules", "OBSERVATION", 100, 113], ["NC\u2013RNA RNPs", "OBSERVATION", 189, 200], ["significant", "OBSERVATION_MODIFIER", 372, 383]]], ["But how could NC be endowed with so many essential functions in virus structure, vDNA synthesis and viral particle morphogenesis?Viral NC\u2013RNA RNPs, fuzziness and functionsBefore providing a possible clue to the above question, one should remember the nature of NC with its structured zinc fingers flanked by disordered basic sequences driving specific and nonspecific interactions, respectively, with NAs (Amarasinghe et al., 2000a, Amarasinghe et al., 2000b, Bazzi et al., 2011, Bourbigot et al., 2008, De Guzman et al., 1998, Morellet et al., 1998).", [["zinc", "CHEMICAL", 284, 288], ["vDNA", "GENE_OR_GENE_PRODUCT", 81, 85], ["Viral NC\u2013RNA RNPs", "PROTEIN", 129, 146], ["zinc fingers", "PROTEIN", 284, 296], ["disordered basic sequences", "PROTEIN", 308, 334], ["vDNA synthesis", "PROBLEM", 81, 95], ["viral particle morphogenesis", "PROBLEM", 100, 128], ["Viral NC\u2013RNA RNPs", "PROBLEM", 129, 146], ["fuzziness", "PROBLEM", 148, 157], ["NC", "TREATMENT", 261, 263], ["viral particle", "OBSERVATION", 100, 114], ["NC\u2013RNA RNPs", "OBSERVATION", 135, 146]]], ["This in turn can result in NA condensation (Krishnamoorthy et al., 2003, Lapadat-Tapolsky et al., 1995, Mirambeau et al., 2006, Stoylov et al., 1997, Tanchou et al., 1995) together with structural rearrangements as it occurs during reverse transcription.", [["NA", "SIMPLE_CHEMICAL", 27, 29]]], ["Thus NC\u2013RNA and GagNC\u2013RNA RNP complexes most probably represent the driving force behind the functions.", [["NC\u2013RNA", "GENE_OR_GENE_PRODUCT", 5, 11], ["GagNC\u2013RNA RNP", "GENE_OR_GENE_PRODUCT", 16, 29], ["NC\u2013RNA and GagNC\u2013RNA RNP complexes", "PROTEIN", 5, 39], ["NC\u2013RNA", "TREATMENT", 5, 11], ["GagNC\u2013RNA RNP complexes", "TREATMENT", 16, 39], ["most probably represent", "UNCERTAINTY", 40, 63]]], ["Indeed NC-based oligomeric structures can be formed in vitro, and are easily seen by electron microscopy (Gabus et al., 2001a) as highly dense heterogeneous complexes exhibiting various sizes and forms.", [["electron microscopy", "TEST", 85, 104], ["highly dense heterogeneous complexes", "PROBLEM", 130, 166], ["NC", "OBSERVATION", 7, 9], ["oligomeric structures", "OBSERVATION", 16, 37], ["dense", "OBSERVATION_MODIFIER", 137, 142], ["heterogeneous", "OBSERVATION_MODIFIER", 143, 156], ["complexes", "OBSERVATION", 157, 166], ["various", "OBSERVATION_MODIFIER", 178, 185], ["sizes", "OBSERVATION_MODIFIER", 186, 191]]], ["In these NC-based oligomeric structures multiple tight nucleoprotein interactions are holding together the NC and RNA molecules causing a molecular crowding phenomenon thus allowing many reactions to take place (Darlix et al., 1995, Darlix et al., 2000, Herschlag, 1995, Rein et al., 1998).", [["NC and RNA molecules", "PROTEIN", 107, 127], ["multiple tight nucleoprotein interactions", "PROBLEM", 40, 81], ["RNA molecules", "PROBLEM", 114, 127], ["a molecular crowding phenomenon", "PROBLEM", 136, 167], ["NC", "ANATOMY", 9, 11], ["oligomeric structures", "OBSERVATION", 18, 39], ["multiple", "OBSERVATION_MODIFIER", 40, 48], ["tight", "OBSERVATION_MODIFIER", 49, 54], ["nucleoprotein interactions", "OBSERVATION", 55, 81], ["crowding phenomenon", "OBSERVATION", 148, 167]]], ["But at the same time these NC-based oligomeric structures are accessible to small ODNs and to the RT enzyme which can gain access to the RNA and perform cDNA synthesis with high efficiency.", [["RT enzyme", "PROTEIN", 98, 107], ["small ODNs", "TREATMENT", 76, 86], ["the RT enzyme", "TEST", 94, 107], ["cDNA synthesis", "TREATMENT", 153, 167], ["high efficiency", "PROBLEM", 173, 188], ["oligomeric structures", "OBSERVATION", 36, 57], ["small", "OBSERVATION_MODIFIER", 76, 81], ["ODNs", "OBSERVATION", 82, 86], ["high efficiency", "OBSERVATION", 173, 188]]], ["Therefore such NC-based oligomers are either porous or else highly dynamic, the latter being probably the case due to the rapid on and off binding kinetics of NC to the nucleic acid (Cruceanu et al., 2006a) together with different modes of interactions driven by the ZFs and/or the disordered basic domains (reviewed in Darlix et al., 2011, Ivanyi-Nagy et al., 2012).", [["nucleic acid", "CHEMICAL", 169, 181], ["ZFs", "GENE_OR_GENE_PRODUCT", 267, 270], ["ZFs", "PROTEIN", 267, 270], ["disordered basic domains", "PROTEIN", 282, 306], ["such NC-based oligomers", "TREATMENT", 10, 33]]], ["Taken together, these findings favor the notion that NC\u2013RNA ribonucleoprotein complexes can be regarded as fuzzy flexible molecular assemblages where multiple different interactions between the viral NC and the NA (Fig. 2) as well as with the RT enzyme and possibly IN are highly dynamic which is essential during the early steps of RV replication.Viral NC\u2013RNA RNPs, fuzziness and functionsThe functionality of such fuzzy nucleocapsid assemblages is also illustrated by the dimeric nature of the genomic RNA, which provides the basis for multiple forced and unforced recombination reactions during vDNA synthesis by RT (Hu et al., 2003a, Hu and Temin, 1990, Katz and Skalka, 1990, Onafuwa-Nuga and Telesnitsky, 2009).", [["RV", "ANATOMY", 333, 335], ["NC\u2013RNA", "GENE_OR_GENE_PRODUCT", 53, 59], ["Fig. 2", "GENE_OR_GENE_PRODUCT", 215, 221], ["RT enzyme", "GENE_OR_GENE_PRODUCT", 243, 252], ["IN", "GENE_OR_GENE_PRODUCT", 266, 268], ["RV", "MULTI-TISSUE_STRUCTURE", 333, 335], ["vDNA", "SIMPLE_CHEMICAL", 598, 602], ["NC\u2013RNA ribonucleoprotein complexes", "PROTEIN", 53, 87], ["RT enzyme", "PROTEIN", 243, 252], ["IN", "PROTEIN", 266, 268], ["Viral NC\u2013RNA RNPs", "PROTEIN", 348, 365], ["genomic RNA", "RNA", 496, 507], ["NC\u2013RNA ribonucleoprotein complexes", "PROBLEM", 53, 87], ["fuzzy flexible molecular assemblages", "PROBLEM", 107, 143], ["the viral NC", "TREATMENT", 190, 202], ["the RT enzyme", "TEST", 239, 252], ["RV replication", "TREATMENT", 333, 347], ["Viral NC\u2013RNA RNPs", "PROBLEM", 348, 365], ["fuzziness", "PROBLEM", 367, 376], ["such fuzzy nucleocapsid assemblages", "PROBLEM", 411, 446], ["multiple forced and unforced recombination reactions", "PROBLEM", 538, 590], ["vDNA synthesis", "TREATMENT", 598, 612], ["flexible", "OBSERVATION_MODIFIER", 113, 121], ["molecular assemblages", "OBSERVATION", 122, 143], ["multiple", "OBSERVATION_MODIFIER", 150, 158], ["different", "OBSERVATION_MODIFIER", 159, 168], ["viral NC", "OBSERVATION", 194, 202], ["RV", "ANATOMY", 333, 335], ["replication", "OBSERVATION", 336, 347], ["NC\u2013RNA RNPs", "OBSERVATION", 354, 365], ["nucleocapsid assemblages", "OBSERVATION", 422, 446], ["genomic RNA", "OBSERVATION", 496, 507]]], ["These recombinations are chaperoned by NC and fulfill two functions, formation of a complete viral DNA by RT in conditions where each RNA monomer contains nicks, and reassortments of specific genetic traits when the two monomers are different, which fuels a high level of genetic diversity resulting in a quasispecies population in HIV-1 infected persons (Wain-Hobson et al., 2003).Anti-NC drugs: an exciting challengeSince resistant HIV-1 strains have been identified for each of the clinically available antiretroviral drugs targeting the viral enzymes, namely RTi, PRi, INi (reviewed in Das and Arnold, 2013a, Das and Arnold, 2013b) there is an urgent need to identify new molecules preferably targeting viral proteins not yet targeted by available therapies.", [["HIV-1 infected", "DISEASE", 332, 346], ["Anti-NC", "CHEMICAL", 382, 389], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["nicks", "CELLULAR_COMPONENT", 155, 160], ["HIV-1", "ORGANISM", 332, 337], ["persons", "ORGANISM", 347, 354], ["Anti-NC", "SIMPLE_CHEMICAL", 382, 389], ["HIV-1", "ORGANISM", 434, 439], ["strains", "ORGANISM", 440, 447], ["viral DNA", "DNA", 93, 102], ["viral enzymes", "PROTEIN", 541, 554], ["RTi", "PROTEIN", 563, 566], ["PRi", "PROTEIN", 568, 571], ["INi", "PROTEIN", 573, 576], ["viral proteins", "PROTEIN", 707, 721], ["HIV-1", "SPECIES", 332, 337], ["persons", "SPECIES", 347, 354], ["HIV-1", "SPECIES", 434, 439], ["HIV-1", "SPECIES", 332, 337], ["HIV-1", "SPECIES", 434, 439], ["NC", "TREATMENT", 39, 41], ["a complete viral DNA", "PROBLEM", 82, 102], ["specific genetic traits", "PROBLEM", 183, 206], ["a quasispecies population", "PROBLEM", 303, 328], ["Anti-NC drugs", "TREATMENT", 382, 395], ["an exciting challengeSince resistant HIV", "TREATMENT", 397, 437], ["1 strains", "PROBLEM", 438, 447], ["antiretroviral drugs", "TREATMENT", 506, 526], ["the viral enzymes", "TEST", 537, 554], ["new molecules", "PROBLEM", 672, 685], ["viral proteins", "PROBLEM", 707, 721], ["nicks", "OBSERVATION_MODIFIER", 155, 160]]], ["Due to its high degree of conservation and to its multiple fundamental roles in HIV-1 replication, NC constitutes a highly promising target.", [["HIV-1", "ORGANISM", 80, 85], ["HIV-1", "SPECIES", 80, 85], ["HIV-1", "SPECIES", 80, 85], ["NC", "TREATMENT", 99, 101], ["high degree", "OBSERVATION_MODIFIER", 11, 22], ["multiple", "OBSERVATION_MODIFIER", 50, 58]]], ["Since the NC properties and functions largely rely on its zinc fingers, the latter were selected as the primary target for developing zinc ejectors able to eject the zinc atoms from the NC fingers, resulting in NC and the concomitant total loss of HIV-1 infectivity.", [["zinc", "CHEMICAL", 134, 138], ["zinc", "CHEMICAL", 166, 170], ["zinc", "CHEMICAL", 58, 62], ["zinc", "CHEMICAL", 134, 138], ["zinc", "CHEMICAL", 166, 170], ["zinc ejectors", "SIMPLE_CHEMICAL", 134, 147], ["zinc atoms", "SIMPLE_CHEMICAL", 166, 176], ["HIV-1", "ORGANISM", 248, 253], ["zinc fingers", "PROTEIN", 58, 70], ["NC fingers", "PROTEIN", 186, 196], ["HIV-1", "SPECIES", 248, 253], ["developing zinc ejectors", "PROBLEM", 123, 147], ["NC", "TREATMENT", 211, 213], ["HIV-1 infectivity", "PROBLEM", 248, 265], ["largely", "OBSERVATION_MODIFIER", 38, 45], ["NC fingers", "ANATOMY", 186, 196]]], ["Starting from 3-nitrosobenzamide, the first identified zinc ejector (Rice et al., 1993) various classes of compounds were designed (reviewed in de Rocquigny et al., 2008, Goldschmidt et al., 2010, Musah, 2004, Turpin et al., 2008).", [["3-nitrosobenzamide", "CHEMICAL", 14, 32], ["zinc", "CHEMICAL", 55, 59], ["3-nitrosobenzamide", "CHEMICAL", 14, 32], ["zinc", "CHEMICAL", 55, 59], ["3-nitrosobenzamide", "SIMPLE_CHEMICAL", 14, 32]]], ["These compounds were found to show strong antiviral activity against a large spectrum of HIV-1 strains and elicit little viral resistance.", [["HIV-1", "ORGANISM", 89, 94], ["HIV-1", "SPECIES", 89, 94], ["HIV-1", "SPECIES", 89, 94], ["HIV-1 strains", "PROBLEM", 89, 102], ["little viral resistance", "PROBLEM", 114, 137], ["viral resistance", "OBSERVATION", 121, 137]]], ["A few of them were tested in clinical assays (Goebel et al., 2001, Turpin, 2003, Vandevelde et al., 1996) that were unfortunately not conclusive.", [["clinical assays", "TEST", 29, 44], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["In fact, these compounds showed limited selectivity and thus were quite toxic, preventing their use in HAART protocols.", [["HAART protocols", "TREATMENT", 103, 118]]], ["Current efforts are directed toward the development of zinc ejectors to be used as topical microbicides in the prevention of sexually transmitted HIV-1 infection (Srivastava et al., 2004, Wallace et al., 2009).", [["zinc", "CHEMICAL", 55, 59], ["sexually transmitted HIV-1 infection", "DISEASE", 125, 161], ["zinc", "CHEMICAL", 55, 59], ["zinc ejectors", "SIMPLE_CHEMICAL", 55, 68], ["HIV-1", "ORGANISM", 146, 151], ["HIV-1", "SPECIES", 146, 151], ["HIV-1", "SPECIES", 146, 151], ["zinc ejectors", "TREATMENT", 55, 68], ["topical microbicides", "TREATMENT", 83, 103], ["sexually transmitted HIV", "PROBLEM", 125, 149]]], ["In this respect, S-acyl-2-mercaptobenzamide thioesters (SAMT) (Jenkins et al., 2005) and more recently 2-methyl-3-phenyl-2H-[1,2,4]thiazol-5-yideneamine (WDO-217) (Vercruysse et al., 2012) were found to constitute valuable candidates for topical microbicide formulations.Anti-NC drugs: an exciting challengeAs an alternative to zinc ejectors, non-covalent NC inhibitors (NCis) were developed as possible antiretroviral therapeutics with greater specificity and thus less toxicity than zinc ejectors.", [["S-acyl-2-mercaptobenzamide thioesters", "CHEMICAL", 17, 54], ["SAMT", "CHEMICAL", 56, 60], ["2-methyl-3-phenyl-2H-[1,2,4]thiazol-5-yideneamine", "CHEMICAL", 103, 152], ["WDO-217", "CHEMICAL", 154, 161], ["zinc", "CHEMICAL", 328, 332], ["toxicity", "DISEASE", 471, 479], ["zinc", "CHEMICAL", 485, 489], ["S-acyl-2-mercaptobenzamide thioesters", "CHEMICAL", 17, 54], ["SAMT", "CHEMICAL", 56, 60], ["2-methyl-3-phenyl-2H-[1,2,4]thiazol-5-yideneamine", "CHEMICAL", 103, 152], ["WDO-217", "CHEMICAL", 154, 161], ["zinc", "CHEMICAL", 328, 332], ["zinc", "CHEMICAL", 485, 489], ["S-acyl-2-mercaptobenzamide thioesters", "SIMPLE_CHEMICAL", 17, 54], ["SAMT", "SIMPLE_CHEMICAL", 56, 60], ["2-methyl-3-phenyl-2H-[1,2,4]thiazol-5-yideneamine", "SIMPLE_CHEMICAL", 103, 152], ["WDO-217", "SIMPLE_CHEMICAL", 154, 161], ["Anti-NC", "SIMPLE_CHEMICAL", 271, 278], ["zinc ejectors", "SIMPLE_CHEMICAL", 328, 341], ["NC inhibitors", "SIMPLE_CHEMICAL", 356, 369], ["NCis", "SIMPLE_CHEMICAL", 371, 375], ["zinc ejectors", "SIMPLE_CHEMICAL", 485, 498], ["S-acyl-2-mercaptobenzamide thioesters", "TREATMENT", 17, 54], ["methyl", "TREATMENT", 105, 111], ["phenyl", "TREATMENT", 114, 120], ["thiazol", "TREATMENT", 131, 138], ["topical microbicide formulations", "TREATMENT", 238, 270], ["Anti-NC drugs", "TREATMENT", 271, 284], ["an exciting challengeAs", "TREATMENT", 286, 309], ["zinc ejectors", "TREATMENT", 328, 341], ["non-covalent NC inhibitors", "TREATMENT", 343, 369], ["antiretroviral therapeutics", "TREATMENT", 404, 431], ["less toxicity than zinc ejectors", "PROBLEM", 466, 498]]], ["Two main classes of compounds were identified, namely (i) non-covalent NCis binding to NC and (ii) non-covalent NCis binding to nucleic acid partners of NC.", [["nucleic acid", "CHEMICAL", 128, 140], ["NCis", "SIMPLE_CHEMICAL", 71, 75], ["NCis", "SIMPLE_CHEMICAL", 112, 116], ["nucleic acid", "SIMPLE_CHEMICAL", 128, 140], ["NCis", "PROTEIN", 112, 116], ["NC and (ii)", "TREATMENT", 87, 98], ["NC", "TREATMENT", 153, 155], ["main", "OBSERVATION_MODIFIER", 4, 8], ["classes", "OBSERVATION_MODIFIER", 9, 16], ["compounds", "OBSERVATION", 20, 29]]], ["Within the first class, high throughput screenings were performed to identify small molecules able to inhibit the NA-binding (Breuer et al., 2012, Stephen et al., 2002) and chaperone properties (Shvadchak et al., 2009) of NC.", [["NA", "CHEMICAL", 114, 116], ["NA", "SIMPLE_CHEMICAL", 114, 116], ["high throughput screenings", "TEST", 24, 50], ["small molecules", "PROBLEM", 78, 93], ["chaperone properties", "TREATMENT", 173, 193], ["NC", "TREATMENT", 222, 224]]], ["Compounds able to bind NC with an affinity in the micromolar range, but with only modest anti-HIV activity were obtained, indicating that these compounds still need to be optimized.", [["bind NC", "TREATMENT", 18, 25], ["these compounds", "PROBLEM", 138, 153]]], ["An important step toward the rational optimization of NCis has been recently achieved by the resolution of the first 3D structure of a complex between NC and an NCi (Goudreau et al., 2013).", [["NCis", "CHEMICAL", 54, 58], ["NCis", "CHEMICAL", 54, 58], ["NCis", "SIMPLE_CHEMICAL", 54, 58], ["NCis", "PROTEIN", 54, 58], ["NC", "TREATMENT", 151, 153]]], ["In this complex, the NCi was found to bind preferentially within the hydrophobic pocket of NCp7 performing a \u03c0\u2013\u03c0 stacking interaction with the side chain of Trp37, and thus, behaving as a guanosine mimetic.", [["NCi", "CHEMICAL", 21, 24], ["guanosine", "CHEMICAL", 188, 197], ["NCi", "CHEMICAL", 21, 24], ["\u03c0\u2013\u03c0", "CHEMICAL", 109, 112], ["guanosine", "CHEMICAL", 188, 197], ["NCi", "SIMPLE_CHEMICAL", 21, 24], ["NCp7", "GENE_OR_GENE_PRODUCT", 91, 95], ["Trp37", "GENE_OR_GENE_PRODUCT", 157, 162], ["guanosine", "SIMPLE_CHEMICAL", 188, 197], ["NCi", "PROTEIN", 21, 24], ["NCp7", "PROTEIN", 91, 95], ["Trp37", "PROTEIN", 157, 162], ["a guanosine mimetic", "TREATMENT", 186, 205], ["hydrophobic pocket", "OBSERVATION", 69, 87]]], ["Moreover, a second NCi molecule was found to bind NC by connecting the hydrophobic pocket with the N-terminal region.", [["N", "CHEMICAL", 99, 100], ["NC", "GENE_OR_GENE_PRODUCT", 50, 52], ["NCi molecule", "PROTEIN", 19, 31], ["N-terminal region", "PROTEIN", 99, 116], ["a second NCi molecule", "PROBLEM", 10, 31], ["bind NC", "TREATMENT", 45, 52], ["hydrophobic pocket", "OBSERVATION", 71, 89], ["terminal", "ANATOMY_MODIFIER", 101, 109], ["region", "ANATOMY_MODIFIER", 110, 116]]], ["Another key progress was achieved by the application of molecular dynamics simulations and molecular modeling studies on NMR structures of NC in complex with oligonucleotides to identify pharmacophoric hot-spots for NCis to compete with NAs for the NC binding sites (Mori et al., 2010, Mori et al., 2011).", [["NCis", "SIMPLE_CHEMICAL", 216, 220], ["NCis", "PROTEIN", 216, 220], ["molecular dynamics simulations", "TEST", 56, 86], ["molecular modeling studies", "TEST", 91, 117], ["oligonucleotides", "TREATMENT", 158, 174], ["NCis", "TREATMENT", 216, 220], ["NC", "ANATOMY", 139, 141]]], ["Based on this knowledge, a virtual screening was performed and NCis with antiviral activity in the low micromolar range were identified (Mori et al., 2012), indicating that this strategy constitutes a promising approach to develop and improve NCis.", [["NCis", "SIMPLE_CHEMICAL", 63, 67], ["NCis", "SIMPLE_CHEMICAL", 243, 247], ["NCis", "PROTEIN", 243, 247], ["a virtual screening", "TEST", 25, 44], ["NCis", "TEST", 63, 67], ["antiviral activity", "TEST", 73, 91], ["antiviral activity", "OBSERVATION", 73, 91], ["low micromolar", "OBSERVATION_MODIFIER", 99, 113]]], ["In parallel, methylated oligoribonucleotides (mODNs) able to inhibit HIV-1 replication in MT4 cells with an IC50 value of 0.3 nM were recently disclosed (Grigorov et al., 2011).", [["MT4 cells", "ANATOMY", 90, 99], ["methylated oligoribonucleotides", "SIMPLE_CHEMICAL", 13, 44], ["mODNs", "SIMPLE_CHEMICAL", 46, 51], ["HIV-1", "ORGANISM", 69, 74], ["MT4 cells", "CELL", 90, 99], ["MT4 cells", "CELL_LINE", 90, 99], ["HIV-1", "SPECIES", 69, 74], ["HIV-1", "SPECIES", 69, 74], ["methylated oligoribonucleotides (mODNs)", "TREATMENT", 13, 52], ["HIV", "TEST", 69, 72], ["an IC50 value", "TEST", 105, 118], ["methylated oligoribonucleotides", "OBSERVATION", 13, 44]]], ["These molecules were found to impair reverse transcription, both by sequestering NCp7 molecules (Avilov et al., 2012) and by direct interaction with reverse transcriptase.", [["NCp7", "GENE_OR_GENE_PRODUCT", 81, 85], ["NCp7 molecules", "PROTEIN", 81, 95], ["reverse transcriptase", "PROTEIN", 149, 170], ["reverse transcriptase", "TREATMENT", 149, 170]]], ["Unfortunately, HIV-1 mutants resistant to these mODNs were obtained, so that their development was stopped.Anti-NC drugs: an exciting challengeA second approach to inhibit NC functions is to target the NA sequences interacting with NC during HIV-1 replication.", [["HIV-1", "ORGANISM", 15, 20], ["mODNs", "GENE_OR_GENE_PRODUCT", 48, 53], ["Anti-NC", "SIMPLE_CHEMICAL", 107, 114], ["NC", "GENE_OR_GENE_PRODUCT", 172, 174], ["NC", "GENE_OR_GENE_PRODUCT", 232, 234], ["HIV-1", "ORGANISM", 242, 247], ["mODNs", "DNA", 48, 53], ["NA sequences", "DNA", 202, 214], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 242, 247], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 242, 247], ["HIV", "PROBLEM", 15, 18], ["Anti-NC drugs", "TREATMENT", 107, 120], ["an exciting challengeA second approach", "TREATMENT", 122, 160], ["NC functions", "TREATMENT", 172, 184], ["NC", "TREATMENT", 232, 234], ["HIV-1 replication", "TREATMENT", 242, 259]]], ["Of special interest are the stem-loops of the 5\u2032 untranslated leader of HIV-1 RNA, which control viral translation and virus assembly through their interaction with NC.", [["HIV-1", "ORGANISM", 72, 77], ["NC", "GENE_OR_GENE_PRODUCT", 165, 167], ["5\u2032 untranslated leader", "DNA", 46, 68], ["HIV-1 RNA", "RNA", 72, 81], ["HIV-1", "SPECIES", 72, 77], ["HIV-1", "SPECIES", 72, 77], ["HIV-1 RNA", "PROBLEM", 72, 81], ["viral translation", "PROBLEM", 97, 114], ["virus", "PROBLEM", 119, 124], ["NC", "TREATMENT", 165, 167], ["stem", "ANATOMY", 28, 32], ["viral translation", "OBSERVATION", 97, 114]]], ["Various classes of molecules such as aminoglycosides, intercalators, anthraquinones and small peptides were designed or screened to target the stem-loops of the \u03c8 packaging signal (Bernacchi et al., 2007, Dietz et al., 2008, Freisz et al., 2008, Pustowka et al., 2003, Turner et al., 2006, Turner et al., 2009, Warui and Baranger, 2009), as well as the PBS and/or the TAR sequence (Raja et al., 2006, Sosic et al., 2013).", [["aminoglycosides", "CHEMICAL", 37, 52], ["anthraquinones", "CHEMICAL", 69, 83], ["aminoglycosides", "CHEMICAL", 37, 52], ["anthraquinones", "CHEMICAL", 69, 83], ["aminoglycosides", "SIMPLE_CHEMICAL", 37, 52], ["intercalators", "SIMPLE_CHEMICAL", 54, 67], ["anthraquinones", "SIMPLE_CHEMICAL", 69, 83], ["PBS and/or the TAR sequence", "DNA", 353, 380], ["aminoglycosides", "TREATMENT", 37, 52], ["intercalators", "TREATMENT", 54, 67], ["anthraquinones", "TREATMENT", 69, 83], ["small peptides", "PROBLEM", 88, 102]]], ["These compounds were able to prevent the interaction of NC with its NA targets or dissociate the already formed nucleoprotein complexes, but showed only limited anti-viral activity (Dietz et al., 2008, Ennifar et al., 2006, Raja et al., 2006, Sosic et al., 2013).", [["NC", "GENE_OR_GENE_PRODUCT", 56, 58], ["NA", "SIMPLE_CHEMICAL", 68, 70], ["nucleoprotein complexes", "PROTEIN", 112, 135], ["NC", "TREATMENT", 56, 58], ["the already formed nucleoprotein complexes", "PROBLEM", 93, 135], ["nucleoprotein complexes", "OBSERVATION", 112, 135]]], ["As for NCi directly targeting NC, it is believed that the structural determinants and the in vivo mechanism of action of NCis targeting the NA targets of NC need to be further understood in order to rationally design the next generation of compounds.ConclusionAs it stands now, RV NC oligomers resemble fuzzy RNP assemblages that probably also exist in simple RV such as ASLV and MuLV and in ancient retrotransposons of yeast such as TY3.", [["NCi", "CHEMICAL", 7, 10], ["NCis", "CHEMICAL", 121, 125], ["NCi", "SIMPLE_CHEMICAL", 7, 10], ["NC", "GENE_OR_GENE_PRODUCT", 30, 32], ["NCis", "SIMPLE_CHEMICAL", 121, 125], ["NC", "GENE_OR_GENE_PRODUCT", 154, 156], ["ASLV", "GENE_OR_GENE_PRODUCT", 371, 375], ["MuLV", "CANCER", 380, 384], ["TY3", "GENE_OR_GENE_PRODUCT", 434, 437], ["NCi", "PROTEIN", 7, 10], ["TY3", "PROTEIN", 434, 437], ["yeast", "SPECIES", 420, 425], ["yeast", "SPECIES", 420, 425], ["NC", "TREATMENT", 30, 32], ["NCis", "TREATMENT", 121, 125], ["NC", "TREATMENT", 154, 156], ["RV NC oligomers", "TREATMENT", 278, 293], ["fuzzy RNP assemblages", "PROBLEM", 303, 324], ["ASLV", "PROBLEM", 371, 375], ["MuLV", "PROBLEM", 380, 384], ["yeast", "PROBLEM", 420, 425], ["RNP assemblages", "OBSERVATION", 309, 324], ["simple RV", "ANATOMY", 353, 362]]], ["NC appears to be central to the formation of such fuzzy assemblies, and by coordinating under a dynamic mode multiple NA:NA, NA:NC and NC:enzymes interactions it fulfills multiple functions from the inner structure of the viral particle to vDNA synthesis and integration (Ivanyi-Nagy et al., 2012).", [["NA", "CHEMICAL", 121, 123], ["NA", "CHEMICAL", 125, 127], ["NA", "SIMPLE_CHEMICAL", 121, 123], ["NA", "SIMPLE_CHEMICAL", 125, 127], ["vDNA", "SIMPLE_CHEMICAL", 240, 244], ["NC", "TREATMENT", 0, 2], ["NC", "TREATMENT", 128, 130], ["enzymes interactions", "PROBLEM", 138, 158], ["multiple functions", "PROBLEM", 171, 189], ["vDNA synthesis", "TREATMENT", 240, 254], ["viral particle", "OBSERVATION", 222, 236]]], ["In addition the dimeric nature of the viral genome is very well accommodated in such vaguely ordered replication machinery, which ensures a genetic diversity of the virus fueled by multiple recombination events.", [["viral genome", "DNA", 38, 50], ["the viral genome", "PROBLEM", 34, 50], ["the virus", "PROBLEM", 161, 170], ["viral genome", "OBSERVATION", 38, 50]]], ["In the case of HIV-1, this turns out to be sufficient for the virus to escape HAART therapies and specific immune responses.ConclusionFrom a general perspective with the aim of better understanding the functions of viral nucleoproteins, the core proteins of flaviviruses, hepadnaviruses (Ivanyi-Nagy and Darlix, 2010), paramyxoviruses (Longhi et al., 2010, Longhi and Oglesbee, 2010) and coronaviruses (Chang et al., 2006, Chang et al., 2009) were studied.", [["HIV-1", "ORGANISM", 15, 20], ["coronaviruses", "ORGANISM", 388, 401], ["viral nucleoproteins", "PROTEIN", 215, 235], ["core proteins", "PROTEIN", 241, 254], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 15, 20], ["HIV", "PROBLEM", 15, 18], ["the virus", "PROBLEM", 58, 67], ["escape HAART therapies", "TREATMENT", 71, 93], ["viral nucleoproteins", "PROBLEM", 215, 235], ["flaviviruses", "PROBLEM", 258, 270], ["hepadnaviruses", "TREATMENT", 272, 286], ["Darlix", "TREATMENT", 304, 310]]], ["In all cases examined so far, it turned out that such viral nucleoproteins, contained intrinsic disordered domains, were forming dense nucleoprotein complexes upon binding to NAs and were endowed with potent NA chaperoning activities (Ivanyi-Nagy et al., 2005, Longhi et al., 2010, Longhi and Oglesbee, 2010).ConclusionTherefore, the determination of the composition of such fuzzy viral functional complexes and of the multiple dynamic interactions in these complexes (Fig. 2) is central to the identification of possible druggable sites in viral nucleoprotein cores from highly pathogenic viruses such as HIV, HCV, HBV, MV and SARS coronavirus (Cheng et al., 2006, Csermely et al., 2005).", [["HIV, HCV, HBV, MV and SARS coronavirus", "DISEASE", 606, 644], ["NA", "SIMPLE_CHEMICAL", 208, 210], ["HIV", "ORGANISM", 606, 609], ["HCV", "ORGANISM", 611, 614], ["HBV", "ORGANISM", 616, 619], ["SARS coronavirus", "ORGANISM", 628, 644], ["viral nucleoproteins", "PROTEIN", 54, 74], ["intrinsic disordered domains", "PROTEIN", 86, 114], ["nucleoprotein complexes", "PROTEIN", 135, 158], ["fuzzy viral functional complexes", "PROTEIN", 375, 407], ["HIV", "SPECIES", 606, 609], ["HIV", "SPECIES", 606, 609], ["HCV", "SPECIES", 611, 614], ["HBV", "SPECIES", 616, 619], ["MV", "SPECIES", 621, 623], ["SARS coronavirus", "SPECIES", 628, 644], ["such viral nucleoproteins", "PROBLEM", 49, 74], ["intrinsic disordered domains", "PROBLEM", 86, 114], ["dense nucleoprotein complexes", "PROBLEM", 129, 158], ["such fuzzy viral functional complexes", "PROBLEM", 370, 407], ["druggable sites", "PROBLEM", 522, 537], ["viral nucleoprotein cores", "PROBLEM", 541, 566], ["highly pathogenic viruses", "PROBLEM", 572, 597], ["HIV", "PROBLEM", 606, 609], ["HCV", "PROBLEM", 611, 614], ["HBV", "PROBLEM", 616, 619], ["SARS coronavirus", "PROBLEM", 628, 644], ["dense", "OBSERVATION_MODIFIER", 129, 134], ["nucleoprotein complexes", "OBSERVATION", 135, 158], ["multiple", "OBSERVATION_MODIFIER", 419, 427], ["possible", "UNCERTAINTY", 513, 521], ["druggable sites", "OBSERVATION", 522, 537], ["viral nucleoprotein cores", "OBSERVATION", 541, 566], ["pathogenic viruses", "OBSERVATION", 579, 597]]]], "PMC4252299": [["IntroductionViral metagenomics characterizes known and divergent viruses in sample preparations enriched for viral nucleic acids.", [["sample", "ANATOMY", 76, 82], ["nucleic acids", "CHEMICAL", 115, 128], ["IntroductionViral metagenomics", "TEST", 0, 30], ["divergent viruses in sample preparations", "PROBLEM", 55, 95], ["viral nucleic acids", "PROBLEM", 109, 128], ["divergent", "OBSERVATION_MODIFIER", 55, 64], ["viruses", "OBSERVATION", 65, 72], ["nucleic acids", "OBSERVATION", 115, 128]]], ["Host DNA or RNA concentration is reduced by nuclease treatment while viral nucleic acids are protected within filterable viral particles (Allander et al., 2001).", [["nucleic acids", "CHEMICAL", 75, 88], ["DNA", "CELLULAR_COMPONENT", 5, 8], ["nuclease", "PROTEIN", 44, 52], ["Host DNA", "PROBLEM", 0, 8], ["RNA concentration", "PROBLEM", 12, 29], ["nuclease treatment", "TREATMENT", 44, 62], ["viral nucleic acids", "TEST", 69, 88], ["RNA concentration", "OBSERVATION_MODIFIER", 12, 29], ["reduced", "OBSERVATION_MODIFIER", 33, 40]]], ["Following non-specific amplification and deep sequencing the viral sequences are recognized through their translated protein sequence similarity to known viral proteins.", [["viral sequences", "DNA", 61, 76], ["viral proteins", "PROTEIN", 154, 168], ["non-specific amplification", "PROBLEM", 10, 36], ["deep sequencing the viral sequences", "TEST", 41, 76], ["known viral proteins", "PROBLEM", 148, 168], ["viral proteins", "OBSERVATION", 154, 168]]], ["Here we characterize viral sequences in beef, pork, and chicken bought from stores in San Francisco.", [["pork", "ANATOMY", 46, 50], ["beef", "ORGANISM_SUBDIVISION", 40, 44], ["pork", "ORGANISM_SUBDIVISION", 46, 50], ["chicken", "ORGANISM", 56, 63], ["viral sequences", "DNA", 21, 36], ["beef", "SPECIES", 40, 44], ["pork", "SPECIES", 46, 50], ["chicken", "SPECIES", 56, 63], ["beef", "SPECIES", 40, 44], ["pork", "SPECIES", 46, 50], ["chicken", "SPECIES", 56, 63], ["viral", "OBSERVATION", 21, 26]]], ["Such viruses are of interest given the enormous scale of their exposure to humans consuming meat products.IntroductionMeat and meat products are the source of numerous enteric infections in humans.", [["meat", "ANATOMY", 92, 96], ["meat", "ANATOMY", 127, 131], ["enteric infections", "DISEASE", 168, 186], ["humans", "ORGANISM", 75, 81], ["meat", "ORGANISM_SUBDIVISION", 92, 96], ["Meat", "ORGANISM_SUBSTANCE", 118, 122], ["meat", "ORGANISM", 127, 131], ["humans", "ORGANISM", 190, 196], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 190, 196], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 190, 196], ["Such viruses", "PROBLEM", 0, 12], ["IntroductionMeat and meat products", "TREATMENT", 106, 140], ["numerous enteric infections in humans", "PROBLEM", 159, 196], ["viruses", "OBSERVATION", 5, 12], ["numerous", "OBSERVATION_MODIFIER", 159, 167], ["enteric", "OBSERVATION_MODIFIER", 168, 175], ["infections", "OBSERVATION", 176, 186]]], ["Enteric viruses harbored by farmed animals may contaminate meat samples during slaughter and meat preparation (Machnowska et al., 2014).", [["meat samples", "ANATOMY", 59, 71], ["meat", "ANATOMY", 93, 97], ["meat samples", "ORGANISM_SUBSTANCE", 59, 71], ["meat", "ORGANISM_SUBDIVISION", 93, 97], ["Enteric viruses", "TREATMENT", 0, 15], ["viruses", "OBSERVATION", 8, 15]]], ["Hepatitis E virus (HEV) replicating in domesticated or wild-pigs can also be transmitted to human through undercooked pork consumption (Christou and Kosmidou, 2013, Meng, 2013).", [["Hepatitis E", "DISEASE", 0, 11], ["Hepatitis E virus", "ORGANISM", 0, 17], ["HEV", "ORGANISM", 19, 22], ["pigs", "ORGANISM", 60, 64], ["human", "ORGANISM", 92, 97], ["pork", "ORGANISM_SUBDIVISION", 118, 122], ["Hepatitis E virus", "SPECIES", 0, 17], ["-pigs", "SPECIES", 59, 64], ["human", "SPECIES", 92, 97], ["Hepatitis E virus", "SPECIES", 0, 17], ["HEV", "SPECIES", 19, 22], ["pigs", "SPECIES", 60, 64], ["human", "SPECIES", 92, 97], ["pork", "SPECIES", 118, 122], ["Hepatitis E virus", "PROBLEM", 0, 17]]], ["At slaughter time (22\u201329 weeks), HEV was present in 12% and 41% of the plasmas and stools from Canadian pigs, respectively (Leblanc et al., 2007).", [["HEV", "ORGANISM", 33, 36], ["stools", "ORGANISM_SUBSTANCE", 83, 89], ["pigs", "ORGANISM", 104, 108], ["pigs", "SPECIES", 104, 108], ["HEV", "SPECIES", 33, 36], ["HEV", "TEST", 33, 36]]], ["Viral transmission between farm animal species or between domesticated and wild animals may also occur increasing risk of adaptation to new host and changes in viral tropism (Ma et al., 2009, Sonnberg et al., 2013).", [["Viral transmission between farm animal species", "PROBLEM", 0, 46], ["viral tropism", "OBSERVATION", 160, 173]]], ["Transmission of viruses in meat or blood may also occur through non-enteric routes such as skin cuts occurring during hunting and butchering as seen for simian T-lymphotropic and simian foamy virus (Betsem et al., 2011, Gessain et al., 2013, Switzer et al., 2004).", [["meat", "ANATOMY", 27, 31], ["blood", "ANATOMY", 35, 40], ["skin", "ANATOMY", 91, 95], ["simian T-lymphotropic and simian foamy virus", "DISEASE", 153, 197], ["meat", "ORGANISM_SUBDIVISION", 27, 31], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["skin", "ORGAN", 91, 95], ["simian T-lymphotropic", "ORGANISM", 153, 174], ["simian foamy virus", "ORGANISM", 179, 197], ["simian foamy virus", "SPECIES", 179, 197], ["simian foamy virus", "SPECIES", 179, 197], ["viruses", "PROBLEM", 16, 23], ["non-enteric routes", "TREATMENT", 64, 82], ["skin cuts", "PROBLEM", 91, 100], ["viruses", "OBSERVATION", 16, 23], ["skin", "ANATOMY", 91, 95]]], ["Cross-species transmissions, likely due to hunting and/or butchering non-human primates, initiated various HIV epidemics (HIV-1 groups M, N, O, P and HIV-2 groups A\u2013H) (Sharp and Hahn, 2011) and Ebola virus outbreaks (Leroy et al., 2004).", [["HIV epidemics", "DISEASE", 107, 120], ["Ebola virus outbreaks", "DISEASE", 195, 216], ["non-human primates", "ORGANISM", 69, 87], ["HIV-1", "ORGANISM", 122, 127], ["HIV-2", "ORGANISM", 150, 155], ["Ebola virus", "ORGANISM", 195, 206], ["HIV", "SPECIES", 107, 110], ["HIV-1", "SPECIES", 122, 127], ["Ebola virus", "SPECIES", 195, 206], ["HIV", "SPECIES", 107, 110], ["HIV-1", "SPECIES", 122, 127], ["Ebola virus", "SPECIES", 195, 206], ["hunting", "PROBLEM", 43, 50], ["various HIV epidemics", "PROBLEM", 99, 120], ["HIV", "TEST", 122, 125], ["HIV", "TEST", 150, 153], ["Ebola virus outbreaks", "PROBLEM", 195, 216], ["likely due to", "UNCERTAINTY", 29, 42]]], ["The possibility of bovine viruses playing a role in carcinogenesis has been raised based on the association of colorectal cancer with consumption of under-cooked beef (Zur Hausen, 2012).Overview of virome ::: ResultsThe Illumina MiSeq 2\u00d7250 bases run generated a total of 4,944,932 unique sequence reads.", [["colorectal cancer", "ANATOMY", 111, 128], ["carcinogenesis", "DISEASE", 52, 66], ["colorectal cancer", "DISEASE", 111, 128], ["bovine", "ORGANISM", 19, 25], ["colorectal cancer", "CANCER", 111, 128], ["beef", "ORGANISM_SUBDIVISION", 162, 166], ["Illumina MiSeq 2\u00d7250 bases", "DNA", 220, 246], ["bovine", "SPECIES", 19, 25], ["beef", "SPECIES", 162, 166], ["beef", "SPECIES", 162, 166], ["bovine viruses", "PROBLEM", 19, 33], ["colorectal cancer", "PROBLEM", 111, 128], ["possibility of", "UNCERTAINTY", 4, 18], ["bovine viruses", "OBSERVATION", 19, 33], ["colorectal", "ANATOMY", 111, 121], ["cancer", "OBSERVATION", 122, 128]]], ["Sequence reads were assembled de novo and compared to the GenBank non-redundant protein database using BLASTx.", [["Sequence reads", "TEST", 0, 14], ["BLASTx", "TEST", 103, 109]]], ["475 sequence reads showed similarity to known eukaryotic viral sequences with an E-value cutoff 10\u22125.Table 1 presents the characterization of the eukaryotic viral sequences detected in the meat samples.Overview of virome ::: ResultsIn the beef samples we detected eukaryotic viral sequences related to parvoviruses, polyomaviruses, anelloviruses and circoviruses (Table 1).", [["meat samples", "ANATOMY", 189, 201], ["beef samples", "ANATOMY", 239, 251], ["meat samples", "ORGANISM_SUBSTANCE", 189, 201], ["parvoviruses", "ORGANISM", 302, 314], ["polyomaviruses", "ORGANISM", 316, 330], ["eukaryotic viral sequences", "DNA", 46, 72], ["E-value cutoff 10\u22125", "DNA", 81, 100], ["eukaryotic viral sequences", "DNA", 146, 172], ["eukaryotic viral sequences", "DNA", 264, 290], ["beef", "SPECIES", 239, 243], ["beef", "SPECIES", 239, 243], ["sequence reads", "TEST", 4, 18], ["known eukaryotic viral sequences", "PROBLEM", 40, 72], ["an E-value cutoff", "TEST", 78, 95], ["the eukaryotic viral sequences", "TEST", 142, 172], ["the beef samples", "TEST", 235, 251], ["eukaryotic viral sequences", "PROBLEM", 264, 290], ["parvoviruses", "PROBLEM", 302, 314], ["polyomaviruses", "PROBLEM", 316, 330], ["anelloviruses", "TREATMENT", 332, 345], ["circoviruses", "TREATMENT", 350, 362]]], ["In the pork samples we identified viral sequences related to parvoviruses, anelloviruses and circoviruses (Table 1).", [["pork samples", "ANATOMY", 7, 19], ["pork samples", "CANCER", 7, 19], ["parvoviruses", "ORGANISM", 61, 73], ["pork", "SPECIES", 7, 11], ["viral sequences", "PROBLEM", 34, 49], ["parvoviruses", "PROBLEM", 61, 73], ["anelloviruses", "TREATMENT", 75, 88], ["circoviruses", "TREATMENT", 93, 105]]], ["In chicken diverse gyroviruses were detected (Table 1).Parvoviruses in beef samples ::: ResultsSequences identical to the previously described bovine parvovirus 3 (BPV3: prototype of the ungulate erythroparvovirus 1 species) were identified.", [["samples", "ANATOMY", 76, 83], ["chicken", "ORGANISM", 3, 10], ["gyroviruses", "CANCER", 19, 30], ["bovine", "ORGANISM", 143, 149], ["parvovirus 3", "ORGANISM", 150, 162], ["BPV3", "ORGANISM", 164, 168], ["chicken", "SPECIES", 3, 10], ["beef", "SPECIES", 71, 75], ["bovine", "SPECIES", 143, 149], ["parvovirus", "SPECIES", 150, 160], ["chicken", "SPECIES", 3, 10], ["beef", "SPECIES", 71, 75], ["bovine parvovirus", "TEST", 143, 160], ["diverse", "OBSERVATION_MODIFIER", 11, 18], ["gyroviruses", "OBSERVATION", 19, 30]]], ["BPV3 was one of two parvoviruses previously identified from bovine serum (Allander et al., 2001).", [["serum", "ANATOMY", 67, 72], ["BPV3", "GENE_OR_GENE_PRODUCT", 0, 4], ["parvoviruses", "ORGANISM", 20, 32], ["bovine", "ORGANISM", 60, 66], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["BPV3", "DNA", 0, 4], ["bovine", "SPECIES", 60, 66], ["bovine", "SPECIES", 60, 66], ["two parvoviruses", "PROBLEM", 16, 32], ["bovine serum", "TEST", 60, 72], ["parvoviruses", "OBSERVATION", 20, 32]]], ["Sequences identical to porcine hokovirus (P-PARV4 in the ungulate tetraparvovirus 2 species), first sequenced from porcine tissues (Lau et al., 2008), were also identified in beef.", [["tissues", "ANATOMY", 123, 130], ["porcine hokovirus", "ORGANISM", 23, 40], ["ungulate tetraparvovirus 2", "ORGANISM", 57, 83], ["porcine", "ORGANISM", 115, 122], ["tissues", "TISSUE", 123, 130], ["beef", "ORGANISM_SUBDIVISION", 175, 179], ["porcine hokovirus", "DNA", 23, 40], ["P", "DNA", 42, 43], ["PARV4", "DNA", 44, 49], ["porcine", "SPECIES", 23, 30], ["porcine", "SPECIES", 115, 122], ["beef", "SPECIES", 175, 179], ["porcine hokovirus", "SPECIES", 23, 40], ["beef", "SPECIES", 175, 179], ["Sequences", "TEST", 0, 9], ["porcine hokovirus", "TEST", 23, 40], ["P", "TEST", 42, 43]]], ["Porcine hokovirus is distinct from bovine hokovirus (B-PARV4-1 in the distinct ungulate tetraparvovirus 1 species) with only 63\u201365% nucleotide identity between them in ORF1 and ORF2 (Lau et al., 2008).Parvoviruses in beef samples ::: ResultsIn order to confirm the existence of porcine hokovirus in beef samples, PCR screening was performed using two sets of nested primers.", [["samples", "ANATOMY", 222, 229], ["samples", "ANATOMY", 304, 311], ["nucleotide", "CHEMICAL", 132, 142], ["nucleotide", "CHEMICAL", 132, 142], ["Porcine", "ORGANISM", 0, 7], ["hokovirus", "GENE_OR_GENE_PRODUCT", 8, 17], ["bovine", "ORGANISM", 35, 41], ["hokovirus", "GENE_OR_GENE_PRODUCT", 42, 51], ["B-PARV4-1", "ORGANISM", 53, 62], ["ungulate tetraparvovirus 1", "ORGANISM", 79, 105], ["ORF1", "GENE_OR_GENE_PRODUCT", 168, 172], ["porcine", "ORGANISM", 278, 285], ["hokovirus", "CELL", 286, 295], ["beef samples", "ORGANISM_SUBSTANCE", 299, 311], ["ORF1", "DNA", 168, 172], ["ORF2", "DNA", 177, 181], ["Porcine", "SPECIES", 0, 7], ["bovine", "SPECIES", 35, 41], ["beef", "SPECIES", 217, 221], ["porcine", "SPECIES", 278, 285], ["beef", "SPECIES", 299, 303], ["Porcine hokovirus", "SPECIES", 0, 17], ["bovine hokovirus", "SPECIES", 35, 51], ["B-PARV4-1", "SPECIES", 53, 62], ["beef", "SPECIES", 217, 221], ["porcine hokovirus", "SPECIES", 278, 295], ["beef", "SPECIES", 299, 303], ["Porcine hokovirus", "PROBLEM", 0, 17], ["bovine hokovirus", "PROBLEM", 35, 51], ["B-PARV4", "TEST", 53, 60], ["porcine hokovirus in beef samples", "PROBLEM", 278, 311], ["PCR screening", "TEST", 313, 326], ["nested primers", "TREATMENT", 359, 373], ["bovine hokovirus", "OBSERVATION", 35, 51]]], ["Twenty-two beef samples, including the 10 samples analyzed here and 12 beef samples collected from stores in San Francisco in 2010 (Li et al., 2011), were tested.", [["samples", "ANATOMY", 16, 23], ["samples", "ANATOMY", 42, 49], ["samples", "ANATOMY", 76, 83], ["beef", "SPECIES", 11, 15], ["beef", "SPECIES", 71, 75], ["the 10 samples", "TEST", 35, 49]]], ["PCR results indicated two beef samples were positive, one from a pool of five samples and the other from a beef sample collected in 2010.", [["samples", "ANATOMY", 31, 38], ["samples", "ANATOMY", 78, 85], ["sample", "ANATOMY", 112, 118], ["beef", "SPECIES", 26, 30], ["beef", "SPECIES", 107, 111], ["PCR", "TEST", 0, 3], ["two beef samples", "TEST", 22, 38], ["a beef sample", "TEST", 105, 118]]], ["The PCR products were sequenced confirmed, sharing 99% sequence identity with a porcine hokovirus strain in GenBank (JQ700068).A novel bovine polyomavirus ::: ResultsPolyomaviruses are small, circular DNA viruses that can cause persistent infections in numerous mammals and can be oncogenic in some hosts.", [["infections", "DISEASE", 239, 249], ["bovine", "ORGANISM", 135, 141], ["polyomavirus", "ORGANISM", 142, 154], ["Polyomaviruses", "GENE_OR_GENE_PRODUCT", 166, 180], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["PCR products", "DNA", 4, 16], ["porcine", "SPECIES", 80, 87], ["bovine", "SPECIES", 135, 141], ["The PCR products", "TEST", 0, 16], ["a porcine hokovirus strain", "TREATMENT", 78, 104], ["Polyomaviruses", "PROBLEM", 166, 180], ["circular DNA viruses", "PROBLEM", 192, 212], ["persistent infections", "PROBLEM", 228, 249], ["bovine polyomavirus", "OBSERVATION", 135, 154], ["Polyomaviruses", "OBSERVATION", 166, 180], ["small", "OBSERVATION_MODIFIER", 185, 190], ["circular", "OBSERVATION_MODIFIER", 192, 200], ["DNA viruses", "OBSERVATION", 201, 212], ["persistent", "OBSERVATION_MODIFIER", 228, 238], ["infections", "OBSERVATION", 239, 249], ["numerous mammals", "OBSERVATION_MODIFIER", 253, 269], ["oncogenic", "OBSERVATION_MODIFIER", 281, 290]]], ["The one previously reported bovine polyomavirus (BPyV) was originally isolated from bovine serum (Schuurman et al., 1990).", [["serum", "ANATOMY", 91, 96], ["bovine", "ORGANISM", 28, 34], ["polyomavirus", "ORGANISM", 35, 47], ["BPyV", "ORGANISM", 49, 53], ["bovine", "ORGANISM", 84, 90], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["bovine", "SPECIES", 28, 34], ["bovine", "SPECIES", 84, 90], ["bovine polyomavirus", "SPECIES", 28, 47], ["BPyV", "SPECIES", 49, 53], ["bovine", "SPECIES", 84, 90], ["bovine polyomavirus (BPyV)", "PROBLEM", 28, 54], ["bovine serum", "TEST", 84, 96], ["bovine polyomavirus", "OBSERVATION", 28, 47]]], ["Due to its high prevalence in cows BPyV is also a frequent environmental contaminant (Hundesa et al., 2006).", [["BPyV", "CHEMICAL", 35, 39], ["cows", "ORGANISM", 30, 34], ["cows", "SPECIES", 30, 34], ["BPyV", "SPECIES", 35, 39], ["a frequent environmental contaminant", "PROBLEM", 48, 84], ["high", "OBSERVATION_MODIFIER", 11, 15]]], ["A high sero-prevalence to BPyV has been reported in people with high exposure to cattle (Parry and Gardner, 1986) but no specific illness in either cows or humans has been attributed to BPyV.A novel bovine polyomavirus ::: ResultsIn one beef samples pool 31 sequence reads generating eight different contigs were found to have strong amino acid similarity to polyomaviruses.", [["samples", "ANATOMY", 242, 249], ["BPyV", "CHEMICAL", 26, 30], ["illness", "DISEASE", 130, 137], ["amino acid", "CHEMICAL", 334, 344], ["amino acid", "CHEMICAL", 334, 344], ["BPyV", "CANCER", 26, 30], ["people", "ORGANISM", 52, 58], ["cattle", "ORGANISM", 81, 87], ["cows", "ORGANISM", 148, 152], ["humans", "ORGANISM", 156, 162], ["bovine", "ORGANISM", 199, 205], ["polyomavirus", "ORGANISM", 206, 218], ["amino acid", "AMINO_ACID", 334, 344], ["polyomaviruses", "ORGANISM", 359, 373], ["people", "SPECIES", 52, 58], ["cattle", "SPECIES", 81, 87], ["cows", "SPECIES", 148, 152], ["humans", "SPECIES", 156, 162], ["bovine", "SPECIES", 199, 205], ["cattle", "SPECIES", 81, 87], ["humans", "SPECIES", 156, 162], ["beef", "SPECIES", 237, 241], ["specific illness", "PROBLEM", 121, 137], ["BPyV", "PROBLEM", 186, 190], ["strong amino acid similarity to polyomaviruses", "PROBLEM", 327, 373], ["high", "OBSERVATION_MODIFIER", 2, 6], ["sero", "OBSERVATION", 7, 11], ["no", "UNCERTAINTY", 118, 120], ["bovine polyomavirus", "OBSERVATION", 199, 218], ["polyomaviruses", "OBSERVATION", 359, 373]]], ["PCR screening of the individual samples with a set of nested primers designed on the LT-Ag sequence indicated that a single beef sample was positive.", [["samples", "ANATOMY", 32, 39], ["sample", "ANATOMY", 129, 135], ["Ag", "CHEMICAL", 88, 90], ["LT-Ag", "GENE_OR_GENE_PRODUCT", 85, 90], ["LT-Ag sequence", "DNA", 85, 99], ["beef", "SPECIES", 124, 128], ["PCR screening", "TEST", 0, 13], ["the individual samples", "TEST", 17, 39], ["nested primers", "TEST", 54, 68], ["the LT-Ag sequence", "TEST", 81, 99], ["a single beef sample", "TEST", 115, 135]]], ["Using inverse PCR the complete genome was acquired and Sanger sequenced (GenBank KM111535).", [["inverse PCR", "TEST", 6, 17]]], ["The sequences of the primers used for PCR screening and inverse PCR are shown in \u201cMaterials and methods\u201d.A novel bovine polyomavirus ::: ResultsThe circular genome of the bovine polyomavirus (named BPyV2-SF) was 5085 bases encoding five major proteins including an early region with regulatory ST-Ag and LT-Ag and a late region coding for the VP1, VP2, and VP3 structural proteins (Fig. 1A), and a 214 aa alternative Large T ORF (ALTO) protein lying in the second exon of LT-Ag gene.", [["Ag", "CHEMICAL", 297, 299], ["Ag", "CHEMICAL", 307, 309], ["bovine", "ORGANISM", 113, 119], ["polyomavirus", "ORGANISM", 120, 132], ["bovine", "ORGANISM", 171, 177], ["polyomavirus", "ORGANISM", 178, 190], ["BPyV2-SF", "GENE_OR_GENE_PRODUCT", 198, 206], ["ST-Ag", "GENE_OR_GENE_PRODUCT", 294, 299], ["LT-Ag", "GENE_OR_GENE_PRODUCT", 304, 309], ["VP1", "GENE_OR_GENE_PRODUCT", 343, 346], ["VP2", "GENE_OR_GENE_PRODUCT", 348, 351], ["VP3 structural proteins", "GENE_OR_GENE_PRODUCT", 357, 380], ["Fig. 1A", "GENE_OR_GENE_PRODUCT", 382, 389], ["Large T ORF", "GENE_OR_GENE_PRODUCT", 417, 428], ["ALTO", "GENE_OR_GENE_PRODUCT", 430, 434], ["LT-Ag", "GENE_OR_GENE_PRODUCT", 472, 477], ["circular genome", "DNA", 148, 163], ["BPyV2", "PROTEIN", 198, 203], ["5085 bases", "DNA", 212, 222], ["ST", "PROTEIN", 294, 296], ["Ag", "PROTEIN", 297, 299], ["LT", "PROTEIN", 304, 306], ["Ag", "PROTEIN", 307, 309], ["VP1", "PROTEIN", 343, 346], ["VP2", "PROTEIN", 348, 351], ["VP3 structural proteins", "PROTEIN", 357, 380], ["Fig. 1A", "PROTEIN", 382, 389], ["214 aa alternative Large T ORF (ALTO) protein", "PROTEIN", 398, 443], ["LT-Ag gene", "DNA", 472, 482], ["bovine", "SPECIES", 113, 119], ["bovine", "SPECIES", 171, 177], ["the primers", "TEST", 17, 28], ["PCR screening", "TEST", 38, 51], ["inverse PCR", "TEST", 56, 67], ["the bovine polyomavirus", "TEST", 167, 190], ["the VP1", "TEST", 339, 346], ["VP2", "TEST", 348, 351], ["Large T ORF", "PROBLEM", 417, 428], ["bovine polyomavirus", "OBSERVATION", 113, 132], ["circular", "OBSERVATION_MODIFIER", 148, 156], ["genome", "OBSERVATION_MODIFIER", 157, 163], ["bovine polyomavirus", "OBSERVATION", 171, 190], ["LT", "ANATOMY", 304, 306], ["LT", "ANATOMY", 472, 474], ["Ag gene", "OBSERVATION", 475, 482]]], ["The early region and late region were separated by a regulatory region that contained typical polyomavirus features (Pipas, 1992) including an AT-rich region on the left side of the putative replication origin.", [["late region", "CELLULAR_COMPONENT", 21, 32], ["regulatory region", "DNA", 53, 70], ["AT-rich region", "DNA", 143, 157], ["putative replication origin", "DNA", 182, 209], ["typical polyomavirus features", "PROBLEM", 86, 115], ["early", "OBSERVATION_MODIFIER", 4, 9], ["region", "ANATOMY_MODIFIER", 10, 16], ["late", "OBSERVATION_MODIFIER", 21, 25], ["region", "ANATOMY_MODIFIER", 26, 32], ["typical", "OBSERVATION_MODIFIER", 86, 93], ["polyomavirus", "OBSERVATION", 94, 106], ["rich", "ANATOMY_MODIFIER", 146, 150], ["region", "ANATOMY_MODIFIER", 151, 157], ["left", "ANATOMY_MODIFIER", 165, 169], ["putative replication", "OBSERVATION", 182, 202], ["origin", "ANATOMY_MODIFIER", 203, 209]]], ["Four repeats of the consensus pentanucleotide LT-Ag binding site GAGGC were present.", [["pentanucleotide", "CHEMICAL", 30, 45], ["Ag", "CHEMICAL", 49, 51], ["Ag", "CHEMICAL", 49, 51], ["consensus pentanucleotide LT-Ag binding site GAGGC", "DNA", 20, 70], ["the consensus pentanucleotide LT", "TEST", 16, 48]]], ["In polyomaviruses VP3 is translated by a leaky ribosomal scanning starting at an internal methionine codon of the larger VP2 ORF.", [["ribosomal", "ANATOMY", 47, 56], ["methionine", "CHEMICAL", 90, 100], ["methionine", "CHEMICAL", 90, 100], ["polyomaviruses", "ORGANISM", 3, 17], ["VP3", "GENE_OR_GENE_PRODUCT", 18, 21], ["ribosomal", "CELLULAR_COMPONENT", 47, 56], ["polyomaviruses VP3", "PROTEIN", 3, 21], ["VP2 ORF", "DNA", 121, 128], ["polyomaviruses VP3", "PROBLEM", 3, 21], ["a leaky ribosomal scanning", "TEST", 39, 65], ["an internal methionine codon", "TREATMENT", 78, 106], ["the larger VP2 ORF", "PROBLEM", 110, 128], ["polyomaviruses VP3", "OBSERVATION", 3, 21], ["methionine codon", "OBSERVATION", 90, 106], ["larger", "OBSERVATION_MODIFIER", 114, 120], ["VP2 ORF", "OBSERVATION", 121, 128]]], ["The known polyomaviruses can be divided into \u201cVP3+\u201d species with a clear homolog of the VP3 N-terminal MALXX\u03a6 motif (\u03a6 is an aromatic residue) and \u201cVP3-less\u201d species lacking the motif (Schowalter and Buck, 2013).", [["polyomaviruses", "ORGANISM", 10, 24], ["VP3", "GENE_OR_GENE_PRODUCT", 46, 49], ["VP3", "PROTEIN", 46, 49], ["VP3 N-terminal MALXX\u03a6 motif", "PROTEIN", 88, 115], ["\u03a6", "PROTEIN", 117, 118], ["VP3", "PROTEIN", 148, 151], ["The known polyomaviruses", "PROBLEM", 0, 24], ["the VP3 N-terminal MALXX\u03a6 motif", "TREATMENT", 84, 115], ["an aromatic residue", "PROBLEM", 122, 141], ["VP3", "TEST", 148, 151], ["polyomaviruses", "OBSERVATION", 10, 24], ["aromatic residue", "OBSERVATION", 125, 141]]], ["Phylogenetic analysis based on complete genome of known polyomaviruses revealed that VP3-less species cluster together into a monophyletic clade to which BpyV2-SF also belongs (Fig. 1B).", [["polyomaviruses", "ORGANISM", 56, 70], ["VP3", "GENE_OR_GENE_PRODUCT", 85, 88], ["VP3", "DNA", 85, 88], ["BpyV2", "DNA", 154, 159], ["Phylogenetic analysis", "TEST", 0, 21], ["known polyomaviruses", "PROBLEM", 50, 70], ["VP3", "TEST", 85, 88], ["a monophyletic clade", "PROBLEM", 124, 144], ["BpyV2", "TEST", 154, 159], ["polyomaviruses", "OBSERVATION", 56, 70]]], ["Sequence analysis reveals that BpyV2-SF fits the characteristics of VP3-less polyomavirus species, such as having an ALTO protein within the LT-Ag frame, lacking the VP3 N-terminal MALXX\u03a6 motif, and missing ~80 aa near the carboxyl terminus of the VP2 compared with the longer VP3+ species (Schowalter and Buck, 2013).A novel bovine polyomavirus ::: ResultsTo determine the divergence in sequence between BPyV2-SF and other VP3-less polyomavirus species, amino acid sequence alignments of LT-Ag, VP1, and VP2 were performed, and neighbor-joining trees generated.", [["amino acid", "CHEMICAL", 455, 465], ["Ag", "CHEMICAL", 144, 146], ["N", "CHEMICAL", 170, 171], ["carboxyl", "CHEMICAL", 223, 231], ["amino acid", "CHEMICAL", 455, 465], ["BpyV2-SF", "GENE_OR_GENE_PRODUCT", 31, 39], ["VP3", "GENE_OR_GENE_PRODUCT", 68, 71], ["polyomavirus", "ORGANISM", 77, 89], ["ALTO", "GENE_OR_GENE_PRODUCT", 117, 121], ["VP2", "GENE_OR_GENE_PRODUCT", 248, 251], ["bovine", "ORGANISM", 326, 332], ["polyomavirus", "ORGANISM", 333, 345], ["BPyV2-SF", "GENE_OR_GENE_PRODUCT", 405, 413], ["VP3", "GENE_OR_GENE_PRODUCT", 424, 427], ["polyomavirus", "ORGANISM", 433, 445], ["amino acid", "AMINO_ACID", 455, 465], ["LT-Ag", "GENE_OR_GENE_PRODUCT", 489, 494], ["VP1", "GENE_OR_GENE_PRODUCT", 496, 499], ["VP2", "GENE_OR_GENE_PRODUCT", 505, 508], ["BpyV2", "PROTEIN", 31, 36], ["SF", "PROTEIN", 37, 39], ["VP3", "PROTEIN", 68, 71], ["ALTO protein", "PROTEIN", 117, 129], ["LT-Ag frame", "DNA", 141, 152], ["VP3 N-terminal MALXX\u03a6 motif", "PROTEIN", 166, 193], ["carboxyl terminus", "PROTEIN", 223, 240], ["VP2", "PROTEIN", 248, 251], ["VP3", "PROTEIN", 277, 280], ["BPyV2", "DNA", 405, 410], ["VP3", "PROTEIN", 424, 427], ["LT", "PROTEIN", 489, 491], ["Ag", "PROTEIN", 492, 494], ["VP1", "PROTEIN", 496, 499], ["VP2", "PROTEIN", 505, 508], ["bovine", "SPECIES", 326, 332], ["Sequence analysis", "TEST", 0, 17], ["BpyV2", "TEST", 31, 36], ["VP3-less polyomavirus species", "PROBLEM", 68, 97], ["an ALTO protein", "TEST", 114, 129], ["the VP2", "TEST", 244, 251], ["BPyV2", "TEST", 405, 410], ["other VP3-less polyomavirus species", "PROBLEM", 418, 453], ["amino acid sequence alignments", "TEST", 455, 485], ["LT", "TEST", 489, 491], ["Ag", "TEST", 492, 494], ["VP1", "TEST", 496, 499], ["VP2", "TEST", 505, 508], ["polyomavirus species", "OBSERVATION", 77, 97], ["LT", "ANATOMY", 141, 143], ["Ag frame", "OBSERVATION", 144, 152], ["carboxyl", "ANATOMY_MODIFIER", 223, 231], ["VP2", "ANATOMY", 248, 251], ["bovine polyomavirus", "OBSERVATION", 326, 345], ["polyomavirus species", "OBSERVATION", 433, 453], ["LT", "ANATOMY", 489, 491], ["VP2", "ANATOMY", 505, 508]]], ["The sequence alignments include BPyV2-SF, 10 representative VP3-less polyomavirus strains, and seven representative VP3+ strains.", [["BPyV2-SF", "GENE_OR_GENE_PRODUCT", 32, 40], ["VP3", "GENE_OR_GENE_PRODUCT", 60, 63], ["polyomavirus", "ORGANISM", 69, 81], ["VP3", "GENE_OR_GENE_PRODUCT", 116, 119], ["VP3", "PROTEIN", 60, 63], ["VP3", "PROTEIN", 116, 119], ["The sequence alignments", "TEST", 0, 23], ["BPyV2", "TEST", 32, 37], ["VP3", "TEST", 60, 63], ["polyomavirus strains", "PROBLEM", 69, 89], ["polyomavirus strains", "OBSERVATION", 69, 89]]], ["Phylogenetic analysis indicated that BpyV2-SF is highly divergent from these other polyomaviruses and that it fell within the VP3-less polyomavirus monophyletic clade together with polyomaviruses from gorilla, chimpanzee, humans, eidolon (megabat), and raccoon (Fig. 1B).Table 2 presents the amino acid distance between BPyV2-SF and the closest relative in LT-Ag, ST-Ag, VP1 and VP2.", [["amino acid", "CHEMICAL", 292, 302], ["amino acid", "CHEMICAL", 292, 302], ["Ag", "CHEMICAL", 360, 362], ["Ag", "CHEMICAL", 367, 369], ["BpyV2-SF", "GENE_OR_GENE_PRODUCT", 37, 45], ["polyomaviruses", "ORGANISM", 83, 97], ["VP3", "GENE_OR_GENE_PRODUCT", 126, 129], ["polyomavirus", "ORGANISM", 135, 147], ["polyomaviruses", "ORGANISM", 181, 195], ["gorilla", "ORGANISM", 201, 208], ["chimpanzee", "ORGANISM", 210, 220], ["humans", "ORGANISM", 222, 228], ["eidolon", "ORGANISM", 230, 237], ["Fig. 1B", "ORGANISM", 262, 269], ["amino acid", "AMINO_ACID", 292, 302], ["BPyV2-SF", "GENE_OR_GENE_PRODUCT", 320, 328], ["LT-Ag", "GENE_OR_GENE_PRODUCT", 357, 362], ["ST-Ag", "GENE_OR_GENE_PRODUCT", 364, 369], ["VP1", "GENE_OR_GENE_PRODUCT", 371, 374], ["VP2", "GENE_OR_GENE_PRODUCT", 379, 382], ["BpyV2", "DNA", 37, 42], ["SF", "PROTEIN", 43, 45], ["VP3", "PROTEIN", 126, 129], ["BPyV2", "PROTEIN", 320, 325], ["SF", "PROTEIN", 326, 328], ["LT", "PROTEIN", 357, 359], ["Ag", "PROTEIN", 360, 362], ["ST", "PROTEIN", 364, 366], ["Ag", "PROTEIN", 367, 369], ["VP1", "PROTEIN", 371, 374], ["VP2", "PROTEIN", 379, 382], ["gorilla", "SPECIES", 201, 208], ["chimpanzee", "SPECIES", 210, 220], ["humans", "SPECIES", 222, 228], ["humans", "SPECIES", 222, 228], ["Phylogenetic analysis", "TEST", 0, 21], ["BpyV2", "TEST", 37, 42], ["these other polyomaviruses", "PROBLEM", 71, 97], ["the VP3", "TEST", 122, 129], ["polyomaviruses", "PROBLEM", 181, 195], ["eidolon (megabat)", "TREATMENT", 230, 247], ["VP1", "TEST", 371, 374], ["VP2", "TEST", 379, 382], ["polyomaviruses", "OBSERVATION", 83, 97], ["LT", "ANATOMY", 357, 359], ["VP2", "ANATOMY", 379, 382]]], ["The high divergence of protein sequences confirms that BPyV2-SF is a novel polyomavirus species.Circovirus-like sequence in the beef ::: ResultsIn a beef pools two sequence reads showed high sequence identity with a previously reported circovirus-like virus PorkNW2 sequence (GenBank accession HQ738638), previously found in both pork and beef samples from San Francisco stores using Circoviridae consensus primers (Li et al., 2011).", [["samples", "ANATOMY", 344, 351], ["BPyV2-SF", "GENE_OR_GENE_PRODUCT", 55, 63], ["polyomavirus", "ORGANISM", 75, 87], ["circovirus-like virus", "ORGANISM", 236, 257], ["pork", "ORGANISM_SUBDIVISION", 330, 334], ["V2", "PROTEIN", 58, 60], ["SF", "PROTEIN", 61, 63], ["Circovirus-like sequence", "DNA", 96, 120], ["circovirus-like virus PorkNW2 sequence", "DNA", 236, 274], ["beef", "SPECIES", 339, 343], ["beef", "SPECIES", 128, 132], ["GenBank accession HQ738638", "SPECIES", 276, 302], ["pork", "SPECIES", 330, 334], ["beef", "SPECIES", 339, 343], ["protein sequences", "TEST", 23, 40], ["BPyV2", "TEST", 55, 60], ["a novel polyomavirus species", "PROBLEM", 67, 95], ["Circovirus", "PROBLEM", 96, 106], ["high sequence identity", "PROBLEM", 186, 208], ["a previously reported circovirus-like virus PorkNW2 sequence", "PROBLEM", 214, 274], ["Circoviridae consensus primers", "TREATMENT", 384, 414], ["polyomavirus species", "OBSERVATION", 75, 95], ["circovirus", "OBSERVATION", 236, 246]]], ["PCR screening with a set of nested primers designed on the sequence detected in this study confirmed that two out of the 10 beef samples were positive.", [["samples", "ANATOMY", 129, 136], ["beef", "SPECIES", 124, 128], ["PCR screening", "TEST", 0, 13], ["nested primers", "TEST", 28, 42], ["the sequence", "TEST", 55, 67], ["this study", "TEST", 80, 90], ["the 10 beef samples", "TEST", 117, 136]]], ["In order to clarify whether this sequence was from a circular DNA molecular, inverse PCR was performed and the amplicon sequenced showing that this circular DNA was 859 bases (named mini PCV-like virus strain MPCLV-SFBeef), shorter than the 1202 bases sequence of the original PorkNW2 genome (Fig. 2).", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["mini", "ORGANISM", 182, 186], ["PCV-like virus", "ORGANISM", 187, 201], ["MPCLV-SFBeef", "GENE_OR_GENE_PRODUCT", 209, 221], ["circular DNA", "DNA", 148, 160], ["1202 bases sequence", "DNA", 241, 260], ["PorkNW2 genome", "DNA", 277, 291], ["a circular DNA molecular, inverse PCR", "TEST", 51, 88], ["the amplicon", "TEST", 107, 119], ["this circular DNA", "TEST", 143, 160], ["mini PCV", "TEST", 182, 190]]], ["Although BLASTx search revealed a partial putative Rep protein (153 aa) with 97% amino acid sequence similarity to SFPorkNW2 [30], no suitably located ATG initiator codon was identified.", [["amino acid", "CHEMICAL", 81, 91], ["amino acid", "CHEMICAL", 81, 91], ["Rep", "GENE_OR_GENE_PRODUCT", 51, 54], ["amino acid", "AMINO_ACID", 81, 91], ["ATG", "GENE_OR_GENE_PRODUCT", 151, 154], ["Rep protein", "PROTEIN", 51, 62], ["153 aa", "PROTEIN", 64, 70], ["ATG initiator codon", "DNA", 151, 170], ["BLASTx search", "TEST", 9, 22], ["a partial putative Rep protein", "TEST", 32, 62], ["aa", "TEST", 68, 70], ["amino acid sequence", "TEST", 81, 100], ["SFPorkNW2", "TEST", 115, 124], ["suitably located ATG initiator codon", "PROBLEM", 134, 170], ["initiator codon", "OBSERVATION", 155, 170]]], ["Protein analysis indicated that the Rep protein of SFBeef is 68Aa shorter than that of SFPorkNW2, missing the RNA helicase domain.", [["Rep", "GENE_OR_GENE_PRODUCT", 36, 39], ["SFBeef", "GENE_OR_GENE_PRODUCT", 51, 57], ["SFPorkNW2", "GENE_OR_GENE_PRODUCT", 87, 96], ["Rep protein", "PROTEIN", 36, 47], ["SFBeef", "PROTEIN", 51, 57], ["68Aa", "PROTEIN", 61, 65], ["SFPorkNW2", "PROTEIN", 87, 96], ["RNA helicase domain", "PROTEIN", 110, 129], ["Protein analysis", "TEST", 0, 16], ["the Rep protein", "TEST", 32, 47], ["SFBeef", "TEST", 51, 57], ["SFPorkNW2", "TEST", 87, 96], ["missing the RNA helicase domain", "PROBLEM", 98, 129]]], ["Nucleotide sequence analysis showed that both genomes contain a identical stem-loop lying upstream of Rep open reading frame with the conserved origin of replication NANTATTAC nonamer atop the stem-loop found in members of the Circoviridae, Nanoviridae and Geminiviridae families.", [["stem-loop", "ANATOMY", 193, 202], ["Rep", "GENE_OR_GENE_PRODUCT", 102, 105], ["Circoviridae", "GENE_OR_GENE_PRODUCT", 227, 239], ["Nanoviridae", "GENE_OR_GENE_PRODUCT", 241, 252], ["Geminiviridae", "GENE_OR_GENE_PRODUCT", 257, 270], ["Rep open reading frame", "DNA", 102, 124], ["replication NANTATTAC nonamer", "DNA", 154, 183], ["Circoviridae, Nanoviridae and Geminiviridae families", "PROTEIN", 227, 279], ["Nucleotide sequence analysis", "TEST", 0, 28], ["replication NANTATTAC nonamer", "TREATMENT", 154, 183], ["the Circoviridae", "TREATMENT", 223, 239], ["Nanoviridae", "TREATMENT", 241, 252], ["stem", "OBSERVATION_MODIFIER", 74, 78], ["origin", "OBSERVATION_MODIFIER", 144, 150], ["stem", "OBSERVATION_MODIFIER", 193, 197]]], ["Another ORF potentially encoding 243 aa protein arranged in the same coding direction as Rep protein was also found yielding an ORF map similar to that of NW2 (Fig. 2A and B).", [["Rep", "GENE_OR_GENE_PRODUCT", 89, 92], ["NW2", "GENE_OR_GENE_PRODUCT", 155, 158], ["B", "GENE_OR_GENE_PRODUCT", 172, 173], ["ORF", "DNA", 8, 11], ["243 aa protein", "PROTEIN", 33, 47], ["Rep protein", "PROTEIN", 89, 100], ["ORF map", "DNA", 128, 135], ["NW2", "DNA", 155, 158], ["B", "PROTEIN", 172, 173], ["Another ORF", "PROBLEM", 0, 11], ["aa protein", "TEST", 37, 47], ["Rep protein", "TEST", 89, 100], ["an ORF map", "TEST", 125, 135]]], ["BLASTp search indicated part of the putative protein (60 aa) shared 47% amino acid sequence identity with the M169 protein of unknown function of Murid herpesvirus (GenBank no. HE610454).Viruses in pork ::: ResultsWe identified sequences from pork-derived viral particles that were identical to porcine parvovirus 4 (PPV4 in the ungulate copiparvovirus 2 species).", [["amino acid", "CHEMICAL", 72, 82], ["HE610454", "CHEMICAL", 177, 185], ["amino acid", "CHEMICAL", 72, 82], ["HE610454", "CHEMICAL", 177, 185], ["amino acid", "AMINO_ACID", 72, 82], ["Murid herpesvirus", "ORGANISM", 146, 163], ["pork", "ORGANISM_SUBDIVISION", 198, 202], ["pork", "ORGANISM_SUBDIVISION", 243, 247], ["porcine parvovirus 4", "ORGANISM", 295, 315], ["putative protein", "PROTEIN", 36, 52], ["60 aa", "PROTEIN", 54, 59], ["M169 protein", "PROTEIN", 110, 122], ["porcine parvovirus", "SPECIES", 295, 313], ["Murid herpesvirus", "SPECIES", 146, 163], ["pork", "SPECIES", 198, 202], ["porcine parvovirus 4", "SPECIES", 295, 315], ["PPV4", "SPECIES", 317, 321], ["BLASTp search", "TEST", 0, 13], ["the putative protein", "TEST", 32, 52], ["amino acid sequence identity", "TEST", 72, 100], ["the M169 protein", "TEST", 106, 122], ["Murid herpesvirus", "PROBLEM", 146, 163], ["viral particles", "PROBLEM", 256, 271], ["porcine parvovirus", "PROBLEM", 295, 313], ["PPV4", "TREATMENT", 317, 321]]], ["PPV4 was initially identified in a lung lavage from a pig co-infected with pig circovirus 2 (Cheung et al., 2010).", [["lung lavage", "ANATOMY", 35, 46], ["PPV4", "CHEMICAL", 0, 4], ["PPV4", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung lavage", "ORGANISM_SUBSTANCE", 35, 46], ["pig", "ORGANISM", 54, 57], ["pig circovirus 2", "ORGANISM", 75, 91], ["PPV4", "PROTEIN", 0, 4], ["pig", "SPECIES", 54, 57], ["pig circovirus", "SPECIES", 75, 89], ["pig", "SPECIES", 54, 57], ["pig circovirus", "SPECIES", 75, 89], ["PPV4", "TREATMENT", 0, 4], ["a lung lavage", "TREATMENT", 33, 46], ["a pig co-infected", "TREATMENT", 52, 69], ["pig circovirus", "TREATMENT", 75, 89], ["lung", "ANATOMY", 35, 39], ["lavage", "OBSERVATION", 40, 46], ["pig circovirus", "OBSERVATION", 75, 89]]], ["We also detected ungulate tetraparvovirus 2 (aka porcine hokovirus, the same virus detected in beef samples) initially reported to infect pigs in Honk Kong at high frequency (Lau et al., 2008).", [["samples", "ANATOMY", 100, 107], ["ungulate tetraparvovirus 2", "ORGANISM", 17, 43], ["aka porcine hokovirus", "ORGANISM", 45, 66], ["pigs", "ORGANISM", 138, 142], ["porcine hokovirus", "SPECIES", 49, 66], ["beef", "SPECIES", 95, 99], ["pigs", "SPECIES", 138, 142], ["beef", "SPECIES", 95, 99], ["pigs", "SPECIES", 138, 142], ["ungulate tetraparvovirus", "PROBLEM", 17, 41], ["aka porcine hokovirus", "TREATMENT", 45, 66], ["the same virus", "PROBLEM", 68, 82], ["ungulate tetraparvovirus", "OBSERVATION", 17, 41]]], ["Sequences from a third parvovirus species in a third genus (ungulate protoparvovirus 1) were also detected.", [["parvovirus", "ORGANISM", 23, 33], ["Sequences", "TEST", 0, 9], ["a third parvovirus species", "TEST", 15, 41]]], ["Last, a fourth set of parvovirus-like sequences closest to a still unclassified copiparvoviruses labeled porcine parvovirus 6 (PPV6 deposited March 31, 2014 GenBank NC_023860) from pigs in China were also detected.", [["parvovirus", "ORGANISM", 22, 32], ["porcine parvovirus 6", "ORGANISM", 105, 125], ["pigs", "ORGANISM", 181, 185], ["parvovirus-like sequences", "DNA", 22, 47], ["porcine parvovirus", "SPECIES", 105, 123], ["pigs", "SPECIES", 181, 185], ["pigs", "SPECIES", 181, 185], ["parvovirus-like sequences", "PROBLEM", 22, 47], ["porcine parvovirus", "PROBLEM", 105, 123], ["parvovirus", "OBSERVATION", 22, 32]]], ["Because PPV6 NS1 shows closest identity to PPV4 but with only 58% identity it likely represents a new copriparvovirus species (proposed name ungulate copiparvovirus 3) (Cotmore et al., 2014).", [["PPV6", "GENE_OR_GENE_PRODUCT", 8, 12], ["PPV4", "GENE_OR_GENE_PRODUCT", 43, 47], ["PPV6 NS1", "PROTEIN", 8, 16], ["PPV4", "DNA", 43, 47], ["PPV6 NS1", "TEST", 8, 16], ["PPV4", "TEST", 43, 47], ["a new copriparvovirus species", "PROBLEM", 96, 125], ["likely represents", "UNCERTAINTY", 78, 95], ["new", "OBSERVATION_MODIFIER", 98, 101]]], ["Four parvovirus species in three distinct Parvoviridae genera were therefore detected in these few pork samples.Viruses in pork ::: ResultsAlso detected in both pork and beef samples were anelloviruses which have been reported in the blood of numerous mammals including cows and pigs (Brassard et al., 2008).", [["samples", "ANATOMY", 104, 111], ["pork", "ANATOMY", 161, 165], ["beef samples", "ANATOMY", 170, 182], ["blood", "ANATOMY", 234, 239], ["parvovirus", "ORGANISM", 5, 15], ["pork", "ORGANISM_SUBDIVISION", 123, 127], ["pork", "ORGANISM_SUBDIVISION", 161, 165], ["beef samples", "ORGANISM_SUBSTANCE", 170, 182], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["cows", "ORGANISM", 270, 274], ["pigs", "ORGANISM", 279, 283], ["beef", "SPECIES", 170, 174], ["cows", "SPECIES", 270, 274], ["pigs", "SPECIES", 279, 283], ["pork", "SPECIES", 99, 103], ["pork", "SPECIES", 123, 127], ["pork", "SPECIES", 161, 165], ["beef", "SPECIES", 170, 174], ["pigs", "SPECIES", 279, 283], ["Four parvovirus species", "PROBLEM", 0, 23], ["three distinct Parvoviridae genera", "TREATMENT", 27, 61], ["parvovirus species", "OBSERVATION", 5, 23], ["three distinct", "OBSERVATION_MODIFIER", 27, 41]]], ["Pig circovirus 2 (PCV2) a frequent infection of pigs occurring world-wide was present.Gyroviruses in chicken ::: ResultsGyroviruses are small nonenveloped DNA viruses with a negative sense single-stranded circular DNA of about 2.3 kb.", [["infection", "DISEASE", 35, 44], ["Pig circovirus 2", "ORGANISM", 0, 16], ["PCV2", "ORGANISM", 18, 22], ["pigs", "ORGANISM", 48, 52], ["chicken", "ORGANISM", 101, 108], ["ResultsGyroviruses", "GENE_OR_GENE_PRODUCT", 113, 131], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["negative sense single-stranded circular DNA", "DNA", 174, 217], ["Pig circovirus", "SPECIES", 0, 14], ["pigs", "SPECIES", 48, 52], ["chicken", "SPECIES", 101, 108], ["Pig circovirus 2", "SPECIES", 0, 16], ["PCV2", "SPECIES", 18, 22], ["pigs", "SPECIES", 48, 52], ["chicken", "SPECIES", 101, 108], ["Pig circovirus", "TREATMENT", 0, 14], ["PCV2", "PROBLEM", 18, 22], ["a frequent infection of pigs", "PROBLEM", 24, 52], ["small nonenveloped DNA viruses", "PROBLEM", 136, 166], ["circovirus", "OBSERVATION", 4, 14], ["frequent", "OBSERVATION_MODIFIER", 26, 34], ["infection", "OBSERVATION", 35, 44], ["wide", "OBSERVATION_MODIFIER", 69, 73], ["small", "OBSERVATION_MODIFIER", 136, 141], ["nonenveloped", "OBSERVATION_MODIFIER", 142, 154], ["DNA viruses", "OBSERVATION", 155, 166]]], ["The genus Gyrovirus is currently in the Circoviridae family but closer (although still distinct) in genetic organization to members of the Anelloviridae (Hino and Prasetyo, 2009).", [["genus Gyrovirus", "OBSERVATION", 4, 19]]], ["Here sequences from six different gyroviruses were detected in the chicken meat samples: chicken anemia virus (CAV), human gyrovirus 1 (HGyV1) and the very closely related gyrovirus 2 (GyV2), GyV3, GyV4 and a novel gyrovirus here named GyV7.", [["meat samples", "ANATOMY", 75, 87], ["chicken anemia", "DISEASE", 89, 103], ["gyroviruses", "GENE_OR_GENE_PRODUCT", 34, 45], ["chicken", "ORGANISM", 67, 74], ["meat samples", "ORGANISM_SUBSTANCE", 75, 87], ["chicken anemia virus", "ORGANISM", 89, 109], ["CAV", "ORGANISM", 111, 114], ["human gyrovirus 1", "ORGANISM", 117, 134], ["HGyV1", "GENE_OR_GENE_PRODUCT", 136, 141], ["very closely related gyrovirus 2", "GENE_OR_GENE_PRODUCT", 151, 183], ["GyV2", "GENE_OR_GENE_PRODUCT", 185, 189], ["GyV3", "GENE_OR_GENE_PRODUCT", 192, 196], ["GyV4", "GENE_OR_GENE_PRODUCT", 198, 202], ["gyrovirus", "CANCER", 215, 224], ["GyV7", "GENE_OR_GENE_PRODUCT", 236, 240], ["gyrovirus 2", "DNA", 172, 183], ["GyV2", "DNA", 185, 189], ["GyV3", "DNA", 192, 196], ["GyV4", "DNA", 198, 202], ["gyrovirus", "DNA", 215, 224], ["GyV7", "DNA", 236, 240], ["chicken", "SPECIES", 67, 74], ["chicken anemia virus", "SPECIES", 89, 109], ["human", "SPECIES", 117, 122], ["chicken", "SPECIES", 67, 74], ["chicken anemia virus", "SPECIES", 89, 109], ["CAV", "SPECIES", 111, 114], ["human gyrovirus 1", "SPECIES", 117, 134], ["HGyV1", "SPECIES", 136, 141], ["six different gyroviruses", "TEST", 20, 45], ["chicken anemia virus", "PROBLEM", 89, 109], ["human gyrovirus", "PROBLEM", 117, 132], ["anemia virus", "OBSERVATION", 97, 109]]], ["BLASTx search indicated that the known gyroviruses found here shared high protein sequence identities (>92%) with their best matches in the GenBank, while the novel gyrovirus (GyV7-SF) showed only 57% protein sequence similarity to its closest matches (Table 1).", [["gyroviruses", "GENE_OR_GENE_PRODUCT", 39, 50], ["gyrovirus", "GENE_OR_GENE_PRODUCT", 165, 174], ["GyV7-SF", "GENE_OR_GENE_PRODUCT", 176, 183], ["gyroviruses", "DNA", 39, 50], ["gyrovirus", "PROTEIN", 165, 174], ["GyV7", "PROTEIN", 176, 180], ["SF", "PROTEIN", 181, 183], ["BLASTx search", "TEST", 0, 13], ["the known gyroviruses", "PROBLEM", 29, 50], ["high protein sequence identities", "PROBLEM", 69, 101], ["the novel gyrovirus", "TEST", 155, 174], ["57% protein sequence similarity", "PROBLEM", 197, 228], ["GenBank", "ANATOMY", 140, 147]]], ["PCR screening with a set of nested primers designed on the novel sequences indicated that only one chicken sample was positive for GyV7-SF.", [["sample", "ANATOMY", 107, 113], ["chicken", "ORGANISM", 99, 106], ["GyV7", "GENE_OR_GENE_PRODUCT", 131, 135], ["GyV7", "PROTEIN", 131, 135], ["chicken", "SPECIES", 99, 106], ["chicken", "SPECIES", 99, 106], ["PCR screening", "TEST", 0, 13], ["nested primers", "TEST", 28, 42], ["the novel sequences", "TEST", 55, 74], ["one chicken sample", "TEST", 95, 113], ["GyV7", "TEST", 131, 135]]], ["The complete circular genome of GyV7-SF1 was acquired using inverse PCR and Sanger sequencing (GenBank KM111536).", [["GyV7-SF1", "GENE_OR_GENE_PRODUCT", 32, 40], ["circular genome", "DNA", 13, 28], ["GyV7", "DNA", 32, 36], ["SF1", "DNA", 37, 40], ["inverse PCR", "TEST", 60, 71], ["Sanger sequencing", "TEST", 76, 93], ["circular", "OBSERVATION_MODIFIER", 13, 21], ["SF1", "ANATOMY", 37, 40]]], ["The GyV7-SF genome is 2439 bases, with a 514 base non-translated region (NTR) and a polyadenylation signal [AATAAA].", [["GyV7-SF", "GENE_OR_GENE_PRODUCT", 4, 11], ["GyV7-SF genome", "DNA", 4, 18], ["514 base non-translated region", "DNA", 41, 71], ["NTR", "DNA", 73, 76], ["a polyadenylation signal", "PROBLEM", 82, 106], ["SF genome", "OBSERVATION", 9, 18], ["bases", "ANATOMY_MODIFIER", 27, 32], ["polyadenylation signal", "OBSERVATION", 84, 106]]], ["ORF prediction revealed three overlapping ORFs for VP1 (465-aa), VP2 (238-aa) and VP3/Apoptin (130-aa).", [["VP3", "GENE_OR_GENE_PRODUCT", 82, 85], ["Apoptin", "GENE_OR_GENE_PRODUCT", 86, 93], ["ORF", "DNA", 0, 3], ["ORFs", "DNA", 42, 46], ["VP1", "DNA", 51, 54], ["VP3", "PROTEIN", 82, 85], ["ORF prediction", "TEST", 0, 14], ["VP1", "TEST", 51, 54], ["aa", "TEST", 60, 62], ["VP2", "TEST", 65, 68], ["aa", "TEST", 74, 76], ["VP3", "TEST", 82, 85], ["Apoptin", "TEST", 86, 93]]], ["The genome organization of GyV7-SF was similar to that of the other gyroviruses (Fig. 3A).", [["GyV7-SF", "GENE_OR_GENE_PRODUCT", 27, 34], ["GyV7", "DNA", 27, 31], ["SF", "PROTEIN", 32, 34], ["GyV7", "TEST", 27, 31]]], ["BLASTp search based on VP1, VP2, and VP3 all revealed the best match with GyV6 (NC_022789), with protein sequence identities of 49%, 53%, and 63%, respectively.", [["VP1", "GENE_OR_GENE_PRODUCT", 23, 26], ["VP2", "GENE_OR_GENE_PRODUCT", 28, 31], ["VP3", "GENE_OR_GENE_PRODUCT", 37, 40], ["GyV6", "GENE_OR_GENE_PRODUCT", 74, 78], ["VP1", "DNA", 23, 26], ["VP2", "DNA", 28, 31], ["VP3", "DNA", 37, 40], ["GyV6", "PROTEIN", 74, 78], ["NC_022789", "PROTEIN", 80, 89], ["BLASTp search", "TEST", 0, 13], ["VP1", "TEST", 23, 26], ["VP2", "TEST", 28, 31], ["VP3", "TEST", 37, 40], ["protein sequence identities", "TEST", 97, 124]]], ["Phylogenetic based the three major protein sequence all indicated that GyV7-SF clustered loosely with GyV6 (Fig. 3B\u2013D), which was detected in diarrhea samples from Tunisian children (Gia Phan et al., 2013).DiscussionOur results indicate that diverse parvoviruses are readily found in meat samples from hoofed farm animals.", [["samples", "ANATOMY", 151, 158], ["meat samples", "ANATOMY", 284, 296], ["diarrhea", "DISEASE", 142, 150], ["GyV7-SF", "GENE_OR_GENE_PRODUCT", 71, 78], ["GyV6", "GENE_OR_GENE_PRODUCT", 102, 106], ["children", "ORGANISM", 173, 181], ["parvoviruses", "ORGANISM", 250, 262], ["meat samples", "ORGANISM_SUBSTANCE", 284, 296], ["GyV7", "PROTEIN", 71, 75], ["SF", "PROTEIN", 76, 78], ["GyV6", "PROTEIN", 102, 106], ["Fig. 3B\u2013D", "PROTEIN", 108, 117], ["children", "SPECIES", 173, 181], ["GyV7", "TEST", 71, 75], ["GyV6 (Fig. 3B\u2013D", "TREATMENT", 102, 117], ["diarrhea", "PROBLEM", 142, 150], ["diverse parvoviruses", "PROBLEM", 242, 262], ["diverse", "OBSERVATION_MODIFIER", 242, 249], ["parvoviruses", "OBSERVATION", 250, 262]]], ["Parvoviruses are frequently detected in domesticated and wild animal as well as human feces (Bodewes et al., 2013, Canuti et al., 2011, Handley et al., 2012, Phan et al., 2012, Shan et al., 2011, Sharp et al., 2010, V\u00e4is\u00e4nen et al., 2014).", [["human", "ORGANISM", 80, 85], ["feces", "ORGANISM_SUBDIVISION", 86, 91], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["Parvoviruses", "PROBLEM", 0, 12]]], ["Some parvovirus can be highly pathogenic, notoriously canine parvovirus which recently adapted from cats to dogs possibly through intermediate species (Stucker et al., 2012) and is thought to be readily transmitted across carnivore species (Allison et al., 2013).", [["parvovirus", "DISEASE", 5, 15], ["canine parvovirus", "DISEASE", 54, 71], ["parvovirus", "ORGANISM", 5, 15], ["canine parvovirus", "ORGANISM", 54, 71], ["cats", "ORGANISM", 100, 104], ["dogs", "ORGANISM", 108, 112], ["canine parvovirus", "SPECIES", 54, 71], ["cats", "SPECIES", 100, 104], ["dogs", "SPECIES", 108, 112], ["canine parvovirus", "SPECIES", 54, 71], ["Some parvovirus", "PROBLEM", 0, 15], ["notoriously canine parvovirus", "PROBLEM", 42, 71], ["parvovirus", "OBSERVATION", 5, 15], ["parvovirus", "OBSERVATION", 61, 71], ["thought to be", "UNCERTAINTY", 181, 194], ["carnivore species", "OBSERVATION", 222, 239]]], ["Parvoviruses can also be detected in blood as exemplified by PARV4 (primate tetraparvovirus 1) and parvovirus B19 (primate erythroparvovirus 1) which is typically a benign infection but which can cause serious anemia or fetal hydrops in susceptible individuals or when infecting fetus (Feldman et al., 2010, Morinet et al., 2011).", [["blood", "ANATOMY", 37, 42], ["fetal", "ANATOMY", 220, 225], ["fetus", "ANATOMY", 279, 284], ["parvovirus B19", "DISEASE", 99, 113], ["infection", "DISEASE", 172, 181], ["anemia", "DISEASE", 210, 216], ["fetal hydrops", "DISEASE", 220, 233], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["PARV4 (", "ORGANISM", 61, 68], ["primate tetraparvovirus 1", "ORGANISM", 68, 93], ["parvovirus B19", "ORGANISM", 99, 113], ["primate erythroparvovirus 1", "ORGANISM", 115, 142], ["fetal hydrops", "PATHOLOGICAL_FORMATION", 220, 233], ["fetus", "ORGANISM", 279, 284], ["primate tetraparvovirus", "SPECIES", 68, 91], ["parvovirus B19", "SPECIES", 99, 113], ["primate erythroparvovirus", "SPECIES", 115, 140], ["primate tetraparvovirus 1", "SPECIES", 68, 93], ["parvovirus B19 (primate erythroparvovirus 1", "SPECIES", 99, 142], ["Parvoviruses", "PROBLEM", 0, 12], ["blood", "TEST", 37, 42], ["PARV4 (primate tetraparvovirus", "TREATMENT", 61, 91], ["parvovirus B19 (primate erythroparvovirus", "TREATMENT", 99, 140], ["a benign infection", "PROBLEM", 163, 181], ["serious anemia", "PROBLEM", 202, 216], ["fetal hydrops in susceptible individuals", "PROBLEM", 220, 260], ["benign", "OBSERVATION_MODIFIER", 165, 171], ["infection", "OBSERVATION", 172, 181], ["fetal", "ANATOMY", 220, 225], ["hydrops", "OBSERVATION", 226, 233]]], ["Parvovirus B19 can also be deposited in muscles and other tissues where it can be PCR amplified even decades after primary infection (Norja et al., 2006).", [["muscles", "ANATOMY", 40, 47], ["tissues", "ANATOMY", 58, 65], ["Parvovirus B19", "DISEASE", 0, 14], ["primary infection", "DISEASE", 115, 132], ["Parvovirus B19", "ORGANISM", 0, 14], ["muscles", "ORGAN", 40, 47], ["tissues", "TISSUE", 58, 65], ["Parvovirus B19", "SPECIES", 0, 14], ["Parvovirus B19", "SPECIES", 0, 14], ["Parvovirus B19", "PROBLEM", 0, 14], ["PCR", "TEST", 82, 85], ["primary infection", "PROBLEM", 115, 132], ["muscles", "ANATOMY", 40, 47]]], ["The detection of ungulate erythroparvovirus 1 virus in beef may therefore reflect either active replication or particle deposition into tissues.", [["tissues", "ANATOMY", 136, 143], ["ungulate", "ORGANISM", 17, 25], ["erythroparvovirus 1 virus", "ORGANISM", 26, 51], ["beef", "ORGANISM_SUBDIVISION", 55, 59], ["tissues", "TISSUE", 136, 143], ["erythroparvovirus 1 virus", "SPECIES", 26, 51], ["beef", "SPECIES", 55, 59], ["ungulate erythroparvovirus 1 virus", "SPECIES", 17, 51], ["beef", "SPECIES", 55, 59], ["The detection", "TEST", 0, 13], ["ungulate erythroparvovirus 1 virus", "PROBLEM", 17, 51], ["active replication", "PROBLEM", 89, 107], ["particle deposition into tissues", "PROBLEM", 111, 143], ["ungulate erythroparvovirus", "OBSERVATION", 17, 43], ["may therefore reflect", "UNCERTAINTY", 60, 81], ["active", "OBSERVATION_MODIFIER", 89, 95], ["replication", "OBSERVATION", 96, 107], ["particle deposition", "OBSERVATION", 111, 130]]], ["Porcine hokovirus (ungulate tetraparvovirus 2) was also found in beef indicating that the tropism of this viral species may include both pigs and cattle.DiscussionAs expected from its previously reported high frequency in pigs (Lau et al., 2008) porcine hokovirus was also found in the pork samples analyzed here.", [["pork samples", "ANATOMY", 286, 298], ["Porcine hokovirus", "ORGANISM", 0, 17], ["ungulate tetraparvovirus 2", "ORGANISM", 19, 45], ["beef", "ORGANISM_SUBDIVISION", 65, 69], ["pigs", "ORGANISM", 137, 141], ["pigs", "ORGANISM", 222, 226], ["porcine", "ORGANISM", 246, 253], ["hokovirus", "GENE_OR_GENE_PRODUCT", 254, 263], ["Porcine", "SPECIES", 0, 7], ["beef", "SPECIES", 65, 69], ["pigs", "SPECIES", 137, 141], ["cattle", "SPECIES", 146, 152], ["pigs", "SPECIES", 222, 226], ["porcine", "SPECIES", 246, 253], ["Porcine hokovirus", "SPECIES", 0, 17], ["beef", "SPECIES", 65, 69], ["pigs", "SPECIES", 137, 141], ["cattle", "SPECIES", 146, 152], ["pigs", "SPECIES", 222, 226], ["pork", "SPECIES", 286, 290], ["Porcine hokovirus (ungulate tetraparvovirus", "TREATMENT", 0, 43], ["this viral species", "PROBLEM", 101, 119], ["porcine hokovirus", "PROBLEM", 246, 263]]], ["The lower number of sequence reads in pork than in beef (Table 2) indicates that laboratory contamination from the pork to the beef samples was unlikely.", [["beef samples", "ANATOMY", 127, 139], ["pork", "ORGANISM_SUBDIVISION", 38, 42], ["beef", "ORGANISM_SUBDIVISION", 51, 55], ["pork", "ORGANISM_SUBDIVISION", 115, 119], ["beef", "SPECIES", 51, 55], ["beef", "SPECIES", 127, 131], ["pork", "SPECIES", 38, 42], ["beef", "SPECIES", 51, 55], ["pork", "SPECIES", 115, 119], ["beef", "SPECIES", 127, 131], ["laboratory contamination", "PROBLEM", 81, 105], ["the beef samples", "TEST", 123, 139]]], ["The possibility that the deep sequencing and PCR detection of parvoviruses in beef or pork were due to cross-contamination during slaughter, shipping, or on store shelves cannot be excluded and will require confirmation in independent studies.DiscussionInfection of polyomaviruses in mammals generally causes persistent asymptomatic infection.", [["infection", "DISEASE", 333, 342], ["parvoviruses", "ORGANISM", 62, 74], ["beef", "ORGANISM_SUBDIVISION", 78, 82], ["pork", "ORGANISM_SUBDIVISION", 86, 90], ["polyomaviruses", "ORGANISM", 266, 280], ["beef", "SPECIES", 78, 82], ["beef", "SPECIES", 78, 82], ["pork", "SPECIES", 86, 90], ["the deep sequencing", "TEST", 21, 40], ["PCR detection", "TEST", 45, 58], ["parvoviruses", "PROBLEM", 62, 74], ["cross-contamination", "PROBLEM", 103, 122], ["confirmation in independent studies", "TEST", 207, 242], ["polyomaviruses", "PROBLEM", 266, 280], ["persistent asymptomatic infection", "PROBLEM", 309, 342], ["deep", "ANATOMY_MODIFIER", 25, 29], ["polyomaviruses", "OBSERVATION", 266, 280], ["persistent", "OBSERVATION_MODIFIER", 309, 319], ["asymptomatic", "OBSERVATION_MODIFIER", 320, 332], ["infection", "OBSERVATION", 333, 342]]], ["Polyomaviruses have also been associated with a broad spectrum of diseases in humans and animals, such as progressive multifocal leukoencephalopathy in immunosuppressed patients (JCV) (Hou and Major, 2000), nephropathy (BKV)(White et al., 2013), Merkel cell cancer (MCV) (Feng et al., 2008, Houben et al., 2010), trichodysplasia spinulosa (TSPyV) (Van der Meijden et al., 2010) and retinal blindness/vasculitic myopathy (Mishra et al., 2014) in humans, fibroma in African elephant (AelPyV-1) (Stevens et al., 2013), brain tumors in raccoons (RacPyV) (Dela Cruz et al., 2013), and sarcoma in laboratory rodents (SV40) (Kirschstein and Gerber, 1962).", [["Merkel cell cancer", "ANATOMY", 246, 264], ["retinal", "ANATOMY", 382, 389], ["fibroma", "ANATOMY", 453, 460], ["brain tumors", "ANATOMY", 516, 528], ["sarcoma", "ANATOMY", 580, 587], ["multifocal leukoencephalopathy", "DISEASE", 118, 148], ["immunosuppressed", "DISEASE", 152, 168], ["nephropathy", "DISEASE", 207, 218], ["BKV", "DISEASE", 220, 223], ["Merkel cell cancer", "DISEASE", 246, 264], ["trichodysplasia spinulosa", "DISEASE", 313, 338], ["retinal blindness", "DISEASE", 382, 399], ["vasculitic myopathy", "DISEASE", 400, 419], ["fibroma", "DISEASE", 453, 460], ["brain tumors", "DISEASE", 516, 528], ["sarcoma", "DISEASE", 580, 587], ["humans", "ORGANISM", 78, 84], ["patients", "ORGANISM", 169, 177], ["JCV", "ORGANISM", 179, 182], ["BKV", "ORGANISM", 220, 223], ["Merkel cell cancer", "CANCER", 246, 264], ["trichodysplasia spinulosa", "ORGANISM", 313, 338], ["retinal", "MULTI-TISSUE_STRUCTURE", 382, 389], ["humans", "ORGANISM", 445, 451], ["fibroma", "CANCER", 453, 460], ["brain tumors", "CANCER", 516, 528], ["raccoons", "ORGANISM", 532, 540], ["sarcoma", "CANCER", 580, 587], ["SV40", "ORGANISM", 611, 615], ["humans", "SPECIES", 78, 84], ["patients", "SPECIES", 169, 177], ["trichodysplasia spinulosa", "SPECIES", 313, 338], ["humans", "SPECIES", 445, 451], ["humans", "SPECIES", 78, 84], ["JCV", "SPECIES", 179, 182], ["BKV", "SPECIES", 220, 223], ["humans", "SPECIES", 445, 451], ["African elephant (AelPyV-1", "SPECIES", 464, 490], ["Polyomaviruses", "PROBLEM", 0, 14], ["diseases in humans", "PROBLEM", 66, 84], ["progressive multifocal leukoencephalopathy", "PROBLEM", 106, 148], ["nephropathy (BKV)", "PROBLEM", 207, 224], ["Merkel cell cancer", "PROBLEM", 246, 264], ["trichodysplasia spinulosa (TSPyV)", "PROBLEM", 313, 346], ["retinal blindness", "PROBLEM", 382, 399], ["vasculitic myopathy", "PROBLEM", 400, 419], ["fibroma", "PROBLEM", 453, 460], ["brain tumors", "PROBLEM", 516, 528], ["sarcoma", "PROBLEM", 580, 587], ["broad", "OBSERVATION_MODIFIER", 48, 53], ["diseases", "OBSERVATION", 66, 74], ["progressive", "OBSERVATION_MODIFIER", 106, 117], ["multifocal", "OBSERVATION_MODIFIER", 118, 128], ["leukoencephalopathy", "OBSERVATION", 129, 148], ["immunosuppressed", "OBSERVATION_MODIFIER", 152, 168], ["nephropathy", "OBSERVATION", 207, 218], ["Merkel cell cancer", "OBSERVATION", 246, 264], ["retinal", "ANATOMY", 382, 389], ["blindness", "OBSERVATION", 390, 399], ["vasculitic myopathy", "OBSERVATION", 400, 419], ["fibroma", "OBSERVATION", 453, 460], ["brain", "ANATOMY", 516, 521], ["tumors", "OBSERVATION", 522, 528], ["sarcoma", "OBSERVATION", 580, 587]]], ["With the increasing utilization of deep sequencing numerous polyomaviruses have been identified in human and in non-human primates (Ehlers and Moens 2014, Scuda et al., 2013, White et al., 2013) and it is anticipated that a similar expansion will occur for other host species.", [["polyomaviruses", "ORGANISM", 60, 74], ["human", "ORGANISM", 99, 104], ["non-human primates", "ORGANISM", 112, 130], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["deep sequencing numerous polyomaviruses", "PROBLEM", 35, 74], ["a similar expansion", "PROBLEM", 222, 241], ["other host species", "PROBLEM", 257, 275], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["deep", "ANATOMY_MODIFIER", 35, 39], ["numerous", "OBSERVATION_MODIFIER", 51, 59], ["polyomaviruses", "OBSERVATION", 60, 74]]], ["BPyV2-SF proteins, while still highly distinct (57\u201347% protein identity), are the most closely related protein sequences (except VP1) to those of primate polyomaviruses infecting human, chimpanzees, and gorillas (Table 2).DiscussionPork samples also contained parvovirus sequences from three genera which had been previously described in other pig samples.", [["samples", "ANATOMY", 237, 244], ["samples", "ANATOMY", 348, 355], ["BPyV2-SF", "GENE_OR_GENE_PRODUCT", 0, 8], ["VP1", "GENE_OR_GENE_PRODUCT", 129, 132], ["primate", "ORGANISM", 146, 153], ["polyomaviruses", "ORGANISM", 154, 168], ["human", "ORGANISM", 179, 184], ["chimpanzees", "ORGANISM", 186, 197], ["gorillas", "ORGANISM", 203, 211], ["parvovirus", "ORGANISM", 260, 270], ["pig", "ORGANISM", 344, 347], ["BPyV2", "PROTEIN", 0, 5], ["SF proteins", "PROTEIN", 6, 17], ["protein sequences", "PROTEIN", 103, 120], ["VP1", "PROTEIN", 129, 132], ["human", "SPECIES", 179, 184], ["pig", "SPECIES", 344, 347], ["human", "SPECIES", 179, 184], ["pig", "SPECIES", 344, 347], ["BPyV2-SF proteins", "TEST", 0, 17], ["protein identity", "TEST", 55, 71], ["protein sequences", "TEST", 103, 120], ["VP1", "PROBLEM", 129, 132], ["DiscussionPork samples", "TEST", 222, 244], ["parvovirus sequences", "TEST", 260, 280]]], ["Surprisingly we did not detect any sequences belonging to the Bocaparvovirus genus frequently detected in pig fecal samples (Jiang et al., 2014, Shan et al., 2011) possibly due to a tropism generally limited to respiratory or gut tissues.DiscussionThe presence of porcine circovirus 2 in pork may be due to either inoculation with a live attenuated vaccine frequently administered to piglets or from a natural infection (Zhai et al., 2014).", [["fecal samples", "ANATOMY", 110, 123], ["respiratory", "ANATOMY", 211, 222], ["gut tissues", "ANATOMY", 226, 237], ["infection", "DISEASE", 410, 419], ["pig", "ORGANISM", 106, 109], ["fecal samples", "ORGANISM_SUBSTANCE", 110, 123], ["gut tissues", "TISSUE", 226, 237], ["porcine circovirus 2", "ORGANISM", 264, 284], ["pork", "ORGANISM_SUBDIVISION", 288, 292], ["piglets", "ORGANISM", 384, 391], ["pig", "SPECIES", 106, 109], ["porcine circovirus", "SPECIES", 264, 282], ["piglets", "SPECIES", 384, 391], ["pig", "SPECIES", 106, 109], ["porcine circovirus", "SPECIES", 264, 282], ["pork", "SPECIES", 288, 292], ["a tropism", "PROBLEM", 180, 189], ["respiratory or gut tissues", "PROBLEM", 211, 237], ["porcine circovirus", "PROBLEM", 264, 282], ["inoculation", "PROBLEM", 314, 325], ["a live attenuated vaccine", "TREATMENT", 331, 356], ["a natural infection", "PROBLEM", 400, 419], ["tropism", "OBSERVATION", 182, 189], ["gut tissues", "ANATOMY", 226, 237], ["may be due to", "UNCERTAINTY", 293, 306], ["infection", "OBSERVATION", 410, 419]]], ["A recent study did not detect human antibodies to PCV2 despite frequent consumption of infected pork therefore reducing concern about zoonosis to humans (Burbelo et al., 2013, Victoria et al., 2010).DiscussionThe 0.8 kb circular genome found in beef reassembled a 1.2 kb genome previously sequenced in both pork and beef from the US (Li et al., 2011).", [["PCV2", "DISEASE", 50, 54], ["zoonosis", "DISEASE", 134, 142], ["human", "ORGANISM", 30, 35], ["PCV2", "ORGANISM", 50, 54], ["pork", "ORGANISM_SUBDIVISION", 96, 100], ["humans", "ORGANISM", 146, 152], ["pork", "ORGANISM_SUBDIVISION", 307, 311], ["beef", "ORGANISM_SUBDIVISION", 316, 320], ["human antibodies", "PROTEIN", 30, 46], ["0.8 kb circular genome", "DNA", 213, 235], ["1.2 kb genome", "DNA", 264, 277], ["human", "SPECIES", 30, 35], ["humans", "SPECIES", 146, 152], ["beef", "SPECIES", 316, 320], ["human", "SPECIES", 30, 35], ["PCV2", "SPECIES", 50, 54], ["pork", "SPECIES", 96, 100], ["humans", "SPECIES", 146, 152], ["beef", "SPECIES", 245, 249], ["pork", "SPECIES", 307, 311], ["beef", "SPECIES", 316, 320], ["A recent study", "TEST", 0, 14], ["human antibodies", "PROBLEM", 30, 46], ["PCV2", "PROBLEM", 50, 54], ["infected pork", "TREATMENT", 87, 100], ["The 0.8 kb circular genome", "TREATMENT", 209, 235], ["a 1.2 kb genome", "PROBLEM", 262, 277]]], ["Short, PCV2-like, rearranged genomes (483\u2013896 bases) have also been reported in Chinese pigs (Wen et al., 2012, Wen et al., 2012, Zhai et al., 2014).", [["PCV2", "ORGANISM", 7, 11], ["pigs", "ORGANISM", 88, 92], ["rearranged genomes", "DNA", 18, 36], ["pigs", "SPECIES", 88, 92], ["Chinese pigs", "SPECIES", 80, 92], ["Short, PCV2", "PROBLEM", 0, 11], ["PCV2", "OBSERVATION", 7, 11]]], ["The generation of such truncated and rearranged genomes may be related to that seen when viruses are passaged at high multiplicity of infection leading to defective interfering viral particles retaining only essential Cis elements required for genome replication and requiring trans-complementation from a helper virus (Mankertz et al., 1997).", [["infection", "DISEASE", 134, 143], ["genome", "CELLULAR_COMPONENT", 244, 250], ["Cis elements", "DNA", 218, 230], ["such truncated", "PROBLEM", 18, 32], ["viruses", "PROBLEM", 89, 96], ["infection", "PROBLEM", 134, 143], ["defective interfering viral particles", "PROBLEM", 155, 192], ["genome replication", "TREATMENT", 244, 262], ["trans-complementation", "TREATMENT", 277, 298], ["infection", "OBSERVATION", 134, 143]]], ["A related phenomenon may be the generation of truncated ssDNA circular geminivirus and anellovirus genome when passaged in vitro (De Villiers et al., 2011).DiscussionChicken meat showed the presence of numerous gyroviruses including the highly prevalent CAV reported world-wide (Schat, 2009, Toro et al., 2006).", [["CAV", "DISEASE", 254, 257], ["ssDNA", "CELLULAR_COMPONENT", 56, 61], ["circular geminivirus", "GENE_OR_GENE_PRODUCT", 62, 82], ["gyroviruses", "CANCER", 211, 222], ["truncated ssDNA circular geminivirus and anellovirus genome", "DNA", 46, 105], ["A related phenomenon", "PROBLEM", 0, 20], ["truncated ssDNA circular geminivirus", "PROBLEM", 46, 82], ["anellovirus genome", "PROBLEM", 87, 105], ["numerous gyroviruses", "PROBLEM", 202, 222], ["may be", "UNCERTAINTY", 21, 27], ["ssDNA circular geminivirus", "OBSERVATION", 56, 82], ["numerous", "OBSERVATION_MODIFIER", 202, 210], ["gyroviruses", "OBSERVATION", 211, 222]]], ["The gyrovirus genus includes several species, namely avian gyrovirus 2 (AGV2) from chicken (Rijsewijk et al., 2011), the closely related HGyV1 from human skin (Sauvage et al., 2011), GyV3 and GyV4 from children feces and chicken meat (Chu et al., 2012, Phan et al., 2012), and GyV5 and GyV6 from children feces (Gia Phan et al., 2013), many of which were also detected in chicken and children feces from South Africa (Smuts, 2014).", [["skin", "ANATOMY", 154, 158], ["feces", "ANATOMY", 211, 216], ["meat", "ANATOMY", 229, 233], ["avian gyrovirus 2", "ORGANISM", 53, 70], ["AGV2", "ORGANISM", 72, 76], ["chicken", "ORGANISM", 83, 90], ["HGyV1", "GENE_OR_GENE_PRODUCT", 137, 142], ["human", "ORGANISM", 148, 153], ["skin", "ORGAN", 154, 158], ["GyV3", "GENE_OR_GENE_PRODUCT", 183, 187], ["GyV4", "GENE_OR_GENE_PRODUCT", 192, 196], ["children", "ORGANISM", 202, 210], ["feces", "ORGANISM_SUBDIVISION", 211, 216], ["chicken", "ORGANISM", 221, 228], ["meat", "ORGANISM_SUBDIVISION", 229, 233], ["GyV5", "GENE_OR_GENE_PRODUCT", 277, 281], ["GyV6", "GENE_OR_GENE_PRODUCT", 286, 290], ["children", "ORGANISM", 296, 304], ["feces", "ORGANISM_SUBDIVISION", 305, 310], ["chicken", "ORGANISM", 372, 379], ["children", "ORGANISM", 384, 392], ["feces", "ORGANISM_SUBDIVISION", 393, 398], ["avian gyrovirus", "SPECIES", 53, 68], ["chicken", "SPECIES", 83, 90], ["human", "SPECIES", 148, 153], ["children", "SPECIES", 202, 210], ["chicken", "SPECIES", 221, 228], ["children", "SPECIES", 296, 304], ["chicken", "SPECIES", 372, 379], ["children", "SPECIES", 384, 392], ["chicken", "SPECIES", 83, 90], ["human", "SPECIES", 148, 153], ["chicken", "SPECIES", 221, 228], ["chicken", "SPECIES", 372, 379], ["The gyrovirus genus", "PROBLEM", 0, 19], ["several species", "PROBLEM", 29, 44], ["gyrovirus genus", "OBSERVATION", 4, 19], ["several", "OBSERVATION_MODIFIER", 29, 36], ["species", "OBSERVATION_MODIFIER", 37, 44], ["skin", "ANATOMY", 154, 158]]], ["The characterization of a seventh species of gyrovirus (GyV7) in this limited sampling of chicken indicates that still more gyroviruses from chicken and other birds are likely to be identified.", [["gyrovirus", "GENE_OR_GENE_PRODUCT", 45, 54], ["GyV7", "GENE_OR_GENE_PRODUCT", 56, 60], ["chicken", "ORGANISM", 90, 97], ["gyroviruses", "CANCER", 124, 135], ["chicken", "ORGANISM", 141, 148], ["birds", "ORGANISM", 159, 164], ["chicken", "SPECIES", 90, 97], ["chicken", "SPECIES", 141, 148], ["chicken", "SPECIES", 90, 97], ["chicken", "SPECIES", 141, 148], ["a seventh species of gyrovirus (GyV7)", "PROBLEM", 24, 61], ["likely to be", "UNCERTAINTY", 169, 181]]], ["The current lack of report describing gyrovirus sero-conversion in human or replication in mammalian cells indicates that a possible explanation for the frequent detection of gyrovirus DNA in human feces (gyrovirus species GyV3\u2013GyV6) (Chu et al., 2012, Gia Phan et al., 2013, Phan et al., 2012, Phan et al., 2012) and recently cat feces (CAT-CAV) (X. Zhang et al., 2014) may reflect their dietary origin from eating chicken or other birds.DiscussionOnly DNA viral sequences were identified in this limited sampling of muscle tissues from presumably healthy animals while RNA viruses such as picornaviruses, caliciviruses, coronaviruses, and astroviruses tend to predominate in the feces of farm animals (Sachsenr\u00f6der et al., 2014, Shan et al., 2011, Zhang et al., 2014).", [["mammalian cells", "ANATOMY", 91, 106], ["muscle tissues", "ANATOMY", 518, 532], ["feces", "ANATOMY", 681, 686], ["gyrovirus", "GENE_OR_GENE_PRODUCT", 38, 47], ["human", "ORGANISM", 67, 72], ["mammalian cells", "CELL", 91, 106], ["gyrovirus", "ORGANISM", 175, 184], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["human", "ORGANISM", 192, 197], ["feces", "ORGANISM_SUBDIVISION", 198, 203], ["gyrovirus species GyV3\u2013GyV6", "ORGANISM", 205, 232], ["cat", "ORGANISM", 327, 330], ["feces", "ORGANISM_SUBDIVISION", 331, 336], ["CAT-CAV", "ORGANISM", 338, 345], ["chicken", "ORGANISM", 416, 423], ["DNA", "CELLULAR_COMPONENT", 454, 457], ["muscle tissues", "TISSUE", 518, 532], ["caliciviruses", "GENE_OR_GENE_PRODUCT", 607, 620], ["coronaviruses", "ORGANISM", 622, 635], ["astroviruses", "GENE_OR_GENE_PRODUCT", 641, 653], ["feces", "ORGANISM_SUBDIVISION", 681, 686], ["mammalian cells", "CELL_TYPE", 91, 106], ["gyrovirus DNA", "DNA", 175, 188], ["CAT", "PROTEIN", 338, 341], ["DiscussionOnly DNA viral sequences", "DNA", 439, 473], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 192, 197], ["cat", "SPECIES", 327, 330], ["chicken", "SPECIES", 416, 423], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 192, 197], ["chicken", "SPECIES", 416, 423], ["gyrovirus sero-conversion", "TREATMENT", 38, 63], ["gyrovirus DNA in human feces", "PROBLEM", 175, 203], ["DNA viral sequences", "TEST", 454, 473], ["muscle tissues", "PROBLEM", 518, 532], ["RNA viruses", "PROBLEM", 571, 582], ["picornaviruses", "PROBLEM", 591, 605], ["caliciviruses", "PROBLEM", 607, 620], ["coronaviruses", "PROBLEM", 622, 635], ["astroviruses", "PROBLEM", 641, 653], ["CAV", "ANATOMY", 342, 345], ["muscle tissues", "ANATOMY", 518, 532]]], ["The absence of detected RNA viruses in the muscle tissues tested here may reflect a low level of contamination with fecal material, a general preference of RNA viruses for enteric rather than systemic infections, and/or as recently reported (Sachsenr\u00f6der et al., 2014) the older age of the animals used for meat production.Sample preparation and metagenomic analysis ::: Materials and methodsRaw pork (7 pieces and 3 ground), beef (7 pieces and 3 ground), chicken (6 pieces and 4 ground) were purchased from six randomly selected meat markets in the Sunset district of San Francisco, USA from Jan 12\u201328, 2014.", [["muscle tissues", "ANATOMY", 43, 57], ["fecal material", "ANATOMY", 116, 130], ["meat", "ANATOMY", 307, 311], ["infections", "DISEASE", 201, 211], ["muscle tissues", "TISSUE", 43, 57], ["meat", "ORGANISM_SUBDIVISION", 307, 311], ["beef", "ORGANISM_SUBDIVISION", 426, 430], ["chicken", "ORGANISM", 456, 463], ["pork", "SPECIES", 396, 400], ["beef", "SPECIES", 426, 430], ["chicken", "SPECIES", 456, 463], ["pork", "SPECIES", 396, 400], ["beef", "SPECIES", 426, 430], ["chicken", "SPECIES", 456, 463], ["RNA viruses in the muscle tissues", "PROBLEM", 24, 57], ["a low level of contamination", "PROBLEM", 82, 110], ["fecal material", "PROBLEM", 116, 130], ["RNA viruses", "PROBLEM", 156, 167], ["systemic infections", "PROBLEM", 192, 211], ["Sample preparation", "TEST", 323, 341], ["metagenomic analysis", "TEST", 346, 366], ["chicken (6 pieces", "TREATMENT", 456, 473], ["RNA viruses", "OBSERVATION", 24, 35], ["muscle tissues", "ANATOMY", 43, 57], ["low level", "OBSERVATION_MODIFIER", 84, 93], ["contamination", "OBSERVATION", 97, 110], ["fecal material", "OBSERVATION", 116, 130], ["infections", "OBSERVATION", 201, 211]]], ["Two samples of beef, pork, and chicken were purchased from each of five stores except for two stores in which only a single sample of chicken was purchased.", [["samples", "ANATOMY", 4, 11], ["pork", "ANATOMY", 21, 25], ["beef", "ORGANISM_SUBDIVISION", 15, 19], ["pork", "ORGANISM_SUBDIVISION", 21, 25], ["chicken", "ORGANISM", 31, 38], ["chicken", "ORGANISM", 134, 141], ["beef", "SPECIES", 15, 19], ["pork", "SPECIES", 21, 25], ["chicken", "SPECIES", 31, 38], ["chicken", "SPECIES", 134, 141], ["beef", "SPECIES", 15, 19], ["pork", "SPECIES", 21, 25], ["chicken", "SPECIES", 31, 38], ["chicken", "SPECIES", 134, 141]]], ["The remaining two chicken samples were purchased from a sixth store.", [["samples", "ANATOMY", 26, 33], ["chicken", "ORGANISM", 18, 25], ["chicken", "SPECIES", 18, 25], ["chicken", "SPECIES", 18, 25]]], ["All ground meats were purchased already wrapped in plastic labeled with name of national conglomerates.", [["ground meats", "ANATOMY", 4, 16], ["ground meats", "OBSERVATION", 4, 16]]], ["Neat piece of meats was collected and immediately placed in zippered plastic bags.", [["meats", "ANATOMY", 14, 19], ["meats", "ORGANISM_SUBSTANCE", 14, 19], ["zippered plastic bags", "TREATMENT", 60, 81], ["meats", "OBSERVATION", 14, 19], ["plastic bags", "OBSERVATION", 69, 81]]], ["All samples were frozen the same day at \u221280 \u00b0C until further processing.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["None of the meat was butchered or ground in the shops.", [["meat", "ANATOMY", 12, 16], ["meat", "ORGANISM_SUBDIVISION", 12, 16]]], ["In order to avoid potential contamination, small inner section of the meat pieces was cut out and used.", [["meat pieces", "ANATOMY", 70, 81], ["meat", "ORGANISM", 70, 74], ["potential contamination", "PROBLEM", 18, 41], ["small inner section of the meat pieces", "TREATMENT", 43, 81], ["contamination", "OBSERVATION", 28, 41], ["small", "OBSERVATION_MODIFIER", 43, 48], ["inner", "OBSERVATION_MODIFIER", 49, 54]]], ["Meat pieces (~25 mg) were frozen and thawed on dry ice three times, homogenized, filtered, and nuclease treated as previously described to enrich for nucleic acids within viral particles (Li et al., 2013).", [["nucleic acids", "CHEMICAL", 150, 163], ["nucleic acids", "SIMPLE_CHEMICAL", 150, 163], ["nuclease", "PROTEIN", 95, 103], ["Meat pieces", "TREATMENT", 0, 11], ["nuclease", "TREATMENT", 95, 103], ["nucleic acids", "TEST", 150, 163]]], ["Remaining total nucleic acid was then isolated using MagMAX\u2122 Viral RNA Isolation Kits (Qiagen) according to manufacturer\u05f3s protocol.", [["nucleic acid", "CHEMICAL", 16, 28], ["MagMAX", "PROTEIN", 53, 59], ["Remaining total nucleic acid", "TREATMENT", 0, 28], ["MagMAX", "TREATMENT", 53, 59], ["Viral RNA Isolation Kits", "TREATMENT", 61, 85], ["manufacturer\u05f3s protocol", "TREATMENT", 108, 131]]], ["A library of randomly amplified PCR products from viral RNA and DNA was prepared by using a Nextera DNA Sample Prep Kit and sequenced on the MiSeq Illumina platform (Illumina, San Diego, CA, USA).", [["DNA", "CELLULAR_COMPONENT", 64, 67], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["viral RNA", "RNA", 50, 59], ["randomly amplified PCR products", "TREATMENT", 13, 44], ["viral RNA", "PROBLEM", 50, 59], ["a Nextera DNA Sample Prep Kit", "TREATMENT", 90, 119], ["viral RNA", "OBSERVATION", 50, 59]]], ["Six separate pools of nucleic acids from the 30 meat specimens, each pool contained five specimens from the same farm animal species, were generated.", [["meat specimens", "ANATOMY", 48, 62], ["specimens", "ANATOMY", 89, 98], ["nucleic acids", "CHEMICAL", 22, 35], ["nucleic acids", "SIMPLE_CHEMICAL", 22, 35], ["nucleic acids", "TREATMENT", 22, 35], ["nucleic acids", "OBSERVATION", 22, 35]]], ["The viral nucleic acid pools, containing both DNA and RNA viral sequences, were subjected to reverse transcription reactions with SuperScript III reverse transcriptase (Invitrogen) and 100 picomoles of random hexamer primer, followed by a single round of DNA synthesis using Klenow fragment polymerase (New England BioLabs).", [["nucleic acid", "CHEMICAL", 10, 22], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["SuperScript III reverse transcriptase", "GENE_OR_GENE_PRODUCT", 130, 167], ["DNA", "CELLULAR_COMPONENT", 255, 258], ["DNA and RNA viral sequences", "DNA", 46, 73], ["SuperScript III reverse transcriptase", "PROTEIN", 130, 167], ["Klenow fragment polymerase", "PROTEIN", 275, 301], ["New England BioLabs", "PROTEIN", 303, 322], ["The viral nucleic acid pools", "PROBLEM", 0, 28], ["RNA viral sequences", "TEST", 54, 73], ["SuperScript III reverse transcriptase (Invitrogen)", "TREATMENT", 130, 180], ["random hexamer primer", "TREATMENT", 202, 223], ["DNA synthesis", "TREATMENT", 255, 268], ["Klenow fragment polymerase", "TREATMENT", 275, 301], ["New England BioLabs)", "TREATMENT", 303, 323], ["viral nucleic", "OBSERVATION", 4, 17], ["acid pools", "OBSERVATION", 18, 28]]], ["A library was then constructed using Nextera XT DNA Sample Preparation Kit (Illumina) and then sequenced using the Miseq Illumina platform with 250 bases paired ends with a distinct molecular tag for each pool.", [["A library", "TREATMENT", 0, 9], ["Nextera XT DNA Sample Preparation Kit (Illumina)", "TREATMENT", 37, 85], ["the Miseq Illumina platform", "TREATMENT", 111, 138], ["a distinct molecular tag", "TREATMENT", 171, 195], ["distinct", "OBSERVATION_MODIFIER", 173, 181], ["molecular tag", "OBSERVATION", 182, 195]]], ["Sequences and contigs were compared to the GenBank non-redundant protein database using BLASTx with an E-value cutoff of <10\u22125.PCR screening and genome sequencing ::: Materials and methodsPCR screening was performed for the bovine polyomavirus, circovirus-like genome, the porcine hokovirus in beef, and the novel gyrovirus in chicken.", [["bovine", "ORGANISM", 224, 230], ["polyomavirus", "ORGANISM", 231, 243], ["circovirus", "ORGANISM", 245, 255], ["porcine", "ORGANISM", 273, 280], ["hokovirus", "ORGANISM", 281, 290], ["gyrovirus", "CANCER", 314, 323], ["chicken", "ORGANISM", 327, 334], ["bovine polyomavirus, circovirus-like genome", "DNA", 224, 267], ["bovine", "SPECIES", 224, 230], ["circovirus", "SPECIES", 245, 255], ["porcine", "SPECIES", 273, 280], ["beef", "SPECIES", 294, 298], ["chicken", "SPECIES", 327, 334], ["bovine polyomavirus", "SPECIES", 224, 243], ["beef", "SPECIES", 294, 298], ["chicken", "SPECIES", 327, 334], ["contigs", "TEST", 14, 21], ["BLASTx", "TEST", 88, 94], ["an E-value cutoff", "TEST", 100, 117], ["PCR screening", "TEST", 127, 140], ["methodsPCR screening", "TEST", 181, 201], ["the bovine polyomavirus", "PROBLEM", 220, 243], ["circovirus", "PROBLEM", 245, 255], ["the porcine hokovirus in beef", "TREATMENT", 269, 298]]], ["Inverse PCR was used to generate the complete genome of the novel polyomavirus and the circovirus-like sequence in beef.", [["polyomavirus", "ORGANISM", 66, 78], ["circovirus", "ORGANISM", 87, 97], ["beef", "ORGANISM_SUBDIVISION", 115, 119], ["circovirus-like sequence", "DNA", 87, 111], ["circovirus", "SPECIES", 87, 97], ["beef", "SPECIES", 115, 119], ["beef", "SPECIES", 115, 119], ["Inverse PCR", "TEST", 0, 11], ["the novel polyomavirus", "PROBLEM", 56, 78], ["the circovirus", "PROBLEM", 83, 97], ["polyomavirus", "OBSERVATION", 66, 78], ["circovirus", "OBSERVATION", 87, 97]]], ["PCR to bridge sequence gaps was used to acquire the whole genome of the novel gyrovirus in chicken.", [["gyrovirus", "CANCER", 78, 87], ["chicken", "ORGANISM", 91, 98], ["gyrovirus", "DNA", 78, 87], ["chicken", "SPECIES", 91, 98], ["chicken", "SPECIES", 91, 98], ["PCR", "TEST", 0, 3], ["sequence gaps", "TEST", 14, 27]]], ["Sequences and characteristics of the primers used in PCR screening and inverse PCR are shown in Supplemental Table 1.", [["the primers", "TEST", 33, 44], ["PCR screening", "TEST", 53, 66], ["inverse PCR", "TEST", 71, 82]]], ["Sanger method was used for sequencing complete viral genomes and to confirm the sequence of PCR products.Phylogenetic analysis ::: Materials and methodsPhylogenetic analyses were performed based on the predicted amino acid or nucleotide sequences in the present study, their closest viral relatives based on best BLASTx hits, and representative members of related viral species or genera.", [["amino acid", "CHEMICAL", 212, 222], ["nucleotide", "CHEMICAL", 226, 236], ["amino acid", "CHEMICAL", 212, 222], ["nucleotide", "CHEMICAL", 226, 236], ["amino acid", "AMINO_ACID", 212, 222], ["viral genomes", "DNA", 47, 60], ["BLASTx hits", "DNA", 313, 324], ["Sanger method", "TEST", 0, 13], ["sequencing complete viral genomes", "PROBLEM", 27, 60], ["PCR products", "TREATMENT", 92, 104], ["Phylogenetic analysis", "TEST", 105, 126], ["methodsPhylogenetic analyses", "TEST", 145, 173], ["the predicted amino acid", "TEST", 198, 222], ["nucleotide sequences", "TEST", 226, 246], ["the present study", "TEST", 250, 267], ["related viral species", "PROBLEM", 356, 377], ["viral species", "OBSERVATION", 364, 377]]], ["Sequence alignment was performed using CLUSTAL W with the default settings.", [["Sequence alignment", "TEST", 0, 18], ["CLUSTAL W", "TREATMENT", 39, 48]]], ["Aligned sequences were trimmed to match the genomic regions of the viral sequences obtained in the study.", [["genomic regions", "DNA", 44, 59], ["viral sequences", "DNA", 67, 82], ["the viral sequences", "TEST", 63, 82], ["the study", "TEST", 95, 104]]], ["A phylogenetic tree with 100 bootstrap resamples of the alignment data sets was generated using the neighbor-joining method based on the Jones\u2013Taylor\u2013Thornton matrix-based model in MEGA5.0 (Tamura et al., 2011).", [["the alignment data sets", "TEST", 52, 75], ["the neighbor-joining method", "TREATMENT", 96, 123], ["tree", "OBSERVATION_MODIFIER", 15, 19]]], ["Bootstrap values (based on 100 replicates) for each node are given.", [["node", "ANATOMY", 52, 56], ["node", "MULTI-TISSUE_STRUCTURE", 52, 56], ["Bootstrap values", "TEST", 0, 16], ["each node", "TREATMENT", 47, 56], ["node", "OBSERVATION", 52, 56]]], ["Putative ORFs in the genome were predicted by NCBI ORF finder.", [["genome", "CELLULAR_COMPONENT", 21, 27], ["ORFs", "DNA", 9, 13], ["NCBI ORF finder", "DNA", 46, 61], ["Putative ORFs", "PROBLEM", 0, 13]]], ["Putative exon and intron were predicted by Netgenes2 at http://www.cbs.dtu.dk/services/NetGene2/.Nucleotide sequence accession numbers ::: Materials and methodsThe genomes of known and new viruses described in detail here were deposited in GenBank under the following accession numbers: KM111535\u2013KM111537.", [["Putative exon and intron", "DNA", 0, 24], ["Netgenes2", "DNA", 43, 52], ["Putative exon and intron", "TREATMENT", 0, 24], ["new viruses", "PROBLEM", 185, 196], ["new", "OBSERVATION_MODIFIER", 185, 188], ["viruses", "OBSERVATION", 189, 196]]]], "d38db804cf2fd958db11b803e1cc73fcd812b66c": [["contact system and coronavirus; bradykinin and coronavirus; and angiotensin receptor and coronavirus.", [["bradykinin", "CHEMICAL", 32, 42], ["angiotensin", "CHEMICAL", 64, 75], ["coronavirus", "ORGANISM", 19, 30], ["bradykinin", "GENE_OR_GENE_PRODUCT", 32, 42], ["coronavirus", "ORGANISM", 47, 58], ["angiotensin receptor", "GENE_OR_GENE_PRODUCT", 64, 84], ["coronavirus", "ORGANISM", 89, 100], ["angiotensin receptor", "PROTEIN", 64, 84], ["coronavirus", "SPECIES", 19, 30], ["coronavirus", "PROBLEM", 19, 30], ["bradykinin", "PROBLEM", 32, 42], ["coronavirus", "PROBLEM", 47, 58], ["angiotensin receptor", "TREATMENT", 64, 84], ["coronavirus", "PROBLEM", 89, 100], ["coronavirus", "OBSERVATION", 19, 30]]], ["The manuscript complies with ethics guidelines and was deemed exempt from institutional review board approval according to Human Subjects Protection Office guidelines.", [["Human", "ORGANISM", 123, 128], ["Human", "SPECIES", 123, 128]]], ["Results: Mouse models are available for the study of coronavirus and complement.", [["Mouse", "ORGANISM", 9, 14], ["coronavirus", "ORGANISM", 53, 64], ["Mouse", "SPECIES", 9, 14], ["coronavirus", "SPECIES", 53, 64], ["coronavirus", "SPECIES", 53, 64], ["the study", "TEST", 40, 49], ["coronavirus", "PROBLEM", 53, 64]]], ["Although complement is effective in protecting against many viruses, it does not seem to be protective against coronavirus.", [["coronavirus", "DISEASE", 111, 122], ["coronavirus", "ORGANISM", 111, 122], ["many viruses", "PROBLEM", 55, 67], ["coronavirus", "PROBLEM", 111, 122], ["effective", "OBSERVATION_MODIFIER", 23, 32], ["viruses", "OBSERVATION", 60, 67]]], ["C3 knockout mice infected with SARS-CoV had less lung disease than wild-type mice, suggesting that complement may play a role in coronavirus pathogenesis.", [["lung", "ANATOMY", 49, 53], ["lung disease", "DISEASE", 49, 61], ["coronavirus", "DISEASE", 129, 140], ["C3", "GENE_OR_GENE_PRODUCT", 0, 2], ["mice", "ORGANISM", 12, 16], ["SARS-CoV", "ORGANISM", 31, 39], ["lung", "ORGAN", 49, 53], ["mice", "ORGANISM", 77, 81], ["coronavirus", "ORGANISM", 129, 140], ["C3", "PROTEIN", 0, 2], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 77, 81], ["coronavirus", "SPECIES", 129, 140], ["mice", "SPECIES", 12, 16], ["SARS-CoV", "SPECIES", 31, 39], ["mice", "SPECIES", 77, 81], ["C3 knockout mice infected", "PROBLEM", 0, 25], ["SARS", "PROBLEM", 31, 35], ["less lung disease", "PROBLEM", 44, 61], ["coronavirus pathogenesis", "PROBLEM", 129, 153], ["infected", "OBSERVATION", 17, 25], ["less", "OBSERVATION_MODIFIER", 44, 48], ["lung", "ANATOMY", 49, 53], ["disease", "OBSERVATION", 54, 61], ["coronavirus", "OBSERVATION", 129, 140]]], ["Some evidence suggests that the observed pulmonary edema may be bradykinininduced and could be the reason that corticosteroids, antihistamines, and other traditional interventions for edema are not effective.", [["pulmonary", "ANATOMY", 41, 50], ["edema", "ANATOMY", 184, 189], ["pulmonary edema", "DISEASE", 41, 56], ["edema", "DISEASE", 184, 189], ["corticosteroids", "CHEMICAL", 111, 126], ["pulmonary", "ORGAN", 41, 50], ["corticosteroids", "SIMPLE_CHEMICAL", 111, 126], ["antihistamines", "SIMPLE_CHEMICAL", 128, 142], ["edema", "PATHOLOGICAL_FORMATION", 184, 189], ["the observed pulmonary edema", "PROBLEM", 28, 56], ["bradykinininduced", "PROBLEM", 64, 81], ["corticosteroids", "TREATMENT", 111, 126], ["antihistamines", "TREATMENT", 128, 142], ["other traditional interventions", "TREATMENT", 148, 179], ["edema", "PROBLEM", 184, 189], ["pulmonary", "ANATOMY", 41, 50], ["edema", "OBSERVATION", 51, 56], ["edema", "OBSERVATION", 184, 189]]], ["Angiotensin-converting enzyme 2 (ACE2) is a co-receptor for SARS-CoV-2, and studies thus far have not concluded a benefit or risk associated with the use of either ACE-inhibitors or angiotensin receptor antagonists.", [["Angiotensin", "CHEMICAL", 0, 11], ["angiotensin", "CHEMICAL", 182, 193], ["Angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 0, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 60, 70], ["ACE", "GENE_OR_GENE_PRODUCT", 164, 167], ["angiotensin receptor antagonists", "GENE_OR_GENE_PRODUCT", 182, 214], ["Angiotensin-converting enzyme 2", "PROTEIN", 0, 31], ["ACE2", "PROTEIN", 33, 37], ["Angiotensin", "TEST", 0, 11], ["converting enzyme", "TEST", 12, 29], ["ACE2", "TEST", 33, 37], ["SARS", "PROBLEM", 60, 64], ["CoV", "TEST", 65, 68], ["studies", "TEST", 76, 83], ["ACE-inhibitors", "TREATMENT", 164, 178], ["angiotensin receptor antagonists", "TREATMENT", 182, 214]]], ["Summary: Activation of complement and the contact system, through generation of bradykinin, may play a role in the SARS-CoV-2-induced pulmonary edema, and our search suggests that further work is necessary to confirm our suspicions.", [["pulmonary", "ANATOMY", 134, 143], ["bradykinin", "CHEMICAL", 80, 90], ["SARS", "DISEASE", 115, 119], ["pulmonary edema", "DISEASE", 134, 149], ["bradykinin", "CHEMICAL", 80, 90], ["complement", "GENE_OR_GENE_PRODUCT", 23, 33], ["bradykinin", "GENE_OR_GENE_PRODUCT", 80, 90], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 115, 125], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 134, 149], ["bradykinin", "TREATMENT", 80, 90], ["the SARS", "PROBLEM", 111, 119], ["pulmonary edema", "PROBLEM", 134, 149], ["pulmonary", "ANATOMY", 134, 143], ["edema", "OBSERVATION", 144, 149]]], ["Is complement essential for protection against coronavirus?", [["coronavirus", "DISEASE", 47, 58], ["coronavirus", "ORGANISM", 47, 58], ["coronavirus", "PROBLEM", 47, 58]]], ["From experiments with C3 knockout mice, it does not seem to be important.", [["C3", "GENE_OR_GENE_PRODUCT", 22, 24], ["mice", "ORGANISM", 34, 38], ["C3", "PROTEIN", 22, 24], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 34, 38], ["C3 knockout mice", "TREATMENT", 22, 38]]]], "PMC7243040": [["A viral infection can acutely affect the cardiovascular system, causing an increased risk of acute coronary syndromes, myocardial depression leading to heart failure (HF) or arrhythmias and myocarditis/pericarditis.1 These complications can be the result of direct invasion of the heart or they can be mediated by the systemic response, including an increase in pulmonary or systemic vascular resistance, systemic inflammation, immune reaction or reduced oxygen delivery.", [["cardiovascular system", "ANATOMY", 41, 62], ["coronary", "ANATOMY", 99, 107], ["myocardial", "ANATOMY", 119, 129], ["heart", "ANATOMY", 152, 157], ["heart", "ANATOMY", 281, 286], ["pulmonary", "ANATOMY", 362, 371], ["vascular", "ANATOMY", 384, 392], ["viral infection", "DISEASE", 2, 17], ["acute coronary syndromes", "DISEASE", 93, 117], ["myocardial depression", "DISEASE", 119, 140], ["heart failure", "DISEASE", 152, 165], ["HF", "DISEASE", 167, 169], ["arrhythmias", "DISEASE", 174, 185], ["myocarditis", "DISEASE", 190, 201], ["pericarditis", "DISEASE", 202, 214], ["inflammation", "DISEASE", 414, 426], ["oxygen", "CHEMICAL", 455, 461], ["oxygen", "CHEMICAL", 455, 461], ["cardiovascular", "ANATOMICAL_SYSTEM", 41, 55], ["system", "ANATOMICAL_SYSTEM", 56, 62], ["coronary", "MULTI-TISSUE_STRUCTURE", 99, 107], ["myocardial", "MULTI-TISSUE_STRUCTURE", 119, 129], ["heart", "ORGAN", 152, 157], ["heart", "ORGAN", 281, 286], ["pulmonary", "ORGAN", 362, 371], ["vascular", "MULTI-TISSUE_STRUCTURE", 384, 392], ["oxygen", "SIMPLE_CHEMICAL", 455, 461], ["A viral infection", "PROBLEM", 0, 17], ["acute coronary syndromes", "PROBLEM", 93, 117], ["myocardial depression", "PROBLEM", 119, 140], ["heart failure", "PROBLEM", 152, 165], ["HF", "PROBLEM", 167, 169], ["arrhythmias", "PROBLEM", 174, 185], ["myocarditis", "PROBLEM", 190, 201], ["pericarditis", "PROBLEM", 202, 214], ["These complications", "PROBLEM", 217, 236], ["direct invasion of the heart", "PROBLEM", 258, 286], ["an increase in pulmonary or systemic vascular resistance", "PROBLEM", 347, 403], ["systemic inflammation", "PROBLEM", 405, 426], ["immune reaction", "PROBLEM", 428, 443], ["reduced oxygen delivery", "TREATMENT", 447, 470], ["viral", "OBSERVATION_MODIFIER", 2, 7], ["infection", "OBSERVATION", 8, 17], ["cardiovascular system", "ANATOMY", 41, 62], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["coronary", "ANATOMY", 99, 107], ["syndromes", "OBSERVATION", 108, 117], ["myocardial", "ANATOMY", 119, 129], ["depression", "OBSERVATION", 130, 140], ["heart", "ANATOMY", 152, 157], ["failure", "OBSERVATION", 158, 165], ["myocarditis", "OBSERVATION", 190, 201], ["pericarditis", "OBSERVATION", 202, 214], ["invasion", "OBSERVATION", 265, 273], ["heart", "ANATOMY", 281, 286], ["increase", "OBSERVATION_MODIFIER", 350, 358], ["pulmonary", "ANATOMY", 362, 371], ["systemic", "OBSERVATION_MODIFIER", 375, 383], ["vascular resistance", "OBSERVATION", 384, 403], ["systemic", "OBSERVATION_MODIFIER", 405, 413], ["inflammation", "OBSERVATION", 414, 426], ["reduced", "OBSERVATION_MODIFIER", 447, 454], ["oxygen delivery", "OBSERVATION", 455, 470]]]], "PMC1783898": [["INTRODUCTIONSevere acute respiratory syndrome (SARS) was one of the most serious epidemic diseases in 2003 and is still a threat to the public health worldwide (1).", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["A specific SARS coronavirus (CoV) was identified to be the contagious agent.", [["SARS coronavirus", "DISEASE", 11, 27], ["SARS coronavirus", "ORGANISM", 11, 27], ["CoV", "ORGANISM", 29, 32], ["SARS coronavirus", "SPECIES", 11, 27], ["CoV", "SPECIES", 29, 32], ["A specific SARS coronavirus", "PROBLEM", 0, 27]]], ["Maturation of the SARS-CoV involves proteolytic processing of the virus polyproteins by the chymotrypsin-like main protease (3CLpro) and a papain-like protease (PLpro).", [["SARS", "DISEASE", 18, 22], ["SARS-CoV", "ORGANISM", 18, 26], ["chymotrypsin-like main protease", "GENE_OR_GENE_PRODUCT", 92, 123], ["3CLpro", "GENE_OR_GENE_PRODUCT", 125, 131], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 139, 159], ["PLpro", "GENE_OR_GENE_PRODUCT", 161, 166], ["virus polyproteins", "PROTEIN", 66, 84], ["chymotrypsin-like main protease", "PROTEIN", 92, 123], ["3CLpro", "PROTEIN", 125, 131], ["papain-like protease", "PROTEIN", 139, 159], ["PLpro", "PROTEIN", 161, 166], ["SARS-CoV", "SPECIES", 18, 26], ["the SARS", "PROBLEM", 14, 22], ["CoV", "PROBLEM", 23, 26], ["the virus polyproteins", "PROBLEM", 62, 84], ["the chymotrypsin", "TREATMENT", 88, 104], ["main protease (3CLpro)", "TREATMENT", 110, 132], ["a papain-like protease (PLpro)", "TREATMENT", 137, 167]]], ["SARS-CoV might invade cells by a protease-mediated endosomal pathway (2).", [["cells", "ANATOMY", 22, 27], ["endosomal", "ANATOMY", 51, 60], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["cells", "CELL", 22, 27], ["endosomal", "CELLULAR_COMPONENT", 51, 60], ["protease", "PROTEIN", 33, 41], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["a protease-mediated endosomal pathway", "TREATMENT", 31, 68]]], ["Any knowledge about the structural stability of viral protease can be very rewarding for the development of antivirus drugs (3\u20136).INTRODUCTIONThe 3CLpro from SARS-CoV was the first protein of this virus to have its three-dimensional structure solved (7,8).", [["SARS", "DISEASE", 158, 162], ["antivirus drugs", "SIMPLE_CHEMICAL", 108, 123], ["3\u20136", "SIMPLE_CHEMICAL", 125, 128], ["3CLpro", "GENE_OR_GENE_PRODUCT", 146, 152], ["SARS-CoV", "ORGANISM", 158, 166], ["viral protease", "PROTEIN", 48, 62], ["3CLpro", "PROTEIN", 146, 152], ["SARS-CoV", "SPECIES", 158, 166], ["viral protease", "PROBLEM", 48, 62], ["antivirus drugs", "TREATMENT", 108, 123], ["CoV", "PROBLEM", 163, 166], ["this virus", "PROBLEM", 192, 202], ["antivirus", "OBSERVATION", 108, 117]]], ["As had previously been shown for the 3CLpro of transmissible gastroenteritis (corona)virus (9), the SARS-CoV enzyme also exists as a dimer in solution and in crystals, with each subunit containing three structural domains (Fig. 1).", [["gastroenteritis", "DISEASE", 61, 76], ["SARS", "DISEASE", 100, 104], ["corona)virus", "ORGANISM", 78, 90], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 100, 108], ["SARS-CoV enzyme", "PROTEIN", 100, 115], ["dimer", "PROTEIN", 133, 138], ["structural domains", "PROTEIN", 203, 221], ["SARS-CoV", "SPECIES", 100, 108], ["transmissible gastroenteritis (corona)virus", "PROBLEM", 47, 90], ["the SARS", "TEST", 96, 104], ["CoV enzyme", "TEST", 105, 115], ["a dimer in solution", "TREATMENT", 131, 150], ["gastroenteritis", "OBSERVATION", 61, 76]]], ["The catalytic dyad His41-Cys145 is located between the interfaces of domains I (residues 8\u201399) and domain II (residues 100\u2013183), which constitute the chymotrypsin-like folding scaffold.", [["His41-Cys", "CHEMICAL", 19, 28], ["His41", "CHEMICAL", 19, 24], ["Cys", "CHEMICAL", 25, 28], ["Cys145", "AMINO_ACID", 25, 31], ["\u2013183", "AMINO_ACID", 122, 126], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 150, 162], ["domains I", "PROTEIN", 69, 78], ["residues 8\u201399", "PROTEIN", 80, 93], ["domain II", "PROTEIN", 99, 108], ["residues 100\u2013183", "PROTEIN", 110, 126], ["chymotrypsin-like folding scaffold", "PROTEIN", 150, 184], ["The catalytic dyad His41", "TEST", 0, 24], ["domain II (residues", "TEST", 99, 118], ["the chymotrypsin-like folding scaffold", "PROBLEM", 146, 184], ["folding scaffold", "OBSERVATION", 168, 184]]], ["This catalytic N-terminal domain is connected by a long loop (residues 184\u2013199) to the helical domain III (residues 200\u2013306).", [["N", "CHEMICAL", 15, 16], ["catalytic N-terminal domain", "PROTEIN", 5, 32], ["long loop", "PROTEIN", 51, 60], ["residues 184\u2013199", "PROTEIN", 62, 78], ["helical domain III", "PROTEIN", 87, 105], ["residues 200\u2013306", "PROTEIN", 107, 123], ["This catalytic N-terminal domain", "TREATMENT", 0, 32], ["a long loop (residues", "TREATMENT", 49, 70], ["terminal", "OBSERVATION_MODIFIER", 17, 25]]], ["The functional role of the extra C-terminal domain III is less clear.", [["C", "CHEMICAL", 33, 34], ["extra C-terminal domain III", "PROTEIN", 27, 54], ["less", "OBSERVATION_MODIFIER", 58, 62], ["clear", "OBSERVATION", 63, 68]]], ["Numerous experimental evidence shows the importance of N- and C-terminal residues in the dimerization (4,10\u201312).", [["N", "CHEMICAL", 55, 56], ["C", "CHEMICAL", 62, 63], ["N- and C-terminal residues", "PROTEIN", 55, 81], ["C-terminal residues", "PROBLEM", 62, 81]]], ["Structural studies indicate the close proximity of C-terminus and N-finger (N-terminal residues 1\u20137) (9) from subunit A to the active site of subunit B that led to the development of a novel autocleavage mechanism that can explain the dimeric nature of the mature enzyme (13).INTRODUCTIONHere we demonstrate that the SARS main protease provides us a very useful model for the folding studies of multisubunit, multidomain proteins.", [["SARS", "DISEASE", 317, 321], ["N", "CHEMICAL", 66, 67], ["N", "CHEMICAL", 76, 77], ["C-terminus", "PROTEIN", 51, 61], ["N-finger (N-terminal residues 1\u20137) (9", "PROTEIN", 66, 103], ["subunit A", "PROTEIN", 110, 119], ["subunit B", "PROTEIN", 142, 151], ["mature enzyme", "PROTEIN", 257, 270], ["SARS main protease", "PROTEIN", 317, 335], ["multisubunit, multidomain proteins", "PROTEIN", 395, 429], ["Structural studies", "TEST", 0, 18], ["finger (N-terminal residues", "TREATMENT", 68, 95], ["a novel autocleavage mechanism", "PROBLEM", 183, 213], ["the SARS main protease", "PROBLEM", 313, 335], ["the folding studies", "TEST", 372, 391], ["finger", "ANATOMY", 68, 74]]], ["Novel folding intermediates were identified, which allow us to delineate unequivocally the functional role of domain III.Construction of 3CLpro expression vectors ::: MATERIALS AND METHODSThe genes of the full-length 3CLpro and C-terminal truncated 3CLI+II of the SARS-CoV main protease were amplified by polymerase chain reaction (PCR) with appropriate primers.", [["C", "CHEMICAL", 228, 229], ["3CLpro", "GENE_OR_GENE_PRODUCT", 137, 143], ["3CLpro", "GENE_OR_GENE_PRODUCT", 217, 223], ["3CLI+II", "GENE_OR_GENE_PRODUCT", 249, 256], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 264, 272], ["domain III", "PROTEIN", 110, 120], ["3CLpro expression vectors", "DNA", 137, 162], ["full-length 3CLpro", "DNA", 205, 223], ["C-terminal truncated 3CLI+II", "DNA", 228, 256], ["SARS-CoV main protease", "PROTEIN", 264, 286], ["SARS-CoV", "SPECIES", 264, 272], ["Novel folding intermediates", "PROBLEM", 0, 27], ["3CLpro", "TEST", 217, 223], ["C", "TEST", 228, 229], ["the SARS", "PROBLEM", 260, 268], ["CoV main protease", "TREATMENT", 269, 286], ["polymerase chain reaction", "PROBLEM", 305, 330], ["PCR", "TEST", 332, 335], ["appropriate primers", "TREATMENT", 342, 361]]], ["The forward primers for full length was 5\u2032-GGTGGTCATATGAGTGGTTTTAGG-3\u2032, and the reverse primer was 5\u2032-AACTCGAGGGTAACACCAGAG-3\u2032.", [["forward primers", "DNA", 4, 19], ["reverse primer", "DNA", 80, 94], ["full length", "TEST", 24, 35], ["GGTGGTCATATGAGTGGTTTTAGG", "TEST", 43, 67], ["AACTCGAGGGTAACACCAGAG", "TEST", 102, 123]]], ["After digestion with BglII and XhoI, the PCR product was divided into two fragments, 168-bp and 747-bp.", [["BglII", "GENE_OR_GENE_PRODUCT", 21, 26], ["XhoI", "GENE_OR_GENE_PRODUCT", 31, 35], ["BglII", "DNA", 21, 26], ["XhoI", "DNA", 31, 35], ["BglII and XhoI", "TREATMENT", 21, 35], ["the PCR product", "TREATMENT", 37, 52], ["bp", "TEST", 89, 91], ["bp", "TEST", 100, 102], ["fragments", "OBSERVATION_MODIFIER", 74, 83]]], ["The 168-bp fragment was then digested with NdeI.", [["NdeI", "GENE_OR_GENE_PRODUCT", 43, 47], ["168-bp fragment", "DNA", 4, 19], ["NdeI", "DNA", 43, 47], ["The 168-bp fragment", "TREATMENT", 0, 19]]], ["Finally, the 168-bp NdeI-BglII and 747-bp BglII-XhoI fragments were coligated to the NdeI and XhoI sites of the vector pET-29a(+) (Novagen, Madison, WI).", [["NdeI", "GENE_OR_GENE_PRODUCT", 20, 24], ["BglII", "GENE_OR_GENE_PRODUCT", 25, 30], ["BglII", "GENE_OR_GENE_PRODUCT", 42, 47], ["XhoI", "GENE_OR_GENE_PRODUCT", 48, 52], ["NdeI", "GENE_OR_GENE_PRODUCT", 85, 89], ["XhoI", "GENE_OR_GENE_PRODUCT", 94, 98], ["pET-29a", "GENE_OR_GENE_PRODUCT", 119, 126], ["Novagen", "GENE_OR_GENE_PRODUCT", 131, 138], ["168-bp NdeI-BglII and 747-bp BglII-XhoI fragments", "DNA", 13, 62], ["NdeI and XhoI sites", "DNA", 85, 104], ["vector pET-29a", "DNA", 112, 126], ["BglII", "TEST", 25, 30], ["bp BglII-XhoI fragments", "TREATMENT", 39, 62], ["the vector pET", "TEST", 108, 122]]], ["The 3CLI+II was subsequently amplified by PCR, using the forward primer of 5\u2032-TGAAGATCTGCTCATTCGCAA-3\u2032, and reverse primer of 5\u2032-AACTCGACTATGGTTGTGTCTG-3\u2032.", [["3CLI+II", "GENE_OR_GENE_PRODUCT", 4, 11], ["3CLI", "DNA", 4, 8], ["reverse primer", "DNA", 108, 122], ["PCR", "TEST", 42, 45], ["the forward primer", "TEST", 53, 71], ["TGAAGATCTGCTCATTCGCAA", "TEST", 78, 99], ["AACTCGACTATGGTTGTGTCTG", "TEST", 129, 151]]], ["After digestion with BglII and XhoI, the PCR products were inserted into the BglII and XhoI sites of the pET-SARS main protease.Construction of 3CLpro expression vectors ::: MATERIALS AND METHODSSite-directed mutagenesis (14) was used to construct pET-H41A, pET-S65A, pET-N84A, pET-C145A, pET-Y161A, and pET-H163A vectors.", [["BglII", "GENE_OR_GENE_PRODUCT", 21, 26], ["XhoI", "GENE_OR_GENE_PRODUCT", 31, 35], ["BglII", "GENE_OR_GENE_PRODUCT", 77, 82], ["XhoI", "GENE_OR_GENE_PRODUCT", 87, 91], ["pET", "GENE_OR_GENE_PRODUCT", 105, 108], ["3CLpro", "GENE_OR_GENE_PRODUCT", 144, 150], ["pET-H41A", "GENE_OR_GENE_PRODUCT", 248, 256], ["pET-S65A", "GENE_OR_GENE_PRODUCT", 258, 266], ["pET-N84A", "GENE_OR_GENE_PRODUCT", 268, 276], ["pET-C145A", "GENE_OR_GENE_PRODUCT", 278, 287], ["pET-Y161A", "GENE_OR_GENE_PRODUCT", 289, 298], ["pET-H163A", "GENE_OR_GENE_PRODUCT", 304, 313], ["BglII", "DNA", 21, 26], ["XhoI", "DNA", 31, 35], ["PCR products", "DNA", 41, 53], ["BglII and XhoI sites", "DNA", 77, 97], ["pET-SARS main protease", "PROTEIN", 105, 127], ["3CLpro expression vectors", "DNA", 144, 169], ["pET-H41A, pET-S65A, pET-N84A, pET-C145A, pET-Y161A, and pET-H163A vectors", "DNA", 248, 321], ["BglII and XhoI", "TREATMENT", 21, 35], ["the PCR products", "TREATMENT", 37, 53], ["the BglII", "TREATMENT", 73, 82], ["the pET", "TEST", 101, 108], ["construct pET", "TEST", 238, 251], ["pET", "TEST", 258, 261], ["pET", "TEST", 268, 271], ["pET", "TEST", 278, 281], ["pET", "TEST", 289, 292], ["pET", "TEST", 304, 307]]], ["The forward primers for H41A, S65A, N84A, C145A, Y161A, and H163A were 5\u2032-CTGTCCAAGAGCGGTCATTTGCAC-3\u2032, 5\u2032-CAAATCCAACCATGCGTTTCTTGTTC-3\u2032, 5\u2032-CATTCTATGCAAGCGTGTCTGCTTAG-3\u2032, 5\u2032-CTTAATGGATCAGCGGGTAGTGTTG-3\u2032, 5\u2032-GTCTTTCTGCGCGATGCATCATATG-3\u2032, and 5\u2032-CTGCTATATGGCGCATATGGAGC-3\u2032, respectively; and the reverse primers were 5\u2032-GTGCAAATGACCGCTCTTGGACAG-3\u2032, 5\u2032-GAACAAGAAACGCATGGTTGGATTTG-3\u2032, 5\u2032-CTAAGCAGACACGCTTGCATAGAATG-3\u2032, 5\u2032-CAACACTACCCGCTGATCCATTAAG-3\u2032, 5\u2032-CATATGATGCATCGCGCAGAAAGAC-3\u2032, and 5\u2032-GCTCCATATGCGCCATATAGCAG-3\u2032, respectively.", [["H41A", "GENE_OR_GENE_PRODUCT", 24, 28], ["H41A", "DNA", 24, 28], ["reverse primers", "DNA", 294, 309], ["H41A", "TEST", 24, 28], ["H163A", "TEST", 60, 65], ["CTGTCCAAGAGCGGTCATTTGCAC", "TEST", 74, 98], ["CAAATCCAACCATGCGTTTCTTGTTC", "TEST", 106, 132], ["CATTCTATGCAAGCGTGTCTGCTTAG", "TEST", 140, 166], ["CTTAATGGATCAGCGGGTAGTGTTG", "TEST", 174, 199], ["GTCTTTCTGCGCGATGCATCATATG", "TEST", 207, 232], ["CTGCTATATGGCGCATATGGAGC", "TEST", 244, 267], ["GTGCAAATGACCGCTCTTGGACAG", "TEST", 318, 342], ["GAACAAGAAACGCATGGTTGGATTTG", "TEST", 350, 376], ["CTAAGCAGACACGCTTGCATAGAATG", "TEST", 384, 410], ["CAACACTACCCGCTGATCCATTAAG", "TEST", 418, 443], ["CATATGATGCATCGCGCAGAAAGAC", "TEST", 451, 476]]], ["The pET-3CL expression vectors were used as templates and the primers as described above were used to mutate the His41, Ser65, Asn84, Cys145, Tyr161, and His163 codons to alanine codon by PCR.", [["alanine", "CHEMICAL", 171, 178], ["His41", "CHEMICAL", 113, 118], ["Ser65", "CHEMICAL", 120, 125], ["Asn84", "CHEMICAL", 127, 132], ["Cys", "CHEMICAL", 134, 137], ["Tyr161", "CHEMICAL", 142, 148], ["His", "CHEMICAL", 154, 157], ["alanine", "CHEMICAL", 171, 178], ["pET-3CL", "GENE_OR_GENE_PRODUCT", 4, 11], ["His41", "GENE_OR_GENE_PRODUCT", 113, 118], ["Ser65", "GENE_OR_GENE_PRODUCT", 120, 125], ["Asn84", "GENE_OR_GENE_PRODUCT", 127, 132], ["Cys145", "AMINO_ACID", 134, 140], ["Tyr161", "GENE_OR_GENE_PRODUCT", 142, 148], ["alanine", "AMINO_ACID", 171, 178], ["codon", "AMINO_ACID", 179, 184], ["pET-3CL expression vectors", "DNA", 4, 30], ["His41, Ser65, Asn84, Cys145, Tyr161, and His163 codons", "DNA", 113, 167], ["The pET-3CL expression vectors", "TREATMENT", 0, 30], ["the primers", "TEST", 58, 69], ["Cys", "TEST", 134, 137], ["Tyr161", "TEST", 142, 148], ["alanine codon", "TEST", 171, 184], ["PCR", "TEST", 188, 191]]], ["The mutational sites are shown underlined and in bold.Construction of 3CLpro expression vectors ::: MATERIALS AND METHODSFor the tryptophan mutants of 3CLpro, the forward primers for W31F, W207F, and W218F were 5\u2032-CTCTTAATGGATTGTTCTTGGATGACACAGT-3\u2032, 5\u2032-CCATAACATTAAATGTTTTGGCATTCCTGTATGCTGC-3\u2032, and 5\u2032-CAATGGTGATAGGTTCTTTCTTAATAGATTCACC-3\u2032, respectively.", [["tryptophan", "CHEMICAL", 129, 139], ["tryptophan", "CHEMICAL", 129, 139], ["3CLpro", "GENE_OR_GENE_PRODUCT", 70, 76], ["tryptophan", "AMINO_ACID", 129, 139], ["3CLpro", "GENE_OR_GENE_PRODUCT", 151, 157], ["W31F", "GENE_OR_GENE_PRODUCT", 183, 187], ["W207F", "GENE_OR_GENE_PRODUCT", 189, 194], ["3CLpro expression vectors", "DNA", 70, 95], ["3CLpro", "PROTEIN", 151, 157], ["3CLpro", "TREATMENT", 151, 157], ["5\u2032-CTCTTAATGGATTGTTCTTGGATGACACAGT", "TEST", 211, 245], ["5\u2032-CCATAACATTAAATGTTTTGGCATTCCTGTATGCTGC", "TEST", 250, 290]]], ["The reverse primers were 5\u2032-ACTGTGTCATCCAAGAACAATCCATTAAGAG-3\u2032, 5\u2032-GCAGCATACAGGAATGCCAAAACATTTAATGTTATGG-3\u2032, and 5\u2032-GGTGAATCTATTAAAGAAGAACCTATCACCATTG-3\u2032, respectively.", [["reverse primers", "DNA", 4, 19], ["The reverse primers", "TEST", 0, 19], ["ACTGTGTCATCCAAGAACAATCCATTAAGAG", "TEST", 28, 59], ["GCAGCATACAGGAATGCCAAAACATTTAATGTTATGG", "TEST", 67, 104], ["GGTGAATCTATTAAAGAAGAACCTATCACCATTG", "TEST", 116, 150]]], ["For W207F/W218F (W31) double mutant, W207F was used as the template.Construction of 3CLpro expression vectors ::: MATERIALS AND METHODSAll nucleotide sequences were confirmed by autosequencing analysis.", [["nucleotide", "CHEMICAL", 139, 149], ["W207F/W218F (W31)", "GENE_OR_GENE_PRODUCT", 4, 21], ["3CLpro", "GENE_OR_GENE_PRODUCT", 84, 90], ["W207F", "PROTEIN", 4, 9], ["W218F", "PROTEIN", 10, 15], ["W31", "PROTEIN", 17, 20], ["W207F", "PROTEIN", 37, 42], ["3CLpro expression vectors", "DNA", 84, 109], ["double mutant, W207F", "TREATMENT", 22, 42], ["METHODSAll nucleotide sequences", "TEST", 128, 159], ["autosequencing analysis", "TEST", 178, 201]]], ["A sequence comparison bearing the mutation positions at the active site region is shown in supplemental Fig. 1S (Supplementary Material).", [["active site region", "DNA", 60, 78], ["active", "OBSERVATION_MODIFIER", 60, 66], ["supplemental Fig", "OBSERVATION", 91, 107]]], ["The wild-type (WT) enzyme and all mutants were successfully expressed and purified to apparent homogeneity by protocols described previously (11).", [["wild-type (WT)", "ORGANISM", 4, 18], ["wild-type (WT) enzyme", "PROTEIN", 4, 25], ["enzyme", "TEST", 19, 25]]], ["Typical CD spectra of the recombinant 3CLpro are shown in Supplementary Material (Fig. 2S).Enzyme activity assay of SARS-CoV main protease using fluorogenic substrate ::: MATERIALS AND METHODSThe enzyme kinetic measurements were performed in 30 mM Tris-Cl buffer (pH 7.7) or phosphate-buffered saline (pH 7.6) at 30\u00b0C. Enhanced fluorescence due to cleavage of the internal quenched fluorogenic substrate peptide (ortho-aminobenzoic acid-TSAVLQSGFRK-2,4-dinitrophenyl amide) was monitored at 420 nm with excitation at 362 nm using a Perkin-Elmer LS-50B luminescence spectrometer.Enzyme activity assay of SARS-CoV main protease using fluorogenic substrate ::: MATERIALS AND METHODSThe kinetic parameters were obtained by assaying the enzyme activity at various peptide substrate concentrations around its Michaelis constant (Km) (11).", [["Tris-Cl", "CHEMICAL", 248, 255], ["phosphate", "CHEMICAL", 275, 284], ["ortho-aminobenzoic acid-TSAVLQSGFRK-2,4-dinitrophenyl amide", "CHEMICAL", 413, 472], ["Tris", "CHEMICAL", 248, 252], ["Cl", "CHEMICAL", 253, 255], ["phosphate", "CHEMICAL", 275, 284], ["ortho-aminobenzoic acid-TSAVLQSGFRK-2,4-dinitrophenyl amide", "CHEMICAL", 413, 472], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 116, 124], ["Tris-Cl", "SIMPLE_CHEMICAL", 248, 255], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 275, 300], ["ortho-aminobenzoic acid-TSAVLQSGFRK-2,4-dinitrophenyl amide", "SIMPLE_CHEMICAL", 413, 472], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 603, 611], ["recombinant 3CLpro", "PROTEIN", 26, 44], ["SARS-CoV main protease", "PROTEIN", 116, 138], ["SARS-CoV main protease", "PROTEIN", 603, 625], ["SARS-CoV", "SPECIES", 116, 124], ["SARS-CoV", "SPECIES", 603, 611], ["the recombinant 3CLpro", "TREATMENT", 22, 44], ["Enzyme activity", "TEST", 91, 106], ["SARS", "PROBLEM", 116, 120], ["METHODSThe enzyme kinetic measurements", "TEST", 185, 223], ["pH", "TEST", 264, 266], ["phosphate", "TEST", 275, 284], ["buffered saline", "TREATMENT", 285, 300], ["pH", "TEST", 302, 304], ["Enhanced fluorescence", "PROBLEM", 319, 340], ["the internal quenched fluorogenic substrate peptide", "TEST", 360, 411], ["ortho-aminobenzoic acid", "TEST", 413, 436], ["TSAVLQSGFRK", "TEST", 437, 448], ["dinitrophenyl amide", "TREATMENT", 453, 472], ["a Perkin-Elmer LS", "TEST", 530, 547], ["Enzyme activity", "TEST", 578, 593], ["SARS", "PROBLEM", 603, 607], ["METHODSThe kinetic parameters", "TEST", 672, 701], ["CD", "OBSERVATION", 8, 10]]], ["The initial velocities (vo) were measured and fitted to the Michaelis-Menten equation (Eq.", [["The initial velocities", "TEST", 0, 22], ["the Michaelis", "TEST", 56, 69], ["velocities", "OBSERVATION_MODIFIER", 12, 22]]]]}